WNK1
Normalized values from positional scanning peptide array
Phospho-serine (pS) is a duplicate of phospho-tyrosine (pT) in PSPA
Position-wise Probabilities
Log-Odds: Probabilities / STY Background
Sites with acceptor types representing >8% and count ≥10 are included
S Sites Probabilities
T Sites Probabilities
Log-Odds: S Sites / S Background
Log-Odds: T Sites / T Background
Sites with acceptor types representing >8% and count ≥10 are included
Motif clusters with count ≥ 10 are shown
Download
| substrate_uniprot | site | source | substrate_genes | site_seq |
|---|---|---|---|---|
| A5A3E0 | S1068 | Sugiyama | POTEF A26C1B | SLSTFQQMWISKQEyDEsGPsIVHRKCL_____________ |
| A5A3E0 | T949 | Sugiyama | POTEF A26C1B | TVAsSSSLEKsyELPDGQVItIGNERFRCPEALFQPCFLGM |
| B2RPK0 | S121 | Sugiyama | HMGB1P1 HMG1L1 HMGB1L1 | AFFLFCSEYHPKIKGEHPGLsIGDVAKKLGEMWNNTAADDK |
| O43423 | S100 | Sugiyama | ANP32CP PP32R1 | AEKCPNLTHLYLSGNKIKDLstIEPLKQLENLKSLDLFNCE |
| O43707 | T445 | Sugiyama | ACTN4 | HEAWtDGKEAMLKHRDyEtAtLsDIKALIRKHEAFEsDLAA |
| O60841 | S178 | Sugiyama | EIF5B IF2 KIAA0741 | NKKWDGsEEDEDNsKKIKERsRINssGEsGDEsDEFLQsRK |
| O60841 | S186 | Sugiyama | EIF5B IF2 KIAA0741 | EDEDNsKKIKERsRINssGEsGDEsDEFLQsRKGQKKNQKN |
| O60841 | T78 | Sugiyama | EIF5B IF2 KIAA0741 | ILKELEELsLEAQGIKADREtVAVKPTENNEEEFtsKDKKK |
| O60927 | T75 | Sugiyama | PPP1R11 HCGV TCTE5 | RRssKCCCIyEKPRAFGEsstEsDEEEEEGCGHtHCVRGHR |
| O94913 | S120 | EPSD|PSP | PCF11 KIAA0824 | FICVFEKVDENTRKSLFKLRstWDEIFPLKKLYALDVRVNS |
| O94913 | T121 | EPSD|PSP | PCF11 KIAA0824 | ICVFEKVDENTRKSLFKLRstWDEIFPLKKLYALDVRVNSL |
| O95218 | T50 | Sugiyama | ZRANB2 ZIS ZNF265 | SCNRCGREKTTEAKMMKAGGtEIGKtLAEKSRGLFsANDWQ |
| O95218 | T55 | Sugiyama | ZRANB2 ZIS ZNF265 | GREKTTEAKMMKAGGtEIGKtLAEKSRGLFsANDWQCKTCs |
| O95626 | S104 | Sugiyama | ANP32D PP32R2 | AEKCPNLIHLNLSGNKIKDLstIEPLKKLENLESLDLFTCE |
| O95747 | S325 | GPS6|SIGNOR|ELM|iPTMNet|EPSD|PSP | OXSR1 KIAA1101 OSR1 | LQRAPtISERAKKVRRVPGssGRLHKtEDGGWEWsDDEFDE |
| O95747 | T185 | GPS6|SIGNOR|ELM|iPTMNet|EPSD|PSP | OXSR1 KIAA1101 OSR1 | FGVSAFLATGGDITRNKVRKtFVGTPCWMAPEVMEQVRGYD |
| P00338 | S161 | Sugiyama | LDHA PIG19 | DILTYVAWKISGFPKNRVIGsGCNLDsARFRyLMGERLGVH |
| P00558 | S399 | Sugiyama | PGK1 PGKA MIG10 OK/SW-cl.110 | CCAKWNtEDKVsHVstGGGAsLELLEGKVLPGVDALsNI__ |
| P00558 | T394 | Sugiyama | PGK1 PGKA MIG10 OK/SW-cl.110 | GDtAtCCAKWNtEDKVsHVstGGGAsLELLEGKVLPGVDAL |
| P04075 | S39 | Sugiyama | ALDOA ALDA | IAHRIVAPGKGILAADEstGsIAKRLQsIGtENtEENRRFy |
| P04083 | S189 | Sugiyama | ANXA1 ANX1 LPC1 | tsDtsGDFRNALLsLAKGDRsEDFGVNEDLADsDARALyEA |
| P04406 | S241 | Sugiyama | GAPDH GAPD CDABP0047 OK/SW-cl.12 | IPELNGKLtGMAFRVPtANVsVVDLtCRLEKPAKyDDIKKV |
| P04406 | T211 | Sugiyama | GAPDH GAPD CDABP0047 OK/SW-cl.12 | PsGKLWRDGRGALQNIIPAstGAAKAVGKVIPELNGKLtGM |
| P04920 | S65 | Sugiyama | SLC4A2 AE2 EPB3L1 HKB3 MPB3L | ERFEEILQEAGsRGGEEPGRsYGEEDFEyHRQSSHHIHHPL |
| P05787 | S330 | Sugiyama | KRT8 CYK8 | MNRNISRLQAEIEGLKGQRAsLEAAIADAEQRGELAIKDAN |
| P06748 | S260 | Sugiyama | NPM1 NPM | GPssVEDIKAKMQAsIEKGGsLPKVEAKFINyVKNCFRMtD |
| P07195 | S162 | Sugiyama | LDHB | DILTYVTWKLSGLPKHRVIGsGCNLDsARFRyLMAEKLGIH |
| P07195 | S303 | Sugiyama | LDHB | GIENEVFLSLPCILNARGLtsVINQKLKDDEVAQLKKsADt |
| P07195 | T323 | Sugiyama | LDHB | sVINQKLKDDEVAQLKKsADtLWDIQKDLKDL_________ |
| P07205 | S399 | Sugiyama | PGK2 PGKB | CCAKWNtEDKVsHVstGGGAsLELLEGKILPGVEALSNM__ |
| P07205 | T394 | Sugiyama | PGK2 PGKB | GDTATCCAKWNtEDKVsHVstGGGAsLELLEGKILPGVEAL |
| P07864 | S161 | Sugiyama | LDHC LDH3 LDHX | DILTYIVWKISGLPVTRVIGsGCNLDsARFRYLIGEKLGVH |
| P07900 | S391 | Sugiyama | HSP90AA1 HSP90A HSPC1 HSPCA | MDNCEELIPEYLNFIRGVVDsEDLPLNIsREMLQQsKILKV |
| P07900 | S53 | Sugiyama | HSP90AA1 HSP90A HSPC1 HSPCA | IINtFySNKEIFLRELIsNssDALDKIRyEsLtDPsKLDsG |
| P07900 | T317 | Sugiyama | HSP90AA1 HSP90A HSPC1 HSPCA | WtRNPDDItNEEyGEFyKsLtNDWEDHLAVKHFSVEGQLEF |
| P07900 | Y284 | Sugiyama | HSP90AA1 HSP90A HSPC1 HSPCA | DEEEEKKDGDKKKKKKIKEKyIDQEELNKtKPIWtRNPDDI |
| P08238 | S383 | Sugiyama | HSP90AB1 HSP90B HSPC2 HSPC3 HSPCB | MDSCDELIPEYLNFIRGVVDsEDLPLNIsREMLQQsKILKV |
| P08238 | S45 | Sugiyama | HSP90AB1 HSP90B HSPC2 HSPC3 HSPCB | MSLIINTFYSNKEIFLRELIsNAsDALDKIRyEsLtDPsKL |
| P08238 | S460 | Sugiyama | HSP90AB1 HSP90B HSPC2 HSPC3 HSPCB | GIHEDstNRRRLsELLRyHtsQsGDEMtsLsEyVsRMKEtQ |
| P08238 | S462 | Sugiyama | HSP90AB1 HSP90B HSPC2 HSPC3 HSPCB | HEDstNRRRLsELLRyHtsQsGDEMtsLsEyVsRMKEtQKs |
| P08238 | T309 | Sugiyama | HSP90AB1 HSP90B HSPC2 HSPC3 HSPCB | WtRNPDDItQEEyGEFyKsLtNDWEDHLAVKHFSVEGQLEF |
| P08238 | Y276 | Sugiyama | HSP90AB1 HSP90B HSPC2 HSPC3 HSPCB | DEEDDsGKDKKKKTKKIKEKyIDQEELNKtKPIWtRNPDDI |
| P08758 | T8 | Sugiyama | ANXA5 ANX5 ENX2 PP4 | _____________MAQVLRGtVtDFPGFDERADAEtLRKAM |
| P09429 | S121 | Sugiyama | HMGB1 HMG1 | AFFLFCSEYRPKIKGEHPGLsIGDVAKKLGEMWNNTAADDK |
| P0CG38 | S1068 | Sugiyama | POTEI | SLSTFQQMWISKQEyDEsGPsIVHRKCF_____________ |
| P0CG39 | S1031 | Sugiyama | POTEJ | SLSTFQQMWISKQEyDEsGPsIVHRKCF_____________ |
| P10412 | S55 | Sugiyama | H1-4 H1F4 HIST1H1E | AsGPPVsELItKAVAASKERsGVsLAALKKALAAAGyDVEK |
| P10412 | S58 | Sugiyama | H1-4 H1F4 HIST1H1E | PPVsELItKAVAASKERsGVsLAALKKALAAAGyDVEKNNS |
| P11142 | S40 | Sugiyama | HSPA8 HSC70 HSP73 HSPA10 | VFQHGKVEIIANDQGNRttPsyVAFtDtERLIGDAAKNQVA |
| P11142 | T163 | Sugiyama | HSPA8 HSC70 HSP73 HSPA10 | VVtVPAyFNDsQRQAtKDAGtIAGLNVLRIINEPtAAAIAy |
| P11142 | T226 | Sugiyama | HSPA8 HSC70 HSP73 HSPA10 | DVSILTIEDGIFEVKstAGDtHLGGEDFDNRMVNHFIAEFK |
| P11142 | T45 | Sugiyama | HSPA8 HSC70 HSP73 HSPA10 | KVEIIANDQGNRttPsyVAFtDtERLIGDAAKNQVAMNPtN |
| P13639 | S584 | Sugiyama | EEF2 EF2 | DHACIPIKKSDPVVsyREtVsEEsNVLCLsKsPNKHNRLyM |
| P14314 | S126 | Sugiyama | PRKCSH G19P1 | yNsGVICENtCKEKGRKEREsLQQMAEVtREGFRLKKILIE |
| P14618 | S55 | Sugiyama | PKM OIP3 PK2 PK3 PKM2 | IDsPPItARNtGIICtIGPAsRsVEtLKEMIKsGMNVARLN |
| P14625 | S106 | Sugiyama | HSP90B1 GRP94 HSPC4 TRA1 | MKLIINSLYKNKEIFLRELIsNAsDALDKIRLISLTDENAL |
| P14625 | S172 | Sugiyama | HSP90B1 GRP94 HSPC4 TRA1 | VGMtREELVKNLGTIAKsGtsEFLNKMTEAQEDGQSTSELI |
| P14625 | S551 | Sugiyama | HSP90B1 GRP94 HSPC4 TRA1 | MKEKQDKIyFMAGsSRKEAEssPFVERLLKKGyEVIyLTEP |
| P14625 | T171 | Sugiyama | HSP90B1 GRP94 HSPC4 TRA1 | GVGMtREELVKNLGTIAKsGtsEFLNKMTEAQEDGQSTSEL |
| P16402 | S56 | Sugiyama | H1-3 H1F3 HIST1H1D | AsGPPVsELItKAVAASKERsGVsLAALKKALAAAGyDVEK |
| P16402 | S59 | Sugiyama | H1-3 H1F3 HIST1H1D | PPVsELItKAVAASKERsGVsLAALKKALAAAGyDVEKNNS |
| P16403 | S55 | Sugiyama | H1-2 H1F2 HIST1H1C | AsGPPVsELItKAVAASKERsGVsLAALKKALAAAGyDVEK |
| P16403 | S58 | Sugiyama | H1-2 H1F2 HIST1H1C | PPVsELItKAVAASKERsGVsLAALKKALAAAGyDVEKNNS |
| P17066 | S42 | Sugiyama | HSPA6 HSP70B' | VFQQGRVEILANDQGNRTtPsyVAFtDtERLVGDAAKsQAA |
| P17066 | T228 | Sugiyama | HSPA6 HSP70B' | DVSVLSIDAGVFEVKAtAGDtHLGGEDFDNRLVNHFMEEFR |
| P17066 | T47 | Sugiyama | HSPA6 HSP70B' | RVEILANDQGNRTtPsyVAFtDtERLVGDAAKsQAALNPHN |
| P18621 | S5 | Sugiyama | RPL17 | ________________MVRysLDPENPtKsCKSRGSNLRVH |
| P19338 | S328 | Sugiyama | NCL | NLFVGNLNFNKSAPELKtGIsDVFAKNDLAVVDVRIGMTRK |
| P19338 | S458 | Sugiyama | NCL | TEADAEKTFEEKQGtEIDGRsIsLyytGEKGQNQDYRGGKN |
| P19338 | S460 | Sugiyama | NCL | ADAEKTFEEKQGtEIDGRsIsLyytGEKGQNQDYRGGKNST |
| P19338 | S580 | Sugiyama | NCL | PRGsPNARSQPSKTLFVKGLsEDttEEtLKEsFDGsVRARI |
| P20290 | S173 | Sugiyama | BTF3 NACB OK/SW-cl.8 | QLGADsLtsLRRLAEALPKQsVDGKAPLAtGEDDDDEVPDL |
| P22626 | S189 | Sugiyama | HNRNPA2B1 HNRPA2B1 | IVLQKyHtINGHNAEVRKALsRQEMQEVQssRsGRGGNFGF |
| P23588 | S207 | Sugiyama | EIF4B | DRNRDsDKtDTDWRARPAtDsFDDyPPRRGDDsFGDKYRDR |
| P23588 | T205 | Sugiyama | EIF4B | GRDRNRDsDKtDTDWRARPAtDsFDDyPPRRGDDsFGDKYR |
| P25705 | S76 | Sugiyama | ATP5F1A ATP5A ATP5A1 ATP5AL2 ATPM | EERILGADtsVDLEETGRVLsIGDGIARVHGLRNVQAEEMV |
| P25789 | S7 | Sugiyama | PSMA4 HC9 PSC9 | ______________MSRRyDsRttIFsPEGRLYQVEYAMEA |
| P25789 | T10 | Sugiyama | PSMA4 HC9 PSC9 | ___________MSRRyDsRttIFsPEGRLYQVEYAMEAIGH |
| P25789 | Y5 | Sugiyama | PSMA4 HC9 PSC9 | ________________MSRRyDsRttIFsPEGRLYQVEYAM |
| P26232 | S667 | Sugiyama | CTNNA2 CAPR | YDVRsRtsVQtEDDQLIAGQsARAIMAQLPQEEKAKIAEQV |
| P26373 | S181 | Sugiyama | RPL13 BBC1 OK/SW-cl.46 | YKKEKARVItEEEKNFKAFAsLRMARANARLFGIRAKRAKE |
| P26373 | S77 | Sugiyama | RPL13 BBC1 OK/SW-cl.46 | PIVRCPTVRYHTKVRAGRGFsLEELRVAGIHKKVARTIGIs |
| P26373 | S97 | Sugiyama | RPL13 BBC1 OK/SW-cl.46 | sLEELRVAGIHKKVARTIGIsVDPRRRNKstEsLQANVQRL |
| P26373 | T107 | Sugiyama | RPL13 BBC1 OK/SW-cl.46 | HKKVARTIGIsVDPRRRNKstEsLQANVQRLKEYRSKLILF |
| P27797 | S52 | Sugiyama | CALR CRTC | GWtsRWIEsKHKSDFGKFVLssGKFyGDEEKDKGLQTSQDA |
| P27797 | S53 | Sugiyama | CALR CRTC | WtsRWIEsKHKSDFGKFVLssGKFyGDEEKDKGLQTSQDAR |
| P27797 | T34 | Sugiyama | CALR CRTC | LAVAEPAVYFKEQFLDGDGWtsRWIEsKHKSDFGKFVLssG |
| P29144 | S93 | Sugiyama | TPP2 | SGDVNTATEVEPKDGEIVGLsGRVLKIPASWTNPSGKYHIG |
| P29692 | S44 | Sugiyama | EEF1D EF1D | RFyEQMNGPVAGAsRQENGAsVILRDIARARENIQKsLAGs |
| P29692 | S74 | Sugiyama | EEF1D EF1D | RENIQKsLAGssGPGAssGtsGDHGELVVRIAsLEVENQsL |
| P29692 | T129 | Sugiyama | EEF1D EF1D | EARLNVLEKssPGHRAtAPQtQHVsPMRQVEPPAKKPAtPA |
| P29692 | T147 | Sugiyama | EEF1D EF1D | PQtQHVsPMRQVEPPAKKPAtPAEDDEDDDIDLFGsDNEEE |
| P29692 | T73 | Sugiyama | EEF1D EF1D | ARENIQKsLAGssGPGAssGtsGDHGELVVRIAsLEVENQs |
| P30050 | S138 | Sugiyama | RPL12 | HRSLARELsGtIKEILGtAQsVGCNVDGRHPHDIIDDINsG |
| P30101 | T485 | Sugiyama | PDIA3 ERP57 ERP60 GRP58 | KKyEGGRELsDFIsyLQREAtNPPVIQEEKPKKKKKAQEDL |
| P31327 | T45 | Sugiyama | CPS1 | AHQKWKFSRPGIRLLSVKAQtAHIVLEDGtKMKGYSFGHPS |
| P34931 | S42 | Sugiyama | HSPA1L | VFQHGKVEIIANDQGNRttPsyVAFtDtERLIGDAAKNQVA |
| P34931 | T228 | Sugiyama | HSPA1L | DVSILTIDDGIFEVKAtAGDtHLGGEDFDNRLVsHFVEEFK |
| P34931 | T47 | Sugiyama | HSPA1L | KVEIIANDQGNRttPsyVAFtDtERLIGDAAKNQVAMNPQN |
| P35221 | S668 | Sugiyama | CTNNA1 | FDVRsRtsVQtEDDQLIAGQsARAIMAQLPQEQKAKIAEQV |
| P36578 | S365 | Sugiyama | RPL4 RPL1 | RNHKLRVDKAAAAAAALQAKsDEKAAVAGKKPVVGKKGKKA |
| P37802 | S185 | Sugiyama | TAGLN2 KIAA0120 CDABP0035 | NQLQEGKNVIGLQMGtNRGAsQAGMtGyGMPRQIL______ |
| P37802 | T180 | Sugiyama | TAGLN2 KIAA0120 CDABP0035 | RNFsDNQLQEGKNVIGLQMGtNRGAsQAGMtGyGMPRQIL_ |
| P37802 | T190 | Sugiyama | TAGLN2 KIAA0120 CDABP0035 | GKNVIGLQMGtNRGAsQAGMtGyGMPRQIL___________ |
| P38646 | S89 | Sugiyama | HSPA9 GRP75 HSPA9B mt-HSP70 | VMEGKQAKVLENAEGARttPsVVAFtADGERLVGMPAKRQA |
| P38646 | T111 | Sugiyama | HSPA9 GRP75 HSPA9B mt-HSP70 | VAFtADGERLVGMPAKRQAVtNPNNtFyAtKRLIGRRYDDP |
| P38646 | T398 | Sugiyama | HSPA9 GRP75 HSPA9B mt-HSP70 | SDIGEVILVGGMTRMPKVQQtVQDLFGRAPsKAVNPDEAVA |
| P39687 | S104 | Sugiyama | ANP32A C15orf1 LANP MAPM PHAP1 | AEKCPNLTHLNLsGNKIKDLstIEPLKKLENLKsLDLFNCE |
| P46013 | S651 | Sugiyama | MKI67 | ISRsQHDILQMICSKRRsGAsEANLIVAKSWADVVKLGAKQ |
| P46776 | S106 | Sugiyama | RPL27A | tRVNAAKNKtGAAPIIDVVRsGyyKVLGKGKLPKQPVIVKA |
| P46776 | S68 | Sugiyama | RPL27A | yHPGyFGKVGMKHYHLKRNQsFCPtVNLDKLWtLVsEQtRV |
| P46776 | T72 | Sugiyama | RPL27A | yFGKVGMKHYHLKRNQsFCPtVNLDKLWtLVsEQtRVNAAK |
| P46776 | Y108 | Sugiyama | RPL27A | VNAAKNKtGAAPIIDVVRsGyyKVLGKGKLPKQPVIVKAKF |
| P46777 | S176 | Sugiyama | RPL5 MSTP030 | GNKVFGALKGAVDGGLsIPHstKRFPGyDsEsKEFNAEVHR |
| P46777 | S224 | Sugiyama | RPL5 MSTP030 | VADyMRyLMEEDEDAyKKQFsQyIKNsVtPDMMEEMyKKAH |
| P46777 | T177 | Sugiyama | RPL5 MSTP030 | NKVFGALKGAVDGGLsIPHstKRFPGyDsEsKEFNAEVHRK |
| P46779 | S115 | Sugiyama | RPL28 | HMIRKNKYRPDLRMAAIRRAsAILRSQKPVMVKRKRTRPTK |
| P46783 | S146 | Sugiyama | RPS10 | TYRRSAVPPGADKKAEAGAGsAtEFQFRGGFGRGRGQPPQ_ |
| P47914 | S142 | Sugiyama | RPL29 | KAKAKAKAKDQTKAQAAAPAsVPAQAPKRtQAPtKAsE___ |
| P47914 | T151 | Sugiyama | RPL29 | DQTKAQAAAPAsVPAQAPKRtQAPtKAsE____________ |
| P47914 | Y98 | Sugiyama | RPL29 | PKEVKPKIPKGVSRKLDRLAyIAHPKLGKRARARIAKGLRL |
| P48741 | S42 | Sugiyama | HSPA7 HSP70B | VFQQGRVEILANDQGNRTtPsyVAFtDtERLVGDAAKsQAA |
| P48741 | T228 | Sugiyama | HSPA7 HSP70B | DVSVLSIDAGVFEVKAtAGDtHLGGEDFDNRLVNHFMEEFR |
| P48741 | T47 | Sugiyama | HSPA7 HSP70B | RVEILANDQGNRTtPsyVAFtDtERLVGDAAKsQAALNPHN |
| P49321 | S659 | Sugiyama | NASP | IEELKELLPEIREKIEDAKEsQRsGNVAELALKATLVEsst |
| P49321 | S662 | Sugiyama | NASP | LKELLPEIREKIEDAKEsQRsGNVAELALKATLVEsstsGF |
| P49327 | T2215 | Sugiyama | FASN FAS | DEAsELACPtPKEDGLAQQQtQLNLRSLLVNPEGPtLMRLN |
| P50238 | Y12 | Sugiyama | CRIP1 CRIP CRP1 | _________MPKCPKCNKEVyFAERVTSLGKDWHRPCLKCE |
| P51116 | T610 | Sugiyama | FXR2 FMR1L2 | RRRNRGNRtDGsIsGDRQPVtVADyIsRAEsQsRQRPPLER |
| P54652 | S41 | Sugiyama | HSPA2 | VFQHGKVEIIANDQGNRttPsyVAFtDtERLIGDAAKNQVA |
| P54652 | T229 | Sugiyama | HSPA2 | DVSILTIEDGIFEVKstAGDtHLGGEDFDNRMVSHLAEEFK |
| P54652 | T46 | Sugiyama | HSPA2 | KVEIIANDQGNRttPsyVAFtDtERLIGDAAKNQVAMNPTN |
| P55011 | T1023 | SIGNOR | SLC12A2 NKCC1 | VADQKLLEASTQFQKKQGKNtIDVWWLFDDGGLTLLIPYLL |
| P57721 | S59 | Sugiyama | PCBP3 PCBP3-OT1 PCBP3OT | EGGLNVTLTIRLLMHGKEVGsIIGKKGETVKKMREESGARI |
| P57723 | S31 | Sugiyama | PCBP4 | EPELSITLTLRMLMHGKEVGsIIGKKGETVKRIREQSSARI |
| P60174 | S106 | Sugiyama | TPI1 TPI | DCGAtWVVLGHsERRHVFGEsDELIGQKVAHALAEGLGVIA |
| P60709 | S199 | Sugiyama | ACTB | DLAGRDLTDyLMKILtERGysFtttAEREIVRDIKEKLCyV |
| P60709 | S323 | Sugiyama | ACTB | ttMyPGIADRMQKEItALAPstMKIKIIAPPERKYsVWIGG |
| P60709 | S368 | Sugiyama | ACTB | sLstFQQMWISKQEyDEsGPsIVHRKCF_____________ |
| P60709 | T249 | Sugiyama | ACTB | tAAssssLEKsyELPDGQVItIGNERFRCPEALFQPsFLGM |
| P60709 | T318 | Sugiyama | ACTB | VLsGGttMyPGIADRMQKEItALAPstMKIKIIAPPERKYs |
| P60709 | T324 | Sugiyama | ACTB | tMyPGIADRMQKEItALAPstMKIKIIAPPERKYsVWIGGs |
| P61254 | T8 | Sugiyama | RPL26 | _____________MKFNPFVtsDRsKNRKRHFNAPsHIRRK |
| P61353 | S86 | Sugiyama | RPL27 | SKIKSFVKVyNyNHLMPtRysVDIPLDKtVVNKDVFRDPAL |
| P61978 | S401 | Sugiyama | HNRNPK HNRPK | GDLGGPIIttQVtIPKDLAGsIIGKGGQRIKQIRHEsGAsI |
| P62249 | S9 | Sugiyama | RPS16 | ____________MPsKGPLQsVQVFGRKKTATAVAHCKRGN |
| P62263 | S137 | Sugiyama | RPS14 PRO2640 | RALARSGMKIGRIEDVtPIPsDstRRKGGRRGRRL______ |
| P62266 | S45 | Sugiyama | RPS23 | KQYKKAHLGtALKANPFGGAsHAKGIVLEKVGVEAKQPNSA |
| P62273 | Y7 | Sugiyama | RPS29 | ______________MGHQQLyWsHPRKFGQGSRSCRVCSNR |
| P62277 | S12 | Sugiyama | RPS13 | _________MGRMHAPGKGLsQsALPyRRsVPtWLKLTsDD |
| P62736 | S325 | Sugiyama | ACTA2 ACTSA ACTVS GIG46 | tTMYPGIADRMQKEItALAPstMKIKIIAPPERKYSVWIGG |
| P62736 | T251 | Sugiyama | ACTA2 ACTSA ACTVS GIG46 | tAAssssLEKsyELPDGQVItIGNERFRCPETLFQPSFIGM |
| P62736 | T320 | Sugiyama | ACTA2 ACTSA ACTVS GIG46 | VLSGGtTMYPGIADRMQKEItALAPstMKIKIIAPPERKYS |
| P62736 | T326 | Sugiyama | ACTA2 ACTSA ACTVS GIG46 | TMYPGIADRMQKEItALAPstMKIKIIAPPERKYSVWIGGS |
| P62750 | T42 | Sugiyama | RPL23A | LKAKKAVLKGVHSHKKKKIRtsPTFRRPKTLRLRRQPKYPR |
| P62826 | T32 | Sugiyama | RAN ARA24 OK/SW-cl.81 | KLVLVGDGGtGKttFVKRHLtGEFEKKyVATLGVEVHPLVF |
| P62899 | S15 | Sugiyama | RPL31 | ______MAPAKKGGEKKKGRsAINEVVtREytINIHKRIHG |
| P62917 | S130 | Sugiyama | RPL8 | GTIVCCLEEKPGDRGKLARAsGNyAtVIsHNPEtKKtRVKL |
| P62917 | T135 | Sugiyama | RPL8 | CLEEKPGDRGKLARAsGNyAtVIsHNPEtKKtRVKLPSGSK |
| P62917 | T143 | Sugiyama | RPL8 | RGKLARAsGNyAtVIsHNPEtKKtRVKLPSGSKKVISSANR |
| P62917 | Y133 | Sugiyama | RPL8 | VCCLEEKPGDRGKLARAsGNyAtVIsHNPEtKKtRVKLPSG |
| P63261 | S199 | Sugiyama | ACTG1 ACTG | DLAGRDLTDyLMKILtERGysFtttAEREIVRDIKEKLCyV |
| P63261 | S323 | Sugiyama | ACTG1 ACTG | ttMyPGIADRMQKEItALAPstMKIKIIAPPERKYsVWIGG |
| P63261 | S368 | Sugiyama | ACTG1 ACTG | sLstFQQMWISKQEyDEsGPsIVHRKCF_____________ |
| P63261 | T249 | Sugiyama | ACTG1 ACTG | tAAssssLEKsyELPDGQVItIGNERFRCPEALFQPsFLGM |
| P63261 | T318 | Sugiyama | ACTG1 ACTG | VLsGGttMyPGIADRMQKEItALAPstMKIKIIAPPERKYs |
| P63261 | T324 | Sugiyama | ACTG1 ACTG | tMyPGIADRMQKEItALAPstMKIKIIAPPERKYsVWIGGs |
| P63267 | S324 | Sugiyama | ACTG2 ACTA3 ACTL3 ACTSG | tTMYPGIADRMQKEItALAPstMKIKIIAPPERKYSVWIGG |
| P63267 | T250 | Sugiyama | ACTG2 ACTA3 ACTL3 ACTSG | tAAssssLEKsyELPDGQVItIGNERFRCPETLFQPSFIGM |
| P63267 | T319 | Sugiyama | ACTG2 ACTA3 ACTL3 ACTSG | VLSGGtTMYPGIADRMQKEItALAPstMKIKIIAPPERKYS |
| P63267 | T325 | Sugiyama | ACTG2 ACTA3 ACTL3 ACTSG | TMYPGIADRMQKEItALAPstMKIKIIAPPERKYSVWIGGS |
| P67809 | S102 | Sugiyama | YBX1 NSEP1 YB1 | EDVFVHQtAIKKNNPRKyLRsVGDGEtVEFDVVEGEKGAEA |
| P67809 | S136 | Sugiyama | YBX1 NSEP1 YB1 | GEKGAEAANVtGPGGVPVQGsKYAADRNHYRRYPRRRGPPR |
| P67809 | S167 | Sugiyama | YBX1 NSEP1 YB1 | RYPRRRGPPRNyQQNyQNsEsGEKNEGsEsAPEGQAQQRRP |
| P67809 | S209 | Sugiyama | YBX1 NSEP1 YB1 | RRRRFPPyyMRRPYGRRPQysNPPVQGEVMEGADNQGAGEQ |
| P67809 | T108 | Sugiyama | YBX1 NSEP1 YB1 | QtAIKKNNPRKyLRsVGDGEtVEFDVVEGEKGAEAANVtGP |
| P67809 | Y99 | Sugiyama | YBX1 NSEP1 YB1 | DtKEDVFVHQtAIKKNNPRKyLRsVGDGEtVEFDVVEGEKG |
| P68032 | S325 | Sugiyama | ACTC1 ACTC | tTMYPGIADRMQKEItALAPstMKIKIIAPPERKYSVWIGG |
| P68032 | T251 | Sugiyama | ACTC1 ACTC | tAAssssLEKsyELPDGQVItIGNERFRCPETLFQPSFIGM |
| P68032 | T320 | Sugiyama | ACTC1 ACTC | VLSGGtTMYPGIADRMQKEItALAPstMKIKIIAPPERKYS |
| P68032 | T326 | Sugiyama | ACTC1 ACTC | TMYPGIADRMQKEItALAPstMKIKIIAPPERKYSVWIGGS |
| P68133 | S325 | Sugiyama | ACTA1 ACTA | TTMYPGIADRMQKEItALAPstMKIKIIAPPERKYSVWIGG |
| P68133 | T251 | Sugiyama | ACTA1 ACTA | tAAssssLEKsyELPDGQVItIGNERFRCPETLFQPSFIGM |
| P68133 | T320 | Sugiyama | ACTA1 ACTA | VMSGGTTMYPGIADRMQKEItALAPstMKIKIIAPPERKYS |
| P68133 | T326 | Sugiyama | ACTA1 ACTA | TMYPGIADRMQKEItALAPstMKIKIIAPPERKYSVWIGGS |
| P68363 | T73 | Sugiyama | TUBA1B | FsEtGAGKHVPRAVFVDLEPtVIDEVRtGtyRQLFHPEQLI |
| P68363 | Y83 | Sugiyama | TUBA1B | PRAVFVDLEPtVIDEVRtGtyRQLFHPEQLItGKEDAANNy |
| P83731 | S38 | Sugiyama | RPL24 | GRRYARTDGKVFQFLNAKCEsAFLSKRNPRQINWtVLyRRK |
| P83731 | S86 | Sugiyama | RPL24 | EIQKKRTRRAVKFQRAItGAsLADIMAKRNQKPEVRKAQRE |
| P83731 | T83 | Sugiyama | RPL24 | QsEEIQKKRTRRAVKFQRAItGAsLADIMAKRNQKPEVRKA |
| P84098 | S37 | Sugiyama | RPL19 | CGKKKVWLDPNEtNEIANANsRQQIRKLIKDGLIIRKPVtV |
| Q01105 | S161 | Sugiyama | SET | FDENPyFENKVLSKEFHLNEsGDPssKstEIKWKSGKDLTK |
| Q01105 | S166 | Sugiyama | SET | yFENKVLSKEFHLNEsGDPssKstEIKWKSGKDLTKRssQT |
| Q01105 | S168 | Sugiyama | SET | ENKVLSKEFHLNEsGDPssKstEIKWKSGKDLTKRssQTQN |
| Q01105 | T169 | Sugiyama | SET | NKVLSKEFHLNEsGDPssKstEIKWKSGKDLTKRssQTQNK |
| Q01650 | S31 | Sugiyama | SLC7A5 CD98LC LAT1 MPE16 | LAAPAAEEKEEAREKMLAAKsADGsAPAGEGEGVtLQRNIT |
| Q02878 | S255 | Sugiyama | RPL6 TXREB1 | tEKEKYEITEQRKIDQKAVDsQILPKIKAIPQLQGYLRSVF |
| Q09028 | S147 | Sugiyama | RBBP4 RBAP48 | VNRARYMPQNPCIIATKtPssDVLVFDyTKHPsKPDPsGEC |
| Q13283 | S67 | Sugiyama | G3BP1 G3BP | sNGKPADAVyGQKEIHRKVMsQNFtNCHTKIRHVDAHATLN |
| Q13428 | S1410 | Sugiyama | TCOF1 | AKRDKASGDVKEKKGKGsLGsQGAKDEPEEELQKGMGTVEG |
| Q14151 | S613 | Sugiyama | SAFB2 KIAA0138 | ERSSKSQDRKSESKEKRDILsFDKIKEQRERERQRQREREI |
| Q14152 | S988 | Sugiyama | EIF3A EIF3S10 KIAA0139 | PRRGPEEDRFsRRGADDDRPsWRNTDDDRPPRRIADEDRGN |
| Q14568 | S53 | Sugiyama | HSP90AA2P HSP90AA2 HSPC2 HSPCAL3 | IINTFYSNKEIFLRELIsNssDALDKIWYESLTDPSKLDSG |
| Q14568 | Y283 | Sugiyama | HSP90AA2P HSP90AA2 HSPC2 HSPCAL3 | sDEEEEKKDGDKKKKKTKEKyIDQEELNKTKPIWTRNPDDI |
| Q15185 | S82 | Sugiyama | PTGES3 P23 TEBP | NDsKHKRtDRsILCCLRKGEsGQsWPRLTKERAKLNWLsVD |
| Q15365 | S27 | Sugiyama | PCBP1 | ESGLNVTLTIRLLMHGKEVGsIIGKKGESVKRIREEsGARI |
| Q15366 | S27 | Sugiyama | PCBP2 | EGGLNVTLTIRLLMHGKEVGsIIGKKGESVKKMREESGARI |
| Q16576 | S146 | Sugiyama | RBBP7 RBAP46 | VNRARYMPQNPHIIATKtPssDVLVFDyTKHPAKPDPsGEC |
| Q562R1 | T250 | Sugiyama | ACTBL2 | RAAAssSPERsyELPDGQVItIGNERFRCPEAIFQPSFLGI |
| Q58FF8 | Y198 | Sugiyama | HSP90AB2P HSP90BB | DEEDDsGKDKKKKTKKIKEKyIDQEELNKTKPIWTRNTEDI |
| Q6S8J3 | S1068 | Sugiyama | POTEE A26C1A POTE2 | SLSTFQQMWISKQEyDEsGPsIVHRKCF_____________ |
| Q6S8J3 | T949 | Sugiyama | POTEE A26C1A POTE2 | tAAssssLEKsyELPDGQVItIGNERFRCPEALFQPCFLGM |
| Q6ZMR3 | S161 | Sugiyama | LDHAL6A LDHL2 | DILTYVAWKLSGFPKNRVIGsGCNLDsARFRYFIGQRLGIH |
| Q71U36 | T73 | Sugiyama | TUBA1A TUBA3 | FsEtGAGKHVPRAVFVDLEPtVIDEVRtGtyRQLFHPEQLI |
| Q71U36 | Y83 | Sugiyama | TUBA1A TUBA3 | PRAVFVDLEPtVIDEVRtGtyRQLFHPEQLItGKEDAANNy |
| Q7Z4V5 | S369 | Sugiyama | HDGFL2 HDGF2 HDGFRP2 HRP2 UNQ785/PRO1604 | EKERRRERADRGEAERGsGGssGDELREDDEPVKKRGRKGR |
| Q7Z4V5 | S396 | Sugiyama | HDGFL2 HDGF2 HDGFRP2 HRP2 UNQ785/PRO1604 | EDDEPVKKRGRKGRGRGPPsssDsEPEAELEREAKKSAKKP |
| Q86V81 | S142 | Sugiyama | ALYREF ALY BEF THOC4 | IQELFAEFGtLKKAAVHYDRsGRsLGtADVHFERKADALKA |
| Q86V81 | S145 | Sugiyama | ALYREF ALY BEF THOC4 | LFAEFGtLKKAAVHYDRsGRsLGtADVHFERKADALKAMKQ |
| Q86VQ1 | S223 | Sugiyama | GLCCI1 | QTPsCWAEEGAEKRSHQRsAsWGsADQLKEQIAKLRQQLQR |
| Q8N9I0 | T199 | SIGNOR | SYT2 | VKVFLLPDKKKKYETKVHRKtLNPAFNETFTFKVPYQELGG |
| Q8NBJ7 | S256 | Sugiyama | SUMF2 PSEC0171 UNQ1968/PRO4500 | EWTASPYQAAEQDMRVLRGAsWIDtADGsANHRARVttRMG |
| Q96CT7 | S122 | Sugiyama | CCDC124 | DtLRRDHQLREAPDTAEKAKsHLEVPLEENVNRRVLEEGsV |
| Q96J92 | S335 | Sugiyama | WNK4 PRKWNK4 | GsVKIGDLGLATLKRAsFAKsVIGtPEFMAPEMYEEKYDEA |
| Q96J92 | T339 | Sugiyama | WNK4 PRKWNK4 | IGDLGLATLKRAsFAKsVIGtPEFMAPEMYEEKYDEAVDVY |
| Q96PU5 | S342 | GPS6|EPSD | NEDD4L KIAA0439 NEDL3 | NGEQFsSLIQREPssRLRsCsVtDAVAEQGHLPPPSAPAGR |
| Q96PU5 | S449 | GPS6|EPSD | NEDD4L KIAA0439 NEDL3 | ATNSNNHLIEPQIRRPRsLssPtVTLSAPLEGAKDsPVRRA |
| Q9BQE3 | T73 | Sugiyama | TUBA1C TUBA6 | FsEtGAGKHVPRAVFVDLEPtVIDEVRtGtyRQLFHPEQLI |
| Q9BQE3 | Y83 | Sugiyama | TUBA1C TUBA6 | PRAVFVDLEPtVIDEVRtGtyRQLFHPEQLItGKEDAANNy |
| Q9BYP7 | T287 | Sugiyama | WNK3 KIAA1566 PRKWNK3 | RTPPIIHRDLKCDNIFItGPtGsVKIGDLGLATLMRtsFAK |
| Q9BYX7 | S368 | Sugiyama | POTEKP ACTBL3 FKSG30 | SLSTFQQMWISKQEyDEsGPsIVHRKCF_____________ |
| Q9BYX7 | T249 | Sugiyama | POTEKP ACTBL3 FKSG30 | MAASSSSVEKsyELPDGQVItIGNERFRCPEALFQPCFLGM |
| Q9H4A3 | S10 | Sugiyama | WNK1 HSN2 KDP KIAA0344 PRKWNK1 | ___________MsGGAAEKQsstPGsLFLsPPAPAPKNGSs |
| Q9H4A3 | S11 | Sugiyama | WNK1 HSN2 KDP KIAA0344 PRKWNK1 | __________MsGGAAEKQsstPGsLFLsPPAPAPKNGSss |
| Q9H4A3 | S15 | Sugiyama | WNK1 HSN2 KDP KIAA0344 PRKWNK1 | ______MsGGAAEKQsstPGsLFLsPPAPAPKNGSssDssV |
| Q9H4A3 | S167 | Sugiyama | WNK1 HSN2 KDP KIAA0344 PRKWNK1 | AVAGPAPSTVPSSTSKDRPVsQPsLVGsKEEPPPARsGsGG |
| Q9H4A3 | S170 | Sugiyama | WNK1 HSN2 KDP KIAA0344 PRKWNK1 | GPAPSTVPSSTSKDRPVsQPsLVGsKEEPPPARsGsGGGsA |
| Q9H4A3 | S19 | Sugiyama | WNK1 HSN2 KDP KIAA0344 PRKWNK1 | __MsGGAAEKQsstPGsLFLsPPAPAPKNGSssDssVGEKL |
| Q9H4A3 | S198 | Sugiyama | WNK1 HSN2 KDP KIAA0344 PRKWNK1 | PPPARsGsGGGsAKEPQEERsQQQDDIEELEtKAVGMSNDG |
| Q9H4A3 | S378 | GPS6 | WNK1 HSN2 KDP KIAA0344 PRKWNK1 | tGPtGsVKIGDLGLATLKRAsFAKsVIGtPEFMAPEMYEEK |
| Q9H4A3 | S382 | GPS6|SIGNOR|EPSD|PSP|Sugiyama | WNK1 HSN2 KDP KIAA0344 PRKWNK1 | GsVKIGDLGLATLKRAsFAKsVIGtPEFMAPEMYEEKYDES |
| Q9H4A3 | T12 | Sugiyama | WNK1 HSN2 KDP KIAA0344 PRKWNK1 | _________MsGGAAEKQsstPGsLFLsPPAPAPKNGSssD |
| Q9H4A3 | T209 | Sugiyama | WNK1 HSN2 KDP KIAA0344 PRKWNK1 | sAKEPQEERsQQQDDIEELEtKAVGMSNDGRFLKFDIEIGR |
| Q9H4A3 | T361 | Sugiyama | WNK1 HSN2 KDP KIAA0344 PRKWNK1 | RTPPIIHRDLKCDNIFItGPtGsVKIGDLGLATLKRAsFAK |
| Q9H4A3 | T386 | Sugiyama | WNK1 HSN2 KDP KIAA0344 PRKWNK1 | IGDLGLATLKRAsFAKsVIGtPEFMAPEMYEEKYDESVDVY |
| Q9H4A3 | T48 | Sugiyama | WNK1 HSN2 KDP KIAA0344 PRKWNK1 | GSssDssVGEKLGAAAADAVtGRtEEyRRRRHtMDKDSRGA |
| Q9H4A3 | T51 | Sugiyama | WNK1 HSN2 KDP KIAA0344 PRKWNK1 | sDssVGEKLGAAAADAVtGRtEEyRRRRHtMDKDSRGAAAt |
| Q9H4A3 | T71 | Sugiyama | WNK1 HSN2 KDP KIAA0344 PRKWNK1 | tEEyRRRRHtMDKDSRGAAAtTtTTEHRFFRRsVICDSNAT |
| Q9H4A3 | T73 | Sugiyama | WNK1 HSN2 KDP KIAA0344 PRKWNK1 | EyRRRRHtMDKDSRGAAAtTtTTEHRFFRRsVICDSNATAL |
| Q9H4A3 | Y54 | Sugiyama | WNK1 HSN2 KDP KIAA0344 PRKWNK1 | sVGEKLGAAAADAVtGRtEEyRRRRHtMDKDSRGAAAtTtT |
| Q9NQ39 | S157 | Sugiyama | RPS10P5 RPS10L | TYRRCSVPPGADKKAEAGAGsAtEFQFRGRCGRGRGQPPQ_ |
| Q9NYF8 | S319 | Sugiyama | BCLAF1 BTF KIAA0164 | RsPAKtIAPQNAPRDEsRGRssFyPDGGDQETAKtGKFLKR |
| Q9UEW8 | S371 | GPS6|SIGNOR|EPSD|PSP | STK39 PASK SPAK | LtRtPDIAQRAKKVRRVPGssGHLHKTEDGDWEWsDDEMDE |
| Q9UEW8 | T231 | GPS6|SIGNOR|EPSD|PSP | STK39 PASK SPAK | FGVSAFLATGGDVTRNKVRKtFVGTPCWMAPEVMEQVRGYD |
| Q9UGY1 | S21 | Sugiyama | NOL12 | MGRNKKKKRDGDDRRPRLVLsFDEEKRREyLTGFHKRKVER |
| Q9UHW9 | T1048 | SIGNOR|EPSD|PSP | SLC12A6 KCC3 | tsIGsDEDEEtETYQEKVHMtWTKDKYMASRGQKAKsMEGF |
| Q9UHW9 | T991 | SIGNOR|EPSD|PSP | SLC12A6 KCC3 | AEVEVVEMHDSDISAYTYERtLMMEQRSQMLRHMRLSKTER |
| Q9UI15 | S185 | Sugiyama | TAGLN3 NP25 | EQLRQGQNVIGLQMGSNKGAsQAGMtGyGMPRQIM______ |
| Q9UI15 | T190 | Sugiyama | TAGLN3 NP25 | GQNVIGLQMGSNKGAsQAGMtGyGMPRQIM___________ |
| Q9UII2 | S39 | Sugiyama | ATP5IF1 ATPI ATPIF1 | TMQARGFGsDQSENVDRGAGsIREAGGAFGKREQAEEERyF |
| Q9UII2 | S63 | Sugiyama | ATP5IF1 ATPI ATPIF1 | AGGAFGKREQAEEERyFRAQsREQLAALKKHHEEEIVHHKK |
| Q9UNX3 | T8 | Sugiyama | RPL26L1 RPL26P1 | _____________MKFNPFVtsDRsKNRKRHFNAPSHVRRK |
| Q9Y2B0 | S115 | Sugiyama | CNPY2 MSAP TMEM4 ZSIG9 UNQ1943/PRO4426 | QIDPstHRKNYVRVVGRNGEssELDLQGIRIDsDISGtLKF |
| Q9Y2T7 | T143 | Sugiyama | YBX2 CSDA3 MSY2 | QtAIKRNNPRKFLRsVGDGEtVEFDVVEGEKGAEATNVTGP |
| Q9Y3S1 | T335 | Sugiyama | WNK2 KIAA1760 PRKWNK2 SDCCAG43 P/OKcl.13 | RTPPIIHRDLKCDNIFItGPtGsVKIGDLGLATLKRAsFAK |
| Q9Y5L4 | S57 | Sugiyama | TIMM13 TIM13B TIMM13A TIMM13B | ELLQRMTDKCFRKCIGKPGGsLDNSEQKCIAMCMDRyMDAW |
| Q9Y5M8 | S257 | Sugiyama | SRPRB PSEC0230 | LPLKVEFLECSAKGGRGDVGsADIQDLEKWLAKIA______ |
Site Promiscuity
Motif of predicted substrate sequence
Reactome pathways of predicted substrates
Download
| name | reactome_id | p | -log10p | ref_path | ref_path_lowest |
|---|---|---|---|---|---|
| Cell Cycle | R-HSA-1640170 | 9.992007e-16 | 15.000 | 0 | 0 |
| Cell Cycle, Mitotic | R-HSA-69278 | 4.162226e-13 | 12.381 | 0 | 0 |
| Axon guidance | R-HSA-422475 | 4.034728e-11 | 10.394 | 0 | 0 |
| Diseases of signal transduction by growth factor receptors and second messengers | R-HSA-5663202 | 1.812274e-10 | 9.742 | 0 | 0 |
| Signal Transduction | R-HSA-162582 | 2.727164e-10 | 9.564 | 0 | 0 |
| Nervous system development | R-HSA-9675108 | 1.325785e-09 | 8.878 | 0 | 0 |
| M Phase | R-HSA-68886 | 2.186537e-09 | 8.660 | 0 | 0 |
| Cellular Senescence | R-HSA-2559583 | 4.793688e-09 | 8.319 | 0 | 0 |
| Constitutive Signaling by AKT1 E17K in Cancer | R-HSA-5674400 | 1.132769e-08 | 7.946 | 0 | 0 |
| Mitotic Prometaphase | R-HSA-68877 | 4.559356e-08 | 7.341 | 0 | 0 |
| Cell Cycle Checkpoints | R-HSA-69620 | 5.673512e-08 | 7.246 | 0 | 0 |
| Post NMDA receptor activation events | R-HSA-438064 | 2.029990e-07 | 6.693 | 0 | 0 |
| Apoptotic execution phase | R-HSA-75153 | 3.696342e-07 | 6.432 | 0 | 0 |
| EML4 and NUDC in mitotic spindle formation | R-HSA-9648025 | 1.024944e-06 | 5.989 | 0 | 0 |
| Resolution of Sister Chromatid Cohesion | R-HSA-2500257 | 1.061426e-06 | 5.974 | 0 | 0 |
| Chromatin modifying enzymes | R-HSA-3247509 | 1.129698e-06 | 5.947 | 0 | 0 |
| Chromatin organization | R-HSA-4839726 | 2.016303e-06 | 5.695 | 0 | 0 |
| EPH-Ephrin signaling | R-HSA-2682334 | 2.117235e-06 | 5.674 | 0 | 0 |
| Regulation of TP53 Activity | R-HSA-5633007 | 2.296898e-06 | 5.639 | 0 | 0 |
| Kinesins | R-HSA-983189 | 2.289934e-06 | 5.640 | 0 | 0 |
| Apoptotic cleavage of cellular proteins | R-HSA-111465 | 3.021598e-06 | 5.520 | 0 | 0 |
| Gene expression (Transcription) | R-HSA-74160 | 4.687644e-06 | 5.329 | 0 | 0 |
| VEGFA-VEGFR2 Pathway | R-HSA-4420097 | 4.603505e-06 | 5.337 | 0 | 0 |
| Mitotic Anaphase | R-HSA-68882 | 6.125018e-06 | 5.213 | 0 | 0 |
| Cellular responses to stimuli | R-HSA-8953897 | 6.266791e-06 | 5.203 | 0 | 0 |
| Transport of Mature mRNA derived from an Intron-Containing Transcript | R-HSA-159236 | 6.978198e-06 | 5.156 | 0 | 0 |
| Mitotic Metaphase and Anaphase | R-HSA-2555396 | 6.939439e-06 | 5.159 | 0 | 0 |
| Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | R-HSA-8864260 | 7.283814e-06 | 5.138 | 0 | 0 |
| Activation of NMDA receptors and postsynaptic events | R-HSA-442755 | 7.607820e-06 | 5.119 | 0 | 0 |
| Cellular responses to stress | R-HSA-2262752 | 7.656860e-06 | 5.116 | 0 | 0 |
| FOXO-mediated transcription of cell cycle genes | R-HSA-9617828 | 9.597046e-06 | 5.018 | 0 | 0 |
| Factors involved in megakaryocyte development and platelet production | R-HSA-983231 | 1.116922e-05 | 4.952 | 0 | 0 |
| Formation of the beta-catenin:TCF transactivating complex | R-HSA-201722 | 1.161505e-05 | 4.935 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of growth factors and their receptors | R-HSA-8866910 | 1.219028e-05 | 4.914 | 0 | 0 |
| Recruitment of NuMA to mitotic centrosomes | R-HSA-380320 | 1.215320e-05 | 4.915 | 0 | 0 |
| Recycling pathway of L1 | R-HSA-437239 | 1.694224e-05 | 4.771 | 0 | 0 |
| HSF1-dependent transactivation | R-HSA-3371571 | 1.642452e-05 | 4.785 | 0 | 0 |
| RNA Polymerase II Transcription | R-HSA-73857 | 1.691637e-05 | 4.772 | 0 | 0 |
| Oxidative Stress Induced Senescence | R-HSA-2559580 | 1.789292e-05 | 4.747 | 0 | 0 |
| Transport of Mature Transcript to Cytoplasm | R-HSA-72202 | 1.850186e-05 | 4.733 | 0 | 0 |
| Estrogen-dependent gene expression | R-HSA-9018519 | 2.128476e-05 | 4.672 | 0 | 0 |
| ESR-mediated signaling | R-HSA-8939211 | 2.098100e-05 | 4.678 | 0 | 0 |
| Cellular response to heat stress | R-HSA-3371556 | 2.809917e-05 | 4.551 | 0 | 0 |
| Signaling by VEGF | R-HSA-194138 | 2.840161e-05 | 4.547 | 0 | 0 |
| Ephrin signaling | R-HSA-3928664 | 3.088319e-05 | 4.510 | 0 | 0 |
| DNA Damage/Telomere Stress Induced Senescence | R-HSA-2559586 | 3.001216e-05 | 4.523 | 0 | 0 |
| Mitotic G2-G2/M phases | R-HSA-453274 | 3.063214e-05 | 4.514 | 0 | 0 |
| Separation of Sister Chromatids | R-HSA-2467813 | 3.509938e-05 | 4.455 | 0 | 0 |
| Translocation of SLC2A4 (GLUT4) to the plasma membrane | R-HSA-1445148 | 4.704330e-05 | 4.328 | 0 | 0 |
| Attenuation phase | R-HSA-3371568 | 5.364234e-05 | 4.270 | 0 | 0 |
| NRAGE signals death through JNK | R-HSA-193648 | 5.570047e-05 | 4.254 | 0 | 0 |
| G2/M DNA damage checkpoint | R-HSA-69473 | 5.750146e-05 | 4.240 | 0 | 0 |
| Developmental Biology | R-HSA-1266738 | 5.943108e-05 | 4.226 | 0 | 0 |
| mRNA 3'-end processing | R-HSA-72187 | 6.006726e-05 | 4.221 | 0 | 0 |
| Intracellular signaling by second messengers | R-HSA-9006925 | 6.017597e-05 | 4.221 | 0 | 0 |
| RNA Polymerase II Transcription Termination | R-HSA-73856 | 6.385003e-05 | 4.195 | 0 | 0 |
| EPHB-mediated forward signaling | R-HSA-3928662 | 6.766616e-05 | 4.170 | 0 | 0 |
| RMTs methylate histone arginines | R-HSA-3214858 | 6.766616e-05 | 4.170 | 0 | 0 |
| PKMTs methylate histone lysines | R-HSA-3214841 | 7.035603e-05 | 4.153 | 0 | 0 |
| Transcriptional regulation of granulopoiesis | R-HSA-9616222 | 7.919467e-05 | 4.101 | 0 | 0 |
| G2/M Transition | R-HSA-69275 | 8.577553e-05 | 4.067 | 0 | 0 |
| Assembly and cell surface presentation of NMDA receptors | R-HSA-9609736 | 9.152587e-05 | 4.038 | 0 | 0 |
| Formation of tubulin folding intermediates by CCT/TriC | R-HSA-389960 | 1.171747e-04 | 3.931 | 0 | 0 |
| Generic Transcription Pathway | R-HSA-212436 | 1.157650e-04 | 3.936 | 0 | 0 |
| G alpha (12/13) signalling events | R-HSA-416482 | 1.234713e-04 | 3.908 | 0 | 0 |
| ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | R-HSA-427389 | 1.602612e-04 | 3.795 | 0 | 0 |
| Aggrephagy | R-HSA-9646399 | 1.602612e-04 | 3.795 | 0 | 0 |
| PI3K/AKT Signaling in Cancer | R-HSA-2219528 | 1.678000e-04 | 3.775 | 0 | 0 |
| COPI-dependent Golgi-to-ER retrograde traffic | R-HSA-6811434 | 1.672254e-04 | 3.777 | 0 | 0 |
| Activation of ATR in response to replication stress | R-HSA-176187 | 1.706679e-04 | 3.768 | 0 | 0 |
| AURKA Activation by TPX2 | R-HSA-8854518 | 1.788036e-04 | 3.748 | 0 | 0 |
| Oncogenic MAPK signaling | R-HSA-6802957 | 1.838576e-04 | 3.736 | 0 | 0 |
| Rap1 signalling | R-HSA-392517 | 1.890127e-04 | 3.724 | 0 | 0 |
| Meiotic synapsis | R-HSA-1221632 | 2.025856e-04 | 3.693 | 0 | 0 |
| Amplification of signal from the kinetochores | R-HSA-141424 | 2.177290e-04 | 3.662 | 0 | 0 |
| Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | R-HSA-141444 | 2.177290e-04 | 3.662 | 0 | 0 |
| RUNX3 regulates BCL2L11 (BIM) transcription | R-HSA-8952158 | 2.313622e-04 | 3.636 | 0 | 0 |
| Signaling by ALK fusions and activated point mutants | R-HSA-9725370 | 2.288858e-04 | 3.640 | 0 | 0 |
| Signaling by ALK in cancer | R-HSA-9700206 | 2.288858e-04 | 3.640 | 0 | 0 |
| L1CAM interactions | R-HSA-373760 | 2.585281e-04 | 3.587 | 0 | 0 |
| Processing of Capped Intron-Containing Pre-mRNA | R-HSA-72203 | 2.615185e-04 | 3.582 | 0 | 0 |
| Recruitment of mitotic centrosome proteins and complexes | R-HSA-380270 | 2.758143e-04 | 3.559 | 0 | 0 |
| FOXO-mediated transcription | R-HSA-9614085 | 2.661912e-04 | 3.575 | 0 | 0 |
| Regulation of endogenous retroelements by the Human Silencing Hub (HUSH) complex | R-HSA-9843970 | 2.944899e-04 | 3.531 | 0 | 0 |
| HDACs deacetylate histones | R-HSA-3214815 | 3.082090e-04 | 3.511 | 0 | 0 |
| G2/M Checkpoints | R-HSA-69481 | 3.236385e-04 | 3.490 | 0 | 0 |
| Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane | R-HSA-190840 | 3.441555e-04 | 3.463 | 0 | 0 |
| Centrosome maturation | R-HSA-380287 | 3.915299e-04 | 3.407 | 0 | 0 |
| Regulation of CDH1 Gene Transcription | R-HSA-9764560 | 3.766554e-04 | 3.424 | 0 | 0 |
| Nuclear Envelope (NE) Reassembly | R-HSA-2995410 | 4.027411e-04 | 3.395 | 0 | 0 |
| Meiosis | R-HSA-1500620 | 4.105680e-04 | 3.387 | 0 | 0 |
| Positive epigenetic regulation of rRNA expression | R-HSA-5250913 | 4.492640e-04 | 3.347 | 0 | 0 |
| Mitotic Prophase | R-HSA-68875 | 4.419870e-04 | 3.355 | 0 | 0 |
| Synthesis of PIPs at the plasma membrane | R-HSA-1660499 | 4.898336e-04 | 3.310 | 0 | 0 |
| FOXO-mediated transcription of cell death genes | R-HSA-9614657 | 4.956876e-04 | 3.305 | 0 | 0 |
| Transport of connexons to the plasma membrane | R-HSA-190872 | 4.956876e-04 | 3.305 | 0 | 0 |
| AKT phosphorylates targets in the cytosol | R-HSA-198323 | 5.097464e-04 | 3.293 | 0 | 0 |
| Regulation of MECP2 expression and activity | R-HSA-9022692 | 5.187096e-04 | 3.285 | 0 | 0 |
| Regulation of TP53 Activity through Phosphorylation | R-HSA-6804756 | 5.623440e-04 | 3.250 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in cell cycle and proliferation | R-HSA-9825892 | 5.339159e-04 | 3.273 | 0 | 0 |
| Loss of proteins required for interphase microtubule organization from the centrosome | R-HSA-380284 | 5.882847e-04 | 3.230 | 0 | 0 |
| Loss of Nlp from mitotic centrosomes | R-HSA-380259 | 5.882847e-04 | 3.230 | 0 | 0 |
| Semaphorin interactions | R-HSA-373755 | 5.882847e-04 | 3.230 | 0 | 0 |
| RUNX3 regulates WNT signaling | R-HSA-8951430 | 6.006402e-04 | 3.221 | 0 | 0 |
| Transcriptional regulation by RUNX1 | R-HSA-8878171 | 6.084415e-04 | 3.216 | 0 | 0 |
| Cell death signalling via NRAGE, NRIF and NADE | R-HSA-204998 | 6.320124e-04 | 3.199 | 0 | 0 |
| Mitotic Spindle Checkpoint | R-HSA-69618 | 6.412927e-04 | 3.193 | 0 | 0 |
| TP53 Regulates Transcription of DNA Repair Genes | R-HSA-6796648 | 6.448210e-04 | 3.191 | 0 | 0 |
| mRNA Splicing - Major Pathway | R-HSA-72163 | 6.486480e-04 | 3.188 | 0 | 0 |
| Signaling by Nuclear Receptors | R-HSA-9006931 | 7.930177e-04 | 3.101 | 0 | 0 |
| Formation of Senescence-Associated Heterochromatin Foci (SAHF) | R-HSA-2559584 | 7.786906e-04 | 3.109 | 0 | 0 |
| Muscle contraction | R-HSA-397014 | 7.975109e-04 | 3.098 | 0 | 0 |
| Transcriptional Regulation by TP53 | R-HSA-3700989 | 8.338710e-04 | 3.079 | 0 | 0 |
| Regulation of HSF1-mediated heat shock response | R-HSA-3371453 | 8.444327e-04 | 3.073 | 0 | 0 |
| Antiviral mechanism by IFN-stimulated genes | R-HSA-1169410 | 8.945715e-04 | 3.048 | 0 | 0 |
| Signaling by ROBO receptors | R-HSA-376176 | 8.978325e-04 | 3.047 | 0 | 0 |
| Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | R-HSA-389958 | 9.126925e-04 | 3.040 | 0 | 0 |
| Prefoldin mediated transfer of substrate to CCT/TriC | R-HSA-389957 | 9.809165e-04 | 3.008 | 0 | 0 |
| RNA Polymerase I Promoter Opening | R-HSA-73728 | 9.584294e-04 | 3.018 | 0 | 0 |
| Transcriptional Regulation by E2F6 | R-HSA-8953750 | 9.838656e-04 | 3.007 | 0 | 0 |
| RUNX3 regulates CDKN1A transcription | R-HSA-8941855 | 1.028975e-03 | 2.988 | 0 | 0 |
| Oncogene Induced Senescence | R-HSA-2559585 | 1.079037e-03 | 2.967 | 0 | 0 |
| HATs acetylate histones | R-HSA-3214847 | 1.129532e-03 | 2.947 | 0 | 0 |
| Apoptosis | R-HSA-109581 | 1.162143e-03 | 2.935 | 0 | 0 |
| Transcriptional Regulation by MECP2 | R-HSA-8986944 | 1.173992e-03 | 2.930 | 0 | 0 |
| Transcriptional regulation by small RNAs | R-HSA-5578749 | 1.191305e-03 | 2.924 | 0 | 0 |
| Activation of AMPK downstream of NMDARs | R-HSA-9619483 | 1.246741e-03 | 2.904 | 0 | 0 |
| PRC2 methylates histones and DNA | R-HSA-212300 | 1.353745e-03 | 2.868 | 0 | 0 |
| RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | R-HSA-8936459 | 1.381395e-03 | 2.860 | 0 | 0 |
| MITF-M-regulated melanocyte development | R-HSA-9730414 | 1.450411e-03 | 2.839 | 0 | 0 |
| CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | R-HSA-442742 | 1.483430e-03 | 2.829 | 0 | 0 |
| Sealing of the nuclear envelope (NE) by ESCRT-III | R-HSA-9668328 | 1.483430e-03 | 2.829 | 0 | 0 |
| HDR through Single Strand Annealing (SSA) | R-HSA-5685938 | 1.483430e-03 | 2.829 | 0 | 0 |
| Assembly of the ORC complex at the origin of replication | R-HSA-68616 | 1.483430e-03 | 2.829 | 0 | 0 |
| PIP3 activates AKT signaling | R-HSA-1257604 | 1.519911e-03 | 2.818 | 0 | 0 |
| Diseases of programmed cell death | R-HSA-9645723 | 1.577615e-03 | 2.802 | 0 | 0 |
| Impaired BRCA2 binding to RAD51 | R-HSA-9709570 | 1.603862e-03 | 2.795 | 0 | 0 |
| Transcriptional regulation by RUNX3 | R-HSA-8878159 | 1.720714e-03 | 2.764 | 0 | 0 |
| Regulation of PLK1 Activity at G2/M Transition | R-HSA-2565942 | 1.602135e-03 | 2.795 | 0 | 0 |
| Cytokine Signaling in Immune system | R-HSA-1280215 | 1.700991e-03 | 2.769 | 0 | 0 |
| Ras activation upon Ca2+ influx through NMDA receptor | R-HSA-442982 | 1.763210e-03 | 2.754 | 0 | 0 |
| mRNA Splicing | R-HSA-72172 | 1.793268e-03 | 2.746 | 0 | 0 |
| Striated Muscle Contraction | R-HSA-390522 | 1.865164e-03 | 2.729 | 0 | 0 |
| Transport of the SLBP Dependant Mature mRNA | R-HSA-159230 | 1.865164e-03 | 2.729 | 0 | 0 |
| Condensation of Prophase Chromosomes | R-HSA-2299718 | 1.978700e-03 | 2.704 | 0 | 0 |
| Anchoring of the basal body to the plasma membrane | R-HSA-5620912 | 2.070933e-03 | 2.684 | 0 | 0 |
| Ion homeostasis | R-HSA-5578775 | 2.142031e-03 | 2.669 | 0 | 0 |
| Metalloprotease DUBs | R-HSA-5689901 | 2.201774e-03 | 2.657 | 0 | 0 |
| Regulation of PD-L1(CD274) transcription | R-HSA-9909649 | 2.202264e-03 | 2.657 | 0 | 0 |
| p75 NTR receptor-mediated signalling | R-HSA-193704 | 2.219612e-03 | 2.654 | 0 | 0 |
| Developmental Lineage of Mammary Stem Cells | R-HSA-9938206 | 2.325421e-03 | 2.633 | 0 | 0 |
| Senescence-Associated Secretory Phenotype (SASP) | R-HSA-2559582 | 2.480986e-03 | 2.605 | 0 | 0 |
| Regulation of TP53 Expression and Degradation | R-HSA-6806003 | 2.551684e-03 | 2.593 | 0 | 0 |
| Interleukin-4 and Interleukin-13 signaling | R-HSA-6785807 | 2.576885e-03 | 2.589 | 0 | 0 |
| Epigenetic regulation by WDR5-containing histone modifying complexes | R-HSA-9917777 | 2.750295e-03 | 2.561 | 0 | 0 |
| Packaging Of Telomere Ends | R-HSA-171306 | 2.813947e-03 | 2.551 | 0 | 0 |
| Presynaptic phase of homologous DNA pairing and strand exchange | R-HSA-5693616 | 2.874537e-03 | 2.541 | 0 | 0 |
| B-WICH complex positively regulates rRNA expression | R-HSA-5250924 | 2.932917e-03 | 2.533 | 0 | 0 |
| Inhibition of DNA recombination at telomere | R-HSA-9670095 | 3.107063e-03 | 2.508 | 0 | 0 |
| MECP2 regulates transcription factors | R-HSA-9022707 | 3.111336e-03 | 2.507 | 0 | 0 |
| Post-chaperonin tubulin folding pathway | R-HSA-389977 | 3.173005e-03 | 2.499 | 0 | 0 |
| TCF dependent signaling in response to WNT | R-HSA-201681 | 3.189878e-03 | 2.496 | 0 | 0 |
| Regulation of TP53 Degradation | R-HSA-6804757 | 3.526341e-03 | 2.453 | 0 | 0 |
| HSF1 activation | R-HSA-3371511 | 3.526341e-03 | 2.453 | 0 | 0 |
| Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | R-HSA-5693565 | 3.491064e-03 | 2.457 | 0 | 0 |
| Neurotransmitter receptors and postsynaptic signal transmission | R-HSA-112314 | 3.492598e-03 | 2.457 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected purine | R-HSA-110330 | 3.213945e-03 | 2.493 | 0 | 0 |
| MITF-M-dependent gene expression | R-HSA-9856651 | 3.210381e-03 | 2.493 | 0 | 0 |
| Ub-specific processing proteases | R-HSA-5689880 | 3.620981e-03 | 2.441 | 0 | 0 |
| VEGFR2 mediated vascular permeability | R-HSA-5218920 | 3.758185e-03 | 2.425 | 0 | 0 |
| Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | R-HSA-5625886 | 3.758185e-03 | 2.425 | 0 | 0 |
| Transcriptional Regulation by VENTX | R-HSA-8853884 | 3.758185e-03 | 2.425 | 0 | 0 |
| CD209 (DC-SIGN) signaling | R-HSA-5621575 | 3.883743e-03 | 2.411 | 0 | 0 |
| DAG and IP3 signaling | R-HSA-1489509 | 3.919015e-03 | 2.407 | 0 | 0 |
| Regulation of localization of FOXO transcription factors | R-HSA-9614399 | 3.943429e-03 | 2.404 | 0 | 0 |
| Transport of the SLBP independent Mature mRNA | R-HSA-159227 | 3.978104e-03 | 2.400 | 0 | 0 |
| Signaling by BRAF and RAF1 fusions | R-HSA-6802952 | 4.045323e-03 | 2.393 | 0 | 0 |
| Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | R-HSA-8950505 | 4.045323e-03 | 2.393 | 0 | 0 |
| Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs) | R-HSA-9845323 | 4.073789e-03 | 2.390 | 0 | 0 |
| Signaling by ERBB2 | R-HSA-1227986 | 4.073789e-03 | 2.390 | 0 | 0 |
| Negative Regulation of CDH1 Gene Transcription | R-HSA-9764725 | 4.073789e-03 | 2.390 | 0 | 0 |
| DNA Double-Strand Break Repair | R-HSA-5693532 | 4.251135e-03 | 2.371 | 0 | 0 |
| DNA methylation | R-HSA-5334118 | 4.451735e-03 | 2.351 | 0 | 0 |
| Developmental Lineage of Mammary Gland Myoepithelial Cells | R-HSA-9927432 | 4.451735e-03 | 2.351 | 0 | 0 |
| Platelet calcium homeostasis | R-HSA-418360 | 4.451735e-03 | 2.351 | 0 | 0 |
| Meiotic recombination | R-HSA-912446 | 4.736677e-03 | 2.325 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescence | R-HSA-9825895 | 4.909963e-03 | 2.309 | 0 | 0 |
| Apoptotic cleavage of cell adhesion proteins | R-HSA-351906 | 4.909963e-03 | 2.309 | 0 | 0 |
| Programmed Cell Death | R-HSA-5357801 | 5.051340e-03 | 2.297 | 0 | 0 |
| Homologous DNA Pairing and Strand Exchange | R-HSA-5693579 | 5.191564e-03 | 2.285 | 0 | 0 |
| Activation of RAC1 | R-HSA-428540 | 5.682444e-03 | 2.245 | 0 | 0 |
| Reproduction | R-HSA-1474165 | 5.764741e-03 | 2.239 | 0 | 0 |
| SARS-CoV-1 targets host intracellular signalling and regulatory pathways | R-HSA-9735871 | 5.873674e-03 | 2.231 | 0 | 0 |
| PI Metabolism | R-HSA-1483255 | 5.930050e-03 | 2.227 | 0 | 0 |
| Diseases of DNA Double-Strand Break Repair | R-HSA-9675136 | 5.945587e-03 | 2.226 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA2 loss of function | R-HSA-9701190 | 5.945587e-03 | 2.226 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected pyrimidine | R-HSA-110328 | 5.945587e-03 | 2.226 | 0 | 0 |
| Deubiquitination | R-HSA-5688426 | 6.078122e-03 | 2.216 | 0 | 0 |
| Selective autophagy | R-HSA-9663891 | 6.092487e-03 | 2.215 | 0 | 0 |
| MECP2 regulates neuronal receptors and channels | R-HSA-9022699 | 6.180728e-03 | 2.209 | 0 | 0 |
| TRP channels | R-HSA-3295583 | 6.180728e-03 | 2.209 | 0 | 0 |
| Nonhomologous End-Joining (NHEJ) | R-HSA-5693571 | 6.485434e-03 | 2.188 | 0 | 0 |
| AKT phosphorylates targets in the nucleus | R-HSA-198693 | 7.374721e-03 | 2.132 | 0 | 0 |
| Epigenetic regulation of gene expression | R-HSA-212165 | 6.616176e-03 | 2.179 | 0 | 0 |
| Golgi-to-ER retrograde transport | R-HSA-8856688 | 6.967447e-03 | 2.157 | 0 | 0 |
| Caspase-mediated cleavage of cytoskeletal proteins | R-HSA-264870 | 7.374721e-03 | 2.132 | 0 | 0 |
| Maternal to zygotic transition (MZT) | R-HSA-9816359 | 7.159305e-03 | 2.145 | 0 | 0 |
| Germ layer formation at gastrulation | R-HSA-9754189 | 7.434514e-03 | 2.129 | 0 | 0 |
| Transport of Mature mRNAs Derived from Intronless Transcripts | R-HSA-159234 | 7.438721e-03 | 2.129 | 0 | 0 |
| PKR-mediated signaling | R-HSA-9833482 | 7.475710e-03 | 2.126 | 0 | 0 |
| Defective Intrinsic Pathway for Apoptosis | R-HSA-9734009 | 7.671910e-03 | 2.115 | 0 | 0 |
| RUNX3 regulates p14-ARF | R-HSA-8951936 | 7.939473e-03 | 2.100 | 0 | 0 |
| Constitutive Signaling by Overexpressed ERBB2 | R-HSA-9634285 | 7.939473e-03 | 2.100 | 0 | 0 |
| Regulation of endogenous retroelements by KRAB-ZFP proteins | R-HSA-9843940 | 8.058596e-03 | 2.094 | 0 | 0 |
| Processing of DNA double-strand break ends | R-HSA-5693607 | 8.437886e-03 | 2.074 | 0 | 0 |
| Calmodulin induced events | R-HSA-111933 | 8.620579e-03 | 2.064 | 0 | 0 |
| CaM pathway | R-HSA-111997 | 8.620579e-03 | 2.064 | 0 | 0 |
| Chromatin modifications during the maternal to zygotic transition (MZT) | R-HSA-9821002 | 8.820719e-03 | 2.054 | 0 | 0 |
| Deposition of new CENPA-containing nucleosomes at the centromere | R-HSA-606279 | 8.886637e-03 | 2.051 | 0 | 0 |
| Nucleosome assembly | R-HSA-774815 | 8.886637e-03 | 2.051 | 0 | 0 |
| Cilium Assembly | R-HSA-5617833 | 8.986475e-03 | 2.046 | 0 | 0 |
| Cell-Cell communication | R-HSA-1500931 | 9.051510e-03 | 2.043 | 0 | 0 |
| Sema4D induced cell migration and growth-cone collapse | R-HSA-416572 | 9.520277e-03 | 2.021 | 0 | 0 |
| Integrin signaling | R-HSA-354192 | 9.965620e-03 | 2.001 | 0 | 0 |
| Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes | R-HSA-9851695 | 9.506698e-03 | 2.022 | 0 | 0 |
| MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis | R-HSA-9841922 | 9.506698e-03 | 2.022 | 0 | 0 |
| Epigenetic regulation of gene expression by MLL3 and MLL4 complexes | R-HSA-9818564 | 9.506698e-03 | 2.022 | 0 | 0 |
| Developmental Lineages of the Mammary Gland | R-HSA-9924644 | 1.037558e-02 | 1.984 | 0 | 0 |
| Regulation of Expression and Function of Type I Classical Cadherins | R-HSA-9764274 | 9.459693e-03 | 2.024 | 0 | 0 |
| Regulation of CDH1 Expression and Function | R-HSA-9764265 | 9.459693e-03 | 2.024 | 0 | 0 |
| MAPK family signaling cascades | R-HSA-5683057 | 9.120012e-03 | 2.040 | 0 | 0 |
| Cleavage of the damaged purine | R-HSA-110331 | 1.027207e-02 | 1.988 | 0 | 0 |
| Signaling by Interleukins | R-HSA-449147 | 9.363109e-03 | 2.029 | 0 | 0 |
| Signaling by RAS mutants | R-HSA-6802949 | 1.038320e-02 | 1.984 | 0 | 0 |
| Paradoxical activation of RAF signaling by kinase inactive BRAF | R-HSA-6802955 | 1.038320e-02 | 1.984 | 0 | 0 |
| Signaling by moderate kinase activity BRAF mutants | R-HSA-6802946 | 1.038320e-02 | 1.984 | 0 | 0 |
| Signaling downstream of RAS mutants | R-HSA-9649948 | 1.038320e-02 | 1.984 | 0 | 0 |
| Transcriptional activation of p53 responsive genes | R-HSA-69560 | 1.050159e-02 | 1.979 | 0 | 0 |
| Transcriptional activation of cell cycle inhibitor p21 | R-HSA-69895 | 1.050159e-02 | 1.979 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of cell cycle factors | R-HSA-8866911 | 1.050159e-02 | 1.979 | 0 | 0 |
| NFE2L2 regulating ER-stress associated genes | R-HSA-9818035 | 1.050159e-02 | 1.979 | 0 | 0 |
| Neuronal System | R-HSA-112316 | 1.056419e-02 | 1.976 | 0 | 0 |
| CaMK IV-mediated phosphorylation of CREB | R-HSA-111932 | 1.062720e-02 | 1.974 | 0 | 0 |
| Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RNA | R-HSA-428359 | 1.062720e-02 | 1.974 | 0 | 0 |
| Regulation of endogenous retroelements | R-HSA-9842860 | 1.063898e-02 | 1.973 | 0 | 0 |
| DNA Double Strand Break Response | R-HSA-5693606 | 1.079612e-02 | 1.967 | 0 | 0 |
| Gene Silencing by RNA | R-HSA-211000 | 1.107953e-02 | 1.955 | 0 | 0 |
| The role of GTSE1 in G2/M progression after G2 checkpoint | R-HSA-8852276 | 1.119144e-02 | 1.951 | 0 | 0 |
| Nuclear Envelope Breakdown | R-HSA-2980766 | 1.154809e-02 | 1.937 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of HSCs | R-HSA-8939236 | 1.194209e-02 | 1.923 | 0 | 0 |
| Depurination | R-HSA-73927 | 1.216003e-02 | 1.915 | 0 | 0 |
| L13a-mediated translational silencing of Ceruloplasmin expression | R-HSA-156827 | 1.221493e-02 | 1.913 | 0 | 0 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | R-HSA-72706 | 1.221493e-02 | 1.913 | 0 | 0 |
| HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand | R-HSA-3371497 | 1.223807e-02 | 1.912 | 0 | 0 |
| S Phase | R-HSA-69242 | 1.226734e-02 | 1.911 | 0 | 0 |
| Death Receptor Signaling | R-HSA-73887 | 1.242000e-02 | 1.906 | 0 | 0 |
| HDMs demethylate histones | R-HSA-3214842 | 1.316136e-02 | 1.881 | 0 | 0 |
| Sema4D in semaphorin signaling | R-HSA-400685 | 1.316136e-02 | 1.881 | 0 | 0 |
| Long-term potentiation | R-HSA-9620244 | 1.316136e-02 | 1.881 | 0 | 0 |
| SHC1 events in ERBB2 signaling | R-HSA-1250196 | 1.385710e-02 | 1.858 | 0 | 0 |
| Binding of TCF/LEF:CTNNB1 to target gene promoters | R-HSA-4411364 | 1.394368e-02 | 1.856 | 0 | 0 |
| Co-stimulation by CD28 | R-HSA-389356 | 1.396631e-02 | 1.855 | 0 | 0 |
| Unblocking of NMDA receptors, glutamate binding and activation | R-HSA-438066 | 1.497837e-02 | 1.825 | 0 | 0 |
| Transport of Mature mRNA Derived from an Intronless Transcript | R-HSA-159231 | 1.430527e-02 | 1.845 | 0 | 0 |
| Translation initiation complex formation | R-HSA-72649 | 1.559646e-02 | 1.807 | 0 | 0 |
| Netrin-1 signaling | R-HSA-373752 | 1.647525e-02 | 1.783 | 0 | 0 |
| Hedgehog 'off' state | R-HSA-5610787 | 1.524027e-02 | 1.817 | 0 | 0 |
| Nuclear import of Rev protein | R-HSA-180746 | 1.421051e-02 | 1.847 | 0 | 0 |
| Defective pyroptosis | R-HSA-9710421 | 1.420696e-02 | 1.847 | 0 | 0 |
| Interleukin-12 signaling | R-HSA-9020591 | 1.659693e-02 | 1.780 | 0 | 0 |
| Signaling by ERBB2 ECD mutants | R-HSA-9665348 | 1.685692e-02 | 1.773 | 0 | 0 |
| Chaperone Mediated Autophagy | R-HSA-9613829 | 1.685692e-02 | 1.773 | 0 | 0 |
| RUNX2 regulates chondrocyte maturation | R-HSA-8941284 | 1.746992e-02 | 1.758 | 0 | 0 |
| Regulation of MITF-M dependent genes involved in invasion | R-HSA-9854909 | 1.746992e-02 | 1.758 | 0 | 0 |
| Cargo trafficking to the periciliary membrane | R-HSA-5620920 | 1.749503e-02 | 1.757 | 0 | 0 |
| Sema3A PAK dependent Axon repulsion | R-HSA-399954 | 1.863134e-02 | 1.730 | 0 | 0 |
| Signaling by WNT | R-HSA-195721 | 1.880965e-02 | 1.726 | 0 | 0 |
| Drug resistance in ERBB2 KD mutants | R-HSA-9665230 | 1.907920e-02 | 1.719 | 0 | 0 |
| Drug-mediated inhibition of ERBB2 signaling | R-HSA-9652282 | 1.907920e-02 | 1.719 | 0 | 0 |
| Resistance of ERBB2 KD mutants to AEE788 | R-HSA-9665250 | 1.907920e-02 | 1.719 | 0 | 0 |
| Resistance of ERBB2 KD mutants to sapitinib | R-HSA-9665244 | 1.907920e-02 | 1.719 | 0 | 0 |
| Resistance of ERBB2 KD mutants to tesevatinib | R-HSA-9665245 | 1.907920e-02 | 1.719 | 0 | 0 |
| Resistance of ERBB2 KD mutants to neratinib | R-HSA-9665246 | 1.907920e-02 | 1.719 | 0 | 0 |
| Resistance of ERBB2 KD mutants to osimertinib | R-HSA-9665247 | 1.907920e-02 | 1.719 | 0 | 0 |
| Resistance of ERBB2 KD mutants to afatinib | R-HSA-9665249 | 1.907920e-02 | 1.719 | 0 | 0 |
| Resistance of ERBB2 KD mutants to lapatinib | R-HSA-9665251 | 1.907920e-02 | 1.719 | 0 | 0 |
| Resistance of ERBB2 KD mutants to trastuzumab | R-HSA-9665233 | 1.907920e-02 | 1.719 | 0 | 0 |
| Drug resistance in ERBB2 TMD/JMD mutants | R-HSA-9665737 | 1.907920e-02 | 1.719 | 0 | 0 |
| PLC beta mediated events | R-HSA-112043 | 1.931158e-02 | 1.714 | 0 | 0 |
| FLT3 Signaling | R-HSA-9607240 | 1.945138e-02 | 1.711 | 0 | 0 |
| Diseases of mitotic cell cycle | R-HSA-9675126 | 1.970027e-02 | 1.706 | 0 | 0 |
| RET signaling | R-HSA-8853659 | 1.970722e-02 | 1.705 | 0 | 0 |
| Reduction of cytosolic Ca++ levels | R-HSA-418359 | 1.995331e-02 | 1.700 | 0 | 0 |
| Signaling by AXIN mutants | R-HSA-4839735 | 1.995331e-02 | 1.700 | 0 | 0 |
| Signaling by GSK3beta mutants | R-HSA-5339716 | 1.995331e-02 | 1.700 | 0 | 0 |
| MHC class II antigen presentation | R-HSA-2132295 | 2.006555e-02 | 1.698 | 0 | 0 |
| ROBO receptors bind AKAP5 | R-HSA-9010642 | 2.009053e-02 | 1.697 | 0 | 0 |
| Ribosomal scanning and start codon recognition | R-HSA-72702 | 2.020156e-02 | 1.695 | 0 | 0 |
| RNA Polymerase I Transcription | R-HSA-73864 | 2.064460e-02 | 1.685 | 0 | 0 |
| G-protein mediated events | R-HSA-112040 | 2.067182e-02 | 1.685 | 0 | 0 |
| Assembly of the pre-replicative complex | R-HSA-68867 | 2.099760e-02 | 1.678 | 0 | 0 |
| Homology Directed Repair | R-HSA-5693538 | 2.149663e-02 | 1.668 | 0 | 0 |
| Response of EIF2AK4 (GCN2) to amino acid deficiency | R-HSA-9633012 | 2.216892e-02 | 1.654 | 0 | 0 |
| Estrogen-dependent nuclear events downstream of ESR-membrane signaling | R-HSA-9634638 | 2.245029e-02 | 1.649 | 0 | 0 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | R-HSA-72662 | 2.577526e-02 | 1.589 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest | R-HSA-6804116 | 2.375809e-02 | 1.624 | 0 | 0 |
| Regulation of TP53 Activity through Acetylation | R-HSA-6804758 | 2.322499e-02 | 1.634 | 0 | 0 |
| TP53 Regulates Transcription of Cell Cycle Genes | R-HSA-6791312 | 2.286045e-02 | 1.641 | 0 | 0 |
| RAF/MAP kinase cascade | R-HSA-5673001 | 2.269473e-02 | 1.644 | 0 | 0 |
| Response of endothelial cells to shear stress | R-HSA-9860931 | 2.216892e-02 | 1.654 | 0 | 0 |
| Signaling by TGFBR3 | R-HSA-9839373 | 2.182945e-02 | 1.661 | 0 | 0 |
| SIRT1 negatively regulates rRNA expression | R-HSA-427359 | 2.298595e-02 | 1.639 | 0 | 0 |
| Ca-dependent events | R-HSA-111996 | 2.587643e-02 | 1.587 | 0 | 0 |
| Base Excision Repair | R-HSA-73884 | 2.466371e-02 | 1.608 | 0 | 0 |
| Diseases of DNA repair | R-HSA-9675135 | 2.182945e-02 | 1.661 | 0 | 0 |
| Cleavage of the damaged pyrimidine | R-HSA-110329 | 2.587643e-02 | 1.587 | 0 | 0 |
| Depyrimidination | R-HSA-73928 | 2.587643e-02 | 1.587 | 0 | 0 |
| Transmission across Chemical Synapses | R-HSA-112315 | 2.588605e-02 | 1.587 | 0 | 0 |
| Glycolysis | R-HSA-70171 | 2.594697e-02 | 1.586 | 0 | 0 |
| Regulation of FOXO transcriptional activity by acetylation | R-HSA-9617629 | 2.623029e-02 | 1.581 | 0 | 0 |
| Signaling by CTNNB1 phospho-site mutants | R-HSA-4839743 | 2.623029e-02 | 1.581 | 0 | 0 |
| CTNNB1 S33 mutants aren't phosphorylated | R-HSA-5358747 | 2.623029e-02 | 1.581 | 0 | 0 |
| CTNNB1 S45 mutants aren't phosphorylated | R-HSA-5358751 | 2.623029e-02 | 1.581 | 0 | 0 |
| CTNNB1 S37 mutants aren't phosphorylated | R-HSA-5358749 | 2.623029e-02 | 1.581 | 0 | 0 |
| CTNNB1 T41 mutants aren't phosphorylated | R-HSA-5358752 | 2.623029e-02 | 1.581 | 0 | 0 |
| Signaling by LTK | R-HSA-9842663 | 2.623029e-02 | 1.581 | 0 | 0 |
| Transcriptional regulation of pluripotent stem cells | R-HSA-452723 | 2.664975e-02 | 1.574 | 0 | 0 |
| Rev-mediated nuclear export of HIV RNA | R-HSA-165054 | 2.664975e-02 | 1.574 | 0 | 0 |
| Regulation of cytoskeletal remodeling and cell spreading by IPP complex components | R-HSA-446388 | 2.677737e-02 | 1.572 | 0 | 0 |
| PKA-mediated phosphorylation of key metabolic factors | R-HSA-163358 | 2.677737e-02 | 1.572 | 0 | 0 |
| Signaling by MAPK mutants | R-HSA-9652817 | 2.677737e-02 | 1.572 | 0 | 0 |
| Neurodegenerative Diseases | R-HSA-8863678 | 2.704765e-02 | 1.568 | 0 | 0 |
| Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models | R-HSA-8862803 | 2.704765e-02 | 1.568 | 0 | 0 |
| Pre-NOTCH Transcription and Translation | R-HSA-1912408 | 2.711216e-02 | 1.567 | 0 | 0 |
| Chromosome Maintenance | R-HSA-73886 | 2.747531e-02 | 1.561 | 0 | 0 |
| ALK mutants bind TKIs | R-HSA-9700645 | 2.778408e-02 | 1.556 | 0 | 0 |
| Extra-nuclear estrogen signaling | R-HSA-9009391 | 2.834225e-02 | 1.548 | 0 | 0 |
| Nonsense-Mediated Decay (NMD) | R-HSA-927802 | 2.919092e-02 | 1.535 | 0 | 0 |
| Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | R-HSA-975957 | 2.919092e-02 | 1.535 | 0 | 0 |
| Eukaryotic Translation Initiation | R-HSA-72613 | 2.949506e-02 | 1.530 | 0 | 0 |
| Cap-dependent Translation Initiation | R-HSA-72737 | 2.949506e-02 | 1.530 | 0 | 0 |
| Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | R-HSA-975956 | 2.974131e-02 | 1.527 | 0 | 0 |
| RNA Polymerase I Promoter Clearance | R-HSA-73854 | 2.996176e-02 | 1.523 | 0 | 0 |
| Metabolism of RNA | R-HSA-8953854 | 3.050529e-02 | 1.516 | 0 | 0 |
| HCMV Early Events | R-HSA-9609690 | 3.066543e-02 | 1.513 | 0 | 0 |
| Regulation of Homotypic Cell-Cell Adhesion | R-HSA-9759476 | 3.066543e-02 | 1.513 | 0 | 0 |
| RAF activation | R-HSA-5673000 | 3.161822e-02 | 1.500 | 0 | 0 |
| Gap junction assembly | R-HSA-190861 | 3.161822e-02 | 1.500 | 0 | 0 |
| Gap junction trafficking and regulation | R-HSA-157858 | 3.216938e-02 | 1.493 | 0 | 0 |
| Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) | R-HSA-5619107 | 3.219236e-02 | 1.492 | 0 | 0 |
| Activation of BH3-only proteins | R-HSA-114452 | 3.219236e-02 | 1.492 | 0 | 0 |
| TGFBR3 expression | R-HSA-9839394 | 3.227087e-02 | 1.491 | 0 | 0 |
| VEGFR2 mediated cell proliferation | R-HSA-5218921 | 3.227087e-02 | 1.491 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere | R-HSA-9670621 | 3.228776e-02 | 1.491 | 0 | 0 |
| Diseases of Telomere Maintenance | R-HSA-9673013 | 3.228776e-02 | 1.491 | 0 | 0 |
| Alternative Lengthening of Telomeres (ALT) | R-HSA-9006821 | 3.228776e-02 | 1.491 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to DAXX Mutations | R-HSA-9670613 | 3.228776e-02 | 1.491 | 0 | 0 |
| Loss of MECP2 binding ability to 5hmC-DNA | R-HSA-9022534 | 3.228776e-02 | 1.491 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to ATRX Mutations | R-HSA-9670615 | 3.228776e-02 | 1.491 | 0 | 0 |
| MAPK1/MAPK3 signaling | R-HSA-5684996 | 3.253183e-02 | 1.488 | 0 | 0 |
| Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects | R-HSA-9659787 | 3.369550e-02 | 1.472 | 0 | 0 |
| Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) | R-HSA-9661069 | 3.369550e-02 | 1.472 | 0 | 0 |
| Cell junction organization | R-HSA-446728 | 3.412981e-02 | 1.467 | 0 | 0 |
| HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | R-HSA-5693567 | 3.430710e-02 | 1.465 | 0 | 0 |
| Autophagy | R-HSA-9612973 | 3.437942e-02 | 1.464 | 0 | 0 |
| Interactions of Rev with host cellular proteins | R-HSA-177243 | 3.522144e-02 | 1.453 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in WNT signaling | R-HSA-8939256 | 3.856152e-02 | 1.414 | 0 | 0 |
| RAS signaling downstream of NF1 loss-of-function variants | R-HSA-6802953 | 3.856152e-02 | 1.414 | 0 | 0 |
| Signaling by EGFRvIII in Cancer | R-HSA-5637812 | 3.675235e-02 | 1.435 | 0 | 0 |
| Constitutive Signaling by EGFRvIII | R-HSA-5637810 | 3.675235e-02 | 1.435 | 0 | 0 |
| IP3 and IP4 transport between cytosol and nucleus | R-HSA-1855196 | 3.757265e-02 | 1.425 | 0 | 0 |
| IP6 and IP7 transport between cytosol and nucleus | R-HSA-1855229 | 3.757265e-02 | 1.425 | 0 | 0 |
| Mitotic G1 phase and G1/S transition | R-HSA-453279 | 3.970402e-02 | 1.401 | 0 | 0 |
| Regulation of NFE2L2 gene expression | R-HSA-9818749 | 3.856152e-02 | 1.414 | 0 | 0 |
| DNA Replication Pre-Initiation | R-HSA-69002 | 3.686947e-02 | 1.433 | 0 | 0 |
| Signaling by Hippo | R-HSA-2028269 | 3.675235e-02 | 1.435 | 0 | 0 |
| Signaling by Receptor Tyrosine Kinases | R-HSA-9006934 | 4.217222e-02 | 1.375 | 0 | 0 |
| Macroautophagy | R-HSA-1632852 | 3.989542e-02 | 1.399 | 0 | 0 |
| Positive Regulation of CDH1 Gene Transcription | R-HSA-9764790 | 3.712650e-02 | 1.430 | 0 | 0 |
| M-decay: degradation of maternal mRNAs by maternally stored factors | R-HSA-9820841 | 4.017058e-02 | 1.396 | 0 | 0 |
| Signaling by PTK6 | R-HSA-8848021 | 4.464400e-02 | 1.350 | 0 | 0 |
| Signaling by Non-Receptor Tyrosine Kinases | R-HSA-9006927 | 4.464400e-02 | 1.350 | 0 | 0 |
| Negative regulation of NMDA receptor-mediated neuronal transmission | R-HSA-9617324 | 3.801847e-02 | 1.420 | 0 | 0 |
| Hemostasis | R-HSA-109582 | 3.997641e-02 | 1.398 | 0 | 0 |
| Apoptosis induced DNA fragmentation | R-HSA-140342 | 3.712650e-02 | 1.430 | 0 | 0 |
| Signaling by cytosolic FGFR1 fusion mutants | R-HSA-1839117 | 4.472186e-02 | 1.349 | 0 | 0 |
| CD28 dependent PI3K/Akt signaling | R-HSA-389357 | 4.472815e-02 | 1.349 | 0 | 0 |
| Signaling by NTRK2 (TRKB) | R-HSA-9006115 | 4.472815e-02 | 1.349 | 0 | 0 |
| Signaling by RAF1 mutants | R-HSA-9656223 | 4.558683e-02 | 1.341 | 0 | 0 |
| Signaling by FGFR1 in disease | R-HSA-5655302 | 4.558683e-02 | 1.341 | 0 | 0 |
| Negative regulation of MAPK pathway | R-HSA-5675221 | 4.558683e-02 | 1.341 | 0 | 0 |
| RNA Polymerase I Promoter Escape | R-HSA-73772 | 4.567351e-02 | 1.340 | 0 | 0 |
| Developmental Lineage of Pancreatic Ductal Cells | R-HSA-9925563 | 4.606399e-02 | 1.337 | 0 | 0 |
| ISG15 antiviral mechanism | R-HSA-1169408 | 4.720897e-02 | 1.326 | 0 | 0 |
| Signaling by high-kinase activity BRAF mutants | R-HSA-6802948 | 4.793369e-02 | 1.319 | 0 | 0 |
| Deactivation of the beta-catenin transactivating complex | R-HSA-3769402 | 4.793369e-02 | 1.319 | 0 | 0 |
| ChREBP activates metabolic gene expression | R-HSA-163765 | 4.818430e-02 | 1.317 | 0 | 0 |
| Signaling by APC mutants | R-HSA-4839744 | 4.818430e-02 | 1.317 | 0 | 0 |
| Truncations of AMER1 destabilize the destruction complex | R-HSA-5467348 | 4.818430e-02 | 1.317 | 0 | 0 |
| AXIN missense mutants destabilize the destruction complex | R-HSA-5467340 | 4.818430e-02 | 1.317 | 0 | 0 |
| APC truncation mutants have impaired AXIN binding | R-HSA-5467337 | 4.818430e-02 | 1.317 | 0 | 0 |
| Signaling by Hedgehog | R-HSA-5358351 | 4.907025e-02 | 1.309 | 0 | 0 |
| IPs transport between nucleus and cytosol | R-HSA-1855170 | 5.012893e-02 | 1.300 | 0 | 0 |
| Platelet activation, signaling and aggregation | R-HSA-76002 | 5.213161e-02 | 1.283 | 0 | 0 |
| DCC mediated attractive signaling | R-HSA-418885 | 5.242565e-02 | 1.280 | 0 | 0 |
| Beta-catenin phosphorylation cascade | R-HSA-196299 | 5.242565e-02 | 1.280 | 0 | 0 |
| Cell-extracellular matrix interactions | R-HSA-446353 | 5.242565e-02 | 1.280 | 0 | 0 |
| SOS-mediated signalling | R-HSA-112412 | 5.287286e-02 | 1.277 | 0 | 0 |
| Metabolism of non-coding RNA | R-HSA-194441 | 5.287853e-02 | 1.277 | 0 | 0 |
| snRNP Assembly | R-HSA-191859 | 5.287853e-02 | 1.277 | 0 | 0 |
| Interleukin-12 family signaling | R-HSA-447115 | 5.312358e-02 | 1.275 | 0 | 0 |
| The NLRP3 inflammasome | R-HSA-844456 | 5.372347e-02 | 1.270 | 0 | 0 |
| Telomere Maintenance | R-HSA-157579 | 5.380617e-02 | 1.269 | 0 | 0 |
| Cellular responses to mechanical stimuli | R-HSA-9855142 | 5.387506e-02 | 1.269 | 0 | 0 |
| Developmental Cell Lineages of the Integumentary System | R-HSA-9734779 | 5.395636e-02 | 1.268 | 0 | 0 |
| Transcriptional and post-translational regulation of MITF-M expression and activity | R-HSA-9856649 | 5.561935e-02 | 1.255 | 0 | 0 |
| Base-Excision Repair, AP Site Formation | R-HSA-73929 | 5.662375e-02 | 1.247 | 0 | 0 |
| Effects of PIP2 hydrolysis | R-HSA-114508 | 5.734659e-02 | 1.241 | 0 | 0 |
| Regulation of Glucokinase by Glucokinase Regulatory Protein | R-HSA-170822 | 5.734659e-02 | 1.241 | 0 | 0 |
| Major pathway of rRNA processing in the nucleolus and cytosol | R-HSA-6791226 | 5.935552e-02 | 1.227 | 0 | 0 |
| Regulation of gene expression in beta cells | R-HSA-210745 | 6.004432e-02 | 1.222 | 0 | 0 |
| Mitotic Telophase/Cytokinesis | R-HSA-68884 | 6.098810e-02 | 1.215 | 0 | 0 |
| Signaling by AMER1 mutants | R-HSA-4839748 | 6.098810e-02 | 1.215 | 0 | 0 |
| G1/S Transition | R-HSA-69206 | 6.119544e-02 | 1.213 | 0 | 0 |
| Expression of BMAL (ARNTL), CLOCK, and NPAS2 | R-HSA-9931509 | 6.152869e-02 | 1.211 | 0 | 0 |
| NS1 Mediated Effects on Host Pathways | R-HSA-168276 | 6.152869e-02 | 1.211 | 0 | 0 |
| Regulation of glycolysis by fructose 2,6-bisphosphate metabolism | R-HSA-9634600 | 6.376154e-02 | 1.195 | 0 | 0 |
| Transcription of E2F targets under negative control by DREAM complex | R-HSA-1362277 | 6.378095e-02 | 1.195 | 0 | 0 |
| Nephrin family interactions | R-HSA-373753 | 6.378095e-02 | 1.195 | 0 | 0 |
| Breakdown of the nuclear lamina | R-HSA-352238 | 6.639234e-02 | 1.178 | 0 | 0 |
| Abasic sugar-phosphate removal via the single-nucleotide replacement pathway | R-HSA-73930 | 6.639234e-02 | 1.178 | 0 | 0 |
| TGFBR3 regulates FGF2 signaling | R-HSA-9839397 | 6.639234e-02 | 1.178 | 0 | 0 |
| Transport of glycerol from adipocytes to the liver by Aquaporins | R-HSA-432030 | 6.639234e-02 | 1.178 | 0 | 0 |
| Interactions of Tat with host cellular proteins | R-HSA-176034 | 6.639234e-02 | 1.178 | 0 | 0 |
| TWIK-releated acid-sensitive K+ channel (TASK) | R-HSA-1299316 | 6.639234e-02 | 1.178 | 0 | 0 |
| SMAD4 MH2 Domain Mutants in Cancer | R-HSA-3311021 | 6.639234e-02 | 1.178 | 0 | 0 |
| Loss of Function of SMAD4 in Cancer | R-HSA-3304347 | 6.639234e-02 | 1.178 | 0 | 0 |
| SMAD2/3 MH2 Domain Mutants in Cancer | R-HSA-3315487 | 6.639234e-02 | 1.178 | 0 | 0 |
| MyD88 deficiency (TLR5) | R-HSA-5602680 | 6.639234e-02 | 1.178 | 0 | 0 |
| Resolution of AP sites via the single-nucleotide replacement pathway | R-HSA-110381 | 7.572731e-02 | 1.121 | 0 | 0 |
| Loss of phosphorylation of MECP2 at T308 | R-HSA-9022535 | 7.572731e-02 | 1.121 | 0 | 0 |
| Type I hemidesmosome assembly | R-HSA-446107 | 6.968363e-02 | 1.157 | 0 | 0 |
| SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs | R-HSA-77588 | 6.968363e-02 | 1.157 | 0 | 0 |
| Activation of RAS in B cells | R-HSA-1169092 | 6.968363e-02 | 1.157 | 0 | 0 |
| RUNX3 regulates NOTCH signaling | R-HSA-8941856 | 7.553397e-02 | 1.122 | 0 | 0 |
| SHC-related events triggered by IGF1R | R-HSA-2428933 | 7.553397e-02 | 1.122 | 0 | 0 |
| Leading Strand Synthesis | R-HSA-69109 | 7.553397e-02 | 1.122 | 0 | 0 |
| Polymerase switching | R-HSA-69091 | 7.553397e-02 | 1.122 | 0 | 0 |
| Disorders of Developmental Biology | R-HSA-9675151 | 7.642690e-02 | 1.117 | 0 | 0 |
| Signaling by Ligand-Responsive EGFR Variants in Cancer | R-HSA-5637815 | 7.490631e-02 | 1.125 | 0 | 0 |
| Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | R-HSA-1236382 | 7.490631e-02 | 1.125 | 0 | 0 |
| Signaling by ERBB2 in Cancer | R-HSA-1227990 | 6.882231e-02 | 1.162 | 0 | 0 |
| Activation of the pre-replicative complex | R-HSA-68962 | 6.882231e-02 | 1.162 | 0 | 0 |
| Aberrant regulation of mitotic cell cycle due to RB1 defects | R-HSA-9687139 | 6.882231e-02 | 1.162 | 0 | 0 |
| Trafficking of AMPA receptors | R-HSA-399719 | 7.836154e-02 | 1.106 | 0 | 0 |
| Nuclear Pore Complex (NPC) Disassembly | R-HSA-3301854 | 7.373694e-02 | 1.132 | 0 | 0 |
| Formation of a pool of free 40S subunits | R-HSA-72689 | 7.285539e-02 | 1.138 | 0 | 0 |
| Transcriptional regulation by RUNX2 | R-HSA-8878166 | 8.618896e-02 | 1.065 | 0 | 0 |
| RUNX2 regulates bone development | R-HSA-8941326 | 8.292785e-02 | 1.081 | 0 | 0 |
| Chaperonin-mediated protein folding | R-HSA-390466 | 8.503860e-02 | 1.070 | 0 | 0 |
| Signaling by EGFR | R-HSA-177929 | 6.923660e-02 | 1.160 | 0 | 0 |
| Formation of WDR5-containing histone-modifying complexes | R-HSA-9772755 | 7.373694e-02 | 1.132 | 0 | 0 |
| G1/S DNA Damage Checkpoints | R-HSA-69615 | 7.738627e-02 | 1.111 | 0 | 0 |
| Platelet Aggregation (Plug Formation) | R-HSA-76009 | 7.221865e-02 | 1.141 | 0 | 0 |
| Neurexins and neuroligins | R-HSA-6794361 | 8.216995e-02 | 1.085 | 0 | 0 |
| MAP2K and MAPK activation | R-HSA-5674135 | 8.626431e-02 | 1.064 | 0 | 0 |
| LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production | R-HSA-3134973 | 7.572731e-02 | 1.121 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex | R-HSA-170834 | 8.409198e-02 | 1.075 | 0 | 0 |
| Role of second messengers in netrin-1 signaling | R-HSA-418890 | 7.553397e-02 | 1.122 | 0 | 0 |
| Signalling to ERKs | R-HSA-187687 | 7.373694e-02 | 1.132 | 0 | 0 |
| rRNA processing in the nucleus and cytosol | R-HSA-8868773 | 7.932910e-02 | 1.101 | 0 | 0 |
| Pre-NOTCH Expression and Processing | R-HSA-1912422 | 7.662076e-02 | 1.116 | 0 | 0 |
| Eukaryotic Translation Elongation | R-HSA-156842 | 8.463657e-02 | 1.072 | 0 | 0 |
| Cardiac conduction | R-HSA-5576891 | 6.470852e-02 | 1.189 | 0 | 0 |
| HDR through Homologous Recombination (HRR) | R-HSA-5685942 | 6.557861e-02 | 1.183 | 0 | 0 |
| CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde | R-HSA-442729 | 6.968363e-02 | 1.157 | 0 | 0 |
| Signaling by NOTCH | R-HSA-157118 | 8.591216e-02 | 1.066 | 0 | 0 |
| Influenza Viral RNA Transcription and Replication | R-HSA-168273 | 6.946159e-02 | 1.158 | 0 | 0 |
| Signaling by NTRKs | R-HSA-166520 | 6.642837e-02 | 1.178 | 0 | 0 |
| Export of Viral Ribonucleoproteins from Nucleus | R-HSA-168274 | 8.017259e-02 | 1.096 | 0 | 0 |
| Gap junction trafficking | R-HSA-190828 | 6.479156e-02 | 1.188 | 0 | 0 |
| SARS-CoV-1-host interactions | R-HSA-9692914 | 7.214851e-02 | 1.142 | 0 | 0 |
| Interleukin-37 signaling | R-HSA-9008059 | 6.882231e-02 | 1.162 | 0 | 0 |
| Glucose metabolism | R-HSA-70326 | 7.587924e-02 | 1.120 | 0 | 0 |
| Influenza Infection | R-HSA-168255 | 6.901861e-02 | 1.161 | 0 | 0 |
| Interferon Signaling | R-HSA-913531 | 8.635661e-02 | 1.064 | 0 | 0 |
| Signaling by NTRK3 (TRKC) | R-HSA-9034015 | 8.709983e-02 | 1.060 | 0 | 0 |
| DNA Replication | R-HSA-69306 | 8.827965e-02 | 1.054 | 0 | 0 |
| DNA strand elongation | R-HSA-69190 | 8.866589e-02 | 1.052 | 0 | 0 |
| Signaling by WNT in cancer | R-HSA-4791275 | 8.866589e-02 | 1.052 | 0 | 0 |
| NFE2L2 regulating MDR associated enzymes | R-HSA-9818032 | 8.889895e-02 | 1.051 | 0 | 0 |
| Activation of RAC1 downstream of NMDARs | R-HSA-9619229 | 8.889895e-02 | 1.051 | 0 | 0 |
| Unwinding of DNA | R-HSA-176974 | 8.889895e-02 | 1.051 | 0 | 0 |
| Elevation of cytosolic Ca2+ levels | R-HSA-139853 | 9.041019e-02 | 1.044 | 0 | 0 |
| Specification of primordial germ cells | R-HSA-9827857 | 9.041019e-02 | 1.044 | 0 | 0 |
| Peptide chain elongation | R-HSA-156902 | 9.150887e-02 | 1.039 | 0 | 0 |
| Regulation of TP53 Activity through Association with Co-factors | R-HSA-6804759 | 9.178581e-02 | 1.037 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression linked to lipogenesis | R-HSA-9029558 | 9.178581e-02 | 1.037 | 0 | 0 |
| Frs2-mediated activation | R-HSA-170968 | 9.178581e-02 | 1.037 | 0 | 0 |
| RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs) | R-HSA-8877330 | 9.178581e-02 | 1.037 | 0 | 0 |
| CREB1 phosphorylation through the activation of Adenylate Cyclase | R-HSA-442720 | 9.178581e-02 | 1.037 | 0 | 0 |
| Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | R-HSA-75035 | 9.178581e-02 | 1.037 | 0 | 0 |
| Organelle biogenesis and maintenance | R-HSA-1852241 | 9.239453e-02 | 1.034 | 0 | 0 |
| Vpr-mediated nuclear import of PICs | R-HSA-180910 | 9.278765e-02 | 1.033 | 0 | 0 |
| EPHA-mediated growth cone collapse | R-HSA-3928663 | 9.454149e-02 | 1.024 | 0 | 0 |
| Developmental Lineage of Mammary Gland Luminal Epithelial Cells | R-HSA-9927418 | 9.569294e-02 | 1.019 | 0 | 0 |
| Interleukin-3, Interleukin-5 and GM-CSF signaling | R-HSA-512988 | 9.569294e-02 | 1.019 | 0 | 0 |
| Intraflagellar transport | R-HSA-5620924 | 9.767694e-02 | 1.010 | 0 | 0 |
| Regulation of T cell activation by CD28 family | R-HSA-388841 | 9.775242e-02 | 1.010 | 0 | 0 |
| Regulation of PTEN gene transcription | R-HSA-8943724 | 9.967560e-02 | 1.001 | 0 | 0 |
| Glutamate binding, activation of AMPA receptors and synaptic plasticity | R-HSA-399721 | 9.973351e-02 | 1.001 | 0 | 0 |
| RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | R-HSA-8939243 | 9.973351e-02 | 1.001 | 0 | 0 |
| FGFR1 mutant receptor activation | R-HSA-1839124 | 9.973351e-02 | 1.001 | 0 | 0 |
| Cyclin A:Cdk2-associated events at S phase entry | R-HSA-69656 | 9.990754e-02 | 1.000 | 0 | 0 |
| mTORC1-mediated signalling | R-HSA-166208 | 1.003503e-01 | 0.998 | 0 | 0 |
| Adherens junctions interactions | R-HSA-418990 | 1.019808e-01 | 0.991 | 0 | 0 |
| GLI proteins bind promoters of Hh responsive genes to promote transcription | R-HSA-5635851 | 1.024409e-01 | 0.990 | 0 | 0 |
| CDH11 homotypic and heterotypic interactions | R-HSA-9833576 | 1.024409e-01 | 0.990 | 0 | 0 |
| Loss of Function of SMAD2/3 in Cancer | R-HSA-3304349 | 1.024409e-01 | 0.990 | 0 | 0 |
| Loss of MECP2 binding ability to the NCoR/SMRT complex | R-HSA-9022537 | 1.024409e-01 | 0.990 | 0 | 0 |
| Regulation of CDH19 Expression and Function | R-HSA-9764302 | 1.024409e-01 | 0.990 | 0 | 0 |
| Intra-Golgi and retrograde Golgi-to-ER traffic | R-HSA-6811442 | 1.038581e-01 | 0.984 | 0 | 0 |
| PCNA-Dependent Long Patch Base Excision Repair | R-HSA-5651801 | 1.056823e-01 | 0.976 | 0 | 0 |
| Polo-like kinase mediated events | R-HSA-156711 | 1.056823e-01 | 0.976 | 0 | 0 |
| Synaptic adhesion-like molecules | R-HSA-8849932 | 1.056823e-01 | 0.976 | 0 | 0 |
| Serotonin Neurotransmitter Release Cycle | R-HSA-181429 | 1.056823e-01 | 0.976 | 0 | 0 |
| Signaling by FGFR4 | R-HSA-5654743 | 1.057142e-01 | 0.976 | 0 | 0 |
| Signaling by NTRK1 (TRKA) | R-HSA-187037 | 1.076021e-01 | 0.968 | 0 | 0 |
| SARS-CoV-1 Infection | R-HSA-9678108 | 1.076744e-01 | 0.968 | 0 | 0 |
| Regulation of TP53 Expression | R-HSA-6804754 | 1.079899e-01 | 0.967 | 0 | 0 |
| Diseases of cellular response to stress | R-HSA-9675132 | 1.079899e-01 | 0.967 | 0 | 0 |
| Diseases of Cellular Senescence | R-HSA-9630747 | 1.079899e-01 | 0.967 | 0 | 0 |
| Localization of the PINCH-ILK-PARVIN complex to focal adhesions | R-HSA-446343 | 1.079899e-01 | 0.967 | 0 | 0 |
| Potassium transport channels | R-HSA-1296067 | 1.079899e-01 | 0.967 | 0 | 0 |
| COPI-independent Golgi-to-ER retrograde traffic | R-HSA-6811436 | 1.080693e-01 | 0.966 | 0 | 0 |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | R-HSA-6811558 | 1.095008e-01 | 0.961 | 0 | 0 |
| Regulation of KIT signaling | R-HSA-1433559 | 1.096786e-01 | 0.960 | 0 | 0 |
| Drug resistance of KIT mutants | R-HSA-9669937 | 1.300288e-01 | 0.886 | 0 | 0 |
| KIT mutants bind TKIs | R-HSA-9669921 | 1.300288e-01 | 0.886 | 0 | 0 |
| Nilotinib-resistant KIT mutants | R-HSA-9669926 | 1.300288e-01 | 0.886 | 0 | 0 |
| Sorafenib-resistant KIT mutants | R-HSA-9669936 | 1.300288e-01 | 0.886 | 0 | 0 |
| Evasion of Oxidative Stress Induced Senescence Due to p14ARF Defects | R-HSA-9646304 | 1.300288e-01 | 0.886 | 0 | 0 |
| Loss of Function of TP53 in Cancer | R-HSA-9723907 | 1.300288e-01 | 0.886 | 0 | 0 |
| Masitinib-resistant KIT mutants | R-HSA-9669924 | 1.300288e-01 | 0.886 | 0 | 0 |
| Deletions in the AXIN1 gene destabilize the destruction complex | R-HSA-5467345 | 1.300288e-01 | 0.886 | 0 | 0 |
| APC truncation mutants are not K63 polyubiquitinated | R-HSA-5467333 | 1.300288e-01 | 0.886 | 0 | 0 |
| Defective translocation of RB1 mutants to the nucleus | R-HSA-9661070 | 1.300288e-01 | 0.886 | 0 | 0 |
| Imatinib-resistant KIT mutants | R-HSA-9669917 | 1.300288e-01 | 0.886 | 0 | 0 |
| Evasion of Oncogene Induced Senescence Due to p14ARF Defects | R-HSA-9646303 | 1.300288e-01 | 0.886 | 0 | 0 |
| Dasatinib-resistant KIT mutants | R-HSA-9669914 | 1.300288e-01 | 0.886 | 0 | 0 |
| Regorafenib-resistant KIT mutants | R-HSA-9669929 | 1.300288e-01 | 0.886 | 0 | 0 |
| Loss of function of TP53 in cancer due to loss of tetramerization ability | R-HSA-9723905 | 1.300288e-01 | 0.886 | 0 | 0 |
| Sunitinib-resistant KIT mutants | R-HSA-9669934 | 1.300288e-01 | 0.886 | 0 | 0 |
| Activation of BIM and translocation to mitochondria | R-HSA-111446 | 1.545570e-01 | 0.811 | 0 | 0 |
| Loss of MECP2 binding ability to 5mC-DNA | R-HSA-9022538 | 1.545570e-01 | 0.811 | 0 | 0 |
| Loss of Function of KMT2D in MLL4 Complex Formation in Kabuki Syndrome | R-HSA-9944997 | 1.545570e-01 | 0.811 | 0 | 0 |
| IRAK4 deficiency (TLR5) | R-HSA-5603037 | 1.545570e-01 | 0.811 | 0 | 0 |
| Loss of Function of KMT2D in Kabuki Syndrome | R-HSA-9944971 | 1.545570e-01 | 0.811 | 0 | 0 |
| TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation | R-HSA-8869496 | 1.322961e-01 | 0.878 | 0 | 0 |
| CREB phosphorylation | R-HSA-199920 | 1.322961e-01 | 0.878 | 0 | 0 |
| PI3K/AKT activation | R-HSA-198203 | 1.103690e-01 | 0.957 | 0 | 0 |
| Establishment of Sister Chromatid Cohesion | R-HSA-2468052 | 1.103690e-01 | 0.957 | 0 | 0 |
| Folding of actin by CCT/TriC | R-HSA-390450 | 1.103690e-01 | 0.957 | 0 | 0 |
| RUNX1 regulates estrogen receptor mediated transcription | R-HSA-8931987 | 1.647456e-01 | 0.783 | 0 | 0 |
| Displacement of DNA glycosylase by APEX1 | R-HSA-110357 | 1.647456e-01 | 0.783 | 0 | 0 |
| POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation | R-HSA-2892245 | 1.647456e-01 | 0.783 | 0 | 0 |
| Activated NTRK3 signals through PI3K | R-HSA-9603381 | 1.647456e-01 | 0.783 | 0 | 0 |
| Role of ABL in ROBO-SLIT signaling | R-HSA-428890 | 1.647456e-01 | 0.783 | 0 | 0 |
| Ca2+ activated K+ channels | R-HSA-1296052 | 1.647456e-01 | 0.783 | 0 | 0 |
| SLBP independent Processing of Histone Pre-mRNAs | R-HSA-111367 | 1.647456e-01 | 0.783 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression linked to triglyceride lipolysis in adipose | R-HSA-9031528 | 1.647456e-01 | 0.783 | 0 | 0 |
| InlA-mediated entry of Listeria monocytogenes into host cells | R-HSA-8876493 | 1.339011e-01 | 0.873 | 0 | 0 |
| Activated NTRK3 signals through RAS | R-HSA-9034864 | 1.339011e-01 | 0.873 | 0 | 0 |
| Activated NTRK2 signals through RAS | R-HSA-9026519 | 1.592712e-01 | 0.798 | 0 | 0 |
| Erythropoietin activates RAS | R-HSA-9027284 | 1.291221e-01 | 0.889 | 0 | 0 |
| TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | R-HSA-2173791 | 1.291221e-01 | 0.889 | 0 | 0 |
| Activation of BAD and translocation to mitochondria | R-HSA-111447 | 1.291221e-01 | 0.889 | 0 | 0 |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | R-HSA-354194 | 1.500049e-01 | 0.824 | 0 | 0 |
| Phase 4 - resting membrane potential | R-HSA-5576886 | 1.500049e-01 | 0.824 | 0 | 0 |
| Signaling by ERBB2 TMD/JMD mutants | R-HSA-9665686 | 1.299224e-01 | 0.886 | 0 | 0 |
| Processing of Capped Intronless Pre-mRNA | R-HSA-75067 | 1.299224e-01 | 0.886 | 0 | 0 |
| Replacement of protamines by nucleosomes in the male pronucleus | R-HSA-9821993 | 1.299224e-01 | 0.886 | 0 | 0 |
| SHC-mediated cascade:FGFR3 | R-HSA-5654704 | 1.587077e-01 | 0.799 | 0 | 0 |
| Downstream signaling of activated FGFR3 | R-HSA-5654708 | 1.204348e-01 | 0.919 | 0 | 0 |
| Signaling by ERBB2 KD Mutants | R-HSA-9664565 | 1.204348e-01 | 0.919 | 0 | 0 |
| Late endosomal microautophagy | R-HSA-9615710 | 1.204348e-01 | 0.919 | 0 | 0 |
| Downstream signaling of activated FGFR4 | R-HSA-5654716 | 1.346538e-01 | 0.871 | 0 | 0 |
| Signaling by EGFR in Cancer | R-HSA-1643713 | 1.633248e-01 | 0.787 | 0 | 0 |
| Formation of the ternary complex, and subsequently, the 43S complex | R-HSA-72695 | 1.392716e-01 | 0.856 | 0 | 0 |
| Carboxyterminal post-translational modifications of tubulin | R-HSA-8955332 | 1.515851e-01 | 0.819 | 0 | 0 |
| PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA | R-HSA-9954714 | 1.127763e-01 | 0.948 | 0 | 0 |
| Nuclear Receptor transcription pathway | R-HSA-383280 | 1.534859e-01 | 0.814 | 0 | 0 |
| ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA | R-HSA-9954716 | 1.543797e-01 | 0.811 | 0 | 0 |
| Neutrophil degranulation | R-HSA-6798695 | 1.619858e-01 | 0.791 | 0 | 0 |
| Protein folding | R-HSA-391251 | 1.285032e-01 | 0.891 | 0 | 0 |
| Resolution of AP sites via the multiple-nucleotide patch replacement pathway | R-HSA-110373 | 1.633248e-01 | 0.787 | 0 | 0 |
| Cyclin D associated events in G1 | R-HSA-69231 | 1.163235e-01 | 0.934 | 0 | 0 |
| G1 Phase | R-HSA-69236 | 1.163235e-01 | 0.934 | 0 | 0 |
| IGF1R signaling cascade | R-HSA-2428924 | 1.371648e-01 | 0.863 | 0 | 0 |
| Specification of the neural plate border | R-HSA-9834899 | 1.221980e-01 | 0.913 | 0 | 0 |
| Resolution of Abasic Sites (AP sites) | R-HSA-73933 | 1.388201e-01 | 0.858 | 0 | 0 |
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | R-HSA-2173793 | 1.176676e-01 | 0.929 | 0 | 0 |
| Postmitotic nuclear pore complex (NPC) reformation | R-HSA-9615933 | 1.633248e-01 | 0.787 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex in Cancer | R-HSA-3304351 | 1.322961e-01 | 0.878 | 0 | 0 |
| PKA-mediated phosphorylation of CREB | R-HSA-111931 | 1.587077e-01 | 0.799 | 0 | 0 |
| NoRC negatively regulates rRNA expression | R-HSA-427413 | 1.457084e-01 | 0.837 | 0 | 0 |
| Cyclin E associated events during G1/S transition | R-HSA-69202 | 1.357607e-01 | 0.867 | 0 | 0 |
| Adipogenesis | R-HSA-9843745 | 1.336215e-01 | 0.874 | 0 | 0 |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | R-HSA-2404192 | 1.476151e-01 | 0.831 | 0 | 0 |
| Signaling by FGFR3 | R-HSA-5654741 | 1.275130e-01 | 0.894 | 0 | 0 |
| EGFR Transactivation by Gastrin | R-HSA-2179392 | 1.103690e-01 | 0.957 | 0 | 0 |
| Polymerase switching on the C-strand of the telomere | R-HSA-174411 | 1.461692e-01 | 0.835 | 0 | 0 |
| Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells | R-HSA-9860927 | 1.374131e-01 | 0.862 | 0 | 0 |
| UCH proteinases | R-HSA-5689603 | 1.341454e-01 | 0.872 | 0 | 0 |
| MET activates RAP1 and RAC1 | R-HSA-8875555 | 1.103690e-01 | 0.957 | 0 | 0 |
| Activation of PUMA and translocation to mitochondria | R-HSA-139915 | 1.647456e-01 | 0.783 | 0 | 0 |
| Gastrin-CREB signalling pathway via PKC and MAPK | R-HSA-881907 | 1.221980e-01 | 0.913 | 0 | 0 |
| NFE2L2 regulates pentose phosphate pathway genes | R-HSA-9818028 | 1.592712e-01 | 0.798 | 0 | 0 |
| Sodium/Calcium exchangers | R-HSA-425561 | 1.592712e-01 | 0.798 | 0 | 0 |
| Prolonged ERK activation events | R-HSA-169893 | 1.500049e-01 | 0.824 | 0 | 0 |
| Opioid Signalling | R-HSA-111885 | 1.320637e-01 | 0.879 | 0 | 0 |
| Activation of anterior HOX genes in hindbrain development during early embryogenesis | R-HSA-5617472 | 1.400180e-01 | 0.854 | 0 | 0 |
| Activation of HOX genes during differentiation | R-HSA-5619507 | 1.400180e-01 | 0.854 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation by EBF2 | R-HSA-9844594 | 1.263431e-01 | 0.898 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation | R-HSA-9843743 | 1.263431e-01 | 0.898 | 0 | 0 |
| High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells | R-HSA-9856530 | 1.152718e-01 | 0.938 | 0 | 0 |
| GPER1 signaling | R-HSA-9634597 | 1.644362e-01 | 0.784 | 0 | 0 |
| Negative regulation of the PI3K/AKT network | R-HSA-199418 | 1.201764e-01 | 0.920 | 0 | 0 |
| Protein-protein interactions at synapses | R-HSA-6794362 | 1.605930e-01 | 0.794 | 0 | 0 |
| Signaling by TGFB family members | R-HSA-9006936 | 1.262590e-01 | 0.899 | 0 | 0 |
| Integration of energy metabolism | R-HSA-163685 | 1.308483e-01 | 0.883 | 0 | 0 |
| HCMV Infection | R-HSA-9609646 | 1.297825e-01 | 0.887 | 0 | 0 |
| DNA Repair | R-HSA-73894 | 1.181779e-01 | 0.927 | 0 | 0 |
| TGFBR3 regulates TGF-beta signaling | R-HSA-9839389 | 1.647456e-01 | 0.783 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in pigmentation | R-HSA-9824585 | 1.275130e-01 | 0.894 | 0 | 0 |
| Nef and signal transduction | R-HSA-164944 | 1.322961e-01 | 0.878 | 0 | 0 |
| SARS-CoV-2 targets host intracellular signalling and regulatory pathways | R-HSA-9755779 | 1.291221e-01 | 0.889 | 0 | 0 |
| Eukaryotic Translation Termination | R-HSA-72764 | 1.635995e-01 | 0.786 | 0 | 0 |
| Regulation of cholesterol biosynthesis by SREBP (SREBF) | R-HSA-1655829 | 1.636919e-01 | 0.786 | 0 | 0 |
| Regulation of gene expression by Hypoxia-inducible Factor | R-HSA-1234158 | 1.592712e-01 | 0.798 | 0 | 0 |
| Downstream signal transduction | R-HSA-186763 | 1.496818e-01 | 0.825 | 0 | 0 |
| Adaptive Immune System | R-HSA-1280218 | 1.202694e-01 | 0.920 | 0 | 0 |
| Intrinsic Pathway for Apoptosis | R-HSA-109606 | 1.176676e-01 | 0.929 | 0 | 0 |
| NEP/NS2 Interacts with the Cellular Export Machinery | R-HSA-168333 | 1.275130e-01 | 0.894 | 0 | 0 |
| Signaling by ALK | R-HSA-201556 | 1.145033e-01 | 0.941 | 0 | 0 |
| SARS-CoV-2-host interactions | R-HSA-9705683 | 1.535634e-01 | 0.814 | 0 | 0 |
| Interactions of Vpr with host cellular proteins | R-HSA-176033 | 1.263431e-01 | 0.898 | 0 | 0 |
| Transport of Ribonucleoproteins into the Host Nucleus | R-HSA-168271 | 1.388201e-01 | 0.858 | 0 | 0 |
| Regulation of expression of SLITs and ROBOs | R-HSA-9010553 | 1.591896e-01 | 0.798 | 0 | 0 |
| IRF3-mediated induction of type I IFN | R-HSA-3270619 | 1.291221e-01 | 0.889 | 0 | 0 |
| SRP-dependent cotranslational protein targeting to membrane | R-HSA-1799339 | 1.654887e-01 | 0.781 | 0 | 0 |
| SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | R-HSA-2173796 | 1.660673e-01 | 0.780 | 0 | 0 |
| Cell-cell junction organization | R-HSA-421270 | 1.715927e-01 | 0.766 | 0 | 0 |
| POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation | R-HSA-2892247 | 1.721985e-01 | 0.764 | 0 | 0 |
| Processing of Intronless Pre-mRNAs | R-HSA-77595 | 1.721985e-01 | 0.764 | 0 | 0 |
| The CRY:PER:kinase complex represses transactivation by the BMAL:CLOCK (ARNTL:CLOCK) complex | R-HSA-9931521 | 1.721985e-01 | 0.764 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | R-HSA-6804114 | 1.721985e-01 | 0.764 | 0 | 0 |
| Transcriptional regulation of white adipocyte differentiation | R-HSA-381340 | 1.731076e-01 | 0.762 | 0 | 0 |
| p53-Dependent G1/S DNA damage checkpoint | R-HSA-69580 | 1.778047e-01 | 0.750 | 0 | 0 |
| p53-Dependent G1 DNA Damage Response | R-HSA-69563 | 1.778047e-01 | 0.750 | 0 | 0 |
| Signaling by FGFR in disease | R-HSA-1226099 | 1.778370e-01 | 0.750 | 0 | 0 |
| SHC-mediated cascade:FGFR4 | R-HSA-5654719 | 1.785455e-01 | 0.748 | 0 | 0 |
| Listeria monocytogenes entry into host cells | R-HSA-8876384 | 1.785455e-01 | 0.748 | 0 | 0 |
| Initiation of Nuclear Envelope (NE) Reformation | R-HSA-2995383 | 1.785455e-01 | 0.748 | 0 | 0 |
| Signaling by SCF-KIT | R-HSA-1433557 | 1.798732e-01 | 0.745 | 0 | 0 |
| Disassembly of the destruction complex and recruitment of AXIN to the membrane | R-HSA-4641262 | 1.813307e-01 | 0.742 | 0 | 0 |
| Tat-mediated HIV elongation arrest and recovery | R-HSA-167243 | 1.813307e-01 | 0.742 | 0 | 0 |
| Pausing and recovery of Tat-mediated HIV elongation | R-HSA-167238 | 1.813307e-01 | 0.742 | 0 | 0 |
| Sensory processing of sound by inner hair cells of the cochlea | R-HSA-9662360 | 1.814174e-01 | 0.741 | 0 | 0 |
| G-protein beta:gamma signalling | R-HSA-397795 | 1.820100e-01 | 0.740 | 0 | 0 |
| Cardiogenesis | R-HSA-9733709 | 1.820100e-01 | 0.740 | 0 | 0 |
| Amyloid fiber formation | R-HSA-977225 | 1.851330e-01 | 0.733 | 0 | 0 |
| Disorders of Nervous System Development | R-HSA-9697154 | 1.862347e-01 | 0.730 | 0 | 0 |
| Loss of function of MECP2 in Rett syndrome | R-HSA-9005891 | 1.862347e-01 | 0.730 | 0 | 0 |
| Pervasive developmental disorders | R-HSA-9005895 | 1.862347e-01 | 0.730 | 0 | 0 |
| Z-decay: degradation of maternal mRNAs by zygotically expressed factors | R-HSA-9820865 | 1.862347e-01 | 0.730 | 0 | 0 |
| Repression of WNT target genes | R-HSA-4641265 | 1.862347e-01 | 0.730 | 0 | 0 |
| Signaling by FGFR1 | R-HSA-5654736 | 1.883913e-01 | 0.725 | 0 | 0 |
| p130Cas linkage to MAPK signaling for integrins | R-HSA-372708 | 1.955615e-01 | 0.709 | 0 | 0 |
| Formation of HIV-1 elongation complex containing HIV-1 Tat | R-HSA-167200 | 1.972768e-01 | 0.705 | 0 | 0 |
| Activation of gene expression by SREBF (SREBP) | R-HSA-2426168 | 1.976690e-01 | 0.704 | 0 | 0 |
| Regulation of CDH1 posttranslational processing and trafficking to plasma membrane | R-HSA-9768727 | 1.992192e-01 | 0.701 | 0 | 0 |
| FGFR1b ligand binding and activation | R-HSA-190370 | 1.992375e-01 | 0.701 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of myeloid cells | R-HSA-8939246 | 1.992375e-01 | 0.701 | 0 | 0 |
| Negative regulation of activity of TFAP2 (AP-2) family transcription factors | R-HSA-8866904 | 1.992375e-01 | 0.701 | 0 | 0 |
| Notch-HLH transcription pathway | R-HSA-350054 | 1.993181e-01 | 0.700 | 0 | 0 |
| TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | R-HSA-6804115 | 1.993181e-01 | 0.700 | 0 | 0 |
| Dopamine Neurotransmitter Release Cycle | R-HSA-212676 | 1.993181e-01 | 0.700 | 0 | 0 |
| HIV elongation arrest and recovery | R-HSA-167287 | 2.001218e-01 | 0.699 | 0 | 0 |
| Pausing and recovery of HIV elongation | R-HSA-167290 | 2.001218e-01 | 0.699 | 0 | 0 |
| RUNX2 regulates osteoblast differentiation | R-HSA-8940973 | 2.001218e-01 | 0.699 | 0 | 0 |
| Inflammasomes | R-HSA-622312 | 2.001218e-01 | 0.699 | 0 | 0 |
| MECP2 regulates transcription of genes involved in GABA signaling | R-HSA-9022927 | 2.040991e-01 | 0.690 | 0 | 0 |
| Regulation of gap junction activity | R-HSA-191650 | 2.040991e-01 | 0.690 | 0 | 0 |
| TNFR1-mediated ceramide production | R-HSA-5626978 | 2.040991e-01 | 0.690 | 0 | 0 |
| PLCG1 events in ERBB2 signaling | R-HSA-1251932 | 2.040991e-01 | 0.690 | 0 | 0 |
| RUNX2 regulates genes involved in differentiation of myeloid cells | R-HSA-8941333 | 2.040991e-01 | 0.690 | 0 | 0 |
| AKT-mediated inactivation of FOXO1A | R-HSA-211163 | 2.040991e-01 | 0.690 | 0 | 0 |
| ATP sensitive Potassium channels | R-HSA-1296025 | 2.040991e-01 | 0.690 | 0 | 0 |
| GRB7 events in ERBB2 signaling | R-HSA-1306955 | 2.040991e-01 | 0.690 | 0 | 0 |
| Loss of Function of FBXW7 in Cancer and NOTCH1 Signaling | R-HSA-2644607 | 2.040991e-01 | 0.690 | 0 | 0 |
| FBXW7 Mutants and NOTCH1 in Cancer | R-HSA-2644605 | 2.040991e-01 | 0.690 | 0 | 0 |
| TGFBR1 KD Mutants in Cancer | R-HSA-3656532 | 2.040991e-01 | 0.690 | 0 | 0 |
| Activation of NOXA and translocation to mitochondria | R-HSA-111448 | 2.040991e-01 | 0.690 | 0 | 0 |
| Dopamine receptors | R-HSA-390651 | 2.040991e-01 | 0.690 | 0 | 0 |
| SARS-CoV-2 targets PDZ proteins in cell-cell junction | R-HSA-9705677 | 2.040991e-01 | 0.690 | 0 | 0 |
| Developmental Cell Lineages | R-HSA-9734767 | 2.045620e-01 | 0.689 | 0 | 0 |
| Regulation of PAK-2p34 activity by PS-GAP/RHG10 | R-HSA-211728 | 2.431566e-01 | 0.614 | 0 | 0 |
| Defective Intrinsic Pathway for Apoptosis Due to p14ARF Loss of Function | R-HSA-9645722 | 2.431566e-01 | 0.614 | 0 | 0 |
| Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 | R-HSA-9632697 | 2.431566e-01 | 0.614 | 0 | 0 |
| Defective DNA double strand break response due to BARD1 loss of function | R-HSA-9699150 | 2.431566e-01 | 0.614 | 0 | 0 |
| Defective DNA double strand break response due to BRCA1 loss of function | R-HSA-9663199 | 2.431566e-01 | 0.614 | 0 | 0 |
| Defective Mismatch Repair Associated With MLH1 | R-HSA-5545483 | 2.431566e-01 | 0.614 | 0 | 0 |
| Defective Mismatch Repair Associated With PMS2 | R-HSA-5632987 | 2.431566e-01 | 0.614 | 0 | 0 |
| Defective SLC2A1 causes GLUT1 deficiency syndrome 1 (GLUT1DS1) | R-HSA-5619043 | 2.431566e-01 | 0.614 | 0 | 0 |
| Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 | R-HSA-9630791 | 2.431566e-01 | 0.614 | 0 | 0 |
| PI and PC transport between ER and Golgi membranes | R-HSA-1483196 | 3.415794e-01 | 0.467 | 0 | 0 |
| Evasion of Oncogene Induced Senescence Due to p16INK4A Defects | R-HSA-9630750 | 3.415794e-01 | 0.467 | 0 | 0 |
| Signaling by extracellular domain mutants of KIT | R-HSA-9680187 | 3.415794e-01 | 0.467 | 0 | 0 |
| Evasion of Oxidative Stress Induced Senescence Due to p16INK4A Defects | R-HSA-9632693 | 3.415794e-01 | 0.467 | 0 | 0 |
| Signaling by juxtamembrane domain KIT mutants | R-HSA-9669935 | 3.415794e-01 | 0.467 | 0 | 0 |
| Mitochondrial transcription initiation | R-HSA-163282 | 3.415794e-01 | 0.467 | 0 | 0 |
| Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6 | R-HSA-9632700 | 3.415794e-01 | 0.467 | 0 | 0 |
| Intestinal infectious diseases | R-HSA-8942233 | 3.415794e-01 | 0.467 | 0 | 0 |
| Defective SLC12A6 causes agenesis of the corpus callosum, with peripheral neuropathy (ACCPN) | R-HSA-5619039 | 3.415794e-01 | 0.467 | 0 | 0 |
| Defective CD320 causes MMATC | R-HSA-3359485 | 3.415794e-01 | 0.467 | 0 | 0 |
| TALDO1 deficiency: failed conversion of SH7P, GA3P to Fru(6)P, E4P | R-HSA-6791055 | 3.415794e-01 | 0.467 | 0 | 0 |
| Defective SLC4A4 causes renal tubular acidosis, proximal, with ocular abnormalities and mental retardation (pRTA-OA) | R-HSA-5619054 | 3.415794e-01 | 0.467 | 0 | 0 |
| Signaling by TCF7L2 mutants | R-HSA-5339700 | 3.415794e-01 | 0.467 | 0 | 0 |
| Defective SLC20A2 causes idiopathic basal ganglia calcification 1 (IBGC1) | R-HSA-5619111 | 3.415794e-01 | 0.467 | 0 | 0 |
| Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6 | R-HSA-9630794 | 3.415794e-01 | 0.467 | 0 | 0 |
| Defective PGM1 causes PGM1-CDG | R-HSA-5609974 | 3.415794e-01 | 0.467 | 0 | 0 |
| Defective SLC6A3 causes Parkinsonism-dystonia infantile (PKDYS) | R-HSA-5660724 | 3.415794e-01 | 0.467 | 0 | 0 |
| Defective SLC6A3 causes Parkinsonism-dystonia infantile (PKDYS) | R-HSA-5619081 | 3.415794e-01 | 0.467 | 0 | 0 |
| Defective ABCC9 causes CMD10, ATFB12 and Cantu syndrome | R-HSA-5678420 | 3.415794e-01 | 0.467 | 0 | 0 |
| TALDO1 deficiency: failed conversion of Fru(6)P, E4P to SH7P, GA3P | R-HSA-6791462 | 3.415794e-01 | 0.467 | 0 | 0 |
| Mitochondrial short-chain enoyl-CoA hydratase deficiency 1 | R-HSA-9916720 | 3.415794e-01 | 0.467 | 0 | 0 |
| Defective SLC6A2 causes orthostatic intolerance (OI) | R-HSA-5619109 | 3.415794e-01 | 0.467 | 0 | 0 |
| Signaling by kinase domain mutants of KIT | R-HSA-9669933 | 3.415794e-01 | 0.467 | 0 | 0 |
| IRS activation | R-HSA-74713 | 2.550562e-01 | 0.593 | 0 | 0 |
| NFE2L2 regulating inflammation associated genes | R-HSA-9818026 | 2.550562e-01 | 0.593 | 0 | 0 |
| NOSIP mediated eNOS trafficking | R-HSA-203754 | 2.550562e-01 | 0.593 | 0 | 0 |
| G2 Phase | R-HSA-68911 | 2.550562e-01 | 0.593 | 0 | 0 |
| Loss of Function of TGFBR1 in Cancer | R-HSA-3656534 | 2.550562e-01 | 0.593 | 0 | 0 |
| Signaling by membrane-tethered fusions of PDGFRA or PDGFRB | R-HSA-9673768 | 2.550562e-01 | 0.593 | 0 | 0 |
| SMAD2/3 Phosphorylation Motif Mutants in Cancer | R-HSA-3304356 | 2.550562e-01 | 0.593 | 0 | 0 |
| Estrogen-stimulated signaling through PRKCZ | R-HSA-9634635 | 2.352382e-01 | 0.628 | 0 | 0 |
| WNT mediated activation of DVL | R-HSA-201688 | 2.352382e-01 | 0.628 | 0 | 0 |
| PTK6 Regulates Cell Cycle | R-HSA-8849470 | 3.062233e-01 | 0.514 | 0 | 0 |
| Activation of caspases through apoptosome-mediated cleavage | R-HSA-111459 | 3.062233e-01 | 0.514 | 0 | 0 |
| Stimulation of the cell death response by PAK-2p34 | R-HSA-211736 | 4.272079e-01 | 0.369 | 0 | 0 |
| RUNX3 regulates RUNX1-mediated transcription | R-HSA-8951911 | 4.272079e-01 | 0.369 | 0 | 0 |
| Interaction between PHLDA1 and AURKA | R-HSA-8854521 | 4.272079e-01 | 0.369 | 0 | 0 |
| TWIK related potassium channel (TREK) | R-HSA-1299503 | 4.272079e-01 | 0.369 | 0 | 0 |
| TGFBR2 Kinase Domain Mutants in Cancer | R-HSA-3645790 | 4.272079e-01 | 0.369 | 0 | 0 |
| Defective SLC6A5 causes hyperekplexia 3 (HKPX3) | R-HSA-5619089 | 4.272079e-01 | 0.369 | 0 | 0 |
| HHAT G278V doesn't palmitoylate Hh-Np | R-HSA-5658034 | 4.272079e-01 | 0.369 | 0 | 0 |
| TGFBR1 LBD Mutants in Cancer | R-HSA-3656535 | 4.272079e-01 | 0.369 | 0 | 0 |
| Signaling by RAS GAP mutants | R-HSA-9753510 | 4.272079e-01 | 0.369 | 0 | 0 |
| Mitotic Metaphase/Anaphase Transition | R-HSA-68881 | 4.272079e-01 | 0.369 | 0 | 0 |
| Defective F8 sulfation at Y1699 | R-HSA-9674519 | 4.272079e-01 | 0.369 | 0 | 0 |
| Formation of axial mesoderm | R-HSA-9796292 | 2.145350e-01 | 0.669 | 0 | 0 |
| MECP2 regulates transcription of neuronal ligands | R-HSA-9022702 | 2.722470e-01 | 0.565 | 0 | 0 |
| Cross-presentation of particulate exogenous antigens (phagosomes) | R-HSA-1236973 | 2.722470e-01 | 0.565 | 0 | 0 |
| Formation of the polybromo-BAF (pBAF) complex | R-HSA-9933939 | 2.439125e-01 | 0.613 | 0 | 0 |
| PTK6 promotes HIF1A stabilization | R-HSA-8857538 | 3.566846e-01 | 0.448 | 0 | 0 |
| E2F-enabled inhibition of pre-replication complex formation | R-HSA-113507 | 3.566846e-01 | 0.448 | 0 | 0 |
| PKA activation in glucagon signalling | R-HSA-164378 | 2.199432e-01 | 0.658 | 0 | 0 |
| RUNX2 regulates genes involved in cell migration | R-HSA-8941332 | 3.098063e-01 | 0.509 | 0 | 0 |
| Formation of the embryonic stem cell BAF (esBAF) complex | R-HSA-9933946 | 2.741100e-01 | 0.562 | 0 | 0 |
| Translesion synthesis by REV1 | R-HSA-110312 | 2.741100e-01 | 0.562 | 0 | 0 |
| SHC1 events in EGFR signaling | R-HSA-180336 | 2.741100e-01 | 0.562 | 0 | 0 |
| ERBB2 Regulates Cell Motility | R-HSA-6785631 | 2.741100e-01 | 0.562 | 0 | 0 |
| Regulation of signaling by CBL | R-HSA-912631 | 2.451875e-01 | 0.611 | 0 | 0 |
| E2F mediated regulation of DNA replication | R-HSA-113510 | 2.451875e-01 | 0.611 | 0 | 0 |
| Signaling by FGFR2 IIIa TM | R-HSA-8851708 | 2.451875e-01 | 0.611 | 0 | 0 |
| Abortive elongation of HIV-1 transcript in the absence of Tat | R-HSA-167242 | 2.451875e-01 | 0.611 | 0 | 0 |
| Impaired BRCA2 binding to PALB2 | R-HSA-9709603 | 2.451875e-01 | 0.611 | 0 | 0 |
| Signaling by Erythropoietin | R-HSA-9006335 | 2.196277e-01 | 0.658 | 0 | 0 |
| SHC-mediated cascade:FGFR1 | R-HSA-5654688 | 2.432649e-01 | 0.614 | 0 | 0 |
| Deadenylation of mRNA | R-HSA-429947 | 2.432649e-01 | 0.614 | 0 | 0 |
| Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | R-HSA-9609523 | 2.711360e-01 | 0.567 | 0 | 0 |
| Co-inhibition by CTLA4 | R-HSA-389513 | 2.711360e-01 | 0.567 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to PALB2 loss of function | R-HSA-9701193 | 2.711360e-01 | 0.567 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA1 loss of function | R-HSA-9701192 | 2.711360e-01 | 0.567 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function | R-HSA-9704646 | 2.711360e-01 | 0.567 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function | R-HSA-9704331 | 2.711360e-01 | 0.567 | 0 | 0 |
| Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 | R-HSA-1362300 | 3.048789e-01 | 0.516 | 0 | 0 |
| Translesion synthesis by POLI | R-HSA-5656121 | 3.048789e-01 | 0.516 | 0 | 0 |
| Aberrant regulation of mitotic exit in cancer due to RB1 defects | R-HSA-9687136 | 3.048789e-01 | 0.516 | 0 | 0 |
| Sema4D mediated inhibition of cell attachment and migration | R-HSA-416550 | 3.475068e-01 | 0.459 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression to control bile acid homeostasis | R-HSA-9623433 | 3.475068e-01 | 0.459 | 0 | 0 |
| Inhibition of replication initiation of damaged DNA by RB1/E2F1 | R-HSA-113501 | 3.475068e-01 | 0.459 | 0 | 0 |
| Phosphorylation of CLOCK, acetylation of BMAL1 (ARNTL) at target gene promoters | R-HSA-9931512 | 3.475068e-01 | 0.459 | 0 | 0 |
| CHL1 interactions | R-HSA-447041 | 4.057587e-01 | 0.392 | 0 | 0 |
| PP2A-mediated dephosphorylation of key metabolic factors | R-HSA-163767 | 4.057587e-01 | 0.392 | 0 | 0 |
| Netrin mediated repulsion signals | R-HSA-418886 | 4.057587e-01 | 0.392 | 0 | 0 |
| Cohesin Loading onto Chromatin | R-HSA-2470946 | 4.057587e-01 | 0.392 | 0 | 0 |
| SHOC2 M1731 mutant abolishes MRAS complex function | R-HSA-9726840 | 4.057587e-01 | 0.392 | 0 | 0 |
| Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) | R-HSA-5693554 | 2.662268e-01 | 0.575 | 0 | 0 |
| HIV Transcription Elongation | R-HSA-167169 | 2.137462e-01 | 0.670 | 0 | 0 |
| Tat-mediated elongation of the HIV-1 transcript | R-HSA-167246 | 2.137462e-01 | 0.670 | 0 | 0 |
| Formation of HIV elongation complex in the absence of HIV Tat | R-HSA-167152 | 2.137462e-01 | 0.670 | 0 | 0 |
| Downstream signaling of activated FGFR1 | R-HSA-5654687 | 2.354670e-01 | 0.628 | 0 | 0 |
| Downstream signaling of activated FGFR2 | R-HSA-5654696 | 2.354670e-01 | 0.628 | 0 | 0 |
| PERK regulates gene expression | R-HSA-381042 | 2.354670e-01 | 0.628 | 0 | 0 |
| GRB2 events in ERBB2 signaling | R-HSA-1963640 | 3.359833e-01 | 0.474 | 0 | 0 |
| Translesion synthesis by POLK | R-HSA-5655862 | 3.359833e-01 | 0.474 | 0 | 0 |
| Phosphorylated BMAL1:CLOCK (ARNTL:CLOCK) activates expression of core clock genes | R-HSA-9931510 | 2.897023e-01 | 0.538 | 0 | 0 |
| NOTCH2 intracellular domain regulates transcription | R-HSA-2197563 | 3.849893e-01 | 0.415 | 0 | 0 |
| Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | R-HSA-9027276 | 3.849893e-01 | 0.415 | 0 | 0 |
| G1/S-Specific Transcription | R-HSA-69205 | 2.543907e-01 | 0.594 | 0 | 0 |
| FRS-mediated FGFR3 signaling | R-HSA-5654706 | 3.245170e-01 | 0.489 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in GG-NER | R-HSA-5696397 | 3.245170e-01 | 0.489 | 0 | 0 |
| Formation of RNA Pol II elongation complex | R-HSA-112382 | 2.207757e-01 | 0.656 | 0 | 0 |
| EPH-ephrin mediated repulsion of cells | R-HSA-3928665 | 2.420332e-01 | 0.616 | 0 | 0 |
| SHC-mediated cascade:FGFR2 | R-HSA-5654699 | 3.135820e-01 | 0.504 | 0 | 0 |
| RNA Polymerase II Transcription Elongation | R-HSA-75955 | 2.359631e-01 | 0.627 | 0 | 0 |
| Signaling by KIT in disease | R-HSA-9669938 | 3.516455e-01 | 0.454 | 0 | 0 |
| Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants | R-HSA-9670439 | 3.516455e-01 | 0.454 | 0 | 0 |
| FRS-mediated FGFR4 signaling | R-HSA-5654712 | 3.516455e-01 | 0.454 | 0 | 0 |
| NFE2L2 regulating tumorigenic genes | R-HSA-9818030 | 4.219451e-01 | 0.375 | 0 | 0 |
| HDR through MMEJ (alt-NHEJ) | R-HSA-5685939 | 4.219451e-01 | 0.375 | 0 | 0 |
| Formation of the non-canonical BAF (ncBAF) complex | R-HSA-9933947 | 4.219451e-01 | 0.375 | 0 | 0 |
| Association of TriC/CCT with target proteins during biosynthesis | R-HSA-390471 | 3.251692e-01 | 0.488 | 0 | 0 |
| Regulation of RUNX2 expression and activity | R-HSA-8939902 | 2.596344e-01 | 0.586 | 0 | 0 |
| Regulation of RAS by GAPs | R-HSA-5658442 | 2.929998e-01 | 0.533 | 0 | 0 |
| Interleukin receptor SHC signaling | R-HSA-912526 | 3.788735e-01 | 0.422 | 0 | 0 |
| G beta:gamma signalling through PI3Kgamma | R-HSA-392451 | 3.788735e-01 | 0.422 | 0 | 0 |
| Dual Incision in GG-NER | R-HSA-5696400 | 3.473162e-01 | 0.459 | 0 | 0 |
| Viral mRNA Translation | R-HSA-192823 | 2.470801e-01 | 0.607 | 0 | 0 |
| mRNA Splicing - Minor Pathway | R-HSA-72165 | 3.409049e-01 | 0.467 | 0 | 0 |
| RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression | R-HSA-9933387 | 3.865810e-01 | 0.413 | 0 | 0 |
| Thromboxane signalling through TP receptor | R-HSA-428930 | 4.060669e-01 | 0.391 | 0 | 0 |
| APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | R-HSA-174178 | 3.464787e-01 | 0.460 | 0 | 0 |
| EGFR downregulation | R-HSA-182971 | 4.110292e-01 | 0.386 | 0 | 0 |
| Constitutive Signaling by Aberrant PI3K in Cancer | R-HSA-2219530 | 3.792705e-01 | 0.421 | 0 | 0 |
| NR1H2 and NR1H3-mediated signaling | R-HSA-9024446 | 4.056616e-01 | 0.392 | 0 | 0 |
| FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | R-HSA-9615017 | 3.752273e-01 | 0.426 | 0 | 0 |
| Formation of definitive endoderm | R-HSA-9823730 | 2.711360e-01 | 0.567 | 0 | 0 |
| Regulation of TP53 Activity through Methylation | R-HSA-6804760 | 2.199432e-01 | 0.658 | 0 | 0 |
| IRS-related events triggered by IGF1R | R-HSA-2428928 | 3.683216e-01 | 0.434 | 0 | 0 |
| COPI-mediated anterograde transport | R-HSA-6807878 | 3.263498e-01 | 0.486 | 0 | 0 |
| Lagging Strand Synthesis | R-HSA-69186 | 2.976307e-01 | 0.526 | 0 | 0 |
| POLB-Dependent Long Patch Base Excision Repair | R-HSA-110362 | 3.475068e-01 | 0.459 | 0 | 0 |
| Signalling to RAS | R-HSA-167044 | 2.976307e-01 | 0.526 | 0 | 0 |
| Signaling by FGFR2 | R-HSA-5654738 | 2.513164e-01 | 0.600 | 0 | 0 |
| G0 and Early G1 | R-HSA-1538133 | 2.816705e-01 | 0.550 | 0 | 0 |
| Downregulation of SMAD2/3:SMAD4 transcriptional activity | R-HSA-2173795 | 2.816705e-01 | 0.550 | 0 | 0 |
| Termination of translesion DNA synthesis | R-HSA-5656169 | 3.621249e-01 | 0.441 | 0 | 0 |
| IRS-mediated signalling | R-HSA-112399 | 4.197076e-01 | 0.377 | 0 | 0 |
| Insulin receptor signalling cascade | R-HSA-74751 | 4.205886e-01 | 0.376 | 0 | 0 |
| Degradation of beta-catenin by the destruction complex | R-HSA-195253 | 2.962926e-01 | 0.528 | 0 | 0 |
| Downstream signaling events of B Cell Receptor (BCR) | R-HSA-1168372 | 4.045445e-01 | 0.393 | 0 | 0 |
| Signal attenuation | R-HSA-74749 | 2.722470e-01 | 0.565 | 0 | 0 |
| Acetylcholine regulates insulin secretion | R-HSA-399997 | 3.359833e-01 | 0.474 | 0 | 0 |
| Myogenesis | R-HSA-525793 | 2.897023e-01 | 0.538 | 0 | 0 |
| Signal amplification | R-HSA-392518 | 3.473162e-01 | 0.459 | 0 | 0 |
| TRAF3-dependent IRF activation pathway | R-HSA-918233 | 3.359833e-01 | 0.474 | 0 | 0 |
| Toxicity of botulinum toxin type E (botE) | R-HSA-5250992 | 3.062233e-01 | 0.514 | 0 | 0 |
| Regulation of CDH11 function | R-HSA-9762292 | 2.722470e-01 | 0.565 | 0 | 0 |
| p38MAPK events | R-HSA-171007 | 2.741100e-01 | 0.562 | 0 | 0 |
| Nef Mediated CD4 Down-regulation | R-HSA-167590 | 4.057587e-01 | 0.392 | 0 | 0 |
| Signaling by CSF1 (M-CSF) in myeloid cells | R-HSA-9680350 | 2.170569e-01 | 0.663 | 0 | 0 |
| Cellular response to starvation | R-HSA-9711097 | 2.652748e-01 | 0.576 | 0 | 0 |
| NOTCH1 Intracellular Domain Regulates Transcription | R-HSA-2122947 | 2.756757e-01 | 0.560 | 0 | 0 |
| Mitochondrial unfolded protein response (UPRmt) | R-HSA-9841251 | 3.135820e-01 | 0.504 | 0 | 0 |
| Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | R-HSA-2894858 | 2.446629e-01 | 0.611 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | R-HSA-2894862 | 2.446629e-01 | 0.611 | 0 | 0 |
| Signaling by NOTCH1 PEST Domain Mutants in Cancer | R-HSA-2644602 | 2.446629e-01 | 0.611 | 0 | 0 |
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | R-HSA-2644606 | 2.446629e-01 | 0.611 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in BCR signaling | R-HSA-8939245 | 2.550562e-01 | 0.593 | 0 | 0 |
| Phosphorylation and nuclear translocation of BMAL1 (ARNTL) and CLOCK | R-HSA-9931529 | 2.550562e-01 | 0.593 | 0 | 0 |
| cGMP effects | R-HSA-418457 | 2.439125e-01 | 0.613 | 0 | 0 |
| PKA activation | R-HSA-163615 | 2.199432e-01 | 0.658 | 0 | 0 |
| Signaling by NODAL | R-HSA-1181150 | 2.711360e-01 | 0.567 | 0 | 0 |
| Phosphorylation and nuclear translocation of the CRY:PER:kinase complex | R-HSA-9931530 | 3.849893e-01 | 0.415 | 0 | 0 |
| VLDLR internalisation and degradation | R-HSA-8866427 | 3.849893e-01 | 0.415 | 0 | 0 |
| Negative epigenetic regulation of rRNA expression | R-HSA-5250941 | 2.513164e-01 | 0.600 | 0 | 0 |
| Potassium Channels | R-HSA-1296071 | 2.424838e-01 | 0.615 | 0 | 0 |
| PTEN Regulation | R-HSA-6807070 | 4.205936e-01 | 0.376 | 0 | 0 |
| Late Phase of HIV Life Cycle | R-HSA-162599 | 2.410700e-01 | 0.618 | 0 | 0 |
| Interleukin-2 signaling | R-HSA-9020558 | 3.098063e-01 | 0.509 | 0 | 0 |
| Nuclear RNA decay | R-HSA-9930044 | 3.032604e-01 | 0.518 | 0 | 0 |
| Signaling by FLT3 fusion proteins | R-HSA-9703465 | 2.897023e-01 | 0.538 | 0 | 0 |
| Activated NTRK2 signals through FRS2 and FRS3 | R-HSA-9028731 | 3.849893e-01 | 0.415 | 0 | 0 |
| Downregulation of TGF-beta receptor signaling | R-HSA-2173788 | 3.516455e-01 | 0.454 | 0 | 0 |
| TP53 Regulates Transcription of Caspase Activators and Caspases | R-HSA-6803207 | 3.048789e-01 | 0.516 | 0 | 0 |
| SMAC(DIABLO)-mediated dissociation of IAP:caspase complexes | R-HSA-111464 | 2.550562e-01 | 0.593 | 0 | 0 |
| GP1b-IX-V activation signalling | R-HSA-430116 | 2.352382e-01 | 0.628 | 0 | 0 |
| Transcription from mitochondrial promoters | R-HSA-75944 | 4.272079e-01 | 0.369 | 0 | 0 |
| CLEC7A (Dectin-1) induces NFAT activation | R-HSA-5607763 | 2.439125e-01 | 0.613 | 0 | 0 |
| Abacavir transmembrane transport | R-HSA-2161517 | 3.566846e-01 | 0.448 | 0 | 0 |
| mRNA Editing: C to U Conversion | R-HSA-72200 | 4.057587e-01 | 0.392 | 0 | 0 |
| GRB2 events in EGFR signaling | R-HSA-179812 | 3.849893e-01 | 0.415 | 0 | 0 |
| FGFR1c ligand binding and activation | R-HSA-190373 | 4.219451e-01 | 0.375 | 0 | 0 |
| Membrane Trafficking | R-HSA-199991 | 2.175332e-01 | 0.662 | 0 | 0 |
| Negative regulation of FGFR3 signaling | R-HSA-5654732 | 3.377580e-01 | 0.471 | 0 | 0 |
| Regulation of CDH11 Expression and Function | R-HSA-9759475 | 3.621249e-01 | 0.441 | 0 | 0 |
| Negative regulation of FGFR4 signaling | R-HSA-5654733 | 3.621249e-01 | 0.441 | 0 | 0 |
| Downregulation of ERBB2 signaling | R-HSA-8863795 | 3.865810e-01 | 0.413 | 0 | 0 |
| Regulation of PD-L1(CD274) expression | R-HSA-9909648 | 2.195903e-01 | 0.658 | 0 | 0 |
| Signaling by FGFR2 in disease | R-HSA-5655253 | 4.184798e-01 | 0.378 | 0 | 0 |
| Signaling by NOTCH1 in Cancer | R-HSA-2644603 | 2.446629e-01 | 0.611 | 0 | 0 |
| PI5P Regulates TP53 Acetylation | R-HSA-6811555 | 4.219451e-01 | 0.375 | 0 | 0 |
| rRNA modification in the nucleus and cytosol | R-HSA-6790901 | 2.904683e-01 | 0.537 | 0 | 0 |
| Co-inhibition by PD-1 | R-HSA-389948 | 4.168370e-01 | 0.380 | 0 | 0 |
| Signaling by FGFR3 in disease | R-HSA-5655332 | 3.135820e-01 | 0.504 | 0 | 0 |
| DEx/H-box helicases activate type I IFN and inflammatory cytokines production | R-HSA-3134963 | 2.550562e-01 | 0.593 | 0 | 0 |
| NOTCH4 Activation and Transmission of Signal to the Nucleus | R-HSA-9013700 | 2.352382e-01 | 0.628 | 0 | 0 |
| MET activates RAS signaling | R-HSA-8851805 | 3.849893e-01 | 0.415 | 0 | 0 |
| KEAP1-NFE2L2 pathway | R-HSA-9755511 | 4.085391e-01 | 0.389 | 0 | 0 |
| Hedgehog 'on' state | R-HSA-5632684 | 4.212086e-01 | 0.376 | 0 | 0 |
| DARPP-32 events | R-HSA-180024 | 3.621249e-01 | 0.441 | 0 | 0 |
| Regulation of insulin secretion | R-HSA-422356 | 2.662696e-01 | 0.575 | 0 | 0 |
| Receptor Mediated Mitophagy | R-HSA-8934903 | 2.722470e-01 | 0.565 | 0 | 0 |
| RAB GEFs exchange GTP for GDP on RABs | R-HSA-8876198 | 3.341566e-01 | 0.476 | 0 | 0 |
| Signaling by NOTCH1 | R-HSA-1980143 | 2.869232e-01 | 0.542 | 0 | 0 |
| MAPK targets/ Nuclear events mediated by MAP kinases | R-HSA-450282 | 3.621249e-01 | 0.441 | 0 | 0 |
| mRNA Editing | R-HSA-75072 | 2.352382e-01 | 0.628 | 0 | 0 |
| MTOR signalling | R-HSA-165159 | 2.660884e-01 | 0.575 | 0 | 0 |
| Toll Like Receptor 5 (TLR5) Cascade | R-HSA-168176 | 3.532520e-01 | 0.452 | 0 | 0 |
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | R-HSA-168643 | 4.205886e-01 | 0.376 | 0 | 0 |
| MyD88 cascade initiated on plasma membrane | R-HSA-975871 | 3.532520e-01 | 0.452 | 0 | 0 |
| Toll Like Receptor 10 (TLR10) Cascade | R-HSA-168142 | 3.532520e-01 | 0.452 | 0 | 0 |
| HIV Life Cycle | R-HSA-162587 | 3.229520e-01 | 0.491 | 0 | 0 |
| Formation of editosomes by ADAR proteins | R-HSA-77042 | 2.431566e-01 | 0.614 | 0 | 0 |
| Inhibition of PKR | R-HSA-169131 | 2.431566e-01 | 0.614 | 0 | 0 |
| SMAC (DIABLO) binds to IAPs | R-HSA-111463 | 2.550562e-01 | 0.593 | 0 | 0 |
| ARMS-mediated activation | R-HSA-170984 | 2.352382e-01 | 0.628 | 0 | 0 |
| Activation of the TFAP2 (AP-2) family of transcription factors | R-HSA-8866907 | 2.352382e-01 | 0.628 | 0 | 0 |
| SMAC, XIAP-regulated apoptotic response | R-HSA-111469 | 3.062233e-01 | 0.514 | 0 | 0 |
| CDC6 association with the ORC:origin complex | R-HSA-68689 | 3.062233e-01 | 0.514 | 0 | 0 |
| Formation of the Editosome | R-HSA-75094 | 3.062233e-01 | 0.514 | 0 | 0 |
| mRNA Editing: A to I Conversion | R-HSA-75064 | 4.272079e-01 | 0.369 | 0 | 0 |
| C6 deamination of adenosine | R-HSA-75102 | 4.272079e-01 | 0.369 | 0 | 0 |
| Defective ABCC8 can cause hypo- and hyper-glycemias | R-HSA-5683177 | 4.272079e-01 | 0.369 | 0 | 0 |
| Regulation of cortical dendrite branching | R-HSA-8985801 | 4.272079e-01 | 0.369 | 0 | 0 |
| Loss of Function of TGFBR2 in Cancer | R-HSA-3642278 | 4.272079e-01 | 0.369 | 0 | 0 |
| Depolymerization of the Nuclear Lamina | R-HSA-4419969 | 2.199432e-01 | 0.658 | 0 | 0 |
| Regulation of PTEN localization | R-HSA-8948747 | 4.057587e-01 | 0.392 | 0 | 0 |
| Regulation of IFNG signaling | R-HSA-877312 | 3.849893e-01 | 0.415 | 0 | 0 |
| Ovarian tumor domain proteases | R-HSA-5689896 | 2.737670e-01 | 0.563 | 0 | 0 |
| Smooth Muscle Contraction | R-HSA-445355 | 2.359631e-01 | 0.627 | 0 | 0 |
| Reversible hydration of carbon dioxide | R-HSA-1475029 | 4.219451e-01 | 0.375 | 0 | 0 |
| The role of Nef in HIV-1 replication and disease pathogenesis | R-HSA-164952 | 3.788735e-01 | 0.422 | 0 | 0 |
| Sensory processing of sound by outer hair cells of the cochlea | R-HSA-9662361 | 2.836816e-01 | 0.547 | 0 | 0 |
| Viral Messenger RNA Synthesis | R-HSA-168325 | 3.683216e-01 | 0.434 | 0 | 0 |
| Signaling by NOTCH4 | R-HSA-9013694 | 3.580590e-01 | 0.446 | 0 | 0 |
| rRNA processing | R-HSA-72312 | 3.959692e-01 | 0.402 | 0 | 0 |
| Host Interactions of HIV factors | R-HSA-162909 | 3.718651e-01 | 0.430 | 0 | 0 |
| Signaling by ERBB4 | R-HSA-1236394 | 3.580590e-01 | 0.446 | 0 | 0 |
| HCMV Late Events | R-HSA-9610379 | 3.229520e-01 | 0.491 | 0 | 0 |
| Ion transport by P-type ATPases | R-HSA-936837 | 3.062713e-01 | 0.514 | 0 | 0 |
| Signaling by FGFR4 in disease | R-HSA-5655291 | 2.439125e-01 | 0.613 | 0 | 0 |
| Sensory processing of sound | R-HSA-9659379 | 2.383133e-01 | 0.623 | 0 | 0 |
| PECAM1 interactions | R-HSA-210990 | 3.098063e-01 | 0.509 | 0 | 0 |
| tRNA processing in the nucleus | R-HSA-6784531 | 2.749127e-01 | 0.561 | 0 | 0 |
| MAPK6/MAPK4 signaling | R-HSA-5687128 | 4.218884e-01 | 0.375 | 0 | 0 |
| Platelet homeostasis | R-HSA-418346 | 2.942884e-01 | 0.531 | 0 | 0 |
| Immune System | R-HSA-168256 | 2.425835e-01 | 0.615 | 0 | 0 |
| Stimuli-sensing channels | R-HSA-2672351 | 4.084451e-01 | 0.389 | 1 | 1 |
| Toxicity of botulinum toxin type C (botC) | R-HSA-5250971 | 2.550562e-01 | 0.593 | 0 | 0 |
| Constitutive Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant | R-HSA-2660826 | 3.062233e-01 | 0.514 | 0 | 0 |
| Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant | R-HSA-2660825 | 3.062233e-01 | 0.514 | 0 | 0 |
| ATF6 (ATF6-alpha) activates chaperone genes | R-HSA-381183 | 3.475068e-01 | 0.459 | 0 | 0 |
| OAS antiviral response | R-HSA-8983711 | 3.849893e-01 | 0.415 | 0 | 0 |
| Cytosolic sensors of pathogen-associated DNA | R-HSA-1834949 | 2.962926e-01 | 0.528 | 0 | 0 |
| Heme signaling | R-HSA-9707616 | 3.856921e-01 | 0.414 | 0 | 0 |
| Caspase activation via Dependence Receptors in the absence of ligand | R-HSA-418889 | 2.352382e-01 | 0.628 | 0 | 0 |
| RUNX1 regulates expression of components of tight junctions | R-HSA-8935964 | 3.062233e-01 | 0.514 | 0 | 0 |
| DSCAM interactions | R-HSA-376172 | 4.272079e-01 | 0.369 | 0 | 0 |
| Tandem pore domain potassium channels | R-HSA-1296346 | 2.722470e-01 | 0.565 | 0 | 0 |
| Formation of the anterior neural plate | R-HSA-9823739 | 2.741100e-01 | 0.562 | 0 | 0 |
| Activation of SMO | R-HSA-5635838 | 3.048789e-01 | 0.516 | 0 | 0 |
| SARS-CoV-1 modulates host translation machinery | R-HSA-9735869 | 2.170569e-01 | 0.663 | 0 | 0 |
| Signaling by PDGFR in disease | R-HSA-9671555 | 3.245170e-01 | 0.489 | 0 | 0 |
| SARS-CoV-2 modulates host translation machinery | R-HSA-9754678 | 2.515319e-01 | 0.599 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9683610 | 4.219451e-01 | 0.375 | 0 | 0 |
| Syndecan interactions | R-HSA-3000170 | 3.788735e-01 | 0.422 | 0 | 0 |
| Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | R-HSA-381676 | 3.959945e-01 | 0.402 | 0 | 0 |
| FLT3 signaling in disease | R-HSA-9682385 | 3.920091e-01 | 0.407 | 0 | 0 |
| Signal regulatory protein family interactions | R-HSA-391160 | 2.439125e-01 | 0.613 | 0 | 0 |
| ATF6 (ATF6-alpha) activates chaperones | R-HSA-381033 | 4.219451e-01 | 0.375 | 0 | 0 |
| Tie2 Signaling | R-HSA-210993 | 2.199432e-01 | 0.658 | 0 | 0 |
| Selenocysteine synthesis | R-HSA-2408557 | 2.247119e-01 | 0.648 | 0 | 0 |
| NrCAM interactions | R-HSA-447038 | 2.550562e-01 | 0.593 | 0 | 0 |
| Nuclear events stimulated by ALK signaling in cancer | R-HSA-9725371 | 2.586731e-01 | 0.587 | 0 | 0 |
| Growth hormone receptor signaling | R-HSA-982772 | 3.788735e-01 | 0.422 | 0 | 0 |
| Regulation of beta-cell development | R-HSA-186712 | 3.339142e-01 | 0.476 | 0 | 0 |
| SARS-CoV-2 Infection | R-HSA-9694516 | 2.763563e-01 | 0.559 | 0 | 0 |
| HDL assembly | R-HSA-8963896 | 2.439125e-01 | 0.613 | 0 | 0 |
| Unfolded Protein Response (UPR) | R-HSA-381119 | 4.205936e-01 | 0.376 | 0 | 0 |
| STING mediated induction of host immune responses | R-HSA-1834941 | 2.451875e-01 | 0.611 | 0 | 0 |
| Signaling by FLT3 ITD and TKD mutants | R-HSA-9703648 | 4.060669e-01 | 0.391 | 0 | 0 |
| ATF6B (ATF6-beta) activates chaperones | R-HSA-8874177 | 4.272079e-01 | 0.369 | 0 | 0 |
| Uptake and function of diphtheria toxin | R-HSA-5336415 | 4.057587e-01 | 0.392 | 0 | 0 |
| Nephron development | R-HSA-9831926 | 3.983337e-01 | 0.400 | 0 | 0 |
| CD28 dependent Vav1 pathway | R-HSA-389359 | 4.219451e-01 | 0.375 | 0 | 0 |
| Signaling by Leptin | R-HSA-2586552 | 2.722470e-01 | 0.565 | 0 | 0 |
| Replication of the SARS-CoV-1 genome | R-HSA-9682706 | 4.219451e-01 | 0.375 | 0 | 0 |
| PI-3K cascade:FGFR3 | R-HSA-5654710 | 4.291934e-01 | 0.367 | 0 | 0 |
| ATP-dependent chromatin remodelers | R-HSA-9932444 | 4.331009e-01 | 0.363 | 0 | 0 |
| SWI/SNF chromatin remodelers | R-HSA-9932451 | 4.331009e-01 | 0.363 | 0 | 0 |
| FRS-mediated FGFR1 signaling | R-HSA-5654693 | 4.331009e-01 | 0.363 | 0 | 0 |
| Interleukin-7 signaling | R-HSA-1266695 | 4.331009e-01 | 0.363 | 0 | 0 |
| Developmental Lineage of Multipotent Pancreatic Progenitor Cells | R-HSA-9937080 | 4.353778e-01 | 0.361 | 0 | 0 |
| Inwardly rectifying K+ channels | R-HSA-1296065 | 4.353778e-01 | 0.361 | 0 | 0 |
| IRE1alpha activates chaperones | R-HSA-381070 | 4.368321e-01 | 0.360 | 0 | 0 |
| Ion channel transport | R-HSA-983712 | 4.487827e-01 | 0.348 | 1 | 0 |
| Signaling by FGFR | R-HSA-190236 | 4.506816e-01 | 0.346 | 0 | 0 |
| XBP1(S) activates chaperone genes | R-HSA-381038 | 4.525882e-01 | 0.344 | 0 | 0 |
| RSK activation | R-HSA-444257 | 4.529532e-01 | 0.344 | 0 | 0 |
| Signaling by MRAS-complex mutants | R-HSA-9660537 | 4.529532e-01 | 0.344 | 0 | 0 |
| Gain-of-function MRAS complexes activate RAF signaling | R-HSA-9726842 | 4.529532e-01 | 0.344 | 0 | 0 |
| Adrenoceptors | R-HSA-390696 | 4.529532e-01 | 0.344 | 0 | 0 |
| Formyl peptide receptors bind formyl peptides and many other ligands | R-HSA-444473 | 4.529532e-01 | 0.344 | 0 | 0 |
| Neurotransmitter uptake and metabolism In glial cells | R-HSA-112313 | 4.529532e-01 | 0.344 | 0 | 0 |
| Astrocytic Glutamate-Glutamine Uptake And Metabolism | R-HSA-210455 | 4.529532e-01 | 0.344 | 0 | 0 |
| Downregulation of ERBB4 signaling | R-HSA-1253288 | 4.529532e-01 | 0.344 | 0 | 0 |
| PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 | R-HSA-8849469 | 4.529532e-01 | 0.344 | 0 | 0 |
| Co-stimulation by ICOS | R-HSA-9927354 | 4.529532e-01 | 0.344 | 0 | 0 |
| Activated NTRK2 signals through FYN | R-HSA-9032500 | 4.529532e-01 | 0.344 | 0 | 0 |
| BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members | R-HSA-111453 | 4.529532e-01 | 0.344 | 0 | 0 |
| Sodium/Proton exchangers | R-HSA-425986 | 4.529532e-01 | 0.344 | 0 | 0 |
| Signaling by MET | R-HSA-6806834 | 4.535485e-01 | 0.343 | 0 | 0 |
| Switching of origins to a post-replicative state | R-HSA-69052 | 4.545086e-01 | 0.342 | 0 | 0 |
| Orc1 removal from chromatin | R-HSA-68949 | 4.573104e-01 | 0.340 | 0 | 0 |
| Uptake and actions of bacterial toxins | R-HSA-5339562 | 4.573104e-01 | 0.340 | 0 | 0 |
| CRMPs in Sema3A signaling | R-HSA-399956 | 4.581140e-01 | 0.339 | 0 | 0 |
| YAP1- and WWTR1 (TAZ)-stimulated gene expression | R-HSA-2032785 | 4.581140e-01 | 0.339 | 0 | 0 |
| SARS-CoV-1 Genome Replication and Transcription | R-HSA-9679514 | 4.581140e-01 | 0.339 | 0 | 0 |
| ADORA2B mediated anti-inflammatory cytokines production | R-HSA-9660821 | 4.581672e-01 | 0.339 | 0 | 0 |
| Stabilization of p53 | R-HSA-69541 | 4.589332e-01 | 0.338 | 0 | 0 |
| Negative regulation of FGFR1 signaling | R-HSA-5654726 | 4.595407e-01 | 0.338 | 0 | 0 |
| Regulation of Expression and Function of Type II Classical Cadherins | R-HSA-9764260 | 4.595407e-01 | 0.338 | 0 | 0 |
| Cyclin A/B1/B2 associated events during G2/M transition | R-HSA-69273 | 4.595407e-01 | 0.338 | 0 | 0 |
| PI-3K cascade:FGFR4 | R-HSA-5654720 | 4.596178e-01 | 0.338 | 0 | 0 |
| Formation of neuronal progenitor and neuronal BAF (npBAF and nBAF) | R-HSA-9934037 | 4.596178e-01 | 0.338 | 0 | 0 |
| Rab regulation of trafficking | R-HSA-9007101 | 4.609636e-01 | 0.336 | 0 | 0 |
| SARS-CoV-2 activates/modulates innate and adaptive immune responses | R-HSA-9705671 | 4.680090e-01 | 0.330 | 0 | 0 |
| Transcriptional activation of mitochondrial biogenesis | R-HSA-2151201 | 4.694527e-01 | 0.328 | 0 | 0 |
| RNA Polymerase II Pre-transcription Events | R-HSA-674695 | 4.710870e-01 | 0.327 | 0 | 0 |
| Purinergic signaling in leishmaniasis infection | R-HSA-9660826 | 4.786666e-01 | 0.320 | 0 | 0 |
| Cell recruitment (pro-inflammatory response) | R-HSA-9664424 | 4.786666e-01 | 0.320 | 0 | 0 |
| Regulation of RUNX3 expression and activity | R-HSA-8941858 | 4.809376e-01 | 0.318 | 0 | 0 |
| Negative regulation of NOTCH4 signaling | R-HSA-9604323 | 4.809376e-01 | 0.318 | 0 | 0 |
| Interleukin-2 family signaling | R-HSA-451927 | 4.809376e-01 | 0.318 | 0 | 0 |
| Resolution of D-Loop Structures | R-HSA-5693537 | 4.834386e-01 | 0.316 | 0 | 0 |
| Miscellaneous transport and binding events | R-HSA-5223345 | 4.834386e-01 | 0.316 | 0 | 0 |
| Interaction between L1 and Ankyrins | R-HSA-445095 | 4.862425e-01 | 0.313 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in Cytochrome C Release | R-HSA-6803204 | 4.862425e-01 | 0.313 | 0 | 0 |
| Signaling by the B Cell Receptor (BCR) | R-HSA-983705 | 4.879589e-01 | 0.312 | 0 | 0 |
| TNFR1-induced proapoptotic signaling | R-HSA-5357786 | 4.894630e-01 | 0.310 | 0 | 0 |
| NOTCH4 Intracellular Domain Regulates Transcription | R-HSA-9013695 | 4.894630e-01 | 0.310 | 0 | 0 |
| Synthesis of DNA | R-HSA-69239 | 4.911645e-01 | 0.309 | 0 | 0 |
| RIP-mediated NFkB activation via ZBP1 | R-HSA-1810476 | 4.932815e-01 | 0.307 | 0 | 0 |
| Telomere C-strand synthesis initiation | R-HSA-174430 | 4.932815e-01 | 0.307 | 0 | 0 |
| Signaling by Activin | R-HSA-1502540 | 4.932815e-01 | 0.307 | 0 | 0 |
| Spry regulation of FGF signaling | R-HSA-1295596 | 4.932815e-01 | 0.307 | 0 | 0 |
| p75NTR signals via NF-kB | R-HSA-193639 | 4.932815e-01 | 0.307 | 0 | 0 |
| Signaling by PDGFRA extracellular domain mutants | R-HSA-9673770 | 4.932815e-01 | 0.307 | 0 | 0 |
| Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | R-HSA-9673767 | 4.932815e-01 | 0.307 | 0 | 0 |
| 5-Phosphoribose 1-diphosphate biosynthesis | R-HSA-73843 | 4.979272e-01 | 0.303 | 0 | 0 |
| Toxicity of botulinum toxin type A (botA) | R-HSA-5250968 | 4.979272e-01 | 0.303 | 0 | 0 |
| APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway | R-HSA-5649702 | 4.979272e-01 | 0.303 | 0 | 0 |
| Regulation of signaling by NODAL | R-HSA-1433617 | 4.979272e-01 | 0.303 | 0 | 0 |
| Calcineurin activates NFAT | R-HSA-2025928 | 4.979272e-01 | 0.303 | 0 | 0 |
| AMPK inhibits chREBP transcriptional activation activity | R-HSA-163680 | 4.979272e-01 | 0.303 | 0 | 0 |
| Regulation of CDH11 gene transcription | R-HSA-9762293 | 4.979272e-01 | 0.303 | 0 | 0 |
| Interleukin-1 processing | R-HSA-448706 | 4.979272e-01 | 0.303 | 0 | 0 |
| Regulation of commissural axon pathfinding by SLIT and ROBO | R-HSA-428542 | 4.979272e-01 | 0.303 | 0 | 0 |
| HuR (ELAVL1) binds and stabilizes mRNA | R-HSA-450520 | 4.979272e-01 | 0.303 | 0 | 0 |
| Respiratory syncytial virus genome replication | R-HSA-9834752 | 4.979272e-01 | 0.303 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of other transcription factors | R-HSA-8866906 | 5.017046e-01 | 0.300 | 0 | 0 |
| Axonal growth stimulation | R-HSA-209563 | 5.017046e-01 | 0.300 | 0 | 0 |
| Classical Kir channels | R-HSA-1296053 | 5.017046e-01 | 0.300 | 0 | 0 |
| Invadopodia formation | R-HSA-8941237 | 5.017046e-01 | 0.300 | 0 | 0 |
| Defective GCLC causes HAGGSD | R-HSA-5578999 | 5.017046e-01 | 0.300 | 0 | 0 |
| Negative regulation of TCF-dependent signaling by DVL-interacting proteins | R-HSA-5368598 | 5.017046e-01 | 0.300 | 0 | 0 |
| Diseases of Mismatch Repair (MMR) | R-HSA-5423599 | 5.017046e-01 | 0.300 | 0 | 0 |
| Histamine receptors | R-HSA-390650 | 5.017046e-01 | 0.300 | 0 | 0 |
| Regulation of MITF-M dependent genes involved in metabolism | R-HSA-9854907 | 5.017046e-01 | 0.300 | 0 | 0 |
| Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template | R-HSA-110313 | 5.026885e-01 | 0.299 | 0 | 0 |
| Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding | R-HSA-6814122 | 5.069984e-01 | 0.295 | 0 | 0 |
| NPAS4 regulates expression of target genes | R-HSA-9768919 | 5.069984e-01 | 0.295 | 0 | 0 |
| Negative regulation of FGFR2 signaling | R-HSA-5654727 | 5.069984e-01 | 0.295 | 0 | 0 |
| Developmental Lineage of Mammary Gland Alveolar Cells | R-HSA-9927426 | 5.069984e-01 | 0.295 | 0 | 0 |
| FRS-mediated FGFR2 signaling | R-HSA-5654700 | 5.121528e-01 | 0.291 | 0 | 0 |
| Formation of the HIV-1 Early Elongation Complex | R-HSA-167158 | 5.121528e-01 | 0.291 | 0 | 0 |
| Formation of the Early Elongation Complex | R-HSA-113418 | 5.121528e-01 | 0.291 | 0 | 0 |
| Degradation of GLI1 by the proteasome | R-HSA-5610780 | 5.241315e-01 | 0.281 | 0 | 0 |
| Degradation of GLI2 by the proteasome | R-HSA-5610783 | 5.241315e-01 | 0.281 | 0 | 0 |
| Telomere C-strand (Lagging Strand) Synthesis | R-HSA-174417 | 5.241315e-01 | 0.281 | 0 | 0 |
| SARS-CoV Infections | R-HSA-9679506 | 5.261682e-01 | 0.279 | 0 | 0 |
| Phosphorylation of the APC/C | R-HSA-176412 | 5.272753e-01 | 0.278 | 0 | 0 |
| WNT5A-dependent internalization of FZD4 | R-HSA-5099900 | 5.272753e-01 | 0.278 | 0 | 0 |
| SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | R-HSA-399955 | 5.272753e-01 | 0.278 | 0 | 0 |
| Negative regulation of FLT3 | R-HSA-9706369 | 5.272753e-01 | 0.278 | 0 | 0 |
| Nitric oxide stimulates guanylate cyclase | R-HSA-392154 | 5.375094e-01 | 0.270 | 0 | 0 |
| Degradation of CDH1 | R-HSA-9766229 | 5.388078e-01 | 0.269 | 0 | 0 |
| Activation of Ca-permeable Kainate Receptor | R-HSA-451308 | 5.404600e-01 | 0.267 | 0 | 0 |
| WNT5A-dependent internalization of FZD2, FZD5 and ROR2 | R-HSA-5140745 | 5.404600e-01 | 0.267 | 0 | 0 |
| Assembly and release of respiratory syncytial virus (RSV) virions | R-HSA-9820962 | 5.404600e-01 | 0.267 | 0 | 0 |
| PI-3K cascade:FGFR1 | R-HSA-5654689 | 5.469386e-01 | 0.262 | 0 | 0 |
| FGFR2 alternative splicing | R-HSA-6803529 | 5.469386e-01 | 0.262 | 0 | 0 |
| NOTCH3 Activation and Transmission of Signal to the Nucleus | R-HSA-9013507 | 5.469386e-01 | 0.262 | 0 | 0 |
| RAF-independent MAPK1/3 activation | R-HSA-112409 | 5.469386e-01 | 0.262 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9694676 | 5.469386e-01 | 0.262 | 0 | 0 |
| HIV Infection | R-HSA-162906 | 5.509863e-01 | 0.259 | 0 | 0 |
| Lysosome Vesicle Biogenesis | R-HSA-432720 | 5.528460e-01 | 0.257 | 0 | 0 |
| PI3K Cascade | R-HSA-109704 | 5.582617e-01 | 0.253 | 0 | 0 |
| Inositol phosphate metabolism | R-HSA-1483249 | 5.586963e-01 | 0.253 | 0 | 0 |
| SHC1 events in ERBB4 signaling | R-HSA-1250347 | 5.599618e-01 | 0.252 | 0 | 0 |
| Antigen processing: Ub, ATP-independent proteasomal degradation | R-HSA-9912633 | 5.599618e-01 | 0.252 | 0 | 0 |
| Transcriptional regulation of testis differentiation | R-HSA-9690406 | 5.599618e-01 | 0.252 | 0 | 0 |
| Passive transport by Aquaporins | R-HSA-432047 | 5.599618e-01 | 0.252 | 0 | 0 |
| DAP12 signaling | R-HSA-2424491 | 5.622406e-01 | 0.250 | 0 | 0 |
| Thrombin signalling through proteinase activated receptors (PARs) | R-HSA-456926 | 5.622406e-01 | 0.250 | 0 | 0 |
| TGF-beta receptor signaling activates SMADs | R-HSA-2173789 | 5.658995e-01 | 0.247 | 0 | 0 |
| HCN channels | R-HSA-1296061 | 5.665161e-01 | 0.247 | 0 | 0 |
| TLR3-mediated TICAM1-dependent programmed cell death | R-HSA-9013957 | 5.665161e-01 | 0.247 | 0 | 0 |
| Drug-mediated inhibition of CDK4/CDK6 activity | R-HSA-9754119 | 5.665161e-01 | 0.247 | 0 | 0 |
| Defective LFNG causes SCDO3 | R-HSA-5083630 | 5.665161e-01 | 0.247 | 0 | 0 |
| Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes | R-HSA-69200 | 5.665161e-01 | 0.247 | 0 | 0 |
| SARS-CoV-1-mediated effects on programmed cell death | R-HSA-9692913 | 5.665161e-01 | 0.247 | 0 | 0 |
| Alanine metabolism | R-HSA-8964540 | 5.665161e-01 | 0.247 | 0 | 0 |
| MDK and PTN in ALK signaling | R-HSA-9851151 | 5.665161e-01 | 0.247 | 0 | 0 |
| FLT3 signaling through SRC family kinases | R-HSA-9706374 | 5.665161e-01 | 0.247 | 0 | 0 |
| Ca2+ pathway | R-HSA-4086398 | 5.737521e-01 | 0.241 | 0 | 0 |
| Response of EIF2AK1 (HRI) to heme deficiency | R-HSA-9648895 | 5.743769e-01 | 0.241 | 0 | 0 |
| Ribosome-associated quality control | R-HSA-9948299 | 5.799942e-01 | 0.237 | 0 | 0 |
| Toll Like Receptor TLR6:TLR2 Cascade | R-HSA-168188 | 5.803001e-01 | 0.236 | 0 | 0 |
| MyD88:MAL(TIRAP) cascade initiated on plasma membrane | R-HSA-166058 | 5.803001e-01 | 0.236 | 0 | 0 |
| NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 | R-HSA-933543 | 5.804259e-01 | 0.236 | 0 | 0 |
| RHOBTB3 ATPase cycle | R-HSA-9706019 | 5.804259e-01 | 0.236 | 0 | 0 |
| FGFR2b ligand binding and activation | R-HSA-190377 | 5.804259e-01 | 0.236 | 0 | 0 |
| Presynaptic depolarization and calcium channel opening | R-HSA-112308 | 5.804259e-01 | 0.236 | 0 | 0 |
| Formation of the posterior neural plate | R-HSA-9832991 | 5.804259e-01 | 0.236 | 0 | 0 |
| Ionotropic activity of kainate receptors | R-HSA-451306 | 5.804259e-01 | 0.236 | 0 | 0 |
| Bicarbonate transporters | R-HSA-425381 | 5.804259e-01 | 0.236 | 0 | 0 |
| Cholesterol biosynthesis via desmosterol | R-HSA-6807047 | 5.804259e-01 | 0.236 | 0 | 0 |
| Transport of RCbl within the body | R-HSA-9758890 | 5.804259e-01 | 0.236 | 0 | 0 |
| LGI-ADAM interactions | R-HSA-5682910 | 5.804259e-01 | 0.236 | 0 | 0 |
| Prostanoid ligand receptors | R-HSA-391908 | 5.804259e-01 | 0.236 | 0 | 0 |
| Evasion by RSV of host interferon responses | R-HSA-9833109 | 5.862850e-01 | 0.232 | 0 | 0 |
| Extension of Telomeres | R-HSA-180786 | 5.876298e-01 | 0.231 | 0 | 0 |
| PI3K events in ERBB2 signaling | R-HSA-1963642 | 5.912413e-01 | 0.228 | 0 | 0 |
| Removal of the Flap Intermediate from the C-strand | R-HSA-174437 | 5.912413e-01 | 0.228 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) | R-HSA-5358565 | 5.912413e-01 | 0.228 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) | R-HSA-5358606 | 5.912413e-01 | 0.228 | 0 | 0 |
| Modulation of host responses by IFN-stimulated genes | R-HSA-9909505 | 5.912413e-01 | 0.228 | 0 | 0 |
| Synthesis of PIPs at the late endosome membrane | R-HSA-1660517 | 5.912413e-01 | 0.228 | 0 | 0 |
| Uptake and function of anthrax toxins | R-HSA-5210891 | 5.912413e-01 | 0.228 | 0 | 0 |
| Replication of the SARS-CoV-2 genome | R-HSA-9694686 | 5.912413e-01 | 0.228 | 0 | 0 |
| Fcgamma receptor (FCGR) dependent phagocytosis | R-HSA-2029480 | 5.943312e-01 | 0.226 | 0 | 0 |
| Response to elevated platelet cytosolic Ca2+ | R-HSA-76005 | 5.959083e-01 | 0.225 | 0 | 0 |
| Transcriptional Regulation by NPAS4 | R-HSA-9634815 | 5.960623e-01 | 0.225 | 0 | 0 |
| MET promotes cell motility | R-HSA-8875878 | 5.966370e-01 | 0.224 | 0 | 0 |
| Platelet degranulation | R-HSA-114608 | 6.004317e-01 | 0.222 | 0 | 0 |
| TRAF6 mediated NF-kB activation | R-HSA-933542 | 6.008499e-01 | 0.221 | 0 | 0 |
| Recognition of DNA damage by PCNA-containing replication complex | R-HSA-110314 | 6.008499e-01 | 0.221 | 0 | 0 |
| Plasma lipoprotein assembly | R-HSA-8963898 | 6.008499e-01 | 0.221 | 0 | 0 |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | R-HSA-975138 | 6.028910e-01 | 0.220 | 0 | 0 |
| RAB geranylgeranylation | R-HSA-8873719 | 6.050780e-01 | 0.218 | 0 | 0 |
| Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A | R-HSA-69601 | 6.059014e-01 | 0.218 | 0 | 0 |
| p53-Independent G1/S DNA Damage Checkpoint | R-HSA-69613 | 6.059014e-01 | 0.218 | 0 | 0 |
| Vasopressin regulates renal water homeostasis via Aquaporins | R-HSA-432040 | 6.059014e-01 | 0.218 | 0 | 0 |
| Transcription of the HIV genome | R-HSA-167172 | 6.133765e-01 | 0.212 | 0 | 0 |
| Golgi Associated Vesicle Biogenesis | R-HSA-432722 | 6.143487e-01 | 0.212 | 0 | 0 |
| MyD88 dependent cascade initiated on endosome | R-HSA-975155 | 6.158661e-01 | 0.211 | 0 | 0 |
| Toll Like Receptor 2 (TLR2) Cascade | R-HSA-181438 | 6.174678e-01 | 0.209 | 0 | 0 |
| Toll Like Receptor TLR1:TLR2 Cascade | R-HSA-168179 | 6.174678e-01 | 0.209 | 0 | 0 |
| Condensation of Prometaphase Chromosomes | R-HSA-2514853 | 6.177731e-01 | 0.209 | 0 | 0 |
| ERKs are inactivated | R-HSA-202670 | 6.177731e-01 | 0.209 | 0 | 0 |
| Cytochrome c-mediated apoptotic response | R-HSA-111461 | 6.177731e-01 | 0.209 | 0 | 0 |
| Sensing of DNA Double Strand Breaks | R-HSA-5693548 | 6.177731e-01 | 0.209 | 0 | 0 |
| Signaling by activated point mutants of FGFR1 | R-HSA-1839122 | 6.177731e-01 | 0.209 | 0 | 0 |
| Trafficking of GluR2-containing AMPA receptors | R-HSA-416993 | 6.210449e-01 | 0.207 | 0 | 0 |
| GAB1 signalosome | R-HSA-180292 | 6.210449e-01 | 0.207 | 0 | 0 |
| Apoptotic factor-mediated response | R-HSA-111471 | 6.210449e-01 | 0.207 | 0 | 0 |
| Mismatch Repair | R-HSA-5358508 | 6.210449e-01 | 0.207 | 0 | 0 |
| FGFR1 ligand binding and activation | R-HSA-190242 | 6.210449e-01 | 0.207 | 0 | 0 |
| ZBP1(DAI) mediated induction of type I IFNs | R-HSA-1606322 | 6.210449e-01 | 0.207 | 0 | 0 |
| Platelet sensitization by LDL | R-HSA-432142 | 6.210449e-01 | 0.207 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9679504 | 6.210449e-01 | 0.207 | 0 | 0 |
| Aquaporin-mediated transport | R-HSA-445717 | 6.221523e-01 | 0.206 | 0 | 0 |
| MAP kinase activation | R-HSA-450294 | 6.221523e-01 | 0.206 | 0 | 0 |
| Activation of AMPA receptors | R-HSA-399710 | 6.229011e-01 | 0.206 | 0 | 0 |
| Defective SLC1A3 causes episodic ataxia 6 (EA6) | R-HSA-5619062 | 6.229011e-01 | 0.206 | 0 | 0 |
| FLT3 signaling by CBL mutants | R-HSA-9706377 | 6.229011e-01 | 0.206 | 0 | 0 |
| Post-transcriptional silencing by small RNAs | R-HSA-426496 | 6.229011e-01 | 0.206 | 0 | 0 |
| Activation of AKT2 | R-HSA-165158 | 6.229011e-01 | 0.206 | 0 | 0 |
| PTK6 Down-Regulation | R-HSA-8849472 | 6.229011e-01 | 0.206 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in interleukin signaling | R-HSA-8939247 | 6.229011e-01 | 0.206 | 0 | 0 |
| Reelin signalling pathway | R-HSA-8866376 | 6.229011e-01 | 0.206 | 0 | 0 |
| Suppression of autophagy | R-HSA-9636569 | 6.229011e-01 | 0.206 | 0 | 0 |
| PTK6 Regulates Proteins Involved in RNA Processing | R-HSA-8849468 | 6.229011e-01 | 0.206 | 0 | 0 |
| Muscarinic acetylcholine receptors | R-HSA-390648 | 6.229011e-01 | 0.206 | 0 | 0 |
| Co-inhibition by BTLA | R-HSA-9927353 | 6.229011e-01 | 0.206 | 0 | 0 |
| PI-3K cascade:FGFR2 | R-HSA-5654695 | 6.263035e-01 | 0.203 | 0 | 0 |
| Glycogen breakdown (glycogenolysis) | R-HSA-70221 | 6.263035e-01 | 0.203 | 0 | 0 |
| Formation of the nephric duct | R-HSA-9830364 | 6.263035e-01 | 0.203 | 0 | 0 |
| CLEC7A (Dectin-1) signaling | R-HSA-5607764 | 6.281720e-01 | 0.202 | 0 | 0 |
| Resolution of D-loop Structures through Holliday Junction Intermediates | R-HSA-5693568 | 6.321184e-01 | 0.199 | 0 | 0 |
| Signaling by PDGF | R-HSA-186797 | 6.388320e-01 | 0.195 | 0 | 0 |
| Potential therapeutics for SARS | R-HSA-9679191 | 6.427810e-01 | 0.192 | 0 | 0 |
| Clathrin-mediated endocytosis | R-HSA-8856828 | 6.477789e-01 | 0.189 | 0 | 0 |
| Pre-NOTCH Processing in Golgi | R-HSA-1912420 | 6.493297e-01 | 0.188 | 0 | 0 |
| Translesion Synthesis by POLH | R-HSA-110320 | 6.493297e-01 | 0.188 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9694631 | 6.493297e-01 | 0.188 | 0 | 0 |
| Other interleukin signaling | R-HSA-449836 | 6.493297e-01 | 0.188 | 0 | 0 |
| SARS-CoV-2 Genome Replication and Transcription | R-HSA-9694682 | 6.493297e-01 | 0.188 | 0 | 0 |
| Caspase activation via extrinsic apoptotic signalling pathway | R-HSA-5357769 | 6.506977e-01 | 0.187 | 0 | 0 |
| Activated NOTCH1 Transmits Signal to the Nucleus | R-HSA-2122948 | 6.506977e-01 | 0.187 | 0 | 0 |
| Glutamate Neurotransmitter Release Cycle | R-HSA-210500 | 6.506977e-01 | 0.187 | 0 | 0 |
| Scavenging by Class F Receptors | R-HSA-3000484 | 6.525066e-01 | 0.185 | 0 | 0 |
| Serotonin clearance from the synaptic cleft | R-HSA-380615 | 6.525066e-01 | 0.185 | 0 | 0 |
| Advanced glycosylation endproduct receptor signaling | R-HSA-879415 | 6.525066e-01 | 0.185 | 0 | 0 |
| p75NTR recruits signalling complexes | R-HSA-209543 | 6.525066e-01 | 0.185 | 0 | 0 |
| Signaling by NOTCH1 HD Domain Mutants in Cancer | R-HSA-2691230 | 6.525066e-01 | 0.185 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD Domain Mutants | R-HSA-2691232 | 6.525066e-01 | 0.185 | 0 | 0 |
| Downregulation of ERBB2:ERBB3 signaling | R-HSA-1358803 | 6.525066e-01 | 0.185 | 0 | 0 |
| Estrogen biosynthesis | R-HSA-193144 | 6.525066e-01 | 0.185 | 0 | 0 |
| Cellular response to chemical stress | R-HSA-9711123 | 6.536975e-01 | 0.185 | 0 | 0 |
| NFE2L2 regulating anti-oxidant/detoxification enzymes | R-HSA-9818027 | 6.538327e-01 | 0.185 | 0 | 0 |
| Glucagon signaling in metabolic regulation | R-HSA-163359 | 6.538327e-01 | 0.185 | 0 | 0 |
| Toll Like Receptor 3 (TLR3) Cascade | R-HSA-168164 | 6.603223e-01 | 0.180 | 0 | 0 |
| APC/C-mediated degradation of cell cycle proteins | R-HSA-174143 | 6.604551e-01 | 0.180 | 0 | 0 |
| Regulation of mitotic cell cycle | R-HSA-453276 | 6.604551e-01 | 0.180 | 0 | 0 |
| NGF-stimulated transcription | R-HSA-9031628 | 6.620317e-01 | 0.179 | 0 | 0 |
| Metal ion SLC transporters | R-HSA-425410 | 6.620317e-01 | 0.179 | 0 | 0 |
| Toll Like Receptor 7/8 (TLR7/8) Cascade | R-HSA-168181 | 6.656922e-01 | 0.177 | 0 | 0 |
| TNF signaling | R-HSA-75893 | 6.664633e-01 | 0.176 | 0 | 0 |
| Circadian clock | R-HSA-9909396 | 6.697324e-01 | 0.174 | 0 | 0 |
| Nef Mediated CD8 Down-regulation | R-HSA-182218 | 6.719546e-01 | 0.173 | 0 | 0 |
| Signaling by Overexpressed Wild-Type EGFR in Cancer | R-HSA-5638302 | 6.719546e-01 | 0.173 | 0 | 0 |
| PDE3B signalling | R-HSA-165160 | 6.719546e-01 | 0.173 | 0 | 0 |
| PKB-mediated events | R-HSA-109703 | 6.719546e-01 | 0.173 | 0 | 0 |
| IkBA variant leads to EDA-ID | R-HSA-5603029 | 6.719546e-01 | 0.173 | 0 | 0 |
| Inhibition of Signaling by Overexpressed EGFR | R-HSA-5638303 | 6.719546e-01 | 0.173 | 0 | 0 |
| Signaling by RNF43 mutants | R-HSA-5340588 | 6.719546e-01 | 0.173 | 0 | 0 |
| Aryl hydrocarbon receptor signalling | R-HSA-8937144 | 6.719546e-01 | 0.173 | 0 | 0 |
| Pentose phosphate pathway disease | R-HSA-6791465 | 6.719546e-01 | 0.173 | 0 | 0 |
| Phosphorylation of Emi1 | R-HSA-176417 | 6.719546e-01 | 0.173 | 0 | 0 |
| SLIT2:ROBO1 increases RHOA activity | R-HSA-8985586 | 6.719546e-01 | 0.173 | 0 | 0 |
| Signalling to p38 via RIT and RIN | R-HSA-187706 | 6.719546e-01 | 0.173 | 0 | 0 |
| Negative feedback regulation of MAPK pathway | R-HSA-5674499 | 6.719546e-01 | 0.173 | 0 | 0 |
| Acetylcholine inhibits contraction of outer hair cells | R-HSA-9667769 | 6.719546e-01 | 0.173 | 0 | 0 |
| CLEC7A/inflammasome pathway | R-HSA-5660668 | 6.719546e-01 | 0.173 | 0 | 0 |
| Sodium-coupled phosphate cotransporters | R-HSA-427652 | 6.719546e-01 | 0.173 | 0 | 0 |
| TYSND1 cleaves peroxisomal proteins | R-HSA-9033500 | 6.719546e-01 | 0.173 | 0 | 0 |
| TNFR1-induced NF-kappa-B signaling pathway | R-HSA-5357956 | 6.740058e-01 | 0.171 | 0 | 0 |
| Signaling by NOTCH2 | R-HSA-1980145 | 6.747101e-01 | 0.171 | 0 | 0 |
| Mitophagy | R-HSA-5205647 | 6.747101e-01 | 0.171 | 0 | 0 |
| trans-Golgi Network Vesicle Budding | R-HSA-199992 | 6.753968e-01 | 0.170 | 0 | 0 |
| Nuclear Events (kinase and transcription factor activation) | R-HSA-198725 | 6.753968e-01 | 0.170 | 0 | 0 |
| Regulation of mRNA stability by proteins that bind AU-rich elements | R-HSA-450531 | 6.753968e-01 | 0.170 | 0 | 0 |
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | R-HSA-983695 | 6.755190e-01 | 0.170 | 0 | 0 |
| VxPx cargo-targeting to cilium | R-HSA-5620916 | 6.760757e-01 | 0.170 | 0 | 0 |
| Negative regulation of MET activity | R-HSA-6807004 | 6.760757e-01 | 0.170 | 0 | 0 |
| Protein hydroxylation | R-HSA-9629569 | 6.760757e-01 | 0.170 | 0 | 0 |
| Signal transduction by L1 | R-HSA-445144 | 6.760757e-01 | 0.170 | 0 | 0 |
| Eicosanoid ligand-binding receptors | R-HSA-391903 | 6.760757e-01 | 0.170 | 0 | 0 |
| BBSome-mediated cargo-targeting to cilium | R-HSA-5620922 | 6.760757e-01 | 0.170 | 0 | 0 |
| GLI3 is processed to GLI3R by the proteasome | R-HSA-5610785 | 6.767917e-01 | 0.170 | 0 | 0 |
| DNA Damage Bypass | R-HSA-73893 | 6.796165e-01 | 0.168 | 0 | 0 |
| G alpha (q) signalling events | R-HSA-416476 | 6.811173e-01 | 0.167 | 0 | 0 |
| Regulation of CDH1 Function | R-HSA-9764561 | 6.828587e-01 | 0.166 | 0 | 0 |
| FGFR2c ligand binding and activation | R-HSA-190375 | 6.846744e-01 | 0.165 | 0 | 0 |
| FGFR4 ligand binding and activation | R-HSA-190322 | 6.846744e-01 | 0.165 | 0 | 0 |
| Signaling by activated point mutants of FGFR3 | R-HSA-1839130 | 6.846744e-01 | 0.165 | 0 | 0 |
| FGFR3 mutant receptor activation | R-HSA-2033514 | 6.846744e-01 | 0.165 | 0 | 0 |
| Nuclear events mediated by NFE2L2 | R-HSA-9759194 | 6.935557e-01 | 0.159 | 0 | 0 |
| RNA Polymerase I Transcription Initiation | R-HSA-73762 | 6.951342e-01 | 0.158 | 0 | 0 |
| ATF4 activates genes in response to endoplasmic reticulum stress | R-HSA-380994 | 6.962129e-01 | 0.157 | 0 | 0 |
| Telomere Extension By Telomerase | R-HSA-171319 | 6.962129e-01 | 0.157 | 0 | 0 |
| Phase 0 - rapid depolarisation | R-HSA-5576892 | 6.962129e-01 | 0.157 | 0 | 0 |
| Pyroptosis | R-HSA-5620971 | 6.962129e-01 | 0.157 | 0 | 0 |
| Viral Infection Pathways | R-HSA-9824446 | 6.974664e-01 | 0.156 | 0 | 0 |
| Early SARS-CoV-2 Infection Events | R-HSA-9772572 | 6.987433e-01 | 0.156 | 0 | 0 |
| Toll Like Receptor 9 (TLR9) Cascade | R-HSA-168138 | 7.006512e-01 | 0.154 | 0 | 0 |
| NOTCH2 Activation and Transmission of Signal to the Nucleus | R-HSA-2979096 | 7.012822e-01 | 0.154 | 0 | 0 |
| MyD88 deficiency (TLR2/4) | R-HSA-5602498 | 7.012822e-01 | 0.154 | 0 | 0 |
| JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | R-HSA-450321 | 7.012822e-01 | 0.154 | 0 | 0 |
| ERK/MAPK targets | R-HSA-198753 | 7.012822e-01 | 0.154 | 0 | 0 |
| Acetylcholine Neurotransmitter Release Cycle | R-HSA-264642 | 7.012822e-01 | 0.154 | 0 | 0 |
| Zygotic genome activation (ZGA) | R-HSA-9819196 | 7.012822e-01 | 0.154 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in apoptosis | R-HSA-9824594 | 7.012822e-01 | 0.154 | 0 | 0 |
| Antigen processing: Ubiquitination & Proteasome degradation | R-HSA-983168 | 7.045617e-01 | 0.152 | 0 | 0 |
| C-type lectin receptors (CLRs) | R-HSA-5621481 | 7.117266e-01 | 0.148 | 0 | 0 |
| Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide | R-HSA-9954709 | 7.132392e-01 | 0.147 | 0 | 0 |
| RNA Polymerase III Abortive And Retractive Initiation | R-HSA-749476 | 7.138935e-01 | 0.146 | 0 | 0 |
| RNA Polymerase III Transcription | R-HSA-74158 | 7.138935e-01 | 0.146 | 0 | 0 |
| AUF1 (hnRNP D0) binds and destabilizes mRNA | R-HSA-450408 | 7.138935e-01 | 0.146 | 0 | 0 |
| FGFR2 mutant receptor activation | R-HSA-1839126 | 7.138935e-01 | 0.146 | 0 | 0 |
| GPVI-mediated activation cascade | R-HSA-114604 | 7.138935e-01 | 0.146 | 0 | 0 |
| Triglyceride catabolism | R-HSA-163560 | 7.138935e-01 | 0.146 | 0 | 0 |
| Regulation of CDH1 mRNA translation by microRNAs | R-HSA-9764562 | 7.143561e-01 | 0.146 | 0 | 0 |
| Formation of the canonical BAF (cBAF) complex | R-HSA-9933937 | 7.143561e-01 | 0.146 | 0 | 0 |
| Removal of the Flap Intermediate | R-HSA-69166 | 7.143561e-01 | 0.146 | 0 | 0 |
| Phospholipase C-mediated cascade; FGFR3 | R-HSA-5654227 | 7.143561e-01 | 0.146 | 0 | 0 |
| Retrograde neurotrophin signalling | R-HSA-177504 | 7.143561e-01 | 0.146 | 0 | 0 |
| ERBB2 Activates PTK6 Signaling | R-HSA-8847993 | 7.143561e-01 | 0.146 | 0 | 0 |
| TP53 Regulates Transcription of Death Receptors and Ligands | R-HSA-6803211 | 7.143561e-01 | 0.146 | 0 | 0 |
| FGFR3c ligand binding and activation | R-HSA-190372 | 7.143561e-01 | 0.146 | 0 | 0 |
| Erythropoietin activates STAT5 | R-HSA-9027283 | 7.146297e-01 | 0.146 | 0 | 0 |
| RUNX3 regulates YAP1-mediated transcription | R-HSA-8951671 | 7.146297e-01 | 0.146 | 0 | 0 |
| Toxicity of botulinum toxin type F (botF) | R-HSA-5250981 | 7.146297e-01 | 0.146 | 0 | 0 |
| Toxicity of botulinum toxin type D (botD) | R-HSA-5250955 | 7.146297e-01 | 0.146 | 0 | 0 |
| Intracellular metabolism of fatty acids regulates insulin secretion | R-HSA-434313 | 7.146297e-01 | 0.146 | 0 | 0 |
| Lactose synthesis | R-HSA-5653890 | 7.146297e-01 | 0.146 | 0 | 0 |
| Activation of NIMA Kinases NEK9, NEK6, NEK7 | R-HSA-2980767 | 7.146297e-01 | 0.146 | 0 | 0 |
| Signaling by LTK in cancer | R-HSA-9842640 | 7.146297e-01 | 0.146 | 0 | 0 |
| Leukotriene receptors | R-HSA-391906 | 7.146297e-01 | 0.146 | 0 | 0 |
| Defective factor VIII causes hemophilia A | R-HSA-9662001 | 7.146297e-01 | 0.146 | 0 | 0 |
| TCR signaling | R-HSA-202403 | 7.195571e-01 | 0.143 | 0 | 0 |
| TRIF (TICAM1)-mediated TLR4 signaling | R-HSA-937061 | 7.195571e-01 | 0.143 | 0 | 0 |
| MyD88-independent TLR4 cascade | R-HSA-166166 | 7.195571e-01 | 0.143 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 2 Promoter | R-HSA-76066 | 7.249646e-01 | 0.140 | 0 | 0 |
| IRAK4 deficiency (TLR2/4) | R-HSA-5603041 | 7.249646e-01 | 0.140 | 0 | 0 |
| Mitochondrial calcium ion transport | R-HSA-8949215 | 7.249646e-01 | 0.140 | 0 | 0 |
| Cargo recognition for clathrin-mediated endocytosis | R-HSA-8856825 | 7.278652e-01 | 0.138 | 0 | 0 |
| SCF(Skp2)-mediated degradation of p27/p21 | R-HSA-187577 | 7.296904e-01 | 0.137 | 0 | 0 |
| Amine ligand-binding receptors | R-HSA-375280 | 7.296904e-01 | 0.137 | 0 | 0 |
| Interferon gamma signaling | R-HSA-877300 | 7.320765e-01 | 0.135 | 0 | 0 |
| Voltage gated Potassium channels | R-HSA-1296072 | 7.321864e-01 | 0.135 | 0 | 0 |
| RNA Polymerase III Transcription Initiation | R-HSA-76046 | 7.373139e-01 | 0.132 | 0 | 0 |
| Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | R-HSA-1474151 | 7.373139e-01 | 0.132 | 0 | 0 |
| GABA synthesis, release, reuptake and degradation | R-HSA-888590 | 7.373139e-01 | 0.132 | 0 | 0 |
| Developmental Cell Lineages of the Exocrine Pancreas | R-HSA-9820448 | 7.381172e-01 | 0.132 | 0 | 0 |
| Interleukin-1 family signaling | R-HSA-446652 | 7.381172e-01 | 0.132 | 0 | 0 |
| Adenylate cyclase inhibitory pathway | R-HSA-170670 | 7.416542e-01 | 0.130 | 0 | 0 |
| Phospholipase C-mediated cascade; FGFR4 | R-HSA-5654228 | 7.416542e-01 | 0.130 | 0 | 0 |
| Processive synthesis on the lagging strand | R-HSA-69183 | 7.416542e-01 | 0.130 | 0 | 0 |
| FGFR3 ligand binding and activation | R-HSA-190239 | 7.416542e-01 | 0.130 | 0 | 0 |
| InlB-mediated entry of Listeria monocytogenes into host cell | R-HSA-8875360 | 7.416542e-01 | 0.130 | 0 | 0 |
| Lysosphingolipid and LPA receptors | R-HSA-419408 | 7.416542e-01 | 0.130 | 0 | 0 |
| Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA | R-HSA-450385 | 7.416542e-01 | 0.130 | 0 | 0 |
| Protein methylation | R-HSA-8876725 | 7.416542e-01 | 0.130 | 0 | 0 |
| Regulation of PTEN stability and activity | R-HSA-8948751 | 7.439799e-01 | 0.128 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 1 Promoter | R-HSA-76061 | 7.471514e-01 | 0.127 | 0 | 0 |
| Regulation of IFNA/IFNB signaling | R-HSA-912694 | 7.471514e-01 | 0.127 | 0 | 0 |
| Neurotoxicity of clostridium toxins | R-HSA-168799 | 7.471514e-01 | 0.127 | 0 | 0 |
| Ethanol oxidation | R-HSA-71384 | 7.471514e-01 | 0.127 | 0 | 0 |
| Cholesterol biosynthesis via lathosterol | R-HSA-6807062 | 7.471514e-01 | 0.127 | 0 | 0 |
| LDL clearance | R-HSA-8964038 | 7.471514e-01 | 0.127 | 0 | 0 |
| Metabolism of nitric oxide: NOS3 activation and regulation | R-HSA-202131 | 7.496143e-01 | 0.125 | 0 | 0 |
| RUNX3 Regulates Immune Response and Cell Migration | R-HSA-8949275 | 7.517554e-01 | 0.124 | 0 | 0 |
| NOSTRIN mediated eNOS trafficking | R-HSA-203641 | 7.517554e-01 | 0.124 | 0 | 0 |
| TRIF-mediated programmed cell death | R-HSA-2562578 | 7.517554e-01 | 0.124 | 0 | 0 |
| IFNG signaling activates MAPKs | R-HSA-9732724 | 7.517554e-01 | 0.124 | 0 | 0 |
| FGFR3b ligand binding and activation | R-HSA-190371 | 7.517554e-01 | 0.124 | 0 | 0 |
| Pre-NOTCH Processing in the Endoplasmic Reticulum | R-HSA-1912399 | 7.517554e-01 | 0.124 | 0 | 0 |
| Disinhibition of SNARE formation | R-HSA-114516 | 7.517554e-01 | 0.124 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression to limit cholesterol uptake | R-HSA-9031525 | 7.517554e-01 | 0.124 | 0 | 0 |
| Recycling of eIF2:GDP | R-HSA-72731 | 7.517554e-01 | 0.124 | 0 | 0 |
| Activated NTRK2 signals through CDK5 | R-HSA-9032845 | 7.517554e-01 | 0.124 | 0 | 0 |
| Microbial modulation of RIPK1-mediated regulated necrosis | R-HSA-9686347 | 7.517554e-01 | 0.124 | 0 | 0 |
| MET activates PI3K/AKT signaling | R-HSA-8851907 | 7.517554e-01 | 0.124 | 0 | 0 |
| VLDL clearance | R-HSA-8964046 | 7.517554e-01 | 0.124 | 0 | 0 |
| Synthesis of PIPs in the nucleus | R-HSA-8847453 | 7.517554e-01 | 0.124 | 0 | 0 |
| Insulin effects increased synthesis of Xylulose-5-Phosphate | R-HSA-163754 | 7.517554e-01 | 0.124 | 0 | 0 |
| Phase 3 - rapid repolarisation | R-HSA-5576890 | 7.517554e-01 | 0.124 | 0 | 0 |
| Glycoprotein hormones | R-HSA-209822 | 7.517554e-01 | 0.124 | 0 | 0 |
| Cation-coupled Chloride cotransporters | R-HSA-426117 | 7.517554e-01 | 0.124 | 0 | 0 |
| Maturation of replicase proteins | R-HSA-9694301 | 7.517554e-01 | 0.124 | 0 | 0 |
| Budding and maturation of HIV virion | R-HSA-162588 | 7.562246e-01 | 0.121 | 0 | 0 |
| Interleukin-17 signaling | R-HSA-448424 | 7.564180e-01 | 0.121 | 0 | 0 |
| Signaling by Insulin receptor | R-HSA-74752 | 7.579088e-01 | 0.120 | 0 | 0 |
| Regulation of TNFR1 signaling | R-HSA-5357905 | 7.613887e-01 | 0.118 | 0 | 0 |
| Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion | R-HSA-434316 | 7.666863e-01 | 0.115 | 0 | 0 |
| KSRP (KHSRP) binds and destabilizes mRNA | R-HSA-450604 | 7.666863e-01 | 0.115 | 0 | 0 |
| Fructose catabolism | R-HSA-70350 | 7.666863e-01 | 0.115 | 0 | 0 |
| Regulation of BACH1 activity | R-HSA-9708530 | 7.666863e-01 | 0.115 | 0 | 0 |
| Regulation of NF-kappa B signaling | R-HSA-9758274 | 7.666863e-01 | 0.115 | 0 | 0 |
| Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells | R-HSA-210744 | 7.666863e-01 | 0.115 | 0 | 0 |
| Free fatty acids regulate insulin secretion | R-HSA-400451 | 7.678819e-01 | 0.115 | 0 | 0 |
| RNA polymerase II transcribes snRNA genes | R-HSA-6807505 | 7.685339e-01 | 0.114 | 0 | 0 |
| Toll Like Receptor 4 (TLR4) Cascade | R-HSA-166016 | 7.712169e-01 | 0.113 | 0 | 0 |
| Signaling by NOTCH3 | R-HSA-9012852 | 7.725138e-01 | 0.112 | 0 | 0 |
| Selenoamino acid metabolism | R-HSA-2408522 | 7.752211e-01 | 0.111 | 0 | 0 |
| TAK1-dependent IKK and NF-kappa-B activation | R-HSA-445989 | 7.761730e-01 | 0.110 | 0 | 0 |
| Diseases associated with the TLR signaling cascade | R-HSA-5602358 | 7.819087e-01 | 0.107 | 0 | 0 |
| Diseases of Immune System | R-HSA-5260271 | 7.819087e-01 | 0.107 | 0 | 0 |
| Nuclear signaling by ERBB4 | R-HSA-1251985 | 7.819087e-01 | 0.107 | 0 | 0 |
| EGFR interacts with phospholipase C-gamma | R-HSA-212718 | 7.840531e-01 | 0.106 | 0 | 0 |
| Activated NTRK2 signals through PI3K | R-HSA-9028335 | 7.840531e-01 | 0.106 | 0 | 0 |
| Formation of annular gap junctions | R-HSA-196025 | 7.840531e-01 | 0.106 | 0 | 0 |
| Regulation of NPAS4 mRNA translation | R-HSA-9768778 | 7.840531e-01 | 0.106 | 0 | 0 |
| Interleukin-9 signaling | R-HSA-8985947 | 7.840531e-01 | 0.106 | 0 | 0 |
| Axonal growth inhibition (RHOA activation) | R-HSA-193634 | 7.840531e-01 | 0.106 | 0 | 0 |
| Regulation by c-FLIP | R-HSA-3371378 | 7.840531e-01 | 0.106 | 0 | 0 |
| Dimerization of procaspase-8 | R-HSA-69416 | 7.840531e-01 | 0.106 | 0 | 0 |
| TGFBR3 PTM regulation | R-HSA-9839383 | 7.840531e-01 | 0.106 | 0 | 0 |
| Regulation of TBK1, IKKε-mediated activation of IRF3, IRF7 upon TLR3 ligation | R-HSA-9828211 | 7.840531e-01 | 0.106 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in TC-NER | R-HSA-6782210 | 7.858738e-01 | 0.105 | 0 | 0 |
| Norepinephrine Neurotransmitter Release Cycle | R-HSA-181430 | 7.872040e-01 | 0.104 | 0 | 0 |
| Inactivation of APC/C via direct inhibition of the APC/C complex | R-HSA-141430 | 7.895800e-01 | 0.103 | 0 | 0 |
| Regulation of innate immune responses to cytosolic DNA | R-HSA-3134975 | 7.895800e-01 | 0.103 | 0 | 0 |
| Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components | R-HSA-141405 | 7.895800e-01 | 0.103 | 0 | 0 |
| Synthesis of PG | R-HSA-1483148 | 7.895800e-01 | 0.103 | 0 | 0 |
| STAT5 activation downstream of FLT3 ITD mutants | R-HSA-9702518 | 7.895800e-01 | 0.103 | 0 | 0 |
| DDX58/IFIH1-mediated induction of interferon-alpha/beta | R-HSA-168928 | 7.900407e-01 | 0.102 | 0 | 0 |
| Synthesis of IP3 and IP4 in the cytosol | R-HSA-1855204 | 7.908595e-01 | 0.102 | 0 | 0 |
| Beta-catenin independent WNT signaling | R-HSA-3858494 | 7.936339e-01 | 0.100 | 0 | 0 |
| Cellular response to hypoxia | R-HSA-1234174 | 7.951682e-01 | 0.100 | 0 | 0 |
| SPOP-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929491 | 7.968023e-01 | 0.099 | 0 | 0 |
| Maturation of spike protein | R-HSA-9694548 | 7.968023e-01 | 0.099 | 0 | 0 |
| G protein gated Potassium channels | R-HSA-1296059 | 8.051717e-01 | 0.094 | 0 | 0 |
| Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits | R-HSA-997272 | 8.051717e-01 | 0.094 | 0 | 0 |
| Activation of G protein gated Potassium channels | R-HSA-1296041 | 8.051717e-01 | 0.094 | 0 | 0 |
| Tight junction interactions | R-HSA-420029 | 8.051717e-01 | 0.094 | 0 | 0 |
| Synthesis of PIPs at the early endosome membrane | R-HSA-1660516 | 8.051717e-01 | 0.094 | 0 | 0 |
| Acyl chain remodelling of PS | R-HSA-1482801 | 8.051717e-01 | 0.094 | 0 | 0 |
| Glutamate and glutamine metabolism | R-HSA-8964539 | 8.066376e-01 | 0.093 | 0 | 0 |
| Phospholipase C-mediated cascade: FGFR1 | R-HSA-5654219 | 8.104678e-01 | 0.091 | 0 | 0 |
| Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase | R-HSA-176407 | 8.104678e-01 | 0.091 | 0 | 0 |
| Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters | R-HSA-164938 | 8.104678e-01 | 0.091 | 0 | 0 |
| Regulation of NPAS4 gene expression | R-HSA-9768759 | 8.104678e-01 | 0.091 | 0 | 0 |
| NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | R-HSA-9029569 | 8.108140e-01 | 0.091 | 0 | 0 |
| Dual incision in TC-NER | R-HSA-6782135 | 8.108140e-01 | 0.091 | 0 | 0 |
| SLC-mediated transport of neurotransmitters | R-HSA-442660 | 8.108842e-01 | 0.091 | 0 | 0 |
| Lipophagy | R-HSA-9613354 | 8.121503e-01 | 0.090 | 0 | 0 |
| Gap junction degradation | R-HSA-190873 | 8.121503e-01 | 0.090 | 0 | 0 |
| CASP8 activity is inhibited | R-HSA-5218900 | 8.121503e-01 | 0.090 | 0 | 0 |
| MASTL Facilitates Mitotic Progression | R-HSA-2465910 | 8.121503e-01 | 0.090 | 0 | 0 |
| p75NTR regulates axonogenesis | R-HSA-193697 | 8.121503e-01 | 0.090 | 0 | 0 |
| Inactivation of CDC42 and RAC1 | R-HSA-428543 | 8.121503e-01 | 0.090 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex | R-HSA-937042 | 8.121503e-01 | 0.090 | 0 | 0 |
| Activation of the AP-1 family of transcription factors | R-HSA-450341 | 8.121503e-01 | 0.090 | 0 | 0 |
| Regulation of NPAS4 gene transcription | R-HSA-9768777 | 8.121503e-01 | 0.090 | 0 | 0 |
| Regulated proteolysis of p75NTR | R-HSA-193692 | 8.121503e-01 | 0.090 | 0 | 0 |
| Zinc influx into cells by the SLC39 gene family | R-HSA-442380 | 8.121503e-01 | 0.090 | 0 | 0 |
| Cellular response to mitochondrial stress | R-HSA-9840373 | 8.121503e-01 | 0.090 | 0 | 0 |
| Transcription-Coupled Nucleotide Excision Repair (TC-NER) | R-HSA-6781827 | 8.147588e-01 | 0.089 | 0 | 0 |
| Kidney development | R-HSA-9830369 | 8.179933e-01 | 0.087 | 0 | 0 |
| BMAL1:CLOCK,NPAS2 activates circadian expression | R-HSA-1368108 | 8.214320e-01 | 0.085 | 0 | 0 |
| Ubiquitin-dependent degradation of Cyclin D | R-HSA-75815 | 8.214320e-01 | 0.085 | 0 | 0 |
| eNOS activation | R-HSA-203615 | 8.214320e-01 | 0.085 | 0 | 0 |
| NOD1/2 Signaling Pathway | R-HSA-168638 | 8.214320e-01 | 0.085 | 0 | 0 |
| Regulation of RUNX1 Expression and Activity | R-HSA-8934593 | 8.218439e-01 | 0.085 | 0 | 0 |
| Global Genome Nucleotide Excision Repair (GG-NER) | R-HSA-5696399 | 8.223635e-01 | 0.085 | 0 | 0 |
| Activation of GABAB receptors | R-HSA-991365 | 8.241757e-01 | 0.084 | 0 | 0 |
| GABA B receptor activation | R-HSA-977444 | 8.241757e-01 | 0.084 | 0 | 0 |
| ER to Golgi Anterograde Transport | R-HSA-199977 | 8.256832e-01 | 0.083 | 0 | 0 |
| Nucleotide Excision Repair | R-HSA-5696398 | 8.267556e-01 | 0.083 | 0 | 0 |
| Activation of NF-kappaB in B cells | R-HSA-1169091 | 8.284383e-01 | 0.082 | 0 | 0 |
| RNA Polymerase III Transcription Termination | R-HSA-73980 | 8.294841e-01 | 0.081 | 0 | 0 |
| Activated point mutants of FGFR2 | R-HSA-2033519 | 8.294841e-01 | 0.081 | 0 | 0 |
| Vitamin D (calciferol) metabolism | R-HSA-196791 | 8.294841e-01 | 0.081 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition | R-HSA-9926550 | 8.294841e-01 | 0.081 | 0 | 0 |
| GABA receptor activation | R-HSA-977443 | 8.334495e-01 | 0.079 | 0 | 0 |
| Erythropoietin activates Phospholipase C gamma (PLCG) | R-HSA-9027277 | 8.365931e-01 | 0.077 | 0 | 0 |
| 2-LTR circle formation | R-HSA-164843 | 8.365931e-01 | 0.077 | 0 | 0 |
| DNA replication initiation | R-HSA-68952 | 8.365931e-01 | 0.077 | 0 | 0 |
| Activation of PPARGC1A (PGC-1alpha) by phosphorylation | R-HSA-2151209 | 8.365931e-01 | 0.077 | 0 | 0 |
| Regulation of the apoptosome activity | R-HSA-9627069 | 8.365931e-01 | 0.077 | 0 | 0 |
| Formation of apoptosome | R-HSA-111458 | 8.365931e-01 | 0.077 | 0 | 0 |
| TET1,2,3 and TDG demethylate DNA | R-HSA-5221030 | 8.365931e-01 | 0.077 | 0 | 0 |
| Defective RIPK1-mediated regulated necrosis | R-HSA-9693928 | 8.365931e-01 | 0.077 | 0 | 0 |
| TICAM1,TRAF6-dependent induction of TAK1 complex | R-HSA-9014325 | 8.365931e-01 | 0.077 | 0 | 0 |
| Metabolism of serotonin | R-HSA-380612 | 8.365931e-01 | 0.077 | 0 | 0 |
| Ion influx/efflux at host-pathogen interface | R-HSA-6803544 | 8.365931e-01 | 0.077 | 0 | 0 |
| Formation of intermediate mesoderm | R-HSA-9761174 | 8.365931e-01 | 0.077 | 0 | 0 |
| Maturation of spike protein | R-HSA-9683686 | 8.365931e-01 | 0.077 | 0 | 0 |
| Metal sequestration by antimicrobial proteins | R-HSA-6799990 | 8.365931e-01 | 0.077 | 0 | 0 |
| Peptide hormone biosynthesis | R-HSA-209952 | 8.365931e-01 | 0.077 | 0 | 0 |
| TBC/RABGAPs | R-HSA-8854214 | 8.367007e-01 | 0.077 | 0 | 0 |
| Processive synthesis on the C-strand of the telomere | R-HSA-174414 | 8.372827e-01 | 0.077 | 0 | 0 |
| RNA Polymerase I Transcription Termination | R-HSA-73863 | 8.372827e-01 | 0.077 | 0 | 0 |
| Insulin processing | R-HSA-264876 | 8.372827e-01 | 0.077 | 0 | 0 |
| Gastrulation | R-HSA-9758941 | 8.397921e-01 | 0.076 | 0 | 0 |
| E3 ubiquitin ligases ubiquitinate target proteins | R-HSA-8866654 | 8.398591e-01 | 0.076 | 0 | 0 |
| SARS-CoV-1 activates/modulates innate immune responses | R-HSA-9692916 | 8.398591e-01 | 0.076 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Cyclin B | R-HSA-174048 | 8.467622e-01 | 0.072 | 0 | 0 |
| Glycosphingolipid transport | R-HSA-9845576 | 8.482155e-01 | 0.071 | 0 | 0 |
| DAP12 interactions | R-HSA-2172127 | 8.484848e-01 | 0.071 | 0 | 0 |
| PINK1-PRKN Mediated Mitophagy | R-HSA-5205685 | 8.515522e-01 | 0.070 | 0 | 0 |
| Activation of kainate receptors upon glutamate binding | R-HSA-451326 | 8.515522e-01 | 0.070 | 0 | 0 |
| Interleukin-1 signaling | R-HSA-9020702 | 8.528308e-01 | 0.069 | 0 | 0 |
| Regulation of CDH11 mRNA translation by microRNAs | R-HSA-9759811 | 8.578567e-01 | 0.067 | 0 | 0 |
| FGFRL1 modulation of FGFR1 signaling | R-HSA-5658623 | 8.578567e-01 | 0.067 | 0 | 0 |
| vRNA Synthesis | R-HSA-192814 | 8.578567e-01 | 0.067 | 0 | 0 |
| vRNP Assembly | R-HSA-192905 | 8.578567e-01 | 0.067 | 0 | 0 |
| CD163 mediating an anti-inflammatory response | R-HSA-9662834 | 8.578567e-01 | 0.067 | 0 | 0 |
| Alpha-protein kinase 1 signaling pathway | R-HSA-9645460 | 8.578567e-01 | 0.067 | 0 | 0 |
| Suppression of apoptosis | R-HSA-9635465 | 8.578567e-01 | 0.067 | 0 | 0 |
| Dissolution of Fibrin Clot | R-HSA-75205 | 8.578567e-01 | 0.067 | 0 | 0 |
| Defective CFTR causes cystic fibrosis | R-HSA-5678895 | 8.595550e-01 | 0.066 | 0 | 0 |
| TRAF6 mediated IRF7 activation | R-HSA-933541 | 8.602822e-01 | 0.065 | 0 | 0 |
| Phospholipase C-mediated cascade; FGFR2 | R-HSA-5654221 | 8.624323e-01 | 0.064 | 0 | 0 |
| Mitochondrial iron-sulfur cluster biogenesis | R-HSA-1362409 | 8.624323e-01 | 0.064 | 0 | 0 |
| GPCR downstream signalling | R-HSA-388396 | 8.640171e-01 | 0.063 | 0 | 0 |
| mRNA Capping | R-HSA-72086 | 8.647172e-01 | 0.063 | 0 | 0 |
| Endosomal Sorting Complex Required For Transport (ESCRT) | R-HSA-917729 | 8.647172e-01 | 0.063 | 0 | 0 |
| Signaling by CSF3 (G-CSF) | R-HSA-9674555 | 8.647172e-01 | 0.063 | 0 | 0 |
| G alpha (z) signalling events | R-HSA-418597 | 8.704640e-01 | 0.060 | 0 | 0 |
| Mitochondrial biogenesis | R-HSA-1592230 | 8.705758e-01 | 0.060 | 0 | 0 |
| SLC-mediated transport of inorganic anions | R-HSA-9958790 | 8.715193e-01 | 0.060 | 0 | 0 |
| Vesicle-mediated transport | R-HSA-5653656 | 8.747067e-01 | 0.058 | 0 | 0 |
| PI3K events in ERBB4 signaling | R-HSA-1250342 | 8.763544e-01 | 0.057 | 0 | 0 |
| Negative regulation of TCF-dependent signaling by WNT ligand antagonists | R-HSA-3772470 | 8.763544e-01 | 0.057 | 0 | 0 |
| NF-kB is activated and signals survival | R-HSA-209560 | 8.763544e-01 | 0.057 | 0 | 0 |
| TICAM1-dependent activation of IRF3/IRF7 | R-HSA-9013973 | 8.763544e-01 | 0.057 | 0 | 0 |
| Viral RNP Complexes in the Host Cell Nucleus | R-HSA-168330 | 8.763544e-01 | 0.057 | 0 | 0 |
| Regulation of TBK1, IKKε (IKBKE)-mediated activation of IRF3, IRF7 | R-HSA-9824878 | 8.763544e-01 | 0.057 | 0 | 0 |
| Integration of provirus | R-HSA-162592 | 8.763544e-01 | 0.057 | 0 | 0 |
| G-protein activation | R-HSA-202040 | 8.766203e-01 | 0.057 | 0 | 0 |
| FGFR2 ligand binding and activation | R-HSA-190241 | 8.766203e-01 | 0.057 | 0 | 0 |
| APC-Cdc20 mediated degradation of Nek2A | R-HSA-179409 | 8.766203e-01 | 0.057 | 0 | 0 |
| Neurotransmitter clearance | R-HSA-112311 | 8.768429e-01 | 0.057 | 0 | 0 |
| NOTCH3 Intracellular Domain Regulates Transcription | R-HSA-9013508 | 8.768429e-01 | 0.057 | 0 | 0 |
| Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176814 | 8.795160e-01 | 0.056 | 0 | 0 |
| Detoxification of Reactive Oxygen Species | R-HSA-3299685 | 8.795160e-01 | 0.056 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Securin | R-HSA-174154 | 8.796666e-01 | 0.056 | 0 | 0 |
| Downstream TCR signaling | R-HSA-202424 | 8.810209e-01 | 0.055 | 0 | 0 |
| RAS processing | R-HSA-9648002 | 8.819679e-01 | 0.055 | 0 | 0 |
| Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin | R-HSA-9725554 | 8.819679e-01 | 0.055 | 0 | 0 |
| Plasma lipoprotein clearance | R-HSA-8964043 | 8.819679e-01 | 0.055 | 0 | 0 |
| Respiratory syncytial virus (RSV) genome replication, transcription and translation | R-HSA-9820965 | 8.819679e-01 | 0.055 | 0 | 0 |
| Class I MHC mediated antigen processing & presentation | R-HSA-983169 | 8.838753e-01 | 0.054 | 0 | 0 |
| Regulation of actin dynamics for phagocytic cup formation | R-HSA-2029482 | 8.844633e-01 | 0.053 | 0 | 0 |
| Regulation of activated PAK-2p34 by proteasome mediated degradation | R-HSA-211733 | 8.879933e-01 | 0.052 | 0 | 0 |
| Negative regulators of DDX58/IFIH1 signaling | R-HSA-936440 | 8.879933e-01 | 0.052 | 0 | 0 |
| Respiratory syncytial virus (RSV) attachment and entry | R-HSA-9820960 | 8.879933e-01 | 0.052 | 0 | 0 |
| activated TAK1 mediates p38 MAPK activation | R-HSA-450302 | 8.894465e-01 | 0.051 | 0 | 0 |
| Protein ubiquitination | R-HSA-8852135 | 8.901096e-01 | 0.051 | 0 | 0 |
| Formation of Incision Complex in GG-NER | R-HSA-5696395 | 8.916692e-01 | 0.050 | 0 | 0 |
| Glycogen metabolism | R-HSA-8982491 | 8.916692e-01 | 0.050 | 0 | 0 |
| Generation of second messenger molecules | R-HSA-202433 | 8.916692e-01 | 0.050 | 0 | 0 |
| IRAK1 recruits IKK complex | R-HSA-937039 | 8.924459e-01 | 0.049 | 0 | 0 |
| IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation | R-HSA-975144 | 8.924459e-01 | 0.049 | 0 | 0 |
| Interleukin-15 signaling | R-HSA-8983432 | 8.924459e-01 | 0.049 | 0 | 0 |
| Erythrocytes take up oxygen and release carbon dioxide | R-HSA-1247673 | 8.924459e-01 | 0.049 | 0 | 0 |
| Reversal of alkylation damage by DNA dioxygenases | R-HSA-73943 | 8.924459e-01 | 0.049 | 0 | 0 |
| N-glycan trimming in the ER and Calnexin/Calreticulin cycle | R-HSA-532668 | 8.972672e-01 | 0.047 | 0 | 0 |
| Plasma lipoprotein assembly, remodeling, and clearance | R-HSA-174824 | 9.007988e-01 | 0.045 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 3 Promoter | R-HSA-76071 | 9.010250e-01 | 0.045 | 0 | 0 |
| TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain | R-HSA-6803205 | 9.010250e-01 | 0.045 | 0 | 0 |
| Fructose metabolism | R-HSA-5652084 | 9.010250e-01 | 0.045 | 0 | 0 |
| Phospholipid metabolism | R-HSA-1483257 | 9.023662e-01 | 0.045 | 0 | 0 |
| Regulated Necrosis | R-HSA-5218859 | 9.032346e-01 | 0.044 | 0 | 0 |
| Deadenylation-dependent mRNA decay | R-HSA-429914 | 9.035300e-01 | 0.044 | 0 | 0 |
| Triglyceride metabolism | R-HSA-8979227 | 9.035300e-01 | 0.044 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9694635 | 9.038533e-01 | 0.044 | 0 | 0 |
| Regulation of PD-L1(CD274) Post-translational modification | R-HSA-9909615 | 9.050908e-01 | 0.043 | 0 | 0 |
| Adenylate cyclase activating pathway | R-HSA-170660 | 9.064440e-01 | 0.043 | 0 | 0 |
| Golgi Cisternae Pericentriolar Stack Reorganization | R-HSA-162658 | 9.064440e-01 | 0.043 | 0 | 0 |
| Membrane binding and targetting of GAG proteins | R-HSA-174490 | 9.064440e-01 | 0.043 | 0 | 0 |
| Chylomicron remodeling | R-HSA-8963901 | 9.064440e-01 | 0.043 | 0 | 0 |
| Mtb iron assimilation by chelation | R-HSA-1222449 | 9.064440e-01 | 0.043 | 0 | 0 |
| Acyl chain remodeling of DAG and TAG | R-HSA-1482883 | 9.064440e-01 | 0.043 | 0 | 0 |
| Interleukin-6 signaling | R-HSA-1059683 | 9.064440e-01 | 0.043 | 0 | 0 |
| Regulation of necroptotic cell death | R-HSA-5675482 | 9.076186e-01 | 0.042 | 0 | 0 |
| Intra-Golgi traffic | R-HSA-6811438 | 9.089928e-01 | 0.041 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9683701 | 9.089928e-01 | 0.041 | 0 | 0 |
| PCP/CE pathway | R-HSA-4086400 | 9.101610e-01 | 0.041 | 0 | 0 |
| Sphingolipid de novo biosynthesis | R-HSA-1660661 | 9.105623e-01 | 0.041 | 0 | 0 |
| Signaling by Retinoic Acid | R-HSA-5362517 | 9.105623e-01 | 0.041 | 0 | 0 |
| Synthesis of pyrophosphates in the cytosol | R-HSA-1855167 | 9.114632e-01 | 0.040 | 0 | 0 |
| Mitochondrial protein degradation | R-HSA-9837999 | 9.123997e-01 | 0.040 | 0 | 0 |
| Vitamin B5 (pantothenate) metabolism | R-HSA-199220 | 9.162137e-01 | 0.038 | 0 | 0 |
| PPARA activates gene expression | R-HSA-1989781 | 9.169805e-01 | 0.038 | 0 | 0 |
| G alpha (s) signalling events | R-HSA-418555 | 9.184925e-01 | 0.037 | 0 | 0 |
| NRIF signals cell death from the nucleus | R-HSA-205043 | 9.186209e-01 | 0.037 | 0 | 0 |
| Synthesis And Processing Of GAG, GAGPOL Polyproteins | R-HSA-174495 | 9.186209e-01 | 0.037 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation | R-HSA-975163 | 9.186209e-01 | 0.037 | 0 | 0 |
| Beta oxidation of hexanoyl-CoA to butanoyl-CoA | R-HSA-77350 | 9.186209e-01 | 0.037 | 0 | 0 |
| Beta oxidation of lauroyl-CoA to decanoyl-CoA-CoA | R-HSA-77310 | 9.186209e-01 | 0.037 | 0 | 0 |
| Beta oxidation of octanoyl-CoA to hexanoyl-CoA | R-HSA-77348 | 9.186209e-01 | 0.037 | 0 | 0 |
| Physiological factors | R-HSA-5578768 | 9.186209e-01 | 0.037 | 0 | 0 |
| Prolactin receptor signaling | R-HSA-1170546 | 9.186209e-01 | 0.037 | 0 | 0 |
| Malate-aspartate shuttle | R-HSA-9856872 | 9.186209e-01 | 0.037 | 0 | 0 |
| Respiratory syncytial virus genome transcription | R-HSA-9828642 | 9.186209e-01 | 0.037 | 0 | 0 |
| Glycerophospholipid catabolism | R-HSA-6814848 | 9.186209e-01 | 0.037 | 0 | 0 |
| Ciprofloxacin ADME | R-HSA-9793528 | 9.186209e-01 | 0.037 | 0 | 0 |
| Zinc transporters | R-HSA-435354 | 9.186209e-01 | 0.037 | 0 | 0 |
| P2Y receptors | R-HSA-417957 | 9.186209e-01 | 0.037 | 0 | 0 |
| ADP signalling through P2Y purinoceptor 1 | R-HSA-418592 | 9.208617e-01 | 0.036 | 0 | 0 |
| Assembly of active LPL and LIPC lipase complexes | R-HSA-8963889 | 9.208617e-01 | 0.036 | 0 | 0 |
| TNFs bind their physiological receptors | R-HSA-5669034 | 9.208617e-01 | 0.036 | 0 | 0 |
| Complex III assembly | R-HSA-9865881 | 9.208617e-01 | 0.036 | 0 | 0 |
| NCAM signaling for neurite out-growth | R-HSA-375165 | 9.233020e-01 | 0.035 | 0 | 0 |
| Hh mutants abrogate ligand secretion | R-HSA-5387390 | 9.238085e-01 | 0.034 | 0 | 0 |
| Autodegradation of the E3 ubiquitin ligase COP1 | R-HSA-349425 | 9.240735e-01 | 0.034 | 0 | 0 |
| RA biosynthesis pathway | R-HSA-5365859 | 9.240735e-01 | 0.034 | 0 | 0 |
| Regulation of lipid metabolism by PPARalpha | R-HSA-400206 | 9.249625e-01 | 0.034 | 0 | 0 |
| Competing endogenous RNAs (ceRNAs) regulate PTEN translation | R-HSA-8948700 | 9.292136e-01 | 0.032 | 0 | 0 |
| G beta:gamma signalling through BTK | R-HSA-8964315 | 9.292136e-01 | 0.032 | 0 | 0 |
| TICAM1, RIP1-mediated IKK complex recruitment | R-HSA-168927 | 9.292136e-01 | 0.032 | 0 | 0 |
| RNA Polymerase III Chain Elongation | R-HSA-73780 | 9.292136e-01 | 0.032 | 0 | 0 |
| TRAF6-mediated induction of TAK1 complex within TLR4 complex | R-HSA-937072 | 9.292136e-01 | 0.032 | 0 | 0 |
| Beta oxidation of butanoyl-CoA to acetyl-CoA | R-HSA-77352 | 9.292136e-01 | 0.032 | 0 | 0 |
| Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA | R-HSA-450513 | 9.292136e-01 | 0.032 | 0 | 0 |
| Dopamine clearance from the synaptic cleft | R-HSA-379401 | 9.292136e-01 | 0.032 | 0 | 0 |
| STAT3 nuclear events downstream of ALK signaling | R-HSA-9701898 | 9.292136e-01 | 0.032 | 0 | 0 |
| DNA Damage Reversal | R-HSA-73942 | 9.292136e-01 | 0.032 | 0 | 0 |
| MicroRNA (miRNA) biogenesis | R-HSA-203927 | 9.293143e-01 | 0.032 | 0 | 0 |
| Hyaluronan degradation | R-HSA-2160916 | 9.293143e-01 | 0.032 | 0 | 0 |
| PIWI-interacting RNA (piRNA) biogenesis | R-HSA-5601884 | 9.293143e-01 | 0.032 | 0 | 0 |
| Regulation of Apoptosis | R-HSA-169911 | 9.312520e-01 | 0.031 | 0 | 0 |
| FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | R-HSA-8854050 | 9.312520e-01 | 0.031 | 0 | 0 |
| Leishmania infection | R-HSA-9658195 | 9.336152e-01 | 0.030 | 0 | 0 |
| Parasitic Infection Pathways | R-HSA-9824443 | 9.336152e-01 | 0.030 | 0 | 0 |
| Cytoprotection by HMOX1 | R-HSA-9707564 | 9.366502e-01 | 0.028 | 0 | 0 |
| MET activates PTK2 signaling | R-HSA-8874081 | 9.369079e-01 | 0.028 | 0 | 0 |
| Synthesis of IP2, IP, and Ins in the cytosol | R-HSA-1855183 | 9.369079e-01 | 0.028 | 0 | 0 |
| Abacavir ADME | R-HSA-2161522 | 9.369079e-01 | 0.028 | 0 | 0 |
| Synthesis of PIPs at the Golgi membrane | R-HSA-1660514 | 9.369079e-01 | 0.028 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176409 | 9.373231e-01 | 0.028 | 0 | 0 |
| Entry of Influenza Virion into Host Cell via Endocytosis | R-HSA-168275 | 9.384280e-01 | 0.028 | 0 | 0 |
| Induction of Cell-Cell Fusion | R-HSA-9733458 | 9.384280e-01 | 0.028 | 0 | 0 |
| Caspase activation via Death Receptors in the presence of ligand | R-HSA-140534 | 9.384280e-01 | 0.028 | 0 | 0 |
| Attachment and Entry | R-HSA-9678110 | 9.384280e-01 | 0.028 | 0 | 0 |
| Serotonin and melatonin biosynthesis | R-HSA-209931 | 9.384280e-01 | 0.028 | 0 | 0 |
| Differentiation of naive CD+ T cells to T helper 1 cells (Th1 cells) | R-HSA-9942503 | 9.384280e-01 | 0.028 | 0 | 0 |
| Differentiation of T cells | R-HSA-9945266 | 9.384280e-01 | 0.028 | 0 | 0 |
| Receptor-type tyrosine-protein phosphatases | R-HSA-388844 | 9.384280e-01 | 0.028 | 0 | 0 |
| Synthesis of wybutosine at G37 of tRNA(Phe) | R-HSA-6782861 | 9.384280e-01 | 0.028 | 0 | 0 |
| Atorvastatin ADME | R-HSA-9754706 | 9.384280e-01 | 0.028 | 0 | 0 |
| Respiratory Syncytial Virus Infection Pathway | R-HSA-9820952 | 9.410863e-01 | 0.026 | 0 | 0 |
| Autodegradation of Cdh1 by Cdh1:APC/C | R-HSA-174084 | 9.419841e-01 | 0.026 | 0 | 0 |
| Inactivation, recovery and regulation of the phototransduction cascade | R-HSA-2514859 | 9.419841e-01 | 0.026 | 0 | 0 |
| TP53 Regulates Transcription of Cell Death Genes | R-HSA-5633008 | 9.421441e-01 | 0.026 | 0 | 0 |
| Non-integrin membrane-ECM interactions | R-HSA-3000171 | 9.421441e-01 | 0.026 | 0 | 0 |
| Cristae formation | R-HSA-8949613 | 9.437230e-01 | 0.025 | 0 | 0 |
| Synthesis of active ubiquitin: roles of E1 and E2 enzymes | R-HSA-8866652 | 9.437230e-01 | 0.025 | 0 | 0 |
| Signaling by BMP | R-HSA-201451 | 9.437230e-01 | 0.025 | 0 | 0 |
| Degradation of AXIN | R-HSA-4641257 | 9.437680e-01 | 0.025 | 0 | 0 |
| Degradation of DVL | R-HSA-4641258 | 9.437680e-01 | 0.025 | 0 | 0 |
| GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2 | R-HSA-9762114 | 9.437680e-01 | 0.025 | 0 | 0 |
| Late SARS-CoV-2 Infection Events | R-HSA-9772573 | 9.445373e-01 | 0.025 | 0 | 0 |
| G beta:gamma signalling through CDC42 | R-HSA-8964616 | 9.464434e-01 | 0.024 | 0 | 0 |
| TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling | R-HSA-975110 | 9.464434e-01 | 0.024 | 0 | 0 |
| Biosynthesis of maresin-like SPMs | R-HSA-9027307 | 9.464434e-01 | 0.024 | 0 | 0 |
| Scavenging by Class B Receptors | R-HSA-3000471 | 9.464434e-01 | 0.024 | 0 | 0 |
| Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE) | R-HSA-936964 | 9.464434e-01 | 0.024 | 0 | 0 |
| Vitamin B6 activation to pyridoxal phosphate | R-HSA-964975 | 9.464434e-01 | 0.024 | 0 | 0 |
| Phase 2 - plateau phase | R-HSA-5576893 | 9.464434e-01 | 0.024 | 0 | 0 |
| Fibronectin matrix formation | R-HSA-1566977 | 9.464434e-01 | 0.024 | 0 | 0 |
| Beta oxidation of decanoyl-CoA to octanoyl-CoA-CoA | R-HSA-77346 | 9.464434e-01 | 0.024 | 0 | 0 |
| Galactose catabolism | R-HSA-70370 | 9.464434e-01 | 0.024 | 0 | 0 |
| Coenzyme A biosynthesis | R-HSA-196783 | 9.464434e-01 | 0.024 | 0 | 0 |
| Defects of contact activation system (CAS) and kallikrein/kinin system (KKS) | R-HSA-9651496 | 9.464434e-01 | 0.024 | 0 | 0 |
| Retrograde transport at the Trans-Golgi-Network | R-HSA-6811440 | 9.471020e-01 | 0.024 | 0 | 0 |
| RIPK1-mediated regulated necrosis | R-HSA-5213460 | 9.491999e-01 | 0.023 | 0 | 0 |
| Regulation of FZD by ubiquitination | R-HSA-4641263 | 9.534158e-01 | 0.021 | 0 | 0 |
| Sulfide oxidation to sulfate | R-HSA-1614517 | 9.534158e-01 | 0.021 | 0 | 0 |
| Cross-presentation of soluble exogenous antigens (endosomes) | R-HSA-1236978 | 9.541393e-01 | 0.020 | 0 | 0 |
| GSK3B-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929356 | 9.541393e-01 | 0.020 | 0 | 0 |
| Pentose phosphate pathway | R-HSA-71336 | 9.541393e-01 | 0.020 | 0 | 0 |
| Toll-like Receptor Cascades | R-HSA-168898 | 9.543635e-01 | 0.020 | 0 | 0 |
| SLC transporter disorders | R-HSA-5619102 | 9.558638e-01 | 0.020 | 0 | 0 |
| G beta:gamma signalling through PLC beta | R-HSA-418217 | 9.594808e-01 | 0.018 | 0 | 0 |
| Presynaptic function of Kainate receptors | R-HSA-500657 | 9.594808e-01 | 0.018 | 0 | 0 |
| Cytosolic iron-sulfur cluster assembly | R-HSA-2564830 | 9.594808e-01 | 0.018 | 0 | 0 |
| Nucleotide-like (purinergic) receptors | R-HSA-418038 | 9.594808e-01 | 0.018 | 0 | 0 |
| Energy dependent regulation of mTOR by LKB1-AMPK | R-HSA-380972 | 9.602064e-01 | 0.018 | 0 | 0 |
| Fc epsilon receptor (FCERI) signaling | R-HSA-2454202 | 9.619327e-01 | 0.017 | 0 | 0 |
| Signaling by GPCR | R-HSA-372790 | 9.623829e-01 | 0.017 | 0 | 0 |
| Hh mutants are degraded by ERAD | R-HSA-5362768 | 9.626991e-01 | 0.017 | 0 | 0 |
| Formation of paraxial mesoderm | R-HSA-9793380 | 9.627558e-01 | 0.016 | 0 | 0 |
| Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | R-HSA-1234176 | 9.636942e-01 | 0.016 | 0 | 0 |
| Hedgehog ligand biogenesis | R-HSA-5358346 | 9.636942e-01 | 0.016 | 0 | 0 |
| The phototransduction cascade | R-HSA-2514856 | 9.636942e-01 | 0.016 | 0 | 0 |
| Formation of the dystrophin-glycoprotein complex (DGC) | R-HSA-9913351 | 9.645878e-01 | 0.016 | 0 | 0 |
| IKK complex recruitment mediated by RIP1 | R-HSA-937041 | 9.647565e-01 | 0.016 | 0 | 0 |
| Mechanical load activates signaling by PIEZO1 and integrins in osteocytes | R-HSA-9856532 | 9.647565e-01 | 0.016 | 0 | 0 |
| Erythrocytes take up carbon dioxide and release oxygen | R-HSA-1237044 | 9.647565e-01 | 0.016 | 0 | 0 |
| O2/CO2 exchange in erythrocytes | R-HSA-1480926 | 9.647565e-01 | 0.016 | 0 | 0 |
| Strand-asynchronous mitochondrial DNA replication | R-HSA-9913635 | 9.647565e-01 | 0.016 | 0 | 0 |
| Diseases of hemostasis | R-HSA-9671793 | 9.647565e-01 | 0.016 | 0 | 0 |
| Neurotransmitter release cycle | R-HSA-112310 | 9.649290e-01 | 0.016 | 0 | 0 |
| Regulation of APC/C activators between G1/S and early anaphase | R-HSA-176408 | 9.659292e-01 | 0.015 | 0 | 0 |
| Cdc20:Phospho-APC/C mediated degradation of Cyclin A | R-HSA-174184 | 9.670091e-01 | 0.015 | 0 | 0 |
| AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274) | R-HSA-9931269 | 9.670091e-01 | 0.015 | 0 | 0 |
| Regulation of ornithine decarboxylase (ODC) | R-HSA-350562 | 9.685033e-01 | 0.014 | 0 | 0 |
| Regulation of PD-L1(CD274) translation | R-HSA-9909620 | 9.693455e-01 | 0.014 | 0 | 0 |
| Formation of ATP by chemiosmotic coupling | R-HSA-163210 | 9.693455e-01 | 0.014 | 0 | 0 |
| Acyl chain remodelling of PI | R-HSA-1482922 | 9.693455e-01 | 0.014 | 0 | 0 |
| Pregnenolone biosynthesis | R-HSA-196108 | 9.693455e-01 | 0.014 | 0 | 0 |
| Glycogen synthesis | R-HSA-3322077 | 9.693455e-01 | 0.014 | 0 | 0 |
| Interferon alpha/beta signaling | R-HSA-909733 | 9.696429e-01 | 0.013 | 0 | 0 |
| Cytosolic tRNA aminoacylation | R-HSA-379716 | 9.697380e-01 | 0.013 | 0 | 0 |
| APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | R-HSA-179419 | 9.700401e-01 | 0.013 | 0 | 0 |
| Leishmania phagocytosis | R-HSA-9664417 | 9.710825e-01 | 0.013 | 0 | 0 |
| FCGR3A-mediated phagocytosis | R-HSA-9664422 | 9.710825e-01 | 0.013 | 0 | 0 |
| Parasite infection | R-HSA-9664407 | 9.710825e-01 | 0.013 | 0 | 0 |
| Response of Mtb to phagocytosis | R-HSA-9637690 | 9.727670e-01 | 0.012 | 0 | 0 |
| CDK-mediated phosphorylation and removal of Cdc6 | R-HSA-69017 | 9.728091e-01 | 0.012 | 0 | 0 |
| ADP signalling through P2Y purinoceptor 12 | R-HSA-392170 | 9.733373e-01 | 0.012 | 0 | 0 |
| Phenylalanine metabolism | R-HSA-8964208 | 9.733373e-01 | 0.012 | 0 | 0 |
| PD-L1(CD274) glycosylation and translocation to plasma membrane | R-HSA-9931295 | 9.733373e-01 | 0.012 | 0 | 0 |
| Synthesis, secretion, and deacylation of Ghrelin | R-HSA-422085 | 9.733373e-01 | 0.012 | 0 | 0 |
| Vitamin C (ascorbate) metabolism | R-HSA-196836 | 9.733373e-01 | 0.012 | 0 | 0 |
| Basigin interactions | R-HSA-210991 | 9.733373e-01 | 0.012 | 0 | 0 |
| Prevention of phagosomal-lysosomal fusion | R-HSA-9636383 | 9.733373e-01 | 0.012 | 0 | 0 |
| Early Phase of HIV Life Cycle | R-HSA-162594 | 9.733373e-01 | 0.012 | 0 | 0 |
| DNA Damage Recognition in GG-NER | R-HSA-5696394 | 9.751200e-01 | 0.011 | 0 | 0 |
| Vpu mediated degradation of CD4 | R-HSA-180534 | 9.751200e-01 | 0.011 | 0 | 0 |
| Heme degradation | R-HSA-189483 | 9.751200e-01 | 0.011 | 0 | 0 |
| Proteasome assembly | R-HSA-9907900 | 9.755068e-01 | 0.011 | 0 | 0 |
| Surfactant metabolism | R-HSA-5683826 | 9.755068e-01 | 0.011 | 0 | 0 |
| Inactivation of CSF3 (G-CSF) signaling | R-HSA-9705462 | 9.768094e-01 | 0.010 | 0 | 0 |
| Attachment and Entry | R-HSA-9694614 | 9.768094e-01 | 0.010 | 0 | 0 |
| Metabolism of Angiotensinogen to Angiotensins | R-HSA-2022377 | 9.768094e-01 | 0.010 | 0 | 0 |
| Assembly Of The HIV Virion | R-HSA-175474 | 9.768094e-01 | 0.010 | 0 | 0 |
| Serine metabolism | R-HSA-977347 | 9.768094e-01 | 0.010 | 0 | 0 |
| Glutathione synthesis and recycling | R-HSA-174403 | 9.768094e-01 | 0.010 | 0 | 0 |
| Antigen Presentation: Folding, assembly and peptide loading of class I MHC | R-HSA-983170 | 9.779027e-01 | 0.010 | 0 | 0 |
| Hyaluronan metabolism | R-HSA-2142845 | 9.779027e-01 | 0.010 | 0 | 0 |
| Calnexin/calreticulin cycle | R-HSA-901042 | 9.779027e-01 | 0.010 | 0 | 0 |
| Somitogenesis | R-HSA-9824272 | 9.779832e-01 | 0.010 | 0 | 0 |
| Asymmetric localization of PCP proteins | R-HSA-4608870 | 9.779832e-01 | 0.010 | 0 | 0 |
| Dectin-1 mediated noncanonical NF-kB signaling | R-HSA-5607761 | 9.779832e-01 | 0.010 | 0 | 0 |
| ABC transporter disorders | R-HSA-5619084 | 9.796298e-01 | 0.009 | 0 | 0 |
| Cholesterol biosynthesis | R-HSA-191273 | 9.796298e-01 | 0.009 | 0 | 0 |
| WNT ligand biogenesis and trafficking | R-HSA-3238698 | 9.798296e-01 | 0.009 | 0 | 0 |
| Cellular hexose transport | R-HSA-189200 | 9.798296e-01 | 0.009 | 0 | 0 |
| SCF-beta-TrCP mediated degradation of Emi1 | R-HSA-174113 | 9.803828e-01 | 0.009 | 0 | 0 |
| Developmental Lineage of Pancreatic Acinar Cells | R-HSA-9925561 | 9.813434e-01 | 0.008 | 0 | 0 |
| Regulation of PTEN mRNA translation | R-HSA-8943723 | 9.824566e-01 | 0.008 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | R-HSA-167160 | 9.824566e-01 | 0.008 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE | R-HSA-77075 | 9.824566e-01 | 0.008 | 0 | 0 |
| Biosynthesis of maresins | R-HSA-9018682 | 9.824566e-01 | 0.008 | 0 | 0 |
| Interleukin-20 family signaling | R-HSA-8854691 | 9.824566e-01 | 0.008 | 0 | 0 |
| Vif-mediated degradation of APOBEC3G | R-HSA-180585 | 9.825918e-01 | 0.008 | 0 | 0 |
| ER-Phagosome pathway | R-HSA-1236974 | 9.826565e-01 | 0.008 | 0 | 0 |
| Assembly of collagen fibrils and other multimeric structures | R-HSA-2022090 | 9.833999e-01 | 0.007 | 0 | 0 |
| SLC-mediated transport of organic cations | R-HSA-549127 | 9.845584e-01 | 0.007 | 0 | 0 |
| Beta-oxidation of very long chain fatty acids | R-HSA-390247 | 9.845584e-01 | 0.007 | 0 | 0 |
| CYP2E1 reactions | R-HSA-211999 | 9.847415e-01 | 0.007 | 0 | 0 |
| Translocation of ZAP-70 to Immunological synapse | R-HSA-202430 | 9.847415e-01 | 0.007 | 0 | 0 |
| Synthesis of dolichyl-phosphate | R-HSA-446199 | 9.847415e-01 | 0.007 | 0 | 0 |
| Mitochondrial RNA degradation | R-HSA-9836573 | 9.847415e-01 | 0.007 | 0 | 0 |
| Interleukin-6 family signaling | R-HSA-6783589 | 9.847415e-01 | 0.007 | 0 | 0 |
| Metabolism of cofactors | R-HSA-8978934 | 9.851101e-01 | 0.007 | 0 | 0 |
| Antigen processing-Cross presentation | R-HSA-1236975 | 9.854704e-01 | 0.006 | 0 | 0 |
| ABC-family proteins mediated transport | R-HSA-382556 | 9.864690e-01 | 0.006 | 0 | 0 |
| Alpha-oxidation of phytanate | R-HSA-389599 | 9.867290e-01 | 0.006 | 0 | 0 |
| Defects in cobalamin (B12) metabolism | R-HSA-3296469 | 9.867290e-01 | 0.006 | 0 | 0 |
| Laminin interactions | R-HSA-3000157 | 9.867290e-01 | 0.006 | 0 | 0 |
| tRNA processing | R-HSA-72306 | 9.882016e-01 | 0.005 | 0 | 0 |
| Adrenaline,noradrenaline inhibits insulin secretion | R-HSA-400042 | 9.884577e-01 | 0.005 | 0 | 0 |
| Diseases of branched-chain amino acid catabolism | R-HSA-9865118 | 9.884577e-01 | 0.005 | 0 | 0 |
| Suppression of phagosomal maturation | R-HSA-9637687 | 9.884577e-01 | 0.005 | 0 | 0 |
| RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | R-HSA-73779 | 9.892473e-01 | 0.005 | 0 | 0 |
| Maturation of TCA enzymes and regulation of TCA cycle | R-HSA-9854311 | 9.892473e-01 | 0.005 | 0 | 0 |
| Phosphorylation of CD3 and TCR zeta chains | R-HSA-202427 | 9.899614e-01 | 0.004 | 0 | 0 |
| Triglyceride biosynthesis | R-HSA-75109 | 9.899614e-01 | 0.004 | 0 | 0 |
| ER Quality Control Compartment (ERQC) | R-HSA-901032 | 9.899614e-01 | 0.004 | 0 | 0 |
| Synthesis of PE | R-HSA-1483213 | 9.899614e-01 | 0.004 | 0 | 0 |
| Synthesis of bile acids and bile salts via 27-hydroxycholesterol | R-HSA-193807 | 9.899614e-01 | 0.004 | 0 | 0 |
| Maturation of hRSV A proteins | R-HSA-9828806 | 9.899614e-01 | 0.004 | 0 | 0 |
| Purine ribonucleoside monophosphate biosynthesis | R-HSA-73817 | 9.904761e-01 | 0.004 | 0 | 0 |
| NIK-->noncanonical NF-kB signaling | R-HSA-5676590 | 9.904761e-01 | 0.004 | 0 | 0 |
| Disease | R-HSA-1643685 | 9.906636e-01 | 0.004 | 0 | 0 |
| Amino acids regulate mTORC1 | R-HSA-9639288 | 9.907832e-01 | 0.004 | 0 | 0 |
| RSV-host interactions | R-HSA-9833110 | 9.910849e-01 | 0.004 | 0 | 0 |
| Transport to the Golgi and subsequent modification | R-HSA-948021 | 9.912257e-01 | 0.004 | 0 | 0 |
| Prednisone ADME | R-HSA-9757110 | 9.912692e-01 | 0.004 | 0 | 0 |
| Insulin receptor recycling | R-HSA-77387 | 9.912692e-01 | 0.004 | 0 | 0 |
| Pyrimidine salvage | R-HSA-73614 | 9.912692e-01 | 0.004 | 0 | 0 |
| RNA Polymerase II HIV Promoter Escape | R-HSA-167162 | 9.915673e-01 | 0.004 | 0 | 0 |
| HIV Transcription Initiation | R-HSA-167161 | 9.915673e-01 | 0.004 | 0 | 0 |
| RNA Polymerase II Transcription Initiation | R-HSA-75953 | 9.915673e-01 | 0.004 | 0 | 0 |
| Degradation of CRY and PER proteins | R-HSA-9932298 | 9.915673e-01 | 0.004 | 0 | 0 |
| Disorders of transmembrane transporters | R-HSA-5619115 | 9.917617e-01 | 0.004 | 0 | 0 |
| tRNA modification in the nucleus and cytosol | R-HSA-6782315 | 9.918585e-01 | 0.004 | 0 | 0 |
| TP53 Regulates Metabolic Genes | R-HSA-5628897 | 9.923762e-01 | 0.003 | 0 | 0 |
| Thyroxine biosynthesis | R-HSA-209968 | 9.924067e-01 | 0.003 | 0 | 0 |
| Activation of Matrix Metalloproteinases | R-HSA-1592389 | 9.924067e-01 | 0.003 | 0 | 0 |
| Regulation of pyruvate dehydrogenase (PDH) complex | R-HSA-204174 | 9.924067e-01 | 0.003 | 0 | 0 |
| RNA Polymerase II Promoter Escape | R-HSA-73776 | 9.933954e-01 | 0.003 | 0 | 0 |
| FCGR3A-mediated IL10 synthesis | R-HSA-9664323 | 9.940112e-01 | 0.003 | 0 | 0 |
| Cobalamin (Cbl, vitamin B12) transport and metabolism | R-HSA-196741 | 9.941576e-01 | 0.003 | 0 | 0 |
| Cargo concentration in the ER | R-HSA-5694530 | 9.942565e-01 | 0.003 | 0 | 0 |
| Molecules associated with elastic fibres | R-HSA-2129379 | 9.942565e-01 | 0.003 | 0 | 0 |
| Synthesis of glycosylphosphatidylinositol (GPI) | R-HSA-162710 | 9.942565e-01 | 0.003 | 0 | 0 |
| Aspartate and asparagine metabolism | R-HSA-8963693 | 9.942565e-01 | 0.003 | 0 | 0 |
| Fatty acyl-CoA biosynthesis | R-HSA-75105 | 9.946349e-01 | 0.002 | 0 | 0 |
| RNA Polymerase II Transcription Initiation And Promoter Clearance | R-HSA-76042 | 9.948334e-01 | 0.002 | 0 | 0 |
| Fanconi Anemia Pathway | R-HSA-6783310 | 9.948334e-01 | 0.002 | 0 | 0 |
| Degradation of cysteine and homocysteine | R-HSA-1614558 | 9.948334e-01 | 0.002 | 0 | 0 |
| HS-GAG degradation | R-HSA-2024096 | 9.950049e-01 | 0.002 | 0 | 0 |
| Peroxisomal protein import | R-HSA-9033241 | 9.952901e-01 | 0.002 | 0 | 0 |
| Formation of TC-NER Pre-Incision Complex | R-HSA-6781823 | 9.954324e-01 | 0.002 | 0 | 0 |
| Regulation of pyruvate metabolism | R-HSA-9861718 | 9.954324e-01 | 0.002 | 0 | 0 |
| Defective B3GALTL causes PpS | R-HSA-5083635 | 9.956559e-01 | 0.002 | 0 | 0 |
| Recycling of bile acids and salts | R-HSA-159418 | 9.956559e-01 | 0.002 | 0 | 0 |
| Diseases associated with glycosylation precursor biosynthesis | R-HSA-5609975 | 9.956559e-01 | 0.002 | 0 | 0 |
| tRNA Aminoacylation | R-HSA-379724 | 9.957943e-01 | 0.002 | 0 | 0 |
| Synthesis of PC | R-HSA-1483191 | 9.959630e-01 | 0.002 | 0 | 0 |
| Collagen formation | R-HSA-1474290 | 9.961056e-01 | 0.002 | 0 | 0 |
| EGR2 and SOX10-mediated initiation of Schwann cell myelination | R-HSA-9619665 | 9.962220e-01 | 0.002 | 0 | 0 |
| Collagen degradation | R-HSA-1442490 | 9.962458e-01 | 0.002 | 0 | 0 |
| Plasma lipoprotein remodeling | R-HSA-8963899 | 9.964329e-01 | 0.002 | 0 | 0 |
| Gluconeogenesis | R-HSA-70263 | 9.964329e-01 | 0.002 | 0 | 0 |
| Innate Immune System | R-HSA-168249 | 9.965367e-01 | 0.002 | 0 | 0 |
| Mitochondrial protein import | R-HSA-1268020 | 9.966500e-01 | 0.001 | 0 | 0 |
| Regulation of TLR by endogenous ligand | R-HSA-5686938 | 9.967144e-01 | 0.001 | 0 | 0 |
| Glyoxylate metabolism and glycine degradation | R-HSA-389661 | 9.968490e-01 | 0.001 | 0 | 0 |
| Metabolism of ingested SeMet, Sec, MeSec into H2Se | R-HSA-2408508 | 9.971426e-01 | 0.001 | 0 | 0 |
| Synthesis of bile acids and bile salts via 24-hydroxycholesterol | R-HSA-193775 | 9.971426e-01 | 0.001 | 0 | 0 |
| Defects in vitamin and cofactor metabolism | R-HSA-3296482 | 9.971426e-01 | 0.001 | 0 | 0 |
| Pyruvate metabolism | R-HSA-70268 | 9.971990e-01 | 0.001 | 0 | 0 |
| Interleukin-10 signaling | R-HSA-6783783 | 9.977136e-01 | 0.001 | 0 | 0 |
| Integrin cell surface interactions | R-HSA-216083 | 9.977136e-01 | 0.001 | 0 | 0 |
| O-glycosylation of TSR domain-containing proteins | R-HSA-5173214 | 9.978390e-01 | 0.001 | 0 | 0 |
| Ubiquinol biosynthesis | R-HSA-2142789 | 9.978390e-01 | 0.001 | 0 | 0 |
| Phenylalanine and tyrosine metabolism | R-HSA-8963691 | 9.978390e-01 | 0.001 | 0 | 0 |
| Collagen chain trimerization | R-HSA-8948216 | 9.978390e-01 | 0.001 | 0 | 0 |
| Nucleotide biosynthesis | R-HSA-8956320 | 9.980859e-01 | 0.001 | 0 | 0 |
| SLC-mediated transport of amino acids | R-HSA-9958863 | 9.981139e-01 | 0.001 | 0 | 0 |
| Metabolism of steroid hormones | R-HSA-196071 | 9.981139e-01 | 0.001 | 0 | 0 |
| Purine salvage | R-HSA-74217 | 9.981207e-01 | 0.001 | 0 | 0 |
| alpha-linolenic acid (ALA) metabolism | R-HSA-2046106 | 9.981207e-01 | 0.001 | 0 | 0 |
| Elastic fibre formation | R-HSA-1566948 | 9.981207e-01 | 0.001 | 0 | 0 |
| Collagen biosynthesis and modifying enzymes | R-HSA-1650814 | 9.983202e-01 | 0.001 | 0 | 0 |
| FCERI mediated MAPK activation | R-HSA-2871796 | 9.983337e-01 | 0.001 | 0 | 0 |
| G alpha (i) signalling events | R-HSA-418594 | 9.983509e-01 | 0.001 | 0 | 0 |
| Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) | R-HSA-381771 | 9.983657e-01 | 0.001 | 0 | 0 |
| Paracetamol ADME | R-HSA-9753281 | 9.985103e-01 | 0.001 | 0 | 0 |
| Mitochondrial tRNA aminoacylation | R-HSA-379726 | 9.985788e-01 | 0.001 | 0 | 0 |
| COPII-mediated vesicle transport | R-HSA-204005 | 9.986686e-01 | 0.001 | 0 | 0 |
| TNFR2 non-canonical NF-kB pathway | R-HSA-5668541 | 9.986735e-01 | 0.001 | 0 | 0 |
| Metabolism of amine-derived hormones | R-HSA-209776 | 9.986861e-01 | 0.001 | 0 | 0 |
| Synthesis of PA | R-HSA-1483166 | 9.988415e-01 | 0.001 | 0 | 0 |
| Protein localization | R-HSA-9609507 | 9.988419e-01 | 0.001 | 0 | 0 |
| Anti-inflammatory response favouring Leishmania parasite infection | R-HSA-9662851 | 9.988814e-01 | 0.000 | 0 | 0 |
| Leishmania parasite growth and survival | R-HSA-9664433 | 9.988814e-01 | 0.000 | 0 | 0 |
| Heme biosynthesis | R-HSA-189451 | 9.989252e-01 | 0.000 | 0 | 0 |
| Interconversion of nucleotide di- and triphosphates | R-HSA-499943 | 9.989460e-01 | 0.000 | 0 | 0 |
| Role of phospholipids in phagocytosis | R-HSA-2029485 | 9.989685e-01 | 0.000 | 0 | 0 |
| Infectious disease | R-HSA-5663205 | 9.990030e-01 | 0.000 | 0 | 0 |
| Incretin synthesis, secretion, and inactivation | R-HSA-400508 | 9.990654e-01 | 0.000 | 0 | 0 |
| Amino acid transport across the plasma membrane | R-HSA-352230 | 9.990998e-01 | 0.000 | 0 | 0 |
| Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation | R-HSA-163841 | 9.991467e-01 | 0.000 | 0 | 0 |
| Peptide hormone metabolism | R-HSA-2980736 | 9.991505e-01 | 0.000 | 0 | 0 |
| ROS and RNS production in phagocytes | R-HSA-1222556 | 9.991665e-01 | 0.000 | 0 | 0 |
| Metabolism of polyamines | R-HSA-351202 | 9.992067e-01 | 0.000 | 0 | 0 |
| Post-translational protein phosphorylation | R-HSA-8957275 | 9.992748e-01 | 0.000 | 0 | 0 |
| Nucleotide salvage | R-HSA-8956321 | 9.993010e-01 | 0.000 | 0 | 0 |
| mitochondrial fatty acid beta-oxidation of saturated fatty acids | R-HSA-77286 | 9.993854e-01 | 0.000 | 0 | 0 |
| Neddylation | R-HSA-8951664 | 9.994420e-01 | 0.000 | 0 | 0 |
| CD22 mediated BCR regulation | R-HSA-5690714 | 9.995224e-01 | 0.000 | 0 | 0 |
| alpha-linolenic (omega3) and linoleic (omega6) acid metabolism | R-HSA-2046104 | 9.995353e-01 | 0.000 | 0 | 0 |
| Formation of the cornified envelope | R-HSA-6809371 | 9.995733e-01 | 0.000 | 0 | 0 |
| FCERI mediated NF-kB activation | R-HSA-2871837 | 9.996222e-01 | 0.000 | 0 | 0 |
| Metabolism of steroids | R-HSA-8957322 | 9.996470e-01 | 0.000 | 0 | 0 |
| Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol | R-HSA-193368 | 9.996742e-01 | 0.000 | 0 | 0 |
| Nicotinate metabolism | R-HSA-196807 | 9.996742e-01 | 0.000 | 0 | 0 |
| FCERI mediated Ca+2 mobilization | R-HSA-2871809 | 9.996809e-01 | 0.000 | 0 | 0 |
| Complex IV assembly | R-HSA-9864848 | 9.997343e-01 | 0.000 | 0 | 0 |
| Cytosolic sulfonation of small molecules | R-HSA-156584 | 9.997343e-01 | 0.000 | 0 | 0 |
| Branched-chain amino acid catabolism | R-HSA-70895 | 9.997343e-01 | 0.000 | 0 | 0 |
| Diseases associated with O-glycosylation of proteins | R-HSA-3906995 | 9.998048e-01 | 0.000 | 0 | 0 |
| ECM proteoglycans | R-HSA-3000178 | 9.998048e-01 | 0.000 | 0 | 0 |
| Metabolism of porphyrins | R-HSA-189445 | 9.998048e-01 | 0.000 | 0 | 0 |
| Retinoid metabolism and transport | R-HSA-975634 | 9.998048e-01 | 0.000 | 0 | 0 |
| Cell surface interactions at the vascular wall | R-HSA-202733 | 9.998427e-01 | 0.000 | 0 | 0 |
| Synthesis of bile acids and bile salts | R-HSA-192105 | 9.998430e-01 | 0.000 | 0 | 0 |
| Digestion | R-HSA-8935690 | 9.998680e-01 | 0.000 | 0 | 0 |
| Citric acid cycle (TCA cycle) | R-HSA-71403 | 9.998833e-01 | 0.000 | 0 | 0 |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | R-HSA-381426 | 9.998970e-01 | 0.000 | 0 | 0 |
| Heparan sulfate/heparin (HS-GAG) metabolism | R-HSA-1638091 | 9.999132e-01 | 0.000 | 0 | 0 |
| Translation | R-HSA-72766 | 9.999163e-01 | 0.000 | 0 | 0 |
| Glutathione conjugation | R-HSA-156590 | 9.999245e-01 | 0.000 | 0 | 0 |
| Endogenous sterols | R-HSA-211976 | 9.999344e-01 | 0.000 | 0 | 0 |
| Metabolism of fat-soluble vitamins | R-HSA-6806667 | 9.999462e-01 | 0.000 | 0 | 0 |
| Metabolism of carbohydrates and carbohydrate derivatives | R-HSA-71387 | 9.999483e-01 | 0.000 | 0 | 0 |
| Complex I biogenesis | R-HSA-6799198 | 9.999504e-01 | 0.000 | 0 | 0 |
| Digestion and absorption | R-HSA-8963743 | 9.999504e-01 | 0.000 | 0 | 0 |
| Xenobiotics | R-HSA-211981 | 9.999569e-01 | 0.000 | 0 | 0 |
| Glycosphingolipid biosynthesis | R-HSA-9840309 | 9.999569e-01 | 0.000 | 0 | 0 |
| Degradation of the extracellular matrix | R-HSA-1474228 | 9.999576e-01 | 0.000 | 0 | 0 |
| Role of LAT2/NTAL/LAB on calcium mobilization | R-HSA-2730905 | 9.999588e-01 | 0.000 | 0 | 0 |
| Bile acid and bile salt metabolism | R-HSA-194068 | 9.999609e-01 | 0.000 | 0 | 0 |
| Latent infection - Other responses of Mtb to phagocytosis | R-HSA-1222499 | 9.999625e-01 | 0.000 | 0 | 0 |
| Peroxisomal lipid metabolism | R-HSA-390918 | 9.999636e-01 | 0.000 | 0 | 0 |
| Sulfur amino acid metabolism | R-HSA-1614635 | 9.999754e-01 | 0.000 | 0 | 0 |
| Class C/3 (Metabotropic glutamate/pheromone receptors) | R-HSA-420499 | 9.999810e-01 | 0.000 | 0 | 0 |
| Glycosphingolipid catabolism | R-HSA-9840310 | 9.999814e-01 | 0.000 | 0 | 0 |
| Purine catabolism | R-HSA-74259 | 9.999859e-01 | 0.000 | 0 | 0 |
| Aspirin ADME | R-HSA-9749641 | 9.999878e-01 | 0.000 | 0 | 0 |
| Diseases of carbohydrate metabolism | R-HSA-5663084 | 9.999878e-01 | 0.000 | 0 | 0 |
| Post-translational protein modification | R-HSA-597592 | 9.999904e-01 | 0.000 | 0 | 0 |
| Iron uptake and transport | R-HSA-917937 | 9.999908e-01 | 0.000 | 0 | 0 |
| FCGR activation | R-HSA-2029481 | 9.999913e-01 | 0.000 | 0 | 0 |
| Infection with Mycobacterium tuberculosis | R-HSA-9635486 | 9.999916e-01 | 0.000 | 0 | 0 |
| Mitochondrial Fatty Acid Beta-Oxidation | R-HSA-77289 | 9.999933e-01 | 0.000 | 0 | 0 |
| Visual phototransduction | R-HSA-2187338 | 9.999935e-01 | 0.000 | 0 | 0 |
| Antimicrobial peptides | R-HSA-6803157 | 9.999943e-01 | 0.000 | 0 | 0 |
| Peptide ligand-binding receptors | R-HSA-375276 | 9.999946e-01 | 0.000 | 0 | 0 |
| Metabolic disorders of biological oxidation enzymes | R-HSA-5579029 | 9.999947e-01 | 0.000 | 0 | 0 |
| Extracellular matrix organization | R-HSA-1474244 | 9.999951e-01 | 0.000 | 0 | 0 |
| Biosynthesis of DHA-derived SPMs | R-HSA-9018677 | 9.999960e-01 | 0.000 | 0 | 0 |
| Glycerophospholipid biosynthesis | R-HSA-1483206 | 9.999967e-01 | 0.000 | 0 | 0 |
| Post-translational modification: synthesis of GPI-anchored proteins | R-HSA-163125 | 9.999984e-01 | 0.000 | 0 | 0 |
| Transport of small molecules | R-HSA-382551 | 9.999990e-01 | 0.000 | 1 | 0 |
| Class B/2 (Secretin family receptors) | R-HSA-373080 | 9.999990e-01 | 0.000 | 0 | 0 |
| Sensory perception of sweet, bitter, and umami (glutamate) taste | R-HSA-9717207 | 9.999990e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation elongation | R-HSA-5389840 | 9.999997e-01 | 0.000 | 0 | 0 |
| Sphingolipid metabolism | R-HSA-428157 | 9.999997e-01 | 0.000 | 0 | 0 |
| Sensory perception of taste | R-HSA-9717189 | 9.999997e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation initiation | R-HSA-5368286 | 9.999998e-01 | 0.000 | 0 | 0 |
| Mitochondrial ribosome-associated quality control | R-HSA-9937383 | 9.999999e-01 | 0.000 | 0 | 0 |
| Glycosphingolipid metabolism | R-HSA-1660662 | 9.999999e-01 | 0.000 | 0 | 0 |
| Asparagine N-linked glycosylation | R-HSA-446203 | 9.999999e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation termination | R-HSA-5419276 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of water-soluble vitamins and cofactors | R-HSA-196849 | 1.000000e+00 | 0.000 | 0 | 0 |
| Keratinization | R-HSA-6805567 | 1.000000e+00 | 0.000 | 0 | 0 |
| Respiratory electron transport | R-HSA-611105 | 1.000000e+00 | 0.000 | 0 | 0 |
| Binding and Uptake of Ligands by Scavenger Receptors | R-HSA-2173782 | 1.000000e+00 | 0.000 | 0 | 0 |
| Class A/1 (Rhodopsin-like receptors) | R-HSA-373076 | 1.000000e+00 | 0.000 | 0 | 0 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | R-HSA-198933 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of nucleotides | R-HSA-15869 | 1.000000e+00 | 0.000 | 0 | 0 |
| SLC-mediated transmembrane transport | R-HSA-425407 | 1.000000e+00 | 0.000 | 0 | 0 |
| Regulation of Complement cascade | R-HSA-977606 | 1.000000e+00 | 0.000 | 0 | 0 |
| Nucleotide catabolism | R-HSA-8956319 | 1.000000e+00 | 0.000 | 0 | 0 |
| Synthesis of substrates in N-glycan biosythesis | R-HSA-446219 | 1.000000e+00 | 0.000 | 0 | 0 |
| Bacterial Infection Pathways | R-HSA-9824439 | 1.000000e+00 | 0.000 | 0 | 0 |
| O-linked glycosylation | R-HSA-5173105 | 1.000000e+00 | 0.000 | 0 | 0 |
| Mitochondrial translation | R-HSA-5368287 | 1.000000e+00 | 0.000 | 0 | 0 |
| Diseases of glycosylation | R-HSA-3781865 | 1.000000e+00 | 0.000 | 0 | 0 |
| Biosynthesis of specialized proresolving mediators (SPMs) | R-HSA-9018678 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of proteins | R-HSA-392499 | 1.000000e+00 | 0.000 | 0 | 0 |
| Cytochrome P450 - arranged by substrate type | R-HSA-211897 | 1.000000e+00 | 0.000 | 0 | 0 |
| Complement cascade | R-HSA-166658 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of vitamins and cofactors | R-HSA-196854 | 1.000000e+00 | 0.000 | 0 | 0 |
| Glycosaminoglycan metabolism | R-HSA-1630316 | 1.000000e+00 | 0.000 | 0 | 0 |
| Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein | R-HSA-446193 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of amino acids and derivatives | R-HSA-71291 | 1.000000e+00 | 0.000 | 0 | 0 |
| Aerobic respiration and respiratory electron transport | R-HSA-1428517 | 1.000000e+00 | 0.000 | 0 | 0 |
| Drug ADME | R-HSA-9748784 | 1.000000e+00 | 0.000 | 0 | 0 |
| Phase I - Functionalization of compounds | R-HSA-211945 | 1.000000e+00 | 0.000 | 0 | 0 |
| Phase II - Conjugation of compounds | R-HSA-156580 | 1.000000e+00 | 0.000 | 0 | 0 |
| GPCR ligand binding | R-HSA-500792 | 1.000000e+00 | 0.000 | 0 | 0 |
| Expression and translocation of olfactory receptors | R-HSA-9752946 | 1.000000e+00 | -0.000 | 0 | 0 |
| Metabolism of lipids | R-HSA-556833 | 1.000000e+00 | -0.000 | 0 | 0 |
| Metabolism | R-HSA-1430728 | 1.000000e+00 | -0.000 | 0 | 0 |
| Olfactory Signaling Pathway | R-HSA-381753 | 1.000000e+00 | -0.000 | 0 | 0 |
| Sensory Perception | R-HSA-9709957 | 1.000000e+00 | -0.000 | 0 | 0 |
| Biological oxidations | R-HSA-211859 | 1.000000e+00 | -0.000 | 0 | 0 |
| Fatty acid metabolism | R-HSA-8978868 | 1.000000e+00 | -0.000 | 0 | 0 |
| Diseases of metabolism | R-HSA-5668914 | 1.000000e+00 | -0.000 | 0 | 0 |
Top15 pathways (red highlights are reference pathways)
Compared with reference pathways
Motif of predicted substrate sequence
Reactome pathways of predicted substrates
Download
| name | reactome_id | p | -log10p | ref_path | ref_path_lowest |
|---|---|---|---|---|---|
| Metabolism of RNA | R-HSA-8953854 | 1.110223e-16 | 15.955 | 0 | 0 |
| Cellular responses to stress | R-HSA-2262752 | 1.110223e-16 | 15.955 | 0 | 0 |
| Cellular responses to stimuli | R-HSA-8953897 | 1.110223e-16 | 15.955 | 0 | 0 |
| Cellular response to heat stress | R-HSA-3371556 | 4.440892e-16 | 15.353 | 0 | 0 |
| Apoptotic execution phase | R-HSA-75153 | 1.443290e-15 | 14.841 | 0 | 0 |
| Cell Cycle | R-HSA-1640170 | 2.331468e-15 | 14.632 | 0 | 0 |
| Regulation of HSF1-mediated heat shock response | R-HSA-3371453 | 2.703393e-13 | 12.568 | 0 | 0 |
| Cell Cycle, Mitotic | R-HSA-69278 | 3.567147e-13 | 12.448 | 0 | 0 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | R-HSA-72706 | 5.935252e-13 | 12.227 | 0 | 0 |
| Eukaryotic Translation Initiation | R-HSA-72613 | 8.055778e-13 | 12.094 | 0 | 0 |
| Cap-dependent Translation Initiation | R-HSA-72737 | 8.055778e-13 | 12.094 | 0 | 0 |
| Processing of Capped Intron-Containing Pre-mRNA | R-HSA-72203 | 1.367129e-12 | 11.864 | 0 | 0 |
| L13a-mediated translational silencing of Ceruloplasmin expression | R-HSA-156827 | 2.099432e-12 | 11.678 | 0 | 0 |
| HSF1-dependent transactivation | R-HSA-3371571 | 2.354339e-12 | 11.628 | 0 | 0 |
| M Phase | R-HSA-68886 | 4.409362e-12 | 11.356 | 0 | 0 |
| Apoptosis | R-HSA-109581 | 4.761080e-12 | 11.322 | 0 | 0 |
| Attenuation phase | R-HSA-3371568 | 6.449397e-12 | 11.190 | 0 | 0 |
| Apoptotic cleavage of cellular proteins | R-HSA-111465 | 1.092793e-11 | 10.961 | 0 | 0 |
| Nervous system development | R-HSA-9675108 | 1.753397e-11 | 10.756 | 0 | 0 |
| HSF1 activation | R-HSA-3371511 | 2.616163e-11 | 10.582 | 0 | 0 |
| Axon guidance | R-HSA-422475 | 3.717027e-11 | 10.430 | 0 | 0 |
| Eukaryotic Translation Elongation | R-HSA-156842 | 2.976072e-10 | 9.526 | 0 | 0 |
| Cell Cycle Checkpoints | R-HSA-69620 | 3.345390e-10 | 9.476 | 0 | 0 |
| Signaling by ROBO receptors | R-HSA-376176 | 7.387413e-10 | 9.132 | 0 | 0 |
| Formation of a pool of free 40S subunits | R-HSA-72689 | 8.577914e-10 | 9.067 | 0 | 0 |
| Mitotic Anaphase | R-HSA-68882 | 1.215210e-09 | 8.915 | 0 | 0 |
| Influenza Infection | R-HSA-168255 | 1.231586e-09 | 8.910 | 0 | 0 |
| Antiviral mechanism by IFN-stimulated genes | R-HSA-1169410 | 1.313350e-09 | 8.882 | 0 | 0 |
| Mitotic Metaphase and Anaphase | R-HSA-2555396 | 1.425746e-09 | 8.846 | 0 | 0 |
| Cell-Cell communication | R-HSA-1500931 | 3.738441e-09 | 8.427 | 0 | 0 |
| Major pathway of rRNA processing in the nucleolus and cytosol | R-HSA-6791226 | 4.270013e-09 | 8.370 | 0 | 0 |
| Diseases of signal transduction by growth factor receptors and second messengers | R-HSA-5663202 | 4.368624e-09 | 8.360 | 0 | 0 |
| rRNA processing in the nucleus and cytosol | R-HSA-8868773 | 5.726650e-09 | 8.242 | 0 | 0 |
| Programmed Cell Death | R-HSA-5357801 | 7.171168e-09 | 8.144 | 0 | 0 |
| Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | R-HSA-975956 | 8.295453e-09 | 8.081 | 0 | 0 |
| Separation of Sister Chromatids | R-HSA-2467813 | 8.201099e-09 | 8.086 | 0 | 0 |
| Peptide chain elongation | R-HSA-156902 | 9.862084e-09 | 8.006 | 0 | 0 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | R-HSA-72662 | 1.077782e-08 | 7.967 | 0 | 0 |
| Influenza Viral RNA Transcription and Replication | R-HSA-168273 | 1.106004e-08 | 7.956 | 0 | 0 |
| Translation initiation complex formation | R-HSA-72649 | 1.154381e-08 | 7.938 | 0 | 0 |
| mRNA Splicing - Major Pathway | R-HSA-72163 | 1.501908e-08 | 7.823 | 0 | 0 |
| Regulation of expression of SLITs and ROBOs | R-HSA-9010553 | 1.675146e-08 | 7.776 | 0 | 0 |
| Ribosomal scanning and start codon recognition | R-HSA-72702 | 2.185558e-08 | 7.660 | 0 | 0 |
| Mitotic Prometaphase | R-HSA-68877 | 3.061327e-08 | 7.514 | 0 | 0 |
| mRNA Splicing | R-HSA-72172 | 3.409796e-08 | 7.467 | 0 | 0 |
| Nonsense-Mediated Decay (NMD) | R-HSA-927802 | 5.340721e-08 | 7.272 | 0 | 0 |
| Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | R-HSA-975957 | 5.340721e-08 | 7.272 | 0 | 0 |
| Ribosome-associated quality control | R-HSA-9948299 | 5.163208e-08 | 7.287 | 0 | 0 |
| PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA | R-HSA-9954714 | 6.365566e-08 | 7.196 | 0 | 0 |
| ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA | R-HSA-9954716 | 6.549666e-08 | 7.184 | 0 | 0 |
| Signaling by Hippo | R-HSA-2028269 | 8.693708e-08 | 7.061 | 0 | 0 |
| Cell junction organization | R-HSA-446728 | 1.204731e-07 | 6.919 | 0 | 0 |
| Cytokine Signaling in Immune system | R-HSA-1280215 | 1.378734e-07 | 6.861 | 0 | 0 |
| SRP-dependent cotranslational protein targeting to membrane | R-HSA-1799339 | 1.524150e-07 | 6.817 | 0 | 0 |
| Resolution of Sister Chromatid Cohesion | R-HSA-2500257 | 1.667104e-07 | 6.778 | 0 | 0 |
| Response of EIF2AK4 (GCN2) to amino acid deficiency | R-HSA-9633012 | 1.901393e-07 | 6.721 | 0 | 0 |
| Regulation of Expression and Function of Type I Classical Cadherins | R-HSA-9764274 | 2.477751e-07 | 6.606 | 0 | 0 |
| Regulation of CDH1 Expression and Function | R-HSA-9764265 | 2.477751e-07 | 6.606 | 0 | 0 |
| Transport of Mature Transcript to Cytoplasm | R-HSA-72202 | 5.491915e-07 | 6.260 | 0 | 0 |
| Eukaryotic Translation Termination | R-HSA-72764 | 6.773113e-07 | 6.169 | 0 | 0 |
| Apoptotic cleavage of cell adhesion proteins | R-HSA-351906 | 9.811577e-07 | 6.008 | 0 | 0 |
| ISG15 antiviral mechanism | R-HSA-1169408 | 1.027234e-06 | 5.988 | 0 | 0 |
| Regulation of Homotypic Cell-Cell Adhesion | R-HSA-9759476 | 1.235793e-06 | 5.908 | 0 | 0 |
| rRNA processing | R-HSA-72312 | 1.424443e-06 | 5.846 | 0 | 0 |
| EML4 and NUDC in mitotic spindle formation | R-HSA-9648025 | 1.615984e-06 | 5.792 | 0 | 0 |
| Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide | R-HSA-9954709 | 1.866408e-06 | 5.729 | 0 | 0 |
| Selenocysteine synthesis | R-HSA-2408557 | 2.158348e-06 | 5.666 | 0 | 0 |
| SARS-CoV-1-host interactions | R-HSA-9692914 | 2.451086e-06 | 5.611 | 0 | 0 |
| Formation of the ternary complex, and subsequently, the 43S complex | R-HSA-72695 | 2.674968e-06 | 5.573 | 0 | 0 |
| Viral mRNA Translation | R-HSA-192823 | 3.108775e-06 | 5.507 | 0 | 0 |
| G2/M Transition | R-HSA-69275 | 3.377206e-06 | 5.471 | 0 | 0 |
| Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | R-HSA-141444 | 3.690865e-06 | 5.433 | 0 | 0 |
| Amplification of signal from the kinetochores | R-HSA-141424 | 3.690865e-06 | 5.433 | 0 | 0 |
| Cell-extracellular matrix interactions | R-HSA-446353 | 3.570109e-06 | 5.447 | 0 | 0 |
| Apoptosis induced DNA fragmentation | R-HSA-140342 | 4.237150e-06 | 5.373 | 0 | 0 |
| Regulation of CDH1 Function | R-HSA-9764561 | 4.264890e-06 | 5.370 | 0 | 0 |
| Mitotic G2-G2/M phases | R-HSA-453274 | 4.358275e-06 | 5.361 | 0 | 0 |
| Mitotic Spindle Checkpoint | R-HSA-69618 | 4.718034e-06 | 5.326 | 0 | 0 |
| Developmental Lineage of Mammary Gland Myoepithelial Cells | R-HSA-9927432 | 5.704829e-06 | 5.244 | 0 | 0 |
| Transport of Mature mRNA derived from an Intron-Containing Transcript | R-HSA-159236 | 5.819907e-06 | 5.235 | 0 | 0 |
| Signaling by ALK fusions and activated point mutants | R-HSA-9725370 | 7.411735e-06 | 5.130 | 0 | 0 |
| Signaling by ALK in cancer | R-HSA-9700206 | 7.411735e-06 | 5.130 | 0 | 0 |
| G2/M Checkpoints | R-HSA-69481 | 8.404227e-06 | 5.076 | 0 | 0 |
| Paradoxical activation of RAF signaling by kinase inactive BRAF | R-HSA-6802955 | 9.193444e-06 | 5.037 | 0 | 0 |
| Signaling by moderate kinase activity BRAF mutants | R-HSA-6802946 | 9.193444e-06 | 5.037 | 0 | 0 |
| Signaling downstream of RAS mutants | R-HSA-9649948 | 9.193444e-06 | 5.037 | 0 | 0 |
| Signaling by RAS mutants | R-HSA-6802949 | 9.193444e-06 | 5.037 | 0 | 0 |
| Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | R-HSA-8950505 | 8.886578e-06 | 5.051 | 0 | 0 |
| Adherens junctions interactions | R-HSA-418990 | 9.715496e-06 | 5.013 | 0 | 0 |
| Gene expression (Transcription) | R-HSA-74160 | 1.065773e-05 | 4.972 | 0 | 0 |
| Transcriptional regulation by RUNX1 | R-HSA-8878171 | 1.186757e-05 | 4.926 | 0 | 0 |
| Transport of Mature mRNA Derived from an Intronless Transcript | R-HSA-159231 | 1.235155e-05 | 4.908 | 0 | 0 |
| Nuclear Envelope Breakdown | R-HSA-2980766 | 1.335331e-05 | 4.874 | 0 | 0 |
| Regulation of mRNA stability by proteins that bind AU-rich elements | R-HSA-450531 | 1.352170e-05 | 4.869 | 0 | 0 |
| The role of GTSE1 in G2/M progression after G2 checkpoint | R-HSA-8852276 | 1.364179e-05 | 4.865 | 0 | 0 |
| Signal Transduction | R-HSA-162582 | 1.391313e-05 | 4.857 | 0 | 0 |
| Interferon Signaling | R-HSA-913531 | 1.548625e-05 | 4.810 | 0 | 0 |
| SARS-CoV-2-host interactions | R-HSA-9705683 | 1.473522e-05 | 4.832 | 0 | 0 |
| Transport of Mature mRNAs Derived from Intronless Transcripts | R-HSA-159234 | 1.634103e-05 | 4.787 | 0 | 0 |
| Transcriptional Regulation by TP53 | R-HSA-3700989 | 1.667848e-05 | 4.778 | 0 | 0 |
| Regulation of PLK1 Activity at G2/M Transition | R-HSA-2565942 | 1.853229e-05 | 4.732 | 0 | 0 |
| Host Interactions of HIV factors | R-HSA-162909 | 2.495763e-05 | 4.603 | 0 | 0 |
| Signaling by BRAF and RAF1 fusions | R-HSA-6802952 | 2.588487e-05 | 4.587 | 0 | 0 |
| Signaling by Interleukins | R-HSA-449147 | 2.657117e-05 | 4.576 | 0 | 0 |
| Signaling by RAF1 mutants | R-HSA-9656223 | 2.792450e-05 | 4.554 | 0 | 0 |
| Interleukin-12 signaling | R-HSA-9020591 | 2.966569e-05 | 4.528 | 0 | 0 |
| Cellular Senescence | R-HSA-2559583 | 3.086380e-05 | 4.511 | 0 | 0 |
| Chromatin organization | R-HSA-4839726 | 3.468228e-05 | 4.460 | 0 | 0 |
| Cellular response to starvation | R-HSA-9711097 | 3.586456e-05 | 4.445 | 0 | 0 |
| Interleukin-12 family signaling | R-HSA-447115 | 3.785206e-05 | 4.422 | 0 | 0 |
| Regulation of endogenous retroelements | R-HSA-9842860 | 4.106321e-05 | 4.387 | 0 | 0 |
| Cell-cell junction organization | R-HSA-421270 | 4.211014e-05 | 4.376 | 0 | 0 |
| TP53 Regulates Transcription of DNA Repair Genes | R-HSA-6796648 | 4.300903e-05 | 4.366 | 0 | 0 |
| Recruitment of NuMA to mitotic centrosomes | R-HSA-380320 | 4.491699e-05 | 4.348 | 0 | 0 |
| Smooth Muscle Contraction | R-HSA-445355 | 4.954879e-05 | 4.305 | 0 | 0 |
| Chromatin modifying enzymes | R-HSA-3247509 | 5.228428e-05 | 4.282 | 0 | 0 |
| Aggrephagy | R-HSA-9646399 | 5.541176e-05 | 4.256 | 0 | 0 |
| Downregulation of ERBB4 signaling | R-HSA-1253288 | 5.617067e-05 | 4.250 | 0 | 0 |
| Oncogenic MAPK signaling | R-HSA-6802957 | 5.735939e-05 | 4.241 | 0 | 0 |
| PKR-mediated signaling | R-HSA-9833482 | 6.152433e-05 | 4.211 | 0 | 0 |
| Formation of the polybromo-BAF (pBAF) complex | R-HSA-9933939 | 6.542640e-05 | 4.184 | 0 | 0 |
| Transport of the SLBP independent Mature mRNA | R-HSA-159227 | 7.638100e-05 | 4.117 | 0 | 0 |
| Epigenetic regulation of gene expression | R-HSA-212165 | 7.439493e-05 | 4.128 | 0 | 0 |
| Mitotic Prophase | R-HSA-68875 | 7.227835e-05 | 4.141 | 0 | 0 |
| Positive epigenetic regulation of rRNA expression | R-HSA-5250913 | 8.326578e-05 | 4.080 | 0 | 0 |
| Signaling by high-kinase activity BRAF mutants | R-HSA-6802948 | 8.512708e-05 | 4.070 | 0 | 0 |
| AURKA Activation by TPX2 | R-HSA-8854518 | 8.764400e-05 | 4.057 | 0 | 0 |
| Viral Infection Pathways | R-HSA-9824446 | 9.598457e-05 | 4.018 | 0 | 0 |
| Developmental Lineages of the Mammary Gland | R-HSA-9924644 | 9.982512e-05 | 4.001 | 0 | 0 |
| Transport of the SLBP Dependant Mature mRNA | R-HSA-159230 | 1.004464e-04 | 3.998 | 0 | 0 |
| Chaperone Mediated Autophagy | R-HSA-9613829 | 1.070660e-04 | 3.970 | 0 | 0 |
| Recycling pathway of L1 | R-HSA-437239 | 1.175784e-04 | 3.930 | 0 | 0 |
| SARS-CoV-1 modulates host translation machinery | R-HSA-9735869 | 1.308700e-04 | 3.883 | 0 | 0 |
| Nuclear import of Rev protein | R-HSA-180746 | 1.308700e-04 | 3.883 | 0 | 0 |
| Loss of proteins required for interphase microtubule organization from the centrosome | R-HSA-380284 | 1.341134e-04 | 3.873 | 0 | 0 |
| Loss of Nlp from mitotic centrosomes | R-HSA-380259 | 1.341134e-04 | 3.873 | 0 | 0 |
| NS1 Mediated Effects on Host Pathways | R-HSA-168276 | 1.401909e-04 | 3.853 | 0 | 0 |
| Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | R-HSA-5693565 | 1.699231e-04 | 3.770 | 0 | 0 |
| Translation | R-HSA-72766 | 1.720356e-04 | 3.764 | 0 | 0 |
| Interactions of Rev with host cellular proteins | R-HSA-177243 | 1.778634e-04 | 3.750 | 0 | 0 |
| Regulation of CDH1 Gene Transcription | R-HSA-9764560 | 1.814064e-04 | 3.741 | 0 | 0 |
| Formation of Senescence-Associated Heterochromatin Foci (SAHF) | R-HSA-2559584 | 2.127440e-04 | 3.672 | 0 | 0 |
| Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs) | R-HSA-9845323 | 2.053017e-04 | 3.688 | 0 | 0 |
| Negative Regulation of CDH1 Gene Transcription | R-HSA-9764725 | 2.053017e-04 | 3.688 | 0 | 0 |
| AUF1 (hnRNP D0) binds and destabilizes mRNA | R-HSA-450408 | 2.164189e-04 | 3.665 | 0 | 0 |
| PKMTs methylate histone lysines | R-HSA-3214841 | 2.240449e-04 | 3.650 | 0 | 0 |
| Regulation of PD-L1(CD274) transcription | R-HSA-9909649 | 2.317313e-04 | 3.635 | 0 | 0 |
| Developmental Cell Lineages of the Integumentary System | R-HSA-9734779 | 2.588341e-04 | 3.587 | 0 | 0 |
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | R-HSA-2173793 | 2.605885e-04 | 3.584 | 0 | 0 |
| Neutrophil degranulation | R-HSA-6798695 | 2.702680e-04 | 3.568 | 0 | 0 |
| Recognition of DNA damage by PCNA-containing replication complex | R-HSA-110314 | 2.711754e-04 | 3.567 | 0 | 0 |
| Vpr-mediated nuclear import of PICs | R-HSA-180910 | 2.749146e-04 | 3.561 | 0 | 0 |
| InlA-mediated entry of Listeria monocytogenes into host cells | R-HSA-8876493 | 2.856591e-04 | 3.544 | 0 | 0 |
| MAP2K and MAPK activation | R-HSA-5674135 | 2.802821e-04 | 3.552 | 0 | 0 |
| Recruitment of mitotic centrosome proteins and complexes | R-HSA-380270 | 3.014007e-04 | 3.521 | 0 | 0 |
| DNA Replication Pre-Initiation | R-HSA-69002 | 2.953963e-04 | 3.530 | 0 | 0 |
| HIV Infection | R-HSA-162906 | 3.058813e-04 | 3.514 | 0 | 0 |
| NRIF signals cell death from the nucleus | R-HSA-205043 | 3.213914e-04 | 3.493 | 0 | 0 |
| HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand | R-HSA-3371497 | 3.273540e-04 | 3.485 | 0 | 0 |
| mRNA 3'-end processing | R-HSA-72187 | 3.303309e-04 | 3.481 | 0 | 0 |
| Striated Muscle Contraction | R-HSA-390522 | 3.345577e-04 | 3.476 | 0 | 0 |
| Regulation of TP53 Activity | R-HSA-5633007 | 3.666846e-04 | 3.436 | 0 | 0 |
| Formation of the beta-catenin:TCF transactivating complex | R-HSA-201722 | 3.776755e-04 | 3.423 | 0 | 0 |
| Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) | R-HSA-5619107 | 4.027435e-04 | 3.395 | 0 | 0 |
| Centrosome maturation | R-HSA-380287 | 4.158039e-04 | 3.381 | 0 | 0 |
| L1CAM interactions | R-HSA-373760 | 4.327930e-04 | 3.364 | 0 | 0 |
| Transcriptional Regulation by E2F6 | R-HSA-8953750 | 4.336589e-04 | 3.363 | 0 | 0 |
| Mitotic Telophase/Cytokinesis | R-HSA-68884 | 4.485844e-04 | 3.348 | 0 | 0 |
| Metabolism of non-coding RNA | R-HSA-194441 | 4.517152e-04 | 3.345 | 0 | 0 |
| snRNP Assembly | R-HSA-191859 | 4.517152e-04 | 3.345 | 0 | 0 |
| Cytosolic sensors of pathogen-associated DNA | R-HSA-1834949 | 4.558418e-04 | 3.341 | 0 | 0 |
| IP3 and IP4 transport between cytosol and nucleus | R-HSA-1855196 | 5.180062e-04 | 3.286 | 0 | 0 |
| IP6 and IP7 transport between cytosol and nucleus | R-HSA-1855229 | 5.180062e-04 | 3.286 | 0 | 0 |
| SARS-CoV-1 Infection | R-HSA-9678108 | 5.087709e-04 | 3.293 | 0 | 0 |
| Nuclear Pore Complex (NPC) Disassembly | R-HSA-3301854 | 5.369299e-04 | 3.270 | 0 | 0 |
| Interactions of Vpr with host cellular proteins | R-HSA-176033 | 5.388694e-04 | 3.269 | 0 | 0 |
| EPH-Ephrin signaling | R-HSA-2682334 | 5.430399e-04 | 3.265 | 0 | 0 |
| Selenoamino acid metabolism | R-HSA-2408522 | 5.511550e-04 | 3.259 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex | R-HSA-170834 | 5.520699e-04 | 3.258 | 0 | 0 |
| Gap junction degradation | R-HSA-190873 | 5.996108e-04 | 3.222 | 0 | 0 |
| Assembly of the pre-replicative complex | R-HSA-68867 | 6.222126e-04 | 3.206 | 0 | 0 |
| Transcriptional regulation by small RNAs | R-HSA-5578749 | 6.261760e-04 | 3.203 | 0 | 0 |
| Regulation of signaling by CBL | R-HSA-912631 | 6.269875e-04 | 3.203 | 0 | 0 |
| DNA Double Strand Break Response | R-HSA-5693606 | 6.890504e-04 | 3.162 | 0 | 0 |
| Translocation of SLC2A4 (GLUT4) to the plasma membrane | R-HSA-1445148 | 7.303210e-04 | 3.136 | 0 | 0 |
| Glycolysis | R-HSA-70171 | 8.142776e-04 | 3.089 | 0 | 0 |
| IPs transport between nucleus and cytosol | R-HSA-1855170 | 8.334964e-04 | 3.079 | 0 | 0 |
| Deactivation of the beta-catenin transactivating complex | R-HSA-3769402 | 8.350342e-04 | 3.078 | 0 | 0 |
| SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | R-HSA-2173796 | 8.350342e-04 | 3.078 | 0 | 0 |
| Nuclear Envelope (NE) Reassembly | R-HSA-2995410 | 8.808003e-04 | 3.055 | 0 | 0 |
| Formation of tubulin folding intermediates by CCT/TriC | R-HSA-389960 | 9.652457e-04 | 3.015 | 0 | 0 |
| Developmental Lineage of Mammary Gland Luminal Epithelial Cells | R-HSA-9927418 | 9.941877e-04 | 3.003 | 0 | 0 |
| Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RNA | R-HSA-428359 | 9.510878e-04 | 3.022 | 0 | 0 |
| HIV Life Cycle | R-HSA-162587 | 9.762954e-04 | 3.010 | 0 | 0 |
| Developmental Biology | R-HSA-1266738 | 9.375428e-04 | 3.028 | 0 | 0 |
| Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | R-HSA-75035 | 9.988517e-04 | 3.000 | 0 | 0 |
| Rev-mediated nuclear export of HIV RNA | R-HSA-165054 | 1.030070e-03 | 2.987 | 0 | 0 |
| Regulation of Glucokinase by Glucokinase Regulatory Protein | R-HSA-170822 | 1.043709e-03 | 2.981 | 0 | 0 |
| B-WICH complex positively regulates rRNA expression | R-HSA-5250924 | 1.053260e-03 | 2.977 | 0 | 0 |
| RNA Polymerase II Transcription | R-HSA-73857 | 1.222371e-03 | 2.913 | 0 | 0 |
| SWI/SNF chromatin remodelers | R-HSA-9932451 | 1.249024e-03 | 2.903 | 0 | 0 |
| ATP-dependent chromatin remodelers | R-HSA-9932444 | 1.249024e-03 | 2.903 | 0 | 0 |
| Regulation of TP53 Expression and Degradation | R-HSA-6806003 | 1.262010e-03 | 2.899 | 0 | 0 |
| Regulation of endogenous retroelements by the Human Silencing Hub (HUSH) complex | R-HSA-9843970 | 1.296482e-03 | 2.887 | 0 | 0 |
| Selective autophagy | R-HSA-9663891 | 1.348294e-03 | 2.870 | 0 | 0 |
| Degradation of CDH1 | R-HSA-9766229 | 1.353297e-03 | 2.869 | 0 | 0 |
| NOTCH1 Intracellular Domain Regulates Transcription | R-HSA-2122947 | 1.353297e-03 | 2.869 | 0 | 0 |
| Gap junction trafficking and regulation | R-HSA-157858 | 1.353297e-03 | 2.869 | 0 | 0 |
| Estrogen-dependent gene expression | R-HSA-9018519 | 1.398018e-03 | 2.854 | 0 | 0 |
| Muscle contraction | R-HSA-397014 | 1.423853e-03 | 2.847 | 0 | 0 |
| PECAM1 interactions | R-HSA-210990 | 1.447492e-03 | 2.839 | 0 | 0 |
| HDACs deacetylate histones | R-HSA-3214815 | 1.475284e-03 | 2.831 | 0 | 0 |
| Listeria monocytogenes entry into host cells | R-HSA-8876384 | 1.498211e-03 | 2.824 | 0 | 0 |
| FLT3 signaling by CBL mutants | R-HSA-9706377 | 1.503666e-03 | 2.823 | 0 | 0 |
| RNA Polymerase II Transcription Termination | R-HSA-73856 | 1.571402e-03 | 2.804 | 0 | 0 |
| Signaling by Receptor Tyrosine Kinases | R-HSA-9006934 | 1.601015e-03 | 2.796 | 0 | 0 |
| Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | R-HSA-389958 | 1.624494e-03 | 2.789 | 0 | 0 |
| Ephrin signaling | R-HSA-3928664 | 1.757465e-03 | 2.755 | 0 | 0 |
| mTORC1-mediated signalling | R-HSA-166208 | 1.946373e-03 | 2.711 | 0 | 0 |
| Regulation of APC/C activators between G1/S and early anaphase | R-HSA-176408 | 1.831340e-03 | 2.737 | 0 | 0 |
| PTEN Regulation | R-HSA-6807070 | 1.879970e-03 | 2.726 | 0 | 0 |
| Transport of Ribonucleoproteins into the Host Nucleus | R-HSA-168271 | 1.858098e-03 | 2.731 | 0 | 0 |
| G2/M DNA damage checkpoint | R-HSA-69473 | 1.946461e-03 | 2.711 | 0 | 0 |
| Regulation of TP53 Degradation | R-HSA-6804757 | 1.955893e-03 | 2.709 | 0 | 0 |
| Formation of the embryonic stem cell BAF (esBAF) complex | R-HSA-9933946 | 1.990807e-03 | 2.701 | 0 | 0 |
| p75NTR signals via NF-kB | R-HSA-193639 | 1.990807e-03 | 2.701 | 0 | 0 |
| SARS-CoV-1 targets host intracellular signalling and regulatory pathways | R-HSA-9735871 | 1.990807e-03 | 2.701 | 0 | 0 |
| Regulation of TBK1, IKKε-mediated activation of IRF3, IRF7 upon TLR3 ligation | R-HSA-9828211 | 2.030682e-03 | 2.692 | 0 | 0 |
| Formation of annular gap junctions | R-HSA-196025 | 2.030682e-03 | 2.692 | 0 | 0 |
| TICAM1-dependent activation of IRF3/IRF7 | R-HSA-9013973 | 2.125933e-03 | 2.672 | 0 | 0 |
| NF-kB is activated and signals survival | R-HSA-209560 | 2.125933e-03 | 2.672 | 0 | 0 |
| Semaphorin interactions | R-HSA-373755 | 2.126589e-03 | 2.672 | 0 | 0 |
| Oxidative Stress Induced Senescence | R-HSA-2559580 | 2.151545e-03 | 2.667 | 0 | 0 |
| Regulation of PD-L1(CD274) expression | R-HSA-9909648 | 2.302258e-03 | 2.638 | 0 | 0 |
| Regulation of TP53 Activity through Acetylation | R-HSA-6804758 | 2.485073e-03 | 2.605 | 0 | 0 |
| RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | R-HSA-8939243 | 2.485073e-03 | 2.605 | 0 | 0 |
| Prefoldin mediated transfer of substrate to CCT/TriC | R-HSA-389957 | 2.496863e-03 | 2.603 | 0 | 0 |
| p75NTR recruits signalling complexes | R-HSA-209543 | 3.027129e-03 | 2.519 | 0 | 0 |
| Z-decay: degradation of maternal mRNAs by zygotically expressed factors | R-HSA-9820865 | 3.027129e-03 | 2.519 | 0 | 0 |
| Formation of neuronal progenitor and neuronal BAF (npBAF and nBAF) | R-HSA-9934037 | 3.041953e-03 | 2.517 | 0 | 0 |
| Caspase-mediated cleavage of cytoskeletal proteins | R-HSA-264870 | 3.107566e-03 | 2.508 | 0 | 0 |
| HCMV Early Events | R-HSA-9609690 | 3.138718e-03 | 2.503 | 0 | 0 |
| Termination of translesion DNA synthesis | R-HSA-5656169 | 3.147814e-03 | 2.502 | 0 | 0 |
| Signaling by ERBB2 | R-HSA-1227986 | 3.189103e-03 | 2.496 | 0 | 0 |
| Dual Incision in GG-NER | R-HSA-5696400 | 3.684923e-03 | 2.434 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of HSCs | R-HSA-8939236 | 3.274248e-03 | 2.485 | 0 | 0 |
| EPHB-mediated forward signaling | R-HSA-3928662 | 3.755665e-03 | 2.425 | 0 | 0 |
| DNA Damage Bypass | R-HSA-73893 | 3.406962e-03 | 2.468 | 0 | 0 |
| Anchoring of the basal body to the plasma membrane | R-HSA-5620912 | 3.628345e-03 | 2.440 | 0 | 0 |
| Stabilization of p53 | R-HSA-69541 | 3.443089e-03 | 2.463 | 0 | 0 |
| Switching of origins to a post-replicative state | R-HSA-69052 | 3.754445e-03 | 2.425 | 0 | 0 |
| Signaling by CSF1 (M-CSF) in myeloid cells | R-HSA-9680350 | 3.684923e-03 | 2.434 | 0 | 0 |
| p53-Dependent G1/S DNA damage checkpoint | R-HSA-69580 | 3.406962e-03 | 2.468 | 0 | 0 |
| p53-Dependent G1 DNA Damage Response | R-HSA-69563 | 3.406962e-03 | 2.468 | 0 | 0 |
| Gap junction trafficking | R-HSA-190828 | 3.755665e-03 | 2.425 | 0 | 0 |
| RMTs methylate histone arginines | R-HSA-3214858 | 3.755665e-03 | 2.425 | 0 | 0 |
| SARS-CoV Infections | R-HSA-9679506 | 3.425327e-03 | 2.465 | 0 | 0 |
| Downregulation of ERBB2 signaling | R-HSA-8863795 | 3.873811e-03 | 2.412 | 0 | 0 |
| Mitotic G1 phase and G1/S transition | R-HSA-453279 | 3.919132e-03 | 2.407 | 0 | 0 |
| DNA Double-Strand Break Repair | R-HSA-5693532 | 4.040589e-03 | 2.394 | 0 | 0 |
| ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | R-HSA-427389 | 4.105862e-03 | 2.387 | 0 | 0 |
| Macroautophagy | R-HSA-1632852 | 4.136354e-03 | 2.383 | 0 | 0 |
| Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176814 | 4.137944e-03 | 2.383 | 0 | 0 |
| DNA Damage/Telomere Stress Induced Senescence | R-HSA-2559586 | 4.229404e-03 | 2.374 | 0 | 0 |
| Co-inhibition by PD-1 | R-HSA-389948 | 4.245433e-03 | 2.372 | 0 | 0 |
| TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation | R-HSA-8869496 | 4.375737e-03 | 2.359 | 0 | 0 |
| TICAM1,TRAF6-dependent induction of TAK1 complex | R-HSA-9014325 | 4.561931e-03 | 2.341 | 0 | 0 |
| Folding of actin by CCT/TriC | R-HSA-390450 | 4.561931e-03 | 2.341 | 0 | 0 |
| S Phase | R-HSA-69242 | 4.653706e-03 | 2.332 | 0 | 0 |
| Regulation of T cell activation by CD28 family | R-HSA-388841 | 4.659909e-03 | 2.332 | 0 | 0 |
| Regulation of activated PAK-2p34 by proteasome mediated degradation | R-HSA-211733 | 4.727541e-03 | 2.325 | 0 | 0 |
| Intracellular signaling by second messengers | R-HSA-9006925 | 4.756634e-03 | 2.323 | 0 | 0 |
| G1/S Transition | R-HSA-69206 | 4.831579e-03 | 2.316 | 0 | 0 |
| G1/S DNA Damage Checkpoints | R-HSA-69615 | 4.845646e-03 | 2.315 | 0 | 0 |
| SPOP-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929491 | 4.867989e-03 | 2.313 | 0 | 0 |
| Transcriptional regulation by RUNX3 | R-HSA-8878159 | 4.920506e-03 | 2.308 | 0 | 0 |
| Late Phase of HIV Life Cycle | R-HSA-162599 | 4.923123e-03 | 2.308 | 0 | 0 |
| Inactivation of CSF3 (G-CSF) signaling | R-HSA-9705462 | 4.972741e-03 | 2.303 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in GG-NER | R-HSA-5696397 | 4.972741e-03 | 2.303 | 0 | 0 |
| Autodegradation of Cdh1 by Cdh1:APC/C | R-HSA-174084 | 5.174553e-03 | 2.286 | 0 | 0 |
| Export of Viral Ribonucleoproteins from Nucleus | R-HSA-168274 | 5.174553e-03 | 2.286 | 0 | 0 |
| Autophagy | R-HSA-9612973 | 5.185897e-03 | 2.285 | 0 | 0 |
| Notch-HLH transcription pathway | R-HSA-350054 | 6.239708e-03 | 2.205 | 0 | 0 |
| PRC2 methylates histones and DNA | R-HSA-212300 | 5.312511e-03 | 2.275 | 0 | 0 |
| Orc1 removal from chromatin | R-HSA-68949 | 5.376440e-03 | 2.270 | 0 | 0 |
| Cdc20:Phospho-APC/C mediated degradation of Cyclin A | R-HSA-174184 | 5.376440e-03 | 2.270 | 0 | 0 |
| APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | R-HSA-179419 | 6.207436e-03 | 2.207 | 0 | 0 |
| APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | R-HSA-174178 | 6.207436e-03 | 2.207 | 0 | 0 |
| Dual incision in TC-NER | R-HSA-6782135 | 5.490834e-03 | 2.260 | 0 | 0 |
| Chromosome Maintenance | R-HSA-73886 | 5.572141e-03 | 2.254 | 0 | 0 |
| APC/C-mediated degradation of cell cycle proteins | R-HSA-174143 | 6.246445e-03 | 2.204 | 0 | 0 |
| Regulation of mitotic cell cycle | R-HSA-453276 | 6.246445e-03 | 2.204 | 0 | 0 |
| Degradation of DVL | R-HSA-4641258 | 6.317058e-03 | 2.199 | 0 | 0 |
| Regulation of TP53 Activity through Methylation | R-HSA-6804760 | 6.164984e-03 | 2.210 | 0 | 0 |
| TCF dependent signaling in response to WNT | R-HSA-201681 | 5.535288e-03 | 2.257 | 0 | 0 |
| Depolymerization of the Nuclear Lamina | R-HSA-4419969 | 6.164984e-03 | 2.210 | 0 | 0 |
| Downregulation of SMAD2/3:SMAD4 transcriptional activity | R-HSA-2173795 | 5.723968e-03 | 2.242 | 0 | 0 |
| Regulation of KIT signaling | R-HSA-1433559 | 5.674589e-03 | 2.246 | 0 | 0 |
| ESR-mediated signaling | R-HSA-8939211 | 5.341775e-03 | 2.272 | 0 | 0 |
| Mitochondrial unfolded protein response (UPRmt) | R-HSA-9841251 | 6.056698e-03 | 2.218 | 0 | 0 |
| Cohesin Loading onto Chromatin | R-HSA-2470946 | 6.747278e-03 | 2.171 | 0 | 0 |
| Regulation of PTEN localization | R-HSA-8948747 | 6.747278e-03 | 2.171 | 0 | 0 |
| RNA Polymerase I Transcription | R-HSA-73864 | 6.908109e-03 | 2.161 | 0 | 0 |
| SARS-CoV-2 Infection | R-HSA-9694516 | 6.963318e-03 | 2.157 | 0 | 0 |
| Nonhomologous End-Joining (NHEJ) | R-HSA-5693571 | 6.996536e-03 | 2.155 | 0 | 0 |
| DNA Replication | R-HSA-69306 | 7.012495e-03 | 2.154 | 0 | 0 |
| Glucose metabolism | R-HSA-70326 | 7.049940e-03 | 2.152 | 0 | 0 |
| CDK-mediated phosphorylation and removal of Cdc6 | R-HSA-69017 | 7.138694e-03 | 2.146 | 0 | 0 |
| SARS-CoV-2 modulates host translation machinery | R-HSA-9754678 | 7.138694e-03 | 2.146 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | R-HSA-2894862 | 7.182157e-03 | 2.144 | 0 | 0 |
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | R-HSA-2644606 | 7.182157e-03 | 2.144 | 0 | 0 |
| Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | R-HSA-2894858 | 7.182157e-03 | 2.144 | 0 | 0 |
| Signaling by NOTCH1 PEST Domain Mutants in Cancer | R-HSA-2644602 | 7.182157e-03 | 2.144 | 0 | 0 |
| Regulation of PTEN gene transcription | R-HSA-8943724 | 7.182157e-03 | 2.144 | 0 | 0 |
| Signaling by NOTCH1 in Cancer | R-HSA-2644603 | 7.182157e-03 | 2.144 | 0 | 0 |
| Membrane Trafficking | R-HSA-199991 | 7.182236e-03 | 2.144 | 0 | 0 |
| TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | R-HSA-2173791 | 7.513824e-03 | 2.124 | 0 | 0 |
| IRF3-mediated induction of type I IFN | R-HSA-3270619 | 7.513824e-03 | 2.124 | 0 | 0 |
| Spry regulation of FGF signaling | R-HSA-1295596 | 7.513824e-03 | 2.124 | 0 | 0 |
| SARS-CoV-2 targets host intracellular signalling and regulatory pathways | R-HSA-9755779 | 7.513824e-03 | 2.124 | 0 | 0 |
| Meiosis | R-HSA-1500620 | 7.515263e-03 | 2.124 | 0 | 0 |
| Synthesis of DNA | R-HSA-69239 | 7.798768e-03 | 2.108 | 0 | 0 |
| Gene Silencing by RNA | R-HSA-211000 | 7.798768e-03 | 2.108 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Cyclin B | R-HSA-174048 | 7.848339e-03 | 2.105 | 0 | 0 |
| STING mediated induction of host immune responses | R-HSA-1834941 | 7.848339e-03 | 2.105 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176409 | 8.178448e-03 | 2.087 | 0 | 0 |
| SARS-CoV-2 activates/modulates innate and adaptive immune responses | R-HSA-9705671 | 8.588523e-03 | 2.066 | 0 | 0 |
| PIP3 activates AKT signaling | R-HSA-1257604 | 8.721010e-03 | 2.059 | 0 | 0 |
| Regulation of TBK1, IKKε (IKBKE)-mediated activation of IRF3, IRF7 | R-HSA-9824878 | 8.885505e-03 | 2.051 | 0 | 0 |
| ATF6 (ATF6-alpha) activates chaperone genes | R-HSA-381183 | 8.885505e-03 | 2.051 | 0 | 0 |
| Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | R-HSA-8864260 | 9.121172e-03 | 2.040 | 0 | 0 |
| Myoclonic epilepsy of Lafora | R-HSA-3785653 | 9.897366e-03 | 2.004 | 0 | 0 |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | R-HSA-354194 | 9.760025e-03 | 2.011 | 0 | 0 |
| Deadenylation of mRNA | R-HSA-429947 | 9.503643e-03 | 2.022 | 0 | 0 |
| SCF-beta-TrCP mediated degradation of Emi1 | R-HSA-174113 | 1.145624e-02 | 1.941 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in TC-NER | R-HSA-6782210 | 9.335180e-03 | 2.030 | 0 | 0 |
| Chaperonin-mediated protein folding | R-HSA-390466 | 1.033037e-02 | 1.986 | 0 | 0 |
| Signaling by EGFR | R-HSA-177929 | 9.335180e-03 | 2.030 | 0 | 0 |
| Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells | R-HSA-9860927 | 1.145624e-02 | 1.941 | 0 | 0 |
| Formation of Incision Complex in GG-NER | R-HSA-5696395 | 1.025143e-02 | 1.989 | 0 | 0 |
| Prolonged ERK activation events | R-HSA-169893 | 9.760025e-03 | 2.011 | 0 | 0 |
| Protein folding | R-HSA-391251 | 9.894098e-03 | 2.005 | 0 | 0 |
| Formation of WDR5-containing histone-modifying complexes | R-HSA-9772755 | 1.145624e-02 | 1.941 | 0 | 0 |
| Regulation of Apoptosis | R-HSA-169911 | 1.145624e-02 | 1.941 | 0 | 0 |
| Activation of NF-kappaB in B cells | R-HSA-1169091 | 1.064989e-02 | 1.973 | 0 | 0 |
| RNA Polymerase I Promoter Clearance | R-HSA-73854 | 1.114885e-02 | 1.953 | 0 | 0 |
| VEGFA-VEGFR2 Pathway | R-HSA-4420097 | 1.064391e-02 | 1.973 | 0 | 0 |
| Autodegradation of the E3 ubiquitin ligase COP1 | R-HSA-349425 | 9.728105e-03 | 2.012 | 0 | 0 |
| Signaling by NOTCH | R-HSA-157118 | 1.010755e-02 | 1.995 | 0 | 0 |
| Signaling by NOTCH1 | R-HSA-1980143 | 1.114885e-02 | 1.953 | 0 | 0 |
| tRNA processing in the nucleus | R-HSA-6784531 | 9.268481e-03 | 2.033 | 0 | 0 |
| Generic Transcription Pathway | R-HSA-212436 | 1.104405e-02 | 1.957 | 0 | 0 |
| NEP/NS2 Interacts with the Cellular Export Machinery | R-HSA-168333 | 1.054175e-02 | 1.977 | 0 | 0 |
| TCR signaling | R-HSA-202403 | 1.029862e-02 | 1.987 | 0 | 0 |
| Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A | R-HSA-69601 | 1.054175e-02 | 1.977 | 0 | 0 |
| p53-Independent G1/S DNA Damage Checkpoint | R-HSA-69613 | 1.054175e-02 | 1.977 | 0 | 0 |
| Negative regulation of FLT3 | R-HSA-9706369 | 9.760025e-03 | 2.011 | 0 | 0 |
| Nephrin family interactions | R-HSA-373753 | 9.855296e-03 | 2.006 | 0 | 0 |
| PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 | R-HSA-8849469 | 9.897366e-03 | 2.004 | 0 | 0 |
| Downstream signaling events of B Cell Receptor (BCR) | R-HSA-1168372 | 1.150718e-02 | 1.939 | 0 | 0 |
| Drug resistance in ERBB2 KD mutants | R-HSA-9665230 | 1.180979e-02 | 1.928 | 0 | 0 |
| Drug-mediated inhibition of ERBB2 signaling | R-HSA-9652282 | 1.180979e-02 | 1.928 | 0 | 0 |
| Localization of the PINCH-ILK-PARVIN complex to focal adhesions | R-HSA-446343 | 1.180979e-02 | 1.928 | 0 | 0 |
| Resistance of ERBB2 KD mutants to afatinib | R-HSA-9665249 | 1.180979e-02 | 1.928 | 0 | 0 |
| Resistance of ERBB2 KD mutants to lapatinib | R-HSA-9665251 | 1.180979e-02 | 1.928 | 0 | 0 |
| Drug resistance in ERBB2 TMD/JMD mutants | R-HSA-9665737 | 1.180979e-02 | 1.928 | 0 | 0 |
| Resistance of ERBB2 KD mutants to neratinib | R-HSA-9665246 | 1.180979e-02 | 1.928 | 0 | 0 |
| Resistance of ERBB2 KD mutants to tesevatinib | R-HSA-9665245 | 1.180979e-02 | 1.928 | 0 | 0 |
| Resistance of ERBB2 KD mutants to sapitinib | R-HSA-9665244 | 1.180979e-02 | 1.928 | 0 | 0 |
| Resistance of ERBB2 KD mutants to AEE788 | R-HSA-9665250 | 1.180979e-02 | 1.928 | 0 | 0 |
| Resistance of ERBB2 KD mutants to trastuzumab | R-HSA-9665233 | 1.180979e-02 | 1.928 | 0 | 0 |
| Resistance of ERBB2 KD mutants to osimertinib | R-HSA-9665247 | 1.180979e-02 | 1.928 | 0 | 0 |
| VLDLR internalisation and degradation | R-HSA-8866427 | 1.189457e-02 | 1.925 | 0 | 0 |
| Nucleotide Excision Repair | R-HSA-5696398 | 1.190507e-02 | 1.924 | 0 | 0 |
| Signaling by TGFB family members | R-HSA-9006936 | 1.191377e-02 | 1.924 | 0 | 0 |
| Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template | R-HSA-110313 | 1.191575e-02 | 1.924 | 0 | 0 |
| FLT3 Signaling | R-HSA-9607240 | 1.191575e-02 | 1.924 | 0 | 0 |
| DNA Repair | R-HSA-73894 | 1.215625e-02 | 1.915 | 0 | 0 |
| Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | R-HSA-1236382 | 1.222033e-02 | 1.913 | 0 | 0 |
| Signaling by Ligand-Responsive EGFR Variants in Cancer | R-HSA-5637815 | 1.222033e-02 | 1.913 | 0 | 0 |
| JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | R-HSA-450321 | 1.222033e-02 | 1.913 | 0 | 0 |
| APC-Cdc20 mediated degradation of Nek2A | R-HSA-179409 | 1.222033e-02 | 1.913 | 0 | 0 |
| Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE) | R-HSA-936964 | 1.246032e-02 | 1.904 | 0 | 0 |
| NoRC negatively regulates rRNA expression | R-HSA-427413 | 1.287216e-02 | 1.890 | 0 | 0 |
| Vif-mediated degradation of APOBEC3G | R-HSA-180585 | 1.340933e-02 | 1.873 | 0 | 0 |
| Meiotic synapsis | R-HSA-1221632 | 1.381572e-02 | 1.860 | 0 | 0 |
| Golgi Associated Vesicle Biogenesis | R-HSA-432722 | 1.381572e-02 | 1.860 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Securin | R-HSA-174154 | 1.389408e-02 | 1.857 | 0 | 0 |
| Postmitotic nuclear pore complex (NPC) reformation | R-HSA-9615933 | 1.391562e-02 | 1.856 | 0 | 0 |
| GP1b-IX-V activation signalling | R-HSA-430116 | 1.393254e-02 | 1.856 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex | R-HSA-937042 | 1.393254e-02 | 1.856 | 0 | 0 |
| trans-Golgi Network Vesicle Budding | R-HSA-199992 | 1.436113e-02 | 1.843 | 0 | 0 |
| MAPK6/MAPK4 signaling | R-HSA-5687128 | 1.462674e-02 | 1.835 | 0 | 0 |
| Aryl hydrocarbon receptor signalling | R-HSA-8937144 | 1.488777e-02 | 1.827 | 0 | 0 |
| Regulation of cytoskeletal remodeling and cell spreading by IPP complex components | R-HSA-446388 | 1.488777e-02 | 1.827 | 0 | 0 |
| RUNX1 regulates expression of components of tight junctions | R-HSA-8935964 | 1.488777e-02 | 1.827 | 0 | 0 |
| Maturation of protein E | R-HSA-9683683 | 1.488777e-02 | 1.827 | 0 | 0 |
| Maturation of protein E | R-HSA-9694493 | 1.488777e-02 | 1.827 | 0 | 0 |
| Positive Regulation of CDH1 Gene Transcription | R-HSA-9764790 | 1.894749e-02 | 1.722 | 0 | 0 |
| MET activates RAP1 and RAC1 | R-HSA-8875555 | 1.894749e-02 | 1.722 | 0 | 0 |
| Formation of the non-canonical BAF (ncBAF) complex | R-HSA-9933947 | 1.555729e-02 | 1.808 | 0 | 0 |
| p130Cas linkage to MAPK signaling for integrins | R-HSA-372708 | 1.566050e-02 | 1.805 | 0 | 0 |
| Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane | R-HSA-190840 | 1.566050e-02 | 1.805 | 0 | 0 |
| Developmental Lineage of Mammary Stem Cells | R-HSA-9938206 | 1.815992e-02 | 1.741 | 0 | 0 |
| EPHA-mediated growth cone collapse | R-HSA-3928663 | 1.661765e-02 | 1.779 | 0 | 0 |
| HIV elongation arrest and recovery | R-HSA-167287 | 1.968448e-02 | 1.706 | 0 | 0 |
| Pausing and recovery of HIV elongation | R-HSA-167290 | 1.968448e-02 | 1.706 | 0 | 0 |
| Transcription-Coupled Nucleotide Excision Repair (TC-NER) | R-HSA-6781827 | 1.964358e-02 | 1.707 | 0 | 0 |
| Regulation of TP53 Activity through Phosphorylation | R-HSA-6804756 | 1.776690e-02 | 1.750 | 0 | 0 |
| Processing of DNA double-strand break ends | R-HSA-5693607 | 1.870450e-02 | 1.728 | 0 | 0 |
| Clathrin-mediated endocytosis | R-HSA-8856828 | 1.565536e-02 | 1.805 | 0 | 0 |
| Frs2-mediated activation | R-HSA-170968 | 1.555729e-02 | 1.808 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation | R-HSA-975163 | 1.993454e-02 | 1.700 | 0 | 0 |
| activated TAK1 mediates p38 MAPK activation | R-HSA-450302 | 1.497749e-02 | 1.825 | 0 | 0 |
| Nuclear RNA decay | R-HSA-9930044 | 1.758713e-02 | 1.755 | 0 | 0 |
| Ovarian tumor domain proteases | R-HSA-5689896 | 1.560448e-02 | 1.807 | 0 | 0 |
| Negative epigenetic regulation of rRNA expression | R-HSA-5250941 | 1.694328e-02 | 1.771 | 0 | 0 |
| Signaling by WNT | R-HSA-195721 | 1.514211e-02 | 1.820 | 0 | 0 |
| RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | R-HSA-8936459 | 1.850923e-02 | 1.733 | 0 | 0 |
| Interleukin-4 and Interleukin-13 signaling | R-HSA-6785807 | 1.658446e-02 | 1.780 | 0 | 0 |
| Josephin domain DUBs | R-HSA-5689877 | 1.894749e-02 | 1.722 | 0 | 0 |
| Transport of connexons to the plasma membrane | R-HSA-190872 | 1.940422e-02 | 1.712 | 0 | 0 |
| RNA Polymerase I Transcription Initiation | R-HSA-73762 | 1.585864e-02 | 1.800 | 0 | 0 |
| Regulation of MECP2 expression and activity | R-HSA-9022692 | 1.758713e-02 | 1.755 | 0 | 0 |
| Signaling by MET | R-HSA-6806834 | 1.694328e-02 | 1.771 | 0 | 0 |
| Post NMDA receptor activation events | R-HSA-438064 | 1.952154e-02 | 1.709 | 0 | 0 |
| Viral Messenger RNA Synthesis | R-HSA-168325 | 1.718305e-02 | 1.765 | 0 | 0 |
| Pexophagy | R-HSA-9664873 | 1.894749e-02 | 1.722 | 0 | 0 |
| Initiation of Nuclear Envelope (NE) Reformation | R-HSA-2995383 | 1.497749e-02 | 1.825 | 0 | 0 |
| ATF6 (ATF6-alpha) activates chaperones | R-HSA-381033 | 1.555729e-02 | 1.808 | 0 | 0 |
| Interleukin-3, Interleukin-5 and GM-CSF signaling | R-HSA-512988 | 1.585864e-02 | 1.800 | 0 | 0 |
| MITF-M-regulated melanocyte development | R-HSA-9730414 | 1.714753e-02 | 1.766 | 0 | 0 |
| Unfolded Protein Response (UPR) | R-HSA-381119 | 1.801363e-02 | 1.744 | 0 | 0 |
| Regulation of RAS by GAPs | R-HSA-5658442 | 2.038205e-02 | 1.691 | 0 | 0 |
| Vpu mediated degradation of CD4 | R-HSA-180534 | 2.049414e-02 | 1.688 | 0 | 0 |
| SCF(Skp2)-mediated degradation of p27/p21 | R-HSA-187577 | 2.071538e-02 | 1.684 | 0 | 0 |
| GSK3B-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929356 | 2.078864e-02 | 1.682 | 0 | 0 |
| Signaling by cytosolic PDGFRA and PDGFRB fusion proteins | R-HSA-9673766 | 2.119567e-02 | 1.674 | 0 | 0 |
| Signaling by PTK6 | R-HSA-8848021 | 2.145483e-02 | 1.668 | 0 | 0 |
| Signaling by Non-Receptor Tyrosine Kinases | R-HSA-9006927 | 2.145483e-02 | 1.668 | 0 | 0 |
| Nef and signal transduction | R-HSA-164944 | 2.180822e-02 | 1.661 | 0 | 0 |
| TP53 Regulates Transcription of Cell Cycle Genes | R-HSA-6791312 | 2.227371e-02 | 1.652 | 0 | 0 |
| Regulation of endogenous retroelements by KRAB-ZFP proteins | R-HSA-9843940 | 2.279604e-02 | 1.642 | 0 | 0 |
| Degradation of beta-catenin by the destruction complex | R-HSA-195253 | 2.279604e-02 | 1.642 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere | R-HSA-9670621 | 2.310564e-02 | 1.636 | 0 | 0 |
| Diseases of Telomere Maintenance | R-HSA-9673013 | 2.310564e-02 | 1.636 | 0 | 0 |
| Alternative Lengthening of Telomeres (ALT) | R-HSA-9006821 | 2.310564e-02 | 1.636 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to DAXX Mutations | R-HSA-9670613 | 2.310564e-02 | 1.636 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to ATRX Mutations | R-HSA-9670615 | 2.310564e-02 | 1.636 | 0 | 0 |
| Signaling by CSF3 (G-CSF) | R-HSA-9674555 | 2.314062e-02 | 1.636 | 0 | 0 |
| Deposition of new CENPA-containing nucleosomes at the centromere | R-HSA-606279 | 2.352145e-02 | 1.629 | 0 | 0 |
| Nucleosome assembly | R-HSA-774815 | 2.352145e-02 | 1.629 | 0 | 0 |
| Asymmetric localization of PCP proteins | R-HSA-4608870 | 2.352145e-02 | 1.629 | 0 | 0 |
| Translesion Synthesis by POLH | R-HSA-110320 | 2.373218e-02 | 1.625 | 0 | 0 |
| Rap1 signalling | R-HSA-392517 | 2.373218e-02 | 1.625 | 0 | 0 |
| RAF activation | R-HSA-5673000 | 2.373671e-02 | 1.625 | 0 | 0 |
| Ubiquitin-dependent degradation of Cyclin D | R-HSA-75815 | 2.373671e-02 | 1.625 | 0 | 0 |
| Regulation of RUNX3 expression and activity | R-HSA-8941858 | 2.381071e-02 | 1.623 | 0 | 0 |
| Negative regulation of NOTCH4 signaling | R-HSA-9604323 | 2.381071e-02 | 1.623 | 0 | 0 |
| Beta-catenin independent WNT signaling | R-HSA-3858494 | 2.390615e-02 | 1.621 | 0 | 0 |
| Global Genome Nucleotide Excision Repair (GG-NER) | R-HSA-5696399 | 2.484170e-02 | 1.605 | 0 | 0 |
| Regulation of localization of FOXO transcription factors | R-HSA-9614399 | 2.502254e-02 | 1.602 | 0 | 0 |
| Alpha-protein kinase 1 signaling pathway | R-HSA-9645460 | 2.502254e-02 | 1.602 | 0 | 0 |
| TRAF6-mediated induction of TAK1 complex within TLR4 complex | R-HSA-937072 | 2.508100e-02 | 1.601 | 0 | 0 |
| Sema3A PAK dependent Axon repulsion | R-HSA-399954 | 2.508100e-02 | 1.601 | 0 | 0 |
| TICAM1, RIP1-mediated IKK complex recruitment | R-HSA-168927 | 2.508100e-02 | 1.601 | 0 | 0 |
| Translesion synthesis by REV1 | R-HSA-110312 | 2.508100e-02 | 1.601 | 0 | 0 |
| InlB-mediated entry of Listeria monocytogenes into host cell | R-HSA-8875360 | 2.508100e-02 | 1.601 | 0 | 0 |
| Activation of BAD and translocation to mitochondria | R-HSA-111447 | 2.508100e-02 | 1.601 | 0 | 0 |
| Cellular responses to mechanical stimuli | R-HSA-9855142 | 2.525251e-02 | 1.598 | 0 | 0 |
| MITF-M-dependent gene expression | R-HSA-9856651 | 2.546570e-02 | 1.594 | 0 | 0 |
| Signaling by VEGF | R-HSA-194138 | 2.557820e-02 | 1.592 | 0 | 0 |
| AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274) | R-HSA-9931269 | 2.582041e-02 | 1.588 | 0 | 0 |
| PCP/CE pathway | R-HSA-4086400 | 2.630018e-02 | 1.580 | 0 | 0 |
| MAPK family signaling cascades | R-HSA-5683057 | 2.644925e-02 | 1.578 | 0 | 0 |
| Cellular response to hypoxia | R-HSA-1234174 | 2.648277e-02 | 1.577 | 0 | 0 |
| Activation of BH3-only proteins | R-HSA-114452 | 2.700938e-02 | 1.568 | 0 | 0 |
| VEGFR2 mediated vascular permeability | R-HSA-5218920 | 2.714070e-02 | 1.566 | 0 | 0 |
| NIK-->noncanonical NF-kB signaling | R-HSA-5676590 | 2.714070e-02 | 1.566 | 0 | 0 |
| Hh mutants are degraded by ERAD | R-HSA-5362768 | 2.714070e-02 | 1.566 | 0 | 0 |
| M-decay: degradation of maternal mRNAs by maternally stored factors | R-HSA-9820841 | 2.714070e-02 | 1.566 | 0 | 0 |
| FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | R-HSA-8854050 | 2.733376e-02 | 1.563 | 0 | 0 |
| Signalling to ERKs | R-HSA-187687 | 2.733376e-02 | 1.563 | 0 | 0 |
| Cyclin A:Cdk2-associated events at S phase entry | R-HSA-69656 | 2.779290e-02 | 1.556 | 0 | 0 |
| CLEC7A (Dectin-1) signaling | R-HSA-5607764 | 2.846273e-02 | 1.546 | 0 | 0 |
| Sema4D induced cell migration and growth-cone collapse | R-HSA-416572 | 2.868149e-02 | 1.542 | 0 | 0 |
| Signal transduction by L1 | R-HSA-445144 | 2.868149e-02 | 1.542 | 0 | 0 |
| Negative regulation of MET activity | R-HSA-6807004 | 2.868149e-02 | 1.542 | 0 | 0 |
| Post-chaperonin tubulin folding pathway | R-HSA-389977 | 2.868149e-02 | 1.542 | 0 | 0 |
| Protein hydroxylation | R-HSA-9629569 | 2.868149e-02 | 1.542 | 0 | 0 |
| Regulation of PTEN stability and activity | R-HSA-8948751 | 2.890837e-02 | 1.539 | 0 | 0 |
| Cation-coupled Chloride cotransporters | R-HSA-426117 | 3.040980e-02 | 1.517 | 0 | 0 |
| Long-term potentiation | R-HSA-9620244 | 3.056657e-02 | 1.515 | 0 | 0 |
| Degradation of GLI1 by the proteasome | R-HSA-5610780 | 3.079373e-02 | 1.512 | 0 | 0 |
| Negative regulation of MAPK pathway | R-HSA-5675221 | 3.079373e-02 | 1.512 | 0 | 0 |
| Kinesins | R-HSA-983189 | 3.080282e-02 | 1.511 | 0 | 0 |
| Translesion synthesis by POLI | R-HSA-5656121 | 3.104410e-02 | 1.508 | 0 | 0 |
| Regulation of NF-kappa B signaling | R-HSA-9758274 | 3.104410e-02 | 1.508 | 0 | 0 |
| Response of endothelial cells to shear stress | R-HSA-9860931 | 3.124069e-02 | 1.505 | 0 | 0 |
| EGFR downregulation | R-HSA-182971 | 3.131261e-02 | 1.504 | 0 | 0 |
| Evasion by RSV of host interferon responses | R-HSA-9833109 | 3.131261e-02 | 1.504 | 0 | 0 |
| Formation of the dystrophin-glycoprotein complex (DGC) | R-HSA-9913351 | 3.131261e-02 | 1.504 | 0 | 0 |
| Reduction of cytosolic Ca++ levels | R-HSA-418359 | 3.222199e-02 | 1.492 | 0 | 0 |
| Signaling by NOTCH4 | R-HSA-9013694 | 3.356159e-02 | 1.474 | 0 | 0 |
| Regulation of gap junction activity | R-HSA-191650 | 3.367473e-02 | 1.473 | 0 | 0 |
| NADE modulates death signalling | R-HSA-205025 | 3.367473e-02 | 1.473 | 0 | 0 |
| FLT3 signaling through SRC family kinases | R-HSA-9706374 | 3.367473e-02 | 1.473 | 0 | 0 |
| p75NTR negatively regulates cell cycle via SC1 | R-HSA-193670 | 3.367473e-02 | 1.473 | 0 | 0 |
| MTOR signalling | R-HSA-165159 | 3.478411e-02 | 1.459 | 0 | 0 |
| Degradation of AXIN | R-HSA-4641257 | 3.566187e-02 | 1.448 | 0 | 0 |
| GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2 | R-HSA-9762114 | 3.566187e-02 | 1.448 | 0 | 0 |
| Signaling by EGFR in Cancer | R-HSA-1643713 | 3.574702e-02 | 1.447 | 0 | 0 |
| G0 and Early G1 | R-HSA-1538133 | 3.607042e-02 | 1.443 | 0 | 0 |
| p75 NTR receptor-mediated signalling | R-HSA-193704 | 3.616034e-02 | 1.442 | 0 | 0 |
| Manipulation of host energy metabolism | R-HSA-9636667 | 4.821195e-02 | 1.317 | 0 | 0 |
| LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production | R-HSA-3134973 | 4.919265e-02 | 1.308 | 0 | 0 |
| DEx/H-box helicases activate type I IFN and inflammatory cytokines production | R-HSA-3134963 | 4.919265e-02 | 1.308 | 0 | 0 |
| IRS activation | R-HSA-74713 | 4.919265e-02 | 1.308 | 0 | 0 |
| ARMS-mediated activation | R-HSA-170984 | 5.284779e-02 | 1.277 | 0 | 0 |
| WNT mediated activation of DVL | R-HSA-201688 | 5.284779e-02 | 1.277 | 0 | 0 |
| Translesion synthesis by POLK | R-HSA-5655862 | 3.786313e-02 | 1.422 | 0 | 0 |
| PCNA-Dependent Long Patch Base Excision Repair | R-HSA-5651801 | 5.418234e-02 | 1.266 | 0 | 0 |
| Activation of AMPK downstream of NMDARs | R-HSA-9619483 | 4.781161e-02 | 1.320 | 0 | 0 |
| Integrin signaling | R-HSA-354192 | 4.130096e-02 | 1.384 | 0 | 0 |
| Signaling by ERBB2 KD Mutants | R-HSA-9664565 | 5.472991e-02 | 1.262 | 0 | 0 |
| DNA methylation | R-HSA-5334118 | 5.472991e-02 | 1.262 | 0 | 0 |
| Late endosomal microautophagy | R-HSA-9615710 | 5.472991e-02 | 1.262 | 0 | 0 |
| DNA Damage Recognition in GG-NER | R-HSA-5696394 | 4.702022e-02 | 1.328 | 0 | 0 |
| Association of TriC/CCT with target proteins during biosynthesis | R-HSA-390471 | 4.702022e-02 | 1.328 | 0 | 0 |
| MET promotes cell motility | R-HSA-8875878 | 4.042512e-02 | 1.393 | 0 | 0 |
| Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding | R-HSA-6814122 | 5.324184e-02 | 1.274 | 0 | 0 |
| Inhibition of DNA recombination at telomere | R-HSA-9670095 | 5.121948e-02 | 1.291 | 0 | 0 |
| Condensation of Prophase Chromosomes | R-HSA-2299718 | 5.437016e-02 | 1.265 | 0 | 0 |
| Formation of TC-NER Pre-Incision Complex | R-HSA-6781823 | 5.437016e-02 | 1.265 | 0 | 0 |
| Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | R-HSA-1234176 | 4.645852e-02 | 1.333 | 0 | 0 |
| Formation of RNA Pol II elongation complex | R-HSA-112382 | 5.140358e-02 | 1.289 | 0 | 0 |
| Cyclin E associated events during G1/S transition | R-HSA-69202 | 4.281142e-02 | 1.368 | 0 | 0 |
| Deubiquitination | R-HSA-5688426 | 4.813661e-02 | 1.318 | 0 | 0 |
| Deadenylation-dependent mRNA decay | R-HSA-429914 | 5.325369e-02 | 1.274 | 0 | 0 |
| Cargo recognition for clathrin-mediated endocytosis | R-HSA-8856825 | 5.224373e-02 | 1.282 | 0 | 0 |
| Dectin-1 mediated noncanonical NF-kB signaling | R-HSA-5607761 | 4.890774e-02 | 1.311 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in BCR signaling | R-HSA-8939245 | 4.919265e-02 | 1.308 | 0 | 0 |
| Downregulation of ERBB2:ERBB3 signaling | R-HSA-1358803 | 4.059305e-02 | 1.392 | 0 | 0 |
| Homology Directed Repair | R-HSA-5693538 | 3.912976e-02 | 1.407 | 0 | 0 |
| ER-Phagosome pathway | R-HSA-1236974 | 4.152160e-02 | 1.382 | 0 | 0 |
| HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | R-HSA-5693567 | 4.207187e-02 | 1.376 | 0 | 0 |
| Platelet activation, signaling and aggregation | R-HSA-76002 | 4.093690e-02 | 1.388 | 0 | 0 |
| HCMV Infection | R-HSA-9609646 | 5.395101e-02 | 1.268 | 0 | 0 |
| Breakdown of the nuclear lamina | R-HSA-352238 | 4.821195e-02 | 1.317 | 0 | 0 |
| Negative regulation of FGFR3 signaling | R-HSA-5654732 | 4.781161e-02 | 1.320 | 0 | 0 |
| Regulation of CDH11 Expression and Function | R-HSA-9759475 | 5.472991e-02 | 1.262 | 0 | 0 |
| Negative regulation of FGFR4 signaling | R-HSA-5654733 | 5.472991e-02 | 1.262 | 0 | 0 |
| ZBP1(DAI) mediated induction of type I IFNs | R-HSA-1606322 | 5.418234e-02 | 1.266 | 0 | 0 |
| Activation of the AP-1 family of transcription factors | R-HSA-450341 | 5.284779e-02 | 1.277 | 0 | 0 |
| RAF/MAP kinase cascade | R-HSA-5673001 | 4.079617e-02 | 1.389 | 0 | 0 |
| MAPK1/MAPK3 signaling | R-HSA-5684996 | 3.981917e-02 | 1.400 | 0 | 0 |
| Hh mutants abrogate ligand secretion | R-HSA-5387390 | 3.912522e-02 | 1.408 | 0 | 0 |
| Regulation of innate immune responses to cytosolic DNA | R-HSA-3134975 | 3.786313e-02 | 1.422 | 0 | 0 |
| COPI-dependent Golgi-to-ER retrograde traffic | R-HSA-6811434 | 4.870191e-02 | 1.312 | 0 | 0 |
| Cellular response to mitochondrial stress | R-HSA-9840373 | 5.284779e-02 | 1.277 | 0 | 0 |
| IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation | R-HSA-975144 | 4.059305e-02 | 1.392 | 0 | 0 |
| IRAK1 recruits IKK complex | R-HSA-937039 | 4.059305e-02 | 1.392 | 0 | 0 |
| Defective CFTR causes cystic fibrosis | R-HSA-5678895 | 4.890774e-02 | 1.311 | 0 | 0 |
| NOTCH3 Activation and Transmission of Signal to the Nucleus | R-HSA-9013507 | 4.756261e-02 | 1.323 | 0 | 0 |
| Immune System | R-HSA-168256 | 4.863324e-02 | 1.313 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescence | R-HSA-9825895 | 4.075057e-02 | 1.390 | 0 | 0 |
| Hedgehog ligand biogenesis | R-HSA-5358346 | 4.645852e-02 | 1.333 | 0 | 0 |
| Senescence-Associated Secretory Phenotype (SASP) | R-HSA-2559582 | 3.763970e-02 | 1.424 | 0 | 0 |
| Factors involved in megakaryocyte development and platelet production | R-HSA-983231 | 5.061606e-02 | 1.296 | 0 | 0 |
| Signaling by ALK | R-HSA-201556 | 4.560690e-02 | 1.341 | 0 | 0 |
| Defective pyroptosis | R-HSA-9710421 | 3.912522e-02 | 1.408 | 0 | 0 |
| Intrinsic Pathway for Apoptosis | R-HSA-109606 | 3.977702e-02 | 1.400 | 0 | 0 |
| KEAP1-NFE2L2 pathway | R-HSA-9755511 | 4.248841e-02 | 1.372 | 0 | 0 |
| Nuclear events mediated by NFE2L2 | R-HSA-9759194 | 4.788162e-02 | 1.320 | 0 | 0 |
| IRE1alpha activates chaperones | R-HSA-381070 | 5.237799e-02 | 1.281 | 0 | 0 |
| Modulation by Mtb of host immune system | R-HSA-9637628 | 4.075057e-02 | 1.390 | 0 | 0 |
| Cell death signalling via NRAGE, NRIF and NADE | R-HSA-204998 | 5.549254e-02 | 1.256 | 0 | 0 |
| XBP1(S) activates chaperone genes | R-HSA-381038 | 5.634587e-02 | 1.249 | 0 | 0 |
| RNA Polymerase II Transcription Elongation | R-HSA-75955 | 5.669435e-02 | 1.246 | 0 | 0 |
| Resolution of Abasic Sites (AP sites) | R-HSA-73933 | 5.727341e-02 | 1.242 | 0 | 0 |
| Toll Like Receptor 3 (TLR3) Cascade | R-HSA-168164 | 5.991601e-02 | 1.222 | 0 | 0 |
| Oncogene Induced Senescence | R-HSA-2559585 | 5.997698e-02 | 1.222 | 0 | 0 |
| EPH-ephrin mediated repulsion of cells | R-HSA-3928665 | 6.022517e-02 | 1.220 | 0 | 0 |
| Reproduction | R-HSA-1474165 | 6.070826e-02 | 1.217 | 0 | 0 |
| Formation of the canonical BAF (cBAF) complex | R-HSA-9933937 | 6.095229e-02 | 1.215 | 0 | 0 |
| ERBB2 Activates PTK6 Signaling | R-HSA-8847993 | 6.095229e-02 | 1.215 | 0 | 0 |
| MAP3K8 (TPL2)-dependent MAPK1/3 activation | R-HSA-5684264 | 6.095229e-02 | 1.215 | 0 | 0 |
| Signaling by ERBB2 in Cancer | R-HSA-1227990 | 6.225572e-02 | 1.206 | 0 | 0 |
| Activation of the pre-replicative complex | R-HSA-68962 | 6.225572e-02 | 1.206 | 0 | 0 |
| SHC1 events in ERBB2 signaling | R-HSA-1250196 | 6.225572e-02 | 1.206 | 0 | 0 |
| IKK complex recruitment mediated by RIP1 | R-HSA-937041 | 6.371638e-02 | 1.196 | 0 | 0 |
| Signaling by ERBB2 TMD/JMD mutants | R-HSA-9665686 | 6.372753e-02 | 1.196 | 0 | 0 |
| Degradation of CRY and PER proteins | R-HSA-9932298 | 6.377735e-02 | 1.195 | 0 | 0 |
| Degradation of GLI2 by the proteasome | R-HSA-5610783 | 6.377735e-02 | 1.195 | 0 | 0 |
| GLI3 is processed to GLI3R by the proteasome | R-HSA-5610785 | 6.377735e-02 | 1.195 | 0 | 0 |
| Assembly and cell surface presentation of NMDA receptors | R-HSA-9609736 | 6.377735e-02 | 1.195 | 0 | 0 |
| MAP kinase activation | R-HSA-450294 | 6.379357e-02 | 1.195 | 0 | 0 |
| Non-integrin membrane-ECM interactions | R-HSA-3000171 | 6.525414e-02 | 1.185 | 0 | 0 |
| Diseases of programmed cell death | R-HSA-9645723 | 6.537606e-02 | 1.185 | 0 | 0 |
| Gluconeogenesis | R-HSA-70263 | 6.647985e-02 | 1.177 | 0 | 0 |
| Establishment of Sister Chromatid Cohesion | R-HSA-2468052 | 6.668179e-02 | 1.176 | 0 | 0 |
| 2-LTR circle formation | R-HSA-164843 | 6.668179e-02 | 1.176 | 0 | 0 |
| Regulation of CDH11 function | R-HSA-9762292 | 6.668179e-02 | 1.176 | 0 | 0 |
| CaMK IV-mediated phosphorylation of CREB | R-HSA-111932 | 6.668179e-02 | 1.176 | 0 | 0 |
| Ub-specific processing proteases | R-HSA-5689880 | 6.703379e-02 | 1.174 | 0 | 0 |
| G1/S-Specific Transcription | R-HSA-69205 | 6.723420e-02 | 1.172 | 0 | 0 |
| CDH11 homotypic and heterotypic interactions | R-HSA-9833576 | 6.758937e-02 | 1.170 | 0 | 0 |
| Negative feedback regulation of MAPK pathway | R-HSA-5674499 | 6.758937e-02 | 1.170 | 0 | 0 |
| IkBA variant leads to EDA-ID | R-HSA-5603029 | 6.758937e-02 | 1.170 | 0 | 0 |
| Phosphorylation of Emi1 | R-HSA-176417 | 6.758937e-02 | 1.170 | 0 | 0 |
| Regulation of CDH19 Expression and Function | R-HSA-9764302 | 6.758937e-02 | 1.170 | 0 | 0 |
| Signaling by NOTCH3 | R-HSA-9012852 | 6.834044e-02 | 1.165 | 0 | 0 |
| Trafficking of AMPA receptors | R-HSA-399719 | 7.039697e-02 | 1.152 | 0 | 0 |
| Negative regulators of DDX58/IFIH1 signaling | R-HSA-936440 | 7.039697e-02 | 1.152 | 0 | 0 |
| UCH proteinases | R-HSA-5689603 | 7.054179e-02 | 1.152 | 0 | 0 |
| Response to elevated platelet cytosolic Ca2+ | R-HSA-76005 | 7.224490e-02 | 1.141 | 0 | 0 |
| HDMs demethylate histones | R-HSA-3214842 | 7.291946e-02 | 1.137 | 0 | 0 |
| Sema4D in semaphorin signaling | R-HSA-400685 | 7.291946e-02 | 1.137 | 0 | 0 |
| Interleukin-7 signaling | R-HSA-1266695 | 7.291946e-02 | 1.137 | 0 | 0 |
| ERBB2 Regulates Cell Motility | R-HSA-6785631 | 7.294928e-02 | 1.137 | 0 | 0 |
| RIP-mediated NFkB activation via ZBP1 | R-HSA-1810476 | 7.294928e-02 | 1.137 | 0 | 0 |
| Protein methylation | R-HSA-8876725 | 7.294928e-02 | 1.137 | 0 | 0 |
| STAT3 nuclear events downstream of ALK signaling | R-HSA-9701898 | 7.294928e-02 | 1.137 | 0 | 0 |
| Activation of NMDA receptors and postsynaptic events | R-HSA-442755 | 7.380342e-02 | 1.132 | 0 | 0 |
| Transcription of E2F targets under negative control by DREAM complex | R-HSA-1362277 | 7.417399e-02 | 1.130 | 0 | 0 |
| Ion homeostasis | R-HSA-5578775 | 7.470659e-02 | 1.127 | 0 | 0 |
| rRNA modification in the nucleus and cytosol | R-HSA-6790901 | 7.563300e-02 | 1.121 | 0 | 0 |
| TGF-beta receptor signaling activates SMADs | R-HSA-2173789 | 7.816014e-02 | 1.107 | 0 | 0 |
| Signaling by SCF-KIT | R-HSA-1433557 | 7.816014e-02 | 1.107 | 0 | 0 |
| Response of Mtb to phagocytosis | R-HSA-9637690 | 7.816014e-02 | 1.107 | 0 | 0 |
| Diseases of mitotic cell cycle | R-HSA-9675126 | 7.915779e-02 | 1.102 | 0 | 0 |
| Regulation of TP53 Expression | R-HSA-6804754 | 7.954698e-02 | 1.099 | 0 | 0 |
| Stimulation of the cell death response by PAK-2p34 | R-HSA-211736 | 7.954698e-02 | 1.099 | 0 | 0 |
| TGFBR1 LBD Mutants in Cancer | R-HSA-3656535 | 7.954698e-02 | 1.099 | 0 | 0 |
| COPI-mediated anterograde transport | R-HSA-6807878 | 7.975950e-02 | 1.098 | 0 | 0 |
| Transcriptional and post-translational regulation of MITF-M expression and activity | R-HSA-9856649 | 8.218378e-02 | 1.085 | 0 | 0 |
| MyD88-independent TLR4 cascade | R-HSA-166166 | 8.243302e-02 | 1.084 | 0 | 0 |
| TRIF (TICAM1)-mediated TLR4 signaling | R-HSA-937061 | 8.243302e-02 | 1.084 | 0 | 0 |
| Metalloprotease DUBs | R-HSA-5689901 | 8.285396e-02 | 1.082 | 0 | 0 |
| Resolution of AP sites via the multiple-nucleotide patch replacement pathway | R-HSA-110373 | 8.285396e-02 | 1.082 | 0 | 0 |
| Telomere Maintenance | R-HSA-157579 | 8.509720e-02 | 1.070 | 0 | 0 |
| Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 | R-HSA-1362300 | 8.613719e-02 | 1.065 | 0 | 0 |
| KSRP (KHSRP) binds and destabilizes mRNA | R-HSA-450604 | 8.613719e-02 | 1.065 | 0 | 0 |
| Phosphorylation of the APC/C | R-HSA-176412 | 8.613719e-02 | 1.065 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest | R-HSA-6804116 | 8.613719e-02 | 1.065 | 0 | 0 |
| Meiotic recombination | R-HSA-912446 | 8.768995e-02 | 1.057 | 0 | 0 |
| Assembly of the ORC complex at the origin of replication | R-HSA-68616 | 8.853847e-02 | 1.053 | 0 | 0 |
| Activation of ATR in response to replication stress | R-HSA-176187 | 8.853847e-02 | 1.053 | 0 | 0 |
| Negative regulation of FGFR1 signaling | R-HSA-5654726 | 8.853847e-02 | 1.053 | 0 | 0 |
| Regulation of Expression and Function of Type II Classical Cadherins | R-HSA-9764260 | 8.853847e-02 | 1.053 | 0 | 0 |
| Glutamate binding, activation of AMPA receptors and synaptic plasticity | R-HSA-399721 | 8.853847e-02 | 1.053 | 0 | 0 |
| MyD88 cascade initiated on plasma membrane | R-HSA-975871 | 9.066208e-02 | 1.043 | 0 | 0 |
| Toll Like Receptor 10 (TLR10) Cascade | R-HSA-168142 | 9.066208e-02 | 1.043 | 0 | 0 |
| Toll Like Receptor 5 (TLR5) Cascade | R-HSA-168176 | 9.066208e-02 | 1.043 | 0 | 0 |
| Developmental Cell Lineages | R-HSA-9734767 | 9.213608e-02 | 1.036 | 0 | 0 |
| Synthesis of active ubiquitin: roles of E1 and E2 enzymes | R-HSA-8866652 | 9.352622e-02 | 1.029 | 0 | 0 |
| Tat-mediated HIV elongation arrest and recovery | R-HSA-167243 | 9.352622e-02 | 1.029 | 0 | 0 |
| Pausing and recovery of Tat-mediated HIV elongation | R-HSA-167238 | 9.352622e-02 | 1.029 | 0 | 0 |
| TNFR1-induced NF-kappa-B signaling pathway | R-HSA-5357956 | 9.352622e-02 | 1.029 | 0 | 0 |
| Platelet Aggregation (Plug Formation) | R-HSA-76009 | 9.439729e-02 | 1.025 | 0 | 0 |
| E3 ubiquitin ligases ubiquitinate target proteins | R-HSA-8866654 | 9.558344e-02 | 1.020 | 0 | 0 |
| RNA Polymerase I Promoter Escape | R-HSA-73772 | 9.558344e-02 | 1.020 | 0 | 0 |
| SARS-CoV-1 activates/modulates innate immune responses | R-HSA-9692916 | 9.558344e-02 | 1.020 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in cell cycle and proliferation | R-HSA-9825892 | 9.782830e-02 | 1.010 | 0 | 0 |
| FOXO-mediated transcription of cell cycle genes | R-HSA-9617828 | 9.782830e-02 | 1.010 | 0 | 0 |
| Integration of provirus | R-HSA-162592 | 9.932428e-02 | 1.003 | 0 | 0 |
| NFE2L2 regulates pentose phosphate pathway genes | R-HSA-9818028 | 9.932428e-02 | 1.003 | 0 | 0 |
| G beta:gamma signalling through CDC42 | R-HSA-8964616 | 1.004824e-01 | 0.998 | 0 | 0 |
| Processing of Intronless Pre-mRNAs | R-HSA-77595 | 1.004824e-01 | 0.998 | 0 | 0 |
| GRB2 events in ERBB2 signaling | R-HSA-1963640 | 1.004824e-01 | 0.998 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | R-HSA-6804114 | 1.004824e-01 | 0.998 | 0 | 0 |
| Disorders of Developmental Biology | R-HSA-9675151 | 1.004824e-01 | 0.998 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of growth factors and their receptors | R-HSA-8866910 | 1.004824e-01 | 0.998 | 0 | 0 |
| Formation of HIV elongation complex in the absence of HIV Tat | R-HSA-167152 | 1.015598e-01 | 0.993 | 0 | 0 |
| Glycogen metabolism | R-HSA-8982491 | 1.015598e-01 | 0.993 | 0 | 0 |
| Generation of second messenger molecules | R-HSA-202433 | 1.015598e-01 | 0.993 | 0 | 0 |
| Transcriptional regulation by RUNX2 | R-HSA-8878166 | 1.016607e-01 | 0.993 | 0 | 0 |
| Golgi-to-ER retrograde transport | R-HSA-8856688 | 1.021461e-01 | 0.991 | 0 | 0 |
| RNA Polymerase II Pre-transcription Events | R-HSA-674695 | 1.023864e-01 | 0.990 | 0 | 0 |
| Cilium Assembly | R-HSA-5617833 | 1.040488e-01 | 0.983 | 0 | 0 |
| Interleukin-1 signaling | R-HSA-9020702 | 1.087300e-01 | 0.964 | 0 | 0 |
| Developmental Lineage of Mammary Gland Alveolar Cells | R-HSA-9927426 | 1.091415e-01 | 0.962 | 0 | 0 |
| Negative regulation of FGFR2 signaling | R-HSA-5654727 | 1.091415e-01 | 0.962 | 0 | 0 |
| Gap junction assembly | R-HSA-190861 | 1.091415e-01 | 0.962 | 0 | 0 |
| Mitophagy | R-HSA-5205647 | 1.091415e-01 | 0.962 | 0 | 0 |
| Death Receptor Signaling | R-HSA-73887 | 1.093586e-01 | 0.961 | 0 | 0 |
| Loss of function of TP53 in cancer due to loss of tetramerization ability | R-HSA-9723905 | 1.095862e-01 | 0.960 | 0 | 0 |
| APC truncation mutants are not K63 polyubiquitinated | R-HSA-5467333 | 1.095862e-01 | 0.960 | 0 | 0 |
| Loss of Function of TP53 in Cancer | R-HSA-9723907 | 1.095862e-01 | 0.960 | 0 | 0 |
| Protein ubiquitination | R-HSA-8852135 | 1.097359e-01 | 0.960 | 0 | 0 |
| Iron uptake and transport | R-HSA-917937 | 1.097359e-01 | 0.960 | 0 | 0 |
| Platelet degranulation | R-HSA-114608 | 1.103005e-01 | 0.957 | 0 | 0 |
| Cellular response to chemical stress | R-HSA-9711123 | 1.107933e-01 | 0.955 | 0 | 0 |
| TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | R-HSA-6804115 | 1.109883e-01 | 0.955 | 0 | 0 |
| TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain | R-HSA-6803205 | 1.109883e-01 | 0.955 | 0 | 0 |
| Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants | R-HSA-9670439 | 1.109883e-01 | 0.955 | 0 | 0 |
| Downregulation of TGF-beta receptor signaling | R-HSA-2173788 | 1.109883e-01 | 0.955 | 0 | 0 |
| Signaling by KIT in disease | R-HSA-9669938 | 1.109883e-01 | 0.955 | 0 | 0 |
| Transcriptional Regulation by VENTX | R-HSA-8853884 | 1.114603e-01 | 0.953 | 0 | 0 |
| Displacement of DNA glycosylase by APEX1 | R-HSA-110357 | 1.120391e-01 | 0.951 | 0 | 0 |
| RUNX3 regulates WNT signaling | R-HSA-8951430 | 1.120391e-01 | 0.951 | 0 | 0 |
| Binding of TCF/LEF:CTNNB1 to target gene promoters | R-HSA-4411364 | 1.120391e-01 | 0.951 | 0 | 0 |
| NOSTRIN mediated eNOS trafficking | R-HSA-203641 | 1.120391e-01 | 0.951 | 0 | 0 |
| SHOC2 M1731 mutant abolishes MRAS complex function | R-HSA-9726840 | 1.120391e-01 | 0.951 | 0 | 0 |
| Uptake and function of diphtheria toxin | R-HSA-5336415 | 1.120391e-01 | 0.951 | 0 | 0 |
| Regulation of RUNX2 expression and activity | R-HSA-8939902 | 1.120738e-01 | 0.950 | 0 | 0 |
| TAK1-dependent IKK and NF-kappa-B activation | R-HSA-445989 | 1.124851e-01 | 0.949 | 0 | 0 |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | R-HSA-975138 | 1.125705e-01 | 0.949 | 0 | 0 |
| Intra-Golgi and retrograde Golgi-to-ER traffic | R-HSA-6811442 | 1.146187e-01 | 0.941 | 0 | 0 |
| MET interacts with TNS proteins | R-HSA-8875513 | 1.154455e-01 | 0.938 | 0 | 0 |
| Negative regulation of TCF-dependent signaling by DVL-interacting proteins | R-HSA-5368598 | 1.154455e-01 | 0.938 | 0 | 0 |
| Loss of Function of KMT2D in Kabuki Syndrome | R-HSA-9944971 | 1.154455e-01 | 0.938 | 0 | 0 |
| Loss of Function of KMT2D in MLL4 Complex Formation in Kabuki Syndrome | R-HSA-9944997 | 1.154455e-01 | 0.938 | 0 | 0 |
| PI3K events in ERBB2 signaling | R-HSA-1963642 | 1.159384e-01 | 0.936 | 0 | 0 |
| Glycogen storage diseases | R-HSA-3229121 | 1.159384e-01 | 0.936 | 0 | 0 |
| Signaling by NTRK1 (TRKA) | R-HSA-187037 | 1.160730e-01 | 0.935 | 0 | 0 |
| Platelet calcium homeostasis | R-HSA-418360 | 1.170379e-01 | 0.932 | 0 | 0 |
| MAPK targets/ Nuclear events mediated by MAP kinases | R-HSA-450282 | 1.170379e-01 | 0.932 | 0 | 0 |
| Toll Like Receptor 4 (TLR4) Cascade | R-HSA-166016 | 1.178034e-01 | 0.929 | 0 | 0 |
| Signaling by NTRKs | R-HSA-166520 | 1.178034e-01 | 0.929 | 0 | 0 |
| Phosphorylation and nuclear translocation of the CRY:PER:kinase complex | R-HSA-9931530 | 1.179510e-01 | 0.928 | 0 | 0 |
| Scavenging by Class F Receptors | R-HSA-3000484 | 1.179510e-01 | 0.928 | 0 | 0 |
| Repression of WNT target genes | R-HSA-4641265 | 1.179510e-01 | 0.928 | 0 | 0 |
| Regulation of IFNG signaling | R-HSA-877312 | 1.179510e-01 | 0.928 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD Domain Mutants | R-HSA-2691232 | 1.179510e-01 | 0.928 | 0 | 0 |
| Signaling by NOTCH1 HD Domain Mutants in Cancer | R-HSA-2691230 | 1.179510e-01 | 0.928 | 0 | 0 |
| MyD88 dependent cascade initiated on endosome | R-HSA-975155 | 1.189687e-01 | 0.925 | 0 | 0 |
| Transcriptional regulation of granulopoiesis | R-HSA-9616222 | 1.206528e-01 | 0.918 | 0 | 0 |
| Nuclear events stimulated by ALK signaling in cancer | R-HSA-9725371 | 1.222128e-01 | 0.913 | 0 | 0 |
| C-type lectin receptors (CLRs) | R-HSA-5621481 | 1.235399e-01 | 0.908 | 0 | 0 |
| MHC class II antigen presentation | R-HSA-2132295 | 1.254065e-01 | 0.902 | 0 | 0 |
| Activation, translocation and oligomerization of BAX | R-HSA-114294 | 2.071689e-01 | 0.684 | 0 | 0 |
| Regulation of PAK-2p34 activity by PS-GAP/RHG10 | R-HSA-211728 | 2.071689e-01 | 0.684 | 0 | 0 |
| Hereditary fructose intolerance | R-HSA-5657560 | 2.071689e-01 | 0.684 | 0 | 0 |
| RPIA deficiency: failed conversion of RU5P to R5P | R-HSA-6791461 | 2.071689e-01 | 0.684 | 0 | 0 |
| Defective Mismatch Repair Associated With MSH6 | R-HSA-5632968 | 2.071689e-01 | 0.684 | 0 | 0 |
| Defective DNA double strand break response due to BRCA1 loss of function | R-HSA-9663199 | 2.071689e-01 | 0.684 | 0 | 0 |
| Defective DNA double strand break response due to BARD1 loss of function | R-HSA-9699150 | 2.071689e-01 | 0.684 | 0 | 0 |
| RPIA deficiency: failed conversion of R5P to RU5P | R-HSA-5659996 | 2.071689e-01 | 0.684 | 0 | 0 |
| TICAM1 deficiency - HSE | R-HSA-5602566 | 2.071689e-01 | 0.684 | 0 | 0 |
| PLCG1 events in ERBB2 signaling | R-HSA-1251932 | 1.545321e-01 | 0.811 | 0 | 0 |
| Loss of Function of TGFBR1 in Cancer | R-HSA-3656534 | 1.956779e-01 | 0.708 | 0 | 0 |
| Type I hemidesmosome assembly | R-HSA-446107 | 1.375039e-01 | 0.862 | 0 | 0 |
| Signaling by MRAS-complex mutants | R-HSA-9660537 | 1.375039e-01 | 0.862 | 0 | 0 |
| Gain-of-function MRAS complexes activate RAF signaling | R-HSA-9726842 | 1.375039e-01 | 0.862 | 0 | 0 |
| Calcineurin activates NFAT | R-HSA-2025928 | 1.647066e-01 | 0.783 | 0 | 0 |
| ALK mutants bind TKIs | R-HSA-9700645 | 1.647066e-01 | 0.783 | 0 | 0 |
| Noncanonical activation of NOTCH3 | R-HSA-9017802 | 2.379627e-01 | 0.623 | 0 | 0 |
| PTK6 Regulates Cell Cycle | R-HSA-8849470 | 2.379627e-01 | 0.623 | 0 | 0 |
| Loss of MECP2 binding ability to the NCoR/SMRT complex | R-HSA-9022537 | 2.379627e-01 | 0.623 | 0 | 0 |
| Erythropoietin activates Phospholipase C gamma (PLCG) | R-HSA-9027277 | 1.933278e-01 | 0.714 | 0 | 0 |
| Regulation of CDH1 mRNA translation by microRNAs | R-HSA-9764562 | 1.592202e-01 | 0.798 | 0 | 0 |
| Signaling by ERBB2 ECD mutants | R-HSA-9665348 | 1.324477e-01 | 0.878 | 0 | 0 |
| Polo-like kinase mediated events | R-HSA-156711 | 1.324477e-01 | 0.878 | 0 | 0 |
| GAB1 signalosome | R-HSA-180292 | 1.324477e-01 | 0.878 | 0 | 0 |
| TRAF6 mediated NF-kB activation | R-HSA-933542 | 1.398256e-01 | 0.854 | 0 | 0 |
| Aberrant regulation of mitotic exit in cancer due to RB1 defects | R-HSA-9687136 | 2.049123e-01 | 0.688 | 0 | 0 |
| Condensation of Prometaphase Chromosomes | R-HSA-2514853 | 2.535996e-01 | 0.596 | 0 | 0 |
| PD-L1(CD274) glycosylation and translocation to plasma membrane | R-HSA-9931295 | 1.875852e-01 | 0.727 | 0 | 0 |
| Inactivation of APC/C via direct inhibition of the APC/C complex | R-HSA-141430 | 2.290465e-01 | 0.640 | 0 | 0 |
| Interaction between L1 and Ankyrins | R-HSA-445095 | 1.887401e-01 | 0.724 | 0 | 0 |
| Endosomal Sorting Complex Required For Transport (ESCRT) | R-HSA-917729 | 2.245168e-01 | 0.649 | 0 | 0 |
| Nuclear signaling by ERBB4 | R-HSA-1251985 | 1.847270e-01 | 0.733 | 0 | 0 |
| Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | R-HSA-5625886 | 1.991118e-01 | 0.701 | 0 | 0 |
| RNA Polymerase III Abortive And Retractive Initiation | R-HSA-749476 | 2.362767e-01 | 0.627 | 0 | 0 |
| Signaling by ERBB4 | R-HSA-1236394 | 1.645012e-01 | 0.784 | 0 | 0 |
| RNA polymerase II transcribes snRNA genes | R-HSA-6807505 | 2.205970e-01 | 0.656 | 0 | 0 |
| RNA Polymerase III Transcription | R-HSA-74158 | 2.362767e-01 | 0.627 | 0 | 0 |
| Regulation of PD-L1(CD274) Post-translational modification | R-HSA-9909615 | 1.388567e-01 | 0.857 | 0 | 0 |
| Epigenetic regulation by WDR5-containing histone modifying complexes | R-HSA-9917777 | 1.535306e-01 | 0.814 | 0 | 0 |
| Interferon alpha/beta signaling | R-HSA-909733 | 2.481192e-01 | 0.605 | 0 | 0 |
| HATs acetylate histones | R-HSA-3214847 | 1.474727e-01 | 0.831 | 0 | 0 |
| Regulation of gene expression by Hypoxia-inducible Factor | R-HSA-1234158 | 2.535996e-01 | 0.596 | 0 | 0 |
| DDX58/IFIH1-mediated induction of interferon-alpha/beta | R-HSA-168928 | 2.445867e-01 | 0.612 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in Cytochrome C Release | R-HSA-6803204 | 1.887401e-01 | 0.724 | 0 | 0 |
| DCC mediated attractive signaling | R-HSA-418885 | 1.815867e-01 | 0.741 | 0 | 0 |
| Toxicity of botulinum toxin type E (botE) | R-HSA-5250992 | 2.379627e-01 | 0.623 | 0 | 0 |
| WNT5A-dependent internalization of FZD4 | R-HSA-5099900 | 2.049123e-01 | 0.688 | 0 | 0 |
| DNA strand elongation | R-HSA-69190 | 1.574210e-01 | 0.803 | 0 | 0 |
| SIRT1 negatively regulates rRNA expression | R-HSA-427359 | 2.534226e-01 | 0.596 | 0 | 0 |
| Membrane binding and targetting of GAG proteins | R-HSA-174490 | 1.379608e-01 | 0.860 | 0 | 0 |
| Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA | R-HSA-450513 | 1.815867e-01 | 0.741 | 0 | 0 |
| MyD88:MAL(TIRAP) cascade initiated on plasma membrane | R-HSA-166058 | 2.118539e-01 | 0.674 | 0 | 0 |
| Toll Like Receptor TLR6:TLR2 Cascade | R-HSA-168188 | 2.118539e-01 | 0.674 | 0 | 0 |
| Toll Like Receptor TLR1:TLR2 Cascade | R-HSA-168179 | 2.392830e-01 | 0.621 | 0 | 0 |
| Toll Like Receptor 2 (TLR2) Cascade | R-HSA-181438 | 2.392830e-01 | 0.621 | 0 | 0 |
| Signaling by the B Cell Receptor (BCR) | R-HSA-983705 | 2.409780e-01 | 0.618 | 0 | 0 |
| Pyrophosphate hydrolysis | R-HSA-71737 | 1.956779e-01 | 0.708 | 0 | 0 |
| Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA | R-HSA-450385 | 1.815867e-01 | 0.741 | 0 | 0 |
| Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components | R-HSA-141405 | 2.290465e-01 | 0.640 | 0 | 0 |
| Defective Intrinsic Pathway for Apoptosis | R-HSA-9734009 | 1.887401e-01 | 0.724 | 0 | 0 |
| Fanconi Anemia Pathway | R-HSA-6783310 | 1.684597e-01 | 0.774 | 0 | 0 |
| Aberrant regulation of mitotic cell cycle due to RB1 defects | R-HSA-9687139 | 2.431793e-01 | 0.614 | 0 | 0 |
| Signaling by Nuclear Receptors | R-HSA-9006931 | 1.429007e-01 | 0.845 | 0 | 0 |
| Mechanical load activates signaling by PIEZO1 and integrins in osteocytes | R-HSA-9856532 | 1.499430e-01 | 0.824 | 0 | 0 |
| Platelet Adhesion to exposed collagen | R-HSA-75892 | 1.379608e-01 | 0.860 | 0 | 0 |
| Activation of gene expression by SREBF (SREBP) | R-HSA-2426168 | 1.295937e-01 | 0.887 | 0 | 0 |
| Synthesis And Processing Of GAG, GAGPOL Polyproteins | R-HSA-174495 | 1.592202e-01 | 0.798 | 0 | 0 |
| Signaling by FGFR2 | R-HSA-5654738 | 2.286395e-01 | 0.641 | 0 | 0 |
| Co-stimulation by CD28 | R-HSA-389356 | 2.080756e-01 | 0.682 | 0 | 0 |
| Circadian clock | R-HSA-9909396 | 2.060662e-01 | 0.686 | 0 | 0 |
| Signal attenuation | R-HSA-74749 | 1.933278e-01 | 0.714 | 0 | 0 |
| Interleukin-17 signaling | R-HSA-448424 | 1.275941e-01 | 0.894 | 0 | 0 |
| PINK1-PRKN Mediated Mitophagy | R-HSA-5205685 | 2.063501e-01 | 0.685 | 0 | 0 |
| Signaling by FGFR4 | R-HSA-5654743 | 1.442142e-01 | 0.841 | 0 | 0 |
| Regulation of cholesterol biosynthesis by SREBP (SREBF) | R-HSA-1655829 | 2.172928e-01 | 0.663 | 0 | 0 |
| NOD1/2 Signaling Pathway | R-HSA-168638 | 2.032298e-01 | 0.692 | 0 | 0 |
| Glycogen synthesis | R-HSA-3322077 | 1.683493e-01 | 0.774 | 0 | 0 |
| Maternal to zygotic transition (MZT) | R-HSA-9816359 | 1.799832e-01 | 0.745 | 0 | 0 |
| Vesicle-mediated transport | R-HSA-5653656 | 1.918810e-01 | 0.717 | 0 | 0 |
| Signaling by FGFR3 | R-HSA-5654741 | 1.684597e-01 | 0.774 | 0 | 0 |
| Signaling by FGFR1 | R-HSA-5654736 | 2.150799e-01 | 0.667 | 0 | 0 |
| Formation of editosomes by ADAR proteins | R-HSA-77042 | 2.071689e-01 | 0.684 | 0 | 0 |
| Inhibition of PKR | R-HSA-169131 | 2.071689e-01 | 0.684 | 0 | 0 |
| SARS-CoV-2 targets PDZ proteins in cell-cell junction | R-HSA-9705677 | 1.545321e-01 | 0.811 | 0 | 0 |
| MTF1 activates gene expression | R-HSA-5660489 | 1.545321e-01 | 0.811 | 0 | 0 |
| Unwinding of DNA | R-HSA-176974 | 1.647066e-01 | 0.783 | 0 | 0 |
| Bicarbonate transporters | R-HSA-425381 | 2.230573e-01 | 0.652 | 0 | 0 |
| RNA Polymerase I Promoter Opening | R-HSA-73728 | 1.887401e-01 | 0.724 | 0 | 0 |
| TNF signaling | R-HSA-75893 | 2.150799e-01 | 0.667 | 0 | 0 |
| Toll Like Receptor 7/8 (TLR7/8) Cascade | R-HSA-168181 | 1.466945e-01 | 0.834 | 0 | 0 |
| Toll Like Receptor 9 (TLR9) Cascade | R-HSA-168138 | 1.696715e-01 | 0.770 | 0 | 0 |
| Early Phase of HIV Life Cycle | R-HSA-162594 | 1.875852e-01 | 0.727 | 0 | 0 |
| ER to Golgi Anterograde Transport | R-HSA-199977 | 2.161620e-01 | 0.665 | 0 | 0 |
| CD163 mediating an anti-inflammatory response | R-HSA-9662834 | 2.230573e-01 | 0.652 | 0 | 0 |
| Calmodulin induced events | R-HSA-111933 | 2.362767e-01 | 0.627 | 0 | 0 |
| Base Excision Repair | R-HSA-73884 | 1.833215e-01 | 0.737 | 0 | 0 |
| Regulation of CDH11 gene transcription | R-HSA-9762293 | 1.647066e-01 | 0.783 | 0 | 0 |
| Activated NOTCH1 Transmits Signal to the Nucleus | R-HSA-2122948 | 1.717460e-01 | 0.765 | 0 | 0 |
| COPI-independent Golgi-to-ER retrograde traffic | R-HSA-6811436 | 2.021457e-01 | 0.694 | 0 | 0 |
| CaM pathway | R-HSA-111997 | 2.362767e-01 | 0.627 | 0 | 0 |
| Epithelial-Mesenchymal Transition (EMT) during gastrulation | R-HSA-9758919 | 2.379627e-01 | 0.623 | 0 | 0 |
| Basigin interactions | R-HSA-210991 | 1.875852e-01 | 0.727 | 0 | 0 |
| Antigen processing-Cross presentation | R-HSA-1236975 | 1.668883e-01 | 0.778 | 0 | 0 |
| Potential therapeutics for SARS | R-HSA-9679191 | 1.290858e-01 | 0.889 | 0 | 0 |
| Formation of definitive endoderm | R-HSA-9823730 | 1.683493e-01 | 0.774 | 0 | 0 |
| Hedgehog 'off' state | R-HSA-5610787 | 1.554735e-01 | 0.808 | 0 | 0 |
| Suppression of phagosomal maturation | R-HSA-9637687 | 1.717460e-01 | 0.765 | 0 | 0 |
| The role of Nef in HIV-1 replication and disease pathogenesis | R-HSA-164952 | 2.493945e-01 | 0.603 | 0 | 0 |
| Regulation of MITF-M dependent genes involved in invasion | R-HSA-9854909 | 1.956779e-01 | 0.708 | 0 | 0 |
| EGR2 and SOX10-mediated initiation of Schwann cell myelination | R-HSA-9619665 | 1.874173e-01 | 0.727 | 0 | 0 |
| Downstream TCR signaling | R-HSA-202424 | 1.833215e-01 | 0.737 | 0 | 0 |
| NOTCH2 Activation and Transmission of Signal to the Nucleus | R-HSA-2979096 | 1.875852e-01 | 0.727 | 0 | 0 |
| MECP2 regulates neuronal receptors and channels | R-HSA-9022699 | 1.717460e-01 | 0.765 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in pigmentation | R-HSA-9824585 | 1.684597e-01 | 0.774 | 0 | 0 |
| Signal regulatory protein family interactions | R-HSA-391160 | 1.592202e-01 | 0.798 | 0 | 0 |
| Infectious disease | R-HSA-5663205 | 1.503917e-01 | 0.823 | 0 | 0 |
| RET signaling | R-HSA-8853659 | 1.321338e-01 | 0.879 | 0 | 0 |
| Prevention of phagosomal-lysosomal fusion | R-HSA-9636383 | 1.875852e-01 | 0.727 | 0 | 0 |
| Syndecan interactions | R-HSA-3000170 | 2.493945e-01 | 0.603 | 0 | 0 |
| ABC-family proteins mediated transport | R-HSA-382556 | 1.554735e-01 | 0.808 | 0 | 0 |
| Activation of RAC1 | R-HSA-428540 | 2.535996e-01 | 0.596 | 0 | 0 |
| Signaling by PDGFR in disease | R-HSA-9671555 | 2.075645e-01 | 0.683 | 0 | 0 |
| Plasma lipoprotein clearance | R-HSA-8964043 | 1.708095e-01 | 0.767 | 0 | 0 |
| Growth hormone receptor signaling | R-HSA-982772 | 2.493945e-01 | 0.603 | 0 | 0 |
| ChREBP activates metabolic gene expression | R-HSA-163765 | 2.230573e-01 | 0.652 | 0 | 0 |
| FLT3 signaling in disease | R-HSA-9682385 | 1.321338e-01 | 0.879 | 0 | 0 |
| TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling | R-HSA-975110 | 2.290465e-01 | 0.640 | 0 | 0 |
| Constitutive Signaling by AKT1 E17K in Cancer | R-HSA-5674400 | 2.493945e-01 | 0.603 | 0 | 0 |
| Regulation of BACH1 activity | R-HSA-9708530 | 2.049123e-01 | 0.688 | 0 | 0 |
| Sensory processing of sound by outer hair cells of the cochlea | R-HSA-9662361 | 2.150799e-01 | 0.667 | 0 | 0 |
| Assembly of Viral Components at the Budding Site | R-HSA-168316 | 1.956779e-01 | 0.708 | 0 | 0 |
| Signaling by EGFRvIII in Cancer | R-HSA-5637812 | 2.538395e-01 | 0.595 | 0 | 0 |
| Constitutive Signaling by EGFRvIII | R-HSA-5637810 | 2.538395e-01 | 0.595 | 0 | 0 |
| Removal of the Flap Intermediate from the C-strand | R-HSA-174437 | 2.538395e-01 | 0.595 | 0 | 0 |
| Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase | R-HSA-176407 | 2.538395e-01 | 0.595 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) | R-HSA-5358565 | 2.538395e-01 | 0.595 | 0 | 0 |
| Regulation of FZD by ubiquitination | R-HSA-4641263 | 2.538395e-01 | 0.595 | 0 | 0 |
| Specification of primordial germ cells | R-HSA-9827857 | 2.538395e-01 | 0.595 | 0 | 0 |
| Interleukin-1 family signaling | R-HSA-446652 | 2.580938e-01 | 0.588 | 0 | 0 |
| Respiratory Syncytial Virus Infection Pathway | R-HSA-9820952 | 2.584954e-01 | 0.588 | 0 | 0 |
| HDR through Homologous Recombination (HRR) | R-HSA-5685942 | 2.593026e-01 | 0.586 | 0 | 0 |
| Proteasome assembly | R-HSA-9907900 | 2.606915e-01 | 0.584 | 0 | 0 |
| G1 Phase | R-HSA-69236 | 2.606915e-01 | 0.584 | 0 | 0 |
| Cyclin D associated events in G1 | R-HSA-69231 | 2.606915e-01 | 0.584 | 0 | 0 |
| SLC-mediated transport of inorganic anions | R-HSA-9958790 | 2.709222e-01 | 0.567 | 0 | 0 |
| ADP signalling through P2Y purinoceptor 1 | R-HSA-418592 | 2.710622e-01 | 0.567 | 0 | 0 |
| Neurodegenerative Diseases | R-HSA-8863678 | 2.710622e-01 | 0.567 | 0 | 0 |
| Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models | R-HSA-8862803 | 2.710622e-01 | 0.567 | 0 | 0 |
| Processing of Capped Intronless Pre-mRNA | R-HSA-75067 | 2.710622e-01 | 0.567 | 0 | 0 |
| CD209 (DC-SIGN) signaling | R-HSA-5621575 | 2.710622e-01 | 0.567 | 0 | 0 |
| Transcription of the HIV genome | R-HSA-167172 | 2.726813e-01 | 0.564 | 0 | 0 |
| Sensory processing of sound by inner hair cells of the cochlea | R-HSA-9662360 | 2.726813e-01 | 0.564 | 0 | 0 |
| DAG and IP3 signaling | R-HSA-1489509 | 2.769256e-01 | 0.558 | 0 | 0 |
| Transcriptional Regulation by MECP2 | R-HSA-8986944 | 2.772541e-01 | 0.557 | 0 | 0 |
| G beta:gamma signalling through PLC beta | R-HSA-418217 | 2.791440e-01 | 0.554 | 0 | 0 |
| Signaling by cytosolic FGFR1 fusion mutants | R-HSA-1839117 | 2.791440e-01 | 0.554 | 0 | 0 |
| Mismatch Repair | R-HSA-5358508 | 2.791440e-01 | 0.554 | 0 | 0 |
| Presynaptic function of Kainate receptors | R-HSA-500657 | 2.791440e-01 | 0.554 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition | R-HSA-9926550 | 2.791440e-01 | 0.554 | 0 | 0 |
| PTK6 promotes HIF1A stabilization | R-HSA-8857538 | 2.806434e-01 | 0.552 | 0 | 0 |
| Erythropoietin activates STAT5 | R-HSA-9027283 | 2.806434e-01 | 0.552 | 0 | 0 |
| RUNX3 regulates YAP1-mediated transcription | R-HSA-8951671 | 2.806434e-01 | 0.552 | 0 | 0 |
| Autointegration results in viral DNA circles | R-HSA-177539 | 2.806434e-01 | 0.552 | 0 | 0 |
| E2F-enabled inhibition of pre-replication complex formation | R-HSA-113507 | 2.806434e-01 | 0.552 | 0 | 0 |
| RAS signaling downstream of NF1 loss-of-function variants | R-HSA-6802953 | 2.806434e-01 | 0.552 | 0 | 0 |
| CREB phosphorylation | R-HSA-199920 | 2.806434e-01 | 0.552 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex in Cancer | R-HSA-3304351 | 2.806434e-01 | 0.552 | 0 | 0 |
| Activation of NIMA Kinases NEK9, NEK6, NEK7 | R-HSA-2980767 | 2.806434e-01 | 0.552 | 0 | 0 |
| Integration of viral DNA into host genomic DNA | R-HSA-175567 | 2.806434e-01 | 0.552 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected purine | R-HSA-110330 | 2.817406e-01 | 0.550 | 0 | 0 |
| Regulation of ornithine decarboxylase (ODC) | R-HSA-350562 | 2.817406e-01 | 0.550 | 0 | 0 |
| Constitutive Signaling by Overexpressed ERBB2 | R-HSA-9634285 | 2.846790e-01 | 0.546 | 0 | 0 |
| Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | R-HSA-9027276 | 2.846790e-01 | 0.546 | 0 | 0 |
| Polymerase switching | R-HSA-69091 | 2.846790e-01 | 0.546 | 0 | 0 |
| Leading Strand Synthesis | R-HSA-69109 | 2.846790e-01 | 0.546 | 0 | 0 |
| Disorders of Nervous System Development | R-HSA-9697154 | 2.846790e-01 | 0.546 | 0 | 0 |
| Pervasive developmental disorders | R-HSA-9005895 | 2.846790e-01 | 0.546 | 0 | 0 |
| Loss of function of MECP2 in Rett syndrome | R-HSA-9005891 | 2.846790e-01 | 0.546 | 0 | 0 |
| Formation of HIV-1 elongation complex containing HIV-1 Tat | R-HSA-167200 | 2.887287e-01 | 0.540 | 0 | 0 |
| Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin | R-HSA-9725554 | 2.887287e-01 | 0.540 | 0 | 0 |
| Polymerase switching on the C-strand of the telomere | R-HSA-174411 | 2.931098e-01 | 0.533 | 0 | 0 |
| Regulation of TNFR1 signaling | R-HSA-5357905 | 2.934237e-01 | 0.533 | 0 | 0 |
| NFG and proNGF binds to p75NTR | R-HSA-205017 | 2.940624e-01 | 0.532 | 0 | 0 |
| Interactions of Tat with host cellular proteins | R-HSA-176034 | 2.940624e-01 | 0.532 | 0 | 0 |
| Abasic sugar-phosphate removal via the single-nucleotide replacement pathway | R-HSA-73930 | 2.940624e-01 | 0.532 | 0 | 0 |
| IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR) | R-HSA-5603027 | 2.940624e-01 | 0.532 | 0 | 0 |
| Defective SLC12A6 causes agenesis of the corpus callosum, with peripheral neuropathy (ACCPN) | R-HSA-5619039 | 2.940624e-01 | 0.532 | 0 | 0 |
| Mitochondrial short-chain enoyl-CoA hydratase deficiency 1 | R-HSA-9916720 | 2.940624e-01 | 0.532 | 0 | 0 |
| IKBKB deficiency causes SCID | R-HSA-5602636 | 2.940624e-01 | 0.532 | 0 | 0 |
| Defective SLC4A1 causes hereditary spherocytosis type 4 (HSP4), distal renal tubular acidosis (dRTA) and dRTA with hemolytic anemia (dRTA-HA) | R-HSA-5619050 | 2.940624e-01 | 0.532 | 0 | 0 |
| Defective SLC4A4 causes renal tubular acidosis, proximal, with ocular abnormalities and mental retardation (pRTA-OA) | R-HSA-5619054 | 2.940624e-01 | 0.532 | 0 | 0 |
| TRAF3 deficiency - HSE | R-HSA-5602571 | 2.940624e-01 | 0.532 | 0 | 0 |
| Defective GFPT1 causes CMSTA1 | R-HSA-4085023 | 2.940624e-01 | 0.532 | 0 | 0 |
| Defective Mismatch Repair Associated With MSH2 | R-HSA-5632928 | 2.940624e-01 | 0.532 | 0 | 0 |
| TGFBR3 regulates FGF2 signaling | R-HSA-9839397 | 2.940624e-01 | 0.532 | 0 | 0 |
| Transport of connexins along the secretory pathway | R-HSA-190827 | 2.940624e-01 | 0.532 | 0 | 0 |
| Inhibition of Host mRNA Processing and RNA Silencing | R-HSA-168315 | 2.940624e-01 | 0.532 | 0 | 0 |
| Inhibition of membrane repair | R-HSA-9635644 | 2.940624e-01 | 0.532 | 0 | 0 |
| Oligomerization of connexins into connexons | R-HSA-190704 | 2.940624e-01 | 0.532 | 0 | 0 |
| NTRK3 as a dependence receptor | R-HSA-9603505 | 2.940624e-01 | 0.532 | 0 | 0 |
| Nuclear Receptor transcription pathway | R-HSA-383280 | 3.008249e-01 | 0.522 | 0 | 0 |
| FOXO-mediated transcription | R-HSA-9614085 | 3.009067e-01 | 0.522 | 0 | 0 |
| G-protein beta:gamma signalling | R-HSA-397795 | 3.015127e-01 | 0.521 | 0 | 0 |
| Cyclin A/B1/B2 associated events during G2/M transition | R-HSA-69273 | 3.015127e-01 | 0.521 | 0 | 0 |
| Sealing of the nuclear envelope (NE) by ESCRT-III | R-HSA-9668328 | 3.015127e-01 | 0.521 | 0 | 0 |
| Germ layer formation at gastrulation | R-HSA-9754189 | 3.048178e-01 | 0.516 | 0 | 0 |
| HIV Transcription Elongation | R-HSA-167169 | 3.067949e-01 | 0.513 | 0 | 0 |
| Tat-mediated elongation of the HIV-1 transcript | R-HSA-167246 | 3.067949e-01 | 0.513 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation | R-HSA-9843743 | 3.067949e-01 | 0.513 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation by EBF2 | R-HSA-9844594 | 3.067949e-01 | 0.513 | 0 | 0 |
| Retrograde transport at the Trans-Golgi-Network | R-HSA-6811440 | 3.101490e-01 | 0.508 | 0 | 0 |
| Hedgehog 'on' state | R-HSA-5632684 | 3.140017e-01 | 0.503 | 0 | 0 |
| Myogenesis | R-HSA-525793 | 3.154475e-01 | 0.501 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression linked to lipogenesis | R-HSA-9029558 | 3.160420e-01 | 0.500 | 0 | 0 |
| CD28 dependent Vav1 pathway | R-HSA-389359 | 3.160420e-01 | 0.500 | 0 | 0 |
| Formation of axial mesoderm | R-HSA-9796292 | 3.160420e-01 | 0.500 | 0 | 0 |
| Golgi Cisternae Pericentriolar Stack Reorganization | R-HSA-162658 | 3.160420e-01 | 0.500 | 0 | 0 |
| Interleukin-6 signaling | R-HSA-1059683 | 3.160420e-01 | 0.500 | 0 | 0 |
| Role of ABL in ROBO-SLIT signaling | R-HSA-428890 | 3.231255e-01 | 0.491 | 0 | 0 |
| SOS-mediated signalling | R-HSA-112412 | 3.231255e-01 | 0.491 | 0 | 0 |
| Disinhibition of SNARE formation | R-HSA-114516 | 3.231255e-01 | 0.491 | 0 | 0 |
| Recycling of eIF2:GDP | R-HSA-72731 | 3.231255e-01 | 0.491 | 0 | 0 |
| Activated NTRK3 signals through PI3K | R-HSA-9603381 | 3.231255e-01 | 0.491 | 0 | 0 |
| CHL1 interactions | R-HSA-447041 | 3.231255e-01 | 0.491 | 0 | 0 |
| Activation of PUMA and translocation to mitochondria | R-HSA-139915 | 3.231255e-01 | 0.491 | 0 | 0 |
| TGFBR3 regulates TGF-beta signaling | R-HSA-9839389 | 3.231255e-01 | 0.491 | 0 | 0 |
| RUNX3 Regulates Immune Response and Cell Migration | R-HSA-8949275 | 3.231255e-01 | 0.491 | 0 | 0 |
| NGF-stimulated transcription | R-HSA-9031628 | 3.270646e-01 | 0.485 | 0 | 0 |
| High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells | R-HSA-9856530 | 3.275258e-01 | 0.485 | 0 | 0 |
| Nuclear Events (kinase and transcription factor activation) | R-HSA-198725 | 3.281012e-01 | 0.484 | 0 | 0 |
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | R-HSA-168643 | 3.283170e-01 | 0.484 | 0 | 0 |
| Co-inhibition by CTLA4 | R-HSA-389513 | 3.307247e-01 | 0.481 | 0 | 0 |
| Packaging Of Telomere Ends | R-HSA-171306 | 3.379879e-01 | 0.471 | 0 | 0 |
| Disassembly of the destruction complex and recruitment of AXIN to the membrane | R-HSA-4641262 | 3.379879e-01 | 0.471 | 0 | 0 |
| RNA Polymerase I Transcription Termination | R-HSA-73863 | 3.379879e-01 | 0.471 | 0 | 0 |
| Signaling by NOTCH2 | R-HSA-1980145 | 3.417256e-01 | 0.466 | 0 | 0 |
| Calnexin/calreticulin cycle | R-HSA-901042 | 3.417256e-01 | 0.466 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected pyrimidine | R-HSA-110328 | 3.417256e-01 | 0.466 | 0 | 0 |
| Ca2+ pathway | R-HSA-4086398 | 3.423288e-01 | 0.466 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9683701 | 3.435183e-01 | 0.464 | 0 | 0 |
| Removal of the Flap Intermediate | R-HSA-69166 | 3.474587e-01 | 0.459 | 0 | 0 |
| Lagging Strand Synthesis | R-HSA-69186 | 3.567364e-01 | 0.448 | 0 | 0 |
| NOTCH4 Intracellular Domain Regulates Transcription | R-HSA-9013695 | 3.567364e-01 | 0.448 | 0 | 0 |
| PERK regulates gene expression | R-HSA-381042 | 3.620438e-01 | 0.441 | 0 | 0 |
| Ca-dependent events | R-HSA-111996 | 3.620826e-01 | 0.441 | 0 | 0 |
| Adaptive Immune System | R-HSA-1280218 | 3.624026e-01 | 0.441 | 0 | 0 |
| Formyl peptide receptors bind formyl peptides and many other ligands | R-HSA-444473 | 3.649404e-01 | 0.438 | 0 | 0 |
| Axonal growth inhibition (RHOA activation) | R-HSA-193634 | 3.649404e-01 | 0.438 | 0 | 0 |
| Adrenoceptors | R-HSA-390696 | 3.649404e-01 | 0.438 | 0 | 0 |
| CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde | R-HSA-442729 | 3.649404e-01 | 0.438 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of myeloid cells | R-HSA-8939246 | 3.649404e-01 | 0.438 | 0 | 0 |
| PI3K/AKT Signaling in Cancer | R-HSA-2219528 | 3.666867e-01 | 0.436 | 0 | 0 |
| Hemostasis | R-HSA-109582 | 3.670179e-01 | 0.435 | 0 | 0 |
| Defective AHCY causes HMAHCHD | R-HSA-5578997 | 3.714370e-01 | 0.430 | 0 | 0 |
| Mitotic Metaphase/Anaphase Transition | R-HSA-68881 | 3.714370e-01 | 0.430 | 0 | 0 |
| Glycogen storage disease type 0 (muscle GYS1) | R-HSA-3828062 | 3.714370e-01 | 0.430 | 0 | 0 |
| Glycogen storage disease type XV (GYG1) | R-HSA-3814836 | 3.714370e-01 | 0.430 | 0 | 0 |
| Defective SLC12A1 causes Bartter syndrome 1 (BS1) | R-HSA-5619104 | 3.714370e-01 | 0.430 | 0 | 0 |
| TGFBR2 Kinase Domain Mutants in Cancer | R-HSA-3645790 | 3.714370e-01 | 0.430 | 0 | 0 |
| mRNA Editing: A to I Conversion | R-HSA-75064 | 3.714370e-01 | 0.430 | 0 | 0 |
| C6 deamination of adenosine | R-HSA-75102 | 3.714370e-01 | 0.430 | 0 | 0 |
| Loss of Function of TGFBR2 in Cancer | R-HSA-3642278 | 3.714370e-01 | 0.430 | 0 | 0 |
| Activation, myristolyation of BID and translocation to mitochondria | R-HSA-75108 | 3.714370e-01 | 0.430 | 0 | 0 |
| tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis | R-HSA-9708296 | 3.714370e-01 | 0.430 | 0 | 0 |
| ATF6B (ATF6-beta) activates chaperones | R-HSA-8874177 | 3.714370e-01 | 0.430 | 0 | 0 |
| Extension of Telomeres | R-HSA-180786 | 3.762057e-01 | 0.425 | 0 | 0 |
| Erythropoietin activates RAS | R-HSA-9027284 | 3.787238e-01 | 0.422 | 0 | 0 |
| G beta:gamma signalling through BTK | R-HSA-8964315 | 3.787238e-01 | 0.422 | 0 | 0 |
| Processive synthesis on the lagging strand | R-HSA-69183 | 3.787238e-01 | 0.422 | 0 | 0 |
| Lysosphingolipid and LPA receptors | R-HSA-419408 | 3.787238e-01 | 0.422 | 0 | 0 |
| p38MAPK events | R-HSA-171007 | 3.787238e-01 | 0.422 | 0 | 0 |
| Formation of the anterior neural plate | R-HSA-9823739 | 3.787238e-01 | 0.422 | 0 | 0 |
| Lysosome Vesicle Biogenesis | R-HSA-432720 | 3.824244e-01 | 0.417 | 0 | 0 |
| GPVI-mediated activation cascade | R-HSA-114604 | 3.824244e-01 | 0.417 | 0 | 0 |
| RUNX2 regulates bone development | R-HSA-8941326 | 3.824244e-01 | 0.417 | 0 | 0 |
| Unblocking of NMDA receptors, glutamate binding and activation | R-HSA-438066 | 3.827327e-01 | 0.417 | 0 | 0 |
| Ras activation upon Ca2+ influx through NMDA receptor | R-HSA-442982 | 3.827327e-01 | 0.417 | 0 | 0 |
| Negative regulation of NMDA receptor-mediated neuronal transmission | R-HSA-9617324 | 3.827327e-01 | 0.417 | 0 | 0 |
| Assembly Of The HIV Virion | R-HSA-175474 | 3.827327e-01 | 0.417 | 0 | 0 |
| Signaling by Erythropoietin | R-HSA-9006335 | 3.833430e-01 | 0.416 | 0 | 0 |
| Regulation of gene expression in beta cells | R-HSA-210745 | 3.833430e-01 | 0.416 | 0 | 0 |
| Gastrulation | R-HSA-9758941 | 3.859797e-01 | 0.413 | 0 | 0 |
| Signaling by FGFR | R-HSA-190236 | 3.885300e-01 | 0.411 | 0 | 0 |
| Toll-like Receptor Cascades | R-HSA-168898 | 3.970799e-01 | 0.401 | 0 | 0 |
| Cleavage of the damaged purine | R-HSA-110331 | 4.028108e-01 | 0.395 | 0 | 0 |
| Lipophagy | R-HSA-9613354 | 4.057241e-01 | 0.392 | 0 | 0 |
| Regulated proteolysis of p75NTR | R-HSA-193692 | 4.057241e-01 | 0.392 | 0 | 0 |
| p75NTR regulates axonogenesis | R-HSA-193697 | 4.057241e-01 | 0.392 | 0 | 0 |
| Activation of RAC1 downstream of NMDARs | R-HSA-9619229 | 4.057241e-01 | 0.392 | 0 | 0 |
| Toxicity of botulinum toxin type A (botA) | R-HSA-5250968 | 4.057241e-01 | 0.392 | 0 | 0 |
| Caspase activation via Dependence Receptors in the absence of ligand | R-HSA-418889 | 4.057241e-01 | 0.392 | 0 | 0 |
| NOTCH4 Activation and Transmission of Signal to the Nucleus | R-HSA-9013700 | 4.057241e-01 | 0.392 | 0 | 0 |
| HuR (ELAVL1) binds and stabilizes mRNA | R-HSA-450520 | 4.057241e-01 | 0.392 | 0 | 0 |
| NFE2L2 regulating MDR associated enzymes | R-HSA-9818032 | 4.057241e-01 | 0.392 | 0 | 0 |
| Respiratory syncytial virus genome replication | R-HSA-9834752 | 4.057241e-01 | 0.392 | 0 | 0 |
| NOTCH3 Intracellular Domain Regulates Transcription | R-HSA-9013508 | 4.060008e-01 | 0.391 | 0 | 0 |
| RNA Polymerase III Transcription Initiation | R-HSA-76046 | 4.060008e-01 | 0.391 | 0 | 0 |
| Thrombin signalling through proteinase activated receptors (PARs) | R-HSA-456926 | 4.060008e-01 | 0.391 | 0 | 0 |
| FGFR2 alternative splicing | R-HSA-6803529 | 4.086027e-01 | 0.389 | 0 | 0 |
| Regulation of IFNA/IFNB signaling | R-HSA-912694 | 4.086027e-01 | 0.389 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in lysosome biogenesis and autophagy | R-HSA-9857377 | 4.086027e-01 | 0.389 | 0 | 0 |
| Formation of paraxial mesoderm | R-HSA-9793380 | 4.086426e-01 | 0.389 | 0 | 0 |
| Class I peroxisomal membrane protein import | R-HSA-9603798 | 4.096561e-01 | 0.388 | 0 | 0 |
| Killing mechanisms | R-HSA-9664420 | 4.096561e-01 | 0.388 | 0 | 0 |
| WNT5:FZD7-mediated leishmania damping | R-HSA-9673324 | 4.096561e-01 | 0.388 | 0 | 0 |
| ABC transporter disorders | R-HSA-5619084 | 4.146541e-01 | 0.382 | 0 | 0 |
| Somitogenesis | R-HSA-9824272 | 4.180502e-01 | 0.379 | 0 | 0 |
| Depurination | R-HSA-73927 | 4.231491e-01 | 0.374 | 0 | 0 |
| Organelle biogenesis and maintenance | R-HSA-1852241 | 4.239065e-01 | 0.373 | 0 | 0 |
| Budding and maturation of HIV virion | R-HSA-162588 | 4.285480e-01 | 0.368 | 0 | 0 |
| Sensory processing of sound | R-HSA-9659379 | 4.292124e-01 | 0.367 | 0 | 0 |
| Estrogen-dependent nuclear events downstream of ESR-membrane signaling | R-HSA-9634638 | 4.342447e-01 | 0.362 | 0 | 0 |
| Cargo trafficking to the periciliary membrane | R-HSA-5620920 | 4.349225e-01 | 0.362 | 0 | 0 |
| mRNA Splicing - Minor Pathway | R-HSA-72165 | 4.366566e-01 | 0.360 | 0 | 0 |
| Signaling by TGFBR3 | R-HSA-9839373 | 4.366566e-01 | 0.360 | 0 | 0 |
| Regulation of pyruvate metabolism | R-HSA-9861718 | 4.366566e-01 | 0.360 | 0 | 0 |
| Signaling by Hedgehog | R-HSA-5358351 | 4.368256e-01 | 0.360 | 0 | 0 |
| SHC1 events in ERBB4 signaling | R-HSA-1250347 | 4.400983e-01 | 0.356 | 0 | 0 |
| Antigen processing: Ub, ATP-independent proteasomal degradation | R-HSA-9912633 | 4.400983e-01 | 0.356 | 0 | 0 |
| The CRY:PER:kinase complex represses transactivation by the BMAL:CLOCK (ARNTL:CLOCK) complex | R-HSA-9931521 | 4.400983e-01 | 0.356 | 0 | 0 |
| Acetylcholine regulates insulin secretion | R-HSA-399997 | 4.400983e-01 | 0.356 | 0 | 0 |
| STAT6-mediated induction of chemokines | R-HSA-3249367 | 4.403349e-01 | 0.356 | 0 | 0 |
| Axonal growth stimulation | R-HSA-209563 | 4.403349e-01 | 0.356 | 0 | 0 |
| MET activates PTPN11 | R-HSA-8865999 | 4.403349e-01 | 0.356 | 0 | 0 |
| Inhibition of nitric oxide production | R-HSA-9636249 | 4.403349e-01 | 0.356 | 0 | 0 |
| Activation of BMF and translocation to mitochondria | R-HSA-139910 | 4.403349e-01 | 0.356 | 0 | 0 |
| Activation of BIM and translocation to mitochondria | R-HSA-111446 | 4.403349e-01 | 0.356 | 0 | 0 |
| Loss of MECP2 binding ability to 5mC-DNA | R-HSA-9022538 | 4.403349e-01 | 0.356 | 0 | 0 |
| Diseases of Mismatch Repair (MMR) | R-HSA-5423599 | 4.403349e-01 | 0.356 | 0 | 0 |
| CASP5-mediated substrate cleavage | R-HSA-9960525 | 4.403349e-01 | 0.356 | 0 | 0 |
| CASP4-mediated substrate cleavage | R-HSA-9960519 | 4.403349e-01 | 0.356 | 0 | 0 |
| Expression of BMAL (ARNTL), CLOCK, and NPAS2 | R-HSA-9931509 | 4.433881e-01 | 0.353 | 0 | 0 |
| Cross-presentation of soluble exogenous antigens (endosomes) | R-HSA-1236978 | 4.433881e-01 | 0.353 | 0 | 0 |
| Respiratory syncytial virus (RSV) genome replication, transcription and translation | R-HSA-9820965 | 4.433881e-01 | 0.353 | 0 | 0 |
| Neurotransmitter receptors and postsynaptic signal transmission | R-HSA-112314 | 4.434399e-01 | 0.353 | 0 | 0 |
| EGFR Transactivation by Gastrin | R-HSA-2179392 | 4.452006e-01 | 0.351 | 0 | 0 |
| PI3K/AKT activation | R-HSA-198203 | 4.452006e-01 | 0.351 | 0 | 0 |
| Interleukin-27 signaling | R-HSA-9020956 | 4.452006e-01 | 0.351 | 0 | 0 |
| Receptor Mediated Mitophagy | R-HSA-8934903 | 4.452006e-01 | 0.351 | 0 | 0 |
| Assembly and release of respiratory syncytial virus (RSV) virions | R-HSA-9820962 | 4.452006e-01 | 0.351 | 0 | 0 |
| Signaling by Leptin | R-HSA-2586552 | 4.452006e-01 | 0.351 | 0 | 0 |
| Ion channel transport | R-HSA-983712 | 4.575611e-01 | 0.340 | 1 | 0 |
| Amyloid fiber formation | R-HSA-977225 | 4.582634e-01 | 0.339 | 0 | 0 |
| Replacement of protamines by nucleosomes in the male pronucleus | R-HSA-9821993 | 4.595668e-01 | 0.338 | 0 | 0 |
| Diseases associated with the TLR signaling cascade | R-HSA-5602358 | 4.634795e-01 | 0.334 | 0 | 0 |
| Diseases of Immune System | R-HSA-5260271 | 4.634795e-01 | 0.334 | 0 | 0 |
| Modulation of host responses by IFN-stimulated genes | R-HSA-9909505 | 4.699153e-01 | 0.328 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) | R-HSA-5358606 | 4.699153e-01 | 0.328 | 0 | 0 |
| Inositol phosphate metabolism | R-HSA-1483249 | 4.712064e-01 | 0.327 | 0 | 0 |
| Regulation of necroptotic cell death | R-HSA-5675482 | 4.730487e-01 | 0.325 | 0 | 0 |
| Activation of anterior HOX genes in hindbrain development during early embryogenesis | R-HSA-5617472 | 4.779661e-01 | 0.321 | 0 | 0 |
| Activation of HOX genes during differentiation | R-HSA-5619507 | 4.779661e-01 | 0.321 | 0 | 0 |
| NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 | R-HSA-933543 | 4.831665e-01 | 0.316 | 0 | 0 |
| Formation of the posterior neural plate | R-HSA-9832991 | 4.831665e-01 | 0.316 | 0 | 0 |
| RHOBTB3 ATPase cycle | R-HSA-9706019 | 4.831665e-01 | 0.316 | 0 | 0 |
| Suppression of apoptosis | R-HSA-9635465 | 4.831665e-01 | 0.316 | 0 | 0 |
| Interleukin-2 signaling | R-HSA-9020558 | 4.831665e-01 | 0.316 | 0 | 0 |
| Chromatin modifications during the maternal to zygotic transition (MZT) | R-HSA-9821002 | 4.833781e-01 | 0.316 | 0 | 0 |
| TGFBR3 expression | R-HSA-9839394 | 4.844867e-01 | 0.315 | 0 | 0 |
| Glycogen breakdown (glycogenolysis) | R-HSA-70221 | 4.844867e-01 | 0.315 | 0 | 0 |
| VEGFR2 mediated cell proliferation | R-HSA-5218921 | 4.844867e-01 | 0.315 | 0 | 0 |
| TNFR2 non-canonical NF-kB pathway | R-HSA-5668541 | 4.871030e-01 | 0.312 | 0 | 0 |
| N-glycan trimming in the ER and Calnexin/Calreticulin cycle | R-HSA-532668 | 4.917846e-01 | 0.308 | 0 | 0 |
| Regulation of CDH1 posttranslational processing and trafficking to plasma membrane | R-HSA-9768727 | 4.948835e-01 | 0.305 | 0 | 0 |
| TP53 Regulates Transcription of Cell Death Genes | R-HSA-5633008 | 4.956645e-01 | 0.305 | 0 | 0 |
| Trafficking of GluR2-containing AMPA receptors | R-HSA-416993 | 4.989936e-01 | 0.302 | 0 | 0 |
| RNA Polymerase III Transcription Termination | R-HSA-73980 | 4.989936e-01 | 0.302 | 0 | 0 |
| Platelet sensitization by LDL | R-HSA-432142 | 4.989936e-01 | 0.302 | 0 | 0 |
| Serotonin Neurotransmitter Release Cycle | R-HSA-181429 | 4.989936e-01 | 0.302 | 0 | 0 |
| Apoptotic factor-mediated response | R-HSA-111471 | 4.989936e-01 | 0.302 | 0 | 0 |
| TLR3-mediated TICAM1-dependent programmed cell death | R-HSA-9013957 | 5.016844e-01 | 0.300 | 0 | 0 |
| GRB7 events in ERBB2 signaling | R-HSA-1306955 | 5.016844e-01 | 0.300 | 0 | 0 |
| TGFBR1 KD Mutants in Cancer | R-HSA-3656532 | 5.016844e-01 | 0.300 | 0 | 0 |
| Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes | R-HSA-69200 | 5.016844e-01 | 0.300 | 0 | 0 |
| Signaling by MAP2K mutants | R-HSA-9652169 | 5.016844e-01 | 0.300 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of cell cycle factors | R-HSA-8866911 | 5.016844e-01 | 0.300 | 0 | 0 |
| Transcriptional activation of p53 responsive genes | R-HSA-69560 | 5.016844e-01 | 0.300 | 0 | 0 |
| Transcriptional activation of cell cycle inhibitor p21 | R-HSA-69895 | 5.016844e-01 | 0.300 | 0 | 0 |
| Dopamine receptors | R-HSA-390651 | 5.016844e-01 | 0.300 | 0 | 0 |
| Electric Transmission Across Gap Junctions | R-HSA-112303 | 5.016844e-01 | 0.300 | 0 | 0 |
| Transmission across Electrical Synapses | R-HSA-112307 | 5.016844e-01 | 0.300 | 0 | 0 |
| Activation of NOXA and translocation to mitochondria | R-HSA-111448 | 5.016844e-01 | 0.300 | 0 | 0 |
| TNFR1-mediated ceramide production | R-HSA-5626978 | 5.016844e-01 | 0.300 | 0 | 0 |
| Interleukin-38 signaling | R-HSA-9007892 | 5.016844e-01 | 0.300 | 0 | 0 |
| Telomere C-strand (Lagging Strand) Synthesis | R-HSA-174417 | 5.030421e-01 | 0.298 | 0 | 0 |
| Signaling by FGFR1 in disease | R-HSA-5655302 | 5.030421e-01 | 0.298 | 0 | 0 |
| MET activates PTK2 signaling | R-HSA-8874081 | 5.089316e-01 | 0.293 | 0 | 0 |
| Signal amplification | R-HSA-392518 | 5.163712e-01 | 0.287 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression to control bile acid homeostasis | R-HSA-9623433 | 5.194787e-01 | 0.284 | 0 | 0 |
| PI3K events in ERBB4 signaling | R-HSA-1250342 | 5.194787e-01 | 0.284 | 0 | 0 |
| Signaling by GSK3beta mutants | R-HSA-5339716 | 5.194787e-01 | 0.284 | 0 | 0 |
| POLB-Dependent Long Patch Base Excision Repair | R-HSA-110362 | 5.194787e-01 | 0.284 | 0 | 0 |
| APOBEC3G mediated resistance to HIV-1 infection | R-HSA-180689 | 5.194787e-01 | 0.284 | 0 | 0 |
| Cytochrome c-mediated apoptotic response | R-HSA-111461 | 5.194787e-01 | 0.284 | 0 | 0 |
| Sodium/Calcium exchangers | R-HSA-425561 | 5.194787e-01 | 0.284 | 0 | 0 |
| TP53 Regulates Metabolic Genes | R-HSA-5628897 | 5.199185e-01 | 0.284 | 0 | 0 |
| Regulated Necrosis | R-HSA-5218859 | 5.207957e-01 | 0.283 | 0 | 0 |
| Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | R-HSA-381676 | 5.224329e-01 | 0.282 | 0 | 0 |
| Cleavage of the damaged pyrimidine | R-HSA-110329 | 5.224329e-01 | 0.282 | 0 | 0 |
| Depyrimidination | R-HSA-73928 | 5.224329e-01 | 0.282 | 0 | 0 |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | R-HSA-6811558 | 5.237824e-01 | 0.281 | 0 | 0 |
| Abortive elongation of HIV-1 transcript in the absence of Tat | R-HSA-167242 | 5.272392e-01 | 0.278 | 0 | 0 |
| Prostacyclin signalling through prostacyclin receptor | R-HSA-392851 | 5.272392e-01 | 0.278 | 0 | 0 |
| The NLRP3 inflammasome | R-HSA-844456 | 5.272392e-01 | 0.278 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9694631 | 5.272392e-01 | 0.278 | 0 | 0 |
| Other interleukin signaling | R-HSA-449836 | 5.272392e-01 | 0.278 | 0 | 0 |
| Pre-NOTCH Processing in Golgi | R-HSA-1912420 | 5.272392e-01 | 0.278 | 0 | 0 |
| Stimuli-sensing channels | R-HSA-2672351 | 5.282547e-01 | 0.277 | 1 | 1 |
| Processive synthesis on the C-strand of the telomere | R-HSA-174414 | 5.328381e-01 | 0.273 | 0 | 0 |
| Phosphorylation of CD3 and TCR zeta chains | R-HSA-202427 | 5.328381e-01 | 0.273 | 0 | 0 |
| CD28 dependent PI3K/Akt signaling | R-HSA-389357 | 5.328381e-01 | 0.273 | 0 | 0 |
| Signaling by NTRK2 (TRKB) | R-HSA-9006115 | 5.328381e-01 | 0.273 | 0 | 0 |
| ER Quality Control Compartment (ERQC) | R-HSA-901032 | 5.328381e-01 | 0.273 | 0 | 0 |
| Developmental Lineage of Pancreatic Ductal Cells | R-HSA-9925563 | 5.363202e-01 | 0.271 | 0 | 0 |
| Transferrin endocytosis and recycling | R-HSA-917977 | 5.374655e-01 | 0.270 | 0 | 0 |
| G alpha (12/13) signalling events | R-HSA-416482 | 5.400980e-01 | 0.268 | 0 | 0 |
| Uptake and actions of bacterial toxins | R-HSA-5339562 | 5.451687e-01 | 0.263 | 0 | 0 |
| Constitutive Signaling by Aberrant PI3K in Cancer | R-HSA-2219530 | 5.468694e-01 | 0.262 | 0 | 0 |
| PLC beta mediated events | R-HSA-112043 | 5.485281e-01 | 0.261 | 0 | 0 |
| Signaling by CTNNB1 phospho-site mutants | R-HSA-4839743 | 5.540437e-01 | 0.256 | 0 | 0 |
| CTNNB1 S33 mutants aren't phosphorylated | R-HSA-5358747 | 5.540437e-01 | 0.256 | 0 | 0 |
| CTNNB1 T41 mutants aren't phosphorylated | R-HSA-5358752 | 5.540437e-01 | 0.256 | 0 | 0 |
| CTNNB1 S37 mutants aren't phosphorylated | R-HSA-5358749 | 5.540437e-01 | 0.256 | 0 | 0 |
| CTNNB1 S45 mutants aren't phosphorylated | R-HSA-5358751 | 5.540437e-01 | 0.256 | 0 | 0 |
| RUNX3 regulates p14-ARF | R-HSA-8951936 | 5.540437e-01 | 0.256 | 0 | 0 |
| RUNX3 regulates NOTCH signaling | R-HSA-8941856 | 5.540437e-01 | 0.256 | 0 | 0 |
| Interleukin-35 Signalling | R-HSA-8984722 | 5.540437e-01 | 0.256 | 0 | 0 |
| AKT phosphorylates targets in the cytosol | R-HSA-198323 | 5.540437e-01 | 0.256 | 0 | 0 |
| Reversal of alkylation damage by DNA dioxygenases | R-HSA-73943 | 5.540437e-01 | 0.256 | 0 | 0 |
| Regulation of PD-L1(CD274) translation | R-HSA-9909620 | 5.545766e-01 | 0.256 | 0 | 0 |
| Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | R-HSA-9609523 | 5.545766e-01 | 0.256 | 0 | 0 |
| Telomere Extension By Telomerase | R-HSA-171319 | 5.561513e-01 | 0.255 | 0 | 0 |
| Insulin receptor recycling | R-HSA-77387 | 5.561513e-01 | 0.255 | 0 | 0 |
| Pyroptosis | R-HSA-5620971 | 5.561513e-01 | 0.255 | 0 | 0 |
| RUNX2 regulates osteoblast differentiation | R-HSA-8940973 | 5.561513e-01 | 0.255 | 0 | 0 |
| Activation of kainate receptors upon glutamate binding | R-HSA-451326 | 5.561513e-01 | 0.255 | 0 | 0 |
| G2 Phase | R-HSA-68911 | 5.563121e-01 | 0.255 | 0 | 0 |
| Signaling by membrane-tethered fusions of PDGFRA or PDGFRB | R-HSA-9673768 | 5.563121e-01 | 0.255 | 0 | 0 |
| Enhanced binding of GP1BA variant to VWF multimer:collagen | R-HSA-9845620 | 5.563121e-01 | 0.255 | 0 | 0 |
| Defective F9 activation | R-HSA-9673221 | 5.563121e-01 | 0.255 | 0 | 0 |
| SMAD2/3 Phosphorylation Motif Mutants in Cancer | R-HSA-3304356 | 5.563121e-01 | 0.255 | 0 | 0 |
| Defective binding of VWF variant to GPIb:IX:V | R-HSA-9846298 | 5.563121e-01 | 0.255 | 0 | 0 |
| IRF3 mediated activation of type 1 IFN | R-HSA-1606341 | 5.563121e-01 | 0.255 | 0 | 0 |
| Post-transcriptional silencing by small RNAs | R-HSA-426496 | 5.563121e-01 | 0.255 | 0 | 0 |
| Toxicity of botulinum toxin type G (botG) | R-HSA-5250989 | 5.563121e-01 | 0.255 | 0 | 0 |
| Resolution of AP sites via the single-nucleotide replacement pathway | R-HSA-110381 | 5.563121e-01 | 0.255 | 0 | 0 |
| Inositol transporters | R-HSA-429593 | 5.563121e-01 | 0.255 | 0 | 0 |
| SMAC(DIABLO)-mediated dissociation of IAP:caspase complexes | R-HSA-111464 | 5.563121e-01 | 0.255 | 0 | 0 |
| SMAC (DIABLO) binds to IAPs | R-HSA-111463 | 5.563121e-01 | 0.255 | 0 | 0 |
| Co-inhibition by BTLA | R-HSA-9927353 | 5.563121e-01 | 0.255 | 0 | 0 |
| RUNX2 regulates chondrocyte maturation | R-HSA-8941284 | 5.563121e-01 | 0.255 | 0 | 0 |
| Phosphorylation and nuclear translocation of BMAL1 (ARNTL) and CLOCK | R-HSA-9931529 | 5.563121e-01 | 0.255 | 0 | 0 |
| Toxicity of botulinum toxin type C (botC) | R-HSA-5250971 | 5.563121e-01 | 0.255 | 0 | 0 |
| PTK6 Regulates Proteins Involved in RNA Processing | R-HSA-8849468 | 5.563121e-01 | 0.255 | 0 | 0 |
| Pyruvate metabolism | R-HSA-70268 | 5.573837e-01 | 0.254 | 0 | 0 |
| Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes | R-HSA-9851695 | 5.583009e-01 | 0.253 | 0 | 0 |
| MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis | R-HSA-9841922 | 5.583009e-01 | 0.253 | 0 | 0 |
| Epigenetic regulation of gene expression by MLL3 and MLL4 complexes | R-HSA-9818564 | 5.583009e-01 | 0.253 | 0 | 0 |
| Opioid Signalling | R-HSA-111885 | 5.750569e-01 | 0.240 | 0 | 0 |
| Interferon gamma signaling | R-HSA-877300 | 5.780044e-01 | 0.238 | 0 | 0 |
| Glucagon-type ligand receptors | R-HSA-420092 | 5.788251e-01 | 0.237 | 0 | 0 |
| Base-Excision Repair, AP Site Formation | R-HSA-73929 | 5.794072e-01 | 0.237 | 0 | 0 |
| G-protein activation | R-HSA-202040 | 5.809466e-01 | 0.236 | 0 | 0 |
| ADP signalling through P2Y purinoceptor 12 | R-HSA-392170 | 5.809466e-01 | 0.236 | 0 | 0 |
| Acetylcholine Neurotransmitter Release Cycle | R-HSA-264642 | 5.809466e-01 | 0.236 | 0 | 0 |
| ERK/MAPK targets | R-HSA-198753 | 5.809466e-01 | 0.236 | 0 | 0 |
| Signalling to RAS | R-HSA-167044 | 5.809466e-01 | 0.236 | 0 | 0 |
| Interconversion of nucleotide di- and triphosphates | R-HSA-499943 | 5.816971e-01 | 0.235 | 0 | 0 |
| HDR through MMEJ (alt-NHEJ) | R-HSA-5685939 | 5.868080e-01 | 0.232 | 0 | 0 |
| Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) | R-HSA-9661069 | 5.868080e-01 | 0.232 | 0 | 0 |
| Regulation of TP53 Activity through Association with Co-factors | R-HSA-6804759 | 5.868080e-01 | 0.232 | 0 | 0 |
| PI5P Regulates TP53 Acetylation | R-HSA-6811555 | 5.868080e-01 | 0.232 | 0 | 0 |
| Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects | R-HSA-9659787 | 5.868080e-01 | 0.232 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9683610 | 5.868080e-01 | 0.232 | 0 | 0 |
| RSV-host interactions | R-HSA-9833110 | 5.873967e-01 | 0.231 | 0 | 0 |
| Pre-NOTCH Expression and Processing | R-HSA-1912422 | 5.888963e-01 | 0.230 | 0 | 0 |
| Ion transport by P-type ATPases | R-HSA-936837 | 5.960307e-01 | 0.225 | 0 | 0 |
| G alpha (z) signalling events | R-HSA-418597 | 5.960506e-01 | 0.225 | 0 | 0 |
| Metabolism of nitric oxide: NOS3 activation and regulation | R-HSA-202131 | 5.980032e-01 | 0.223 | 0 | 0 |
| RIPK1-mediated regulated necrosis | R-HSA-5213460 | 5.980032e-01 | 0.223 | 0 | 0 |
| RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression | R-HSA-9933387 | 6.008215e-01 | 0.221 | 0 | 0 |
| Interleukin-37 signaling | R-HSA-9008059 | 6.008215e-01 | 0.221 | 0 | 0 |
| Inhibition of Signaling by Overexpressed EGFR | R-HSA-5638303 | 6.049541e-01 | 0.218 | 0 | 0 |
| Signaling by Overexpressed Wild-Type EGFR in Cancer | R-HSA-5638302 | 6.049541e-01 | 0.218 | 0 | 0 |
| SLIT2:ROBO1 increases RHOA activity | R-HSA-8985586 | 6.049541e-01 | 0.218 | 0 | 0 |
| Loss-of-function mutations in DLD cause MSUD3/DLDD | R-HSA-9907570 | 6.049541e-01 | 0.218 | 0 | 0 |
| Loss-of-function mutations in DBT cause MSUD2 | R-HSA-9865113 | 6.049541e-01 | 0.218 | 0 | 0 |
| Pentose phosphate pathway disease | R-HSA-6791465 | 6.049541e-01 | 0.218 | 0 | 0 |
| Release of apoptotic factors from the mitochondria | R-HSA-111457 | 6.049541e-01 | 0.218 | 0 | 0 |
| Activation of caspases through apoptosome-mediated cleavage | R-HSA-111459 | 6.049541e-01 | 0.218 | 0 | 0 |
| Loss of Function of SMAD2/3 in Cancer | R-HSA-3304349 | 6.049541e-01 | 0.218 | 0 | 0 |
| CDC6 association with the ORC:origin complex | R-HSA-68689 | 6.049541e-01 | 0.218 | 0 | 0 |
| Ceramide signalling | R-HSA-193681 | 6.049541e-01 | 0.218 | 0 | 0 |
| Defects of platelet adhesion to exposed collagen | R-HSA-9823587 | 6.049541e-01 | 0.218 | 0 | 0 |
| Signalling to p38 via RIT and RIN | R-HSA-187706 | 6.049541e-01 | 0.218 | 0 | 0 |
| SMAC, XIAP-regulated apoptotic response | R-HSA-111469 | 6.049541e-01 | 0.218 | 0 | 0 |
| Signaling by MST1 | R-HSA-8852405 | 6.049541e-01 | 0.218 | 0 | 0 |
| Orexin and neuropeptides FF and QRFP bind to their respective receptors | R-HSA-389397 | 6.049541e-01 | 0.218 | 0 | 0 |
| SLC15A4:TASL-dependent IRF5 activation | R-HSA-9860276 | 6.049541e-01 | 0.218 | 0 | 0 |
| RUNX3 regulates CDKN1A transcription | R-HSA-8941855 | 6.049541e-01 | 0.218 | 0 | 0 |
| TYSND1 cleaves peroxisomal proteins | R-HSA-9033500 | 6.049541e-01 | 0.218 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 2 Promoter | R-HSA-76066 | 6.063050e-01 | 0.217 | 0 | 0 |
| Mitochondrial calcium ion transport | R-HSA-8949215 | 6.063050e-01 | 0.217 | 0 | 0 |
| Signaling by NTRK3 (TRKC) | R-HSA-9034015 | 6.063050e-01 | 0.217 | 0 | 0 |
| Ribavirin ADME | R-HSA-9755088 | 6.063050e-01 | 0.217 | 0 | 0 |
| Serine metabolism | R-HSA-977347 | 6.063050e-01 | 0.217 | 0 | 0 |
| Pre-NOTCH Transcription and Translation | R-HSA-1912408 | 6.107742e-01 | 0.214 | 0 | 0 |
| Post-translational protein phosphorylation | R-HSA-8957275 | 6.111101e-01 | 0.214 | 0 | 0 |
| Platelet homeostasis | R-HSA-418346 | 6.116024e-01 | 0.214 | 0 | 0 |
| Detoxification of Reactive Oxygen Species | R-HSA-3299685 | 6.123508e-01 | 0.213 | 0 | 0 |
| Negative regulation of the PI3K/AKT network | R-HSA-199418 | 6.137061e-01 | 0.212 | 0 | 0 |
| Carboxyterminal post-translational modifications of tubulin | R-HSA-8955332 | 6.141659e-01 | 0.212 | 0 | 0 |
| YAP1- and WWTR1 (TAZ)-stimulated gene expression | R-HSA-2032785 | 6.177512e-01 | 0.209 | 0 | 0 |
| Retrograde neurotrophin signalling | R-HSA-177504 | 6.177512e-01 | 0.209 | 0 | 0 |
| TP53 Regulates Transcription of Death Receptors and Ligands | R-HSA-6803211 | 6.177512e-01 | 0.209 | 0 | 0 |
| CRMPs in Sema3A signaling | R-HSA-399956 | 6.177512e-01 | 0.209 | 0 | 0 |
| Signaling by FGFR4 in disease | R-HSA-5655291 | 6.177512e-01 | 0.209 | 0 | 0 |
| CLEC7A (Dectin-1) induces NFAT activation | R-HSA-5607763 | 6.177512e-01 | 0.209 | 0 | 0 |
| Malate-aspartate shuttle | R-HSA-9856872 | 6.177512e-01 | 0.209 | 0 | 0 |
| Downstream signal transduction | R-HSA-186763 | 6.221096e-01 | 0.206 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 3 Promoter | R-HSA-76071 | 6.306211e-01 | 0.200 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 1 Promoter | R-HSA-76061 | 6.306211e-01 | 0.200 | 0 | 0 |
| Neurotoxicity of clostridium toxins | R-HSA-168799 | 6.306211e-01 | 0.200 | 0 | 0 |
| RAF-independent MAPK1/3 activation | R-HSA-112409 | 6.306211e-01 | 0.200 | 0 | 0 |
| Dopamine Neurotransmitter Release Cycle | R-HSA-212676 | 6.306211e-01 | 0.200 | 0 | 0 |
| GPER1 signaling | R-HSA-9634597 | 6.312895e-01 | 0.200 | 0 | 0 |
| Intraflagellar transport | R-HSA-5620924 | 6.312895e-01 | 0.200 | 0 | 0 |
| Innate Immune System | R-HSA-168249 | 6.328233e-01 | 0.199 | 0 | 0 |
| G-protein mediated events | R-HSA-112040 | 6.409258e-01 | 0.193 | 0 | 0 |
| HCMV Late Events | R-HSA-9610379 | 6.454695e-01 | 0.190 | 0 | 0 |
| Fcgamma receptor (FCGR) dependent phagocytosis | R-HSA-2029480 | 6.460023e-01 | 0.190 | 0 | 0 |
| Competing endogenous RNAs (ceRNAs) regulate PTEN translation | R-HSA-8948700 | 6.468786e-01 | 0.189 | 0 | 0 |
| Beta-catenin phosphorylation cascade | R-HSA-196299 | 6.468786e-01 | 0.189 | 0 | 0 |
| Biotin transport and metabolism | R-HSA-196780 | 6.468786e-01 | 0.189 | 0 | 0 |
| DNA Damage Reversal | R-HSA-73942 | 6.468786e-01 | 0.189 | 0 | 0 |
| Extra-nuclear estrogen signaling | R-HSA-9009391 | 6.474743e-01 | 0.189 | 0 | 0 |
| Signaling by LTK in cancer | R-HSA-9842640 | 6.482660e-01 | 0.188 | 0 | 0 |
| G2/M DNA replication checkpoint | R-HSA-69478 | 6.482660e-01 | 0.188 | 0 | 0 |
| Branched-chain ketoacid dehydrogenase kinase deficiency | R-HSA-9912481 | 6.482660e-01 | 0.188 | 0 | 0 |
| H139Hfs13* PPM1K causes a mild variant of MSUD | R-HSA-9912529 | 6.482660e-01 | 0.188 | 0 | 0 |
| Toxicity of botulinum toxin type F (botF) | R-HSA-5250981 | 6.482660e-01 | 0.188 | 0 | 0 |
| Toxicity of botulinum toxin type D (botD) | R-HSA-5250955 | 6.482660e-01 | 0.188 | 0 | 0 |
| Regulation of NFE2L2 gene expression | R-HSA-9818749 | 6.482660e-01 | 0.188 | 0 | 0 |
| MET Receptor Activation | R-HSA-6806942 | 6.482660e-01 | 0.188 | 0 | 0 |
| VLDL assembly | R-HSA-8866423 | 6.482660e-01 | 0.188 | 0 | 0 |
| HDL clearance | R-HSA-8964011 | 6.482660e-01 | 0.188 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9694635 | 6.524109e-01 | 0.185 | 0 | 0 |
| G beta:gamma signalling through PI3Kgamma | R-HSA-392451 | 6.538759e-01 | 0.185 | 0 | 0 |
| Response of EIF2AK1 (HRI) to heme deficiency | R-HSA-9648895 | 6.538759e-01 | 0.185 | 0 | 0 |
| Peroxisomal protein import | R-HSA-9033241 | 6.590348e-01 | 0.181 | 0 | 0 |
| Regulation of beta-cell development | R-HSA-186712 | 6.590348e-01 | 0.181 | 0 | 0 |
| FGFR1 mutant receptor activation | R-HSA-1839124 | 6.624728e-01 | 0.179 | 0 | 0 |
| CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | R-HSA-442742 | 6.624728e-01 | 0.179 | 0 | 0 |
| Cardiogenesis | R-HSA-9733709 | 6.624728e-01 | 0.179 | 0 | 0 |
| Fc epsilon receptor (FCERI) signaling | R-HSA-2454202 | 6.640515e-01 | 0.178 | 0 | 0 |
| Integrin cell surface interactions | R-HSA-216083 | 6.657066e-01 | 0.177 | 0 | 0 |
| tRNA Aminoacylation | R-HSA-379724 | 6.738153e-01 | 0.171 | 0 | 0 |
| Defective GALNT3 causes HFTC | R-HSA-5083625 | 6.742165e-01 | 0.171 | 0 | 0 |
| Defective GALNT12 causes CRCS1 | R-HSA-5083636 | 6.742165e-01 | 0.171 | 0 | 0 |
| TP53 Regulates Transcription of Caspase Activators and Caspases | R-HSA-6803207 | 6.742165e-01 | 0.171 | 0 | 0 |
| SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | R-HSA-399955 | 6.742165e-01 | 0.171 | 0 | 0 |
| Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells | R-HSA-210744 | 6.742165e-01 | 0.171 | 0 | 0 |
| Receptor-type tyrosine-protein phosphatases | R-HSA-388844 | 6.742165e-01 | 0.171 | 0 | 0 |
| Virus Assembly and Release | R-HSA-168268 | 6.742165e-01 | 0.171 | 0 | 0 |
| Thromboxane signalling through TP receptor | R-HSA-428930 | 6.760608e-01 | 0.170 | 0 | 0 |
| Norepinephrine Neurotransmitter Release Cycle | R-HSA-181430 | 6.760608e-01 | 0.170 | 0 | 0 |
| Interleukin-6 family signaling | R-HSA-6783589 | 6.760608e-01 | 0.170 | 0 | 0 |
| Glucagon signaling in metabolic regulation | R-HSA-163359 | 6.815192e-01 | 0.167 | 0 | 0 |
| POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation | R-HSA-2892245 | 6.868315e-01 | 0.163 | 0 | 0 |
| MET activates PI3K/AKT signaling | R-HSA-8851907 | 6.868315e-01 | 0.163 | 0 | 0 |
| IFNG signaling activates MAPKs | R-HSA-9732724 | 6.868315e-01 | 0.163 | 0 | 0 |
| TRIF-mediated programmed cell death | R-HSA-2562578 | 6.868315e-01 | 0.163 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression linked to triglyceride lipolysis in adipose | R-HSA-9031528 | 6.868315e-01 | 0.163 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression to limit cholesterol uptake | R-HSA-9031525 | 6.868315e-01 | 0.163 | 0 | 0 |
| Insulin effects increased synthesis of Xylulose-5-Phosphate | R-HSA-163754 | 6.868315e-01 | 0.163 | 0 | 0 |
| Activated NTRK2 signals through CDK5 | R-HSA-9032845 | 6.868315e-01 | 0.163 | 0 | 0 |
| VLDL clearance | R-HSA-8964046 | 6.868315e-01 | 0.163 | 0 | 0 |
| Synthesis of PIPs in the nucleus | R-HSA-8847453 | 6.868315e-01 | 0.163 | 0 | 0 |
| LDL remodeling | R-HSA-8964041 | 6.868315e-01 | 0.163 | 0 | 0 |
| Netrin mediated repulsion signals | R-HSA-418886 | 6.868315e-01 | 0.163 | 0 | 0 |
| Defective HLCS causes multiple carboxylase deficiency | R-HSA-3371599 | 6.868315e-01 | 0.163 | 0 | 0 |
| Nef Mediated CD4 Down-regulation | R-HSA-167590 | 6.868315e-01 | 0.163 | 0 | 0 |
| Cytosolic tRNA aminoacylation | R-HSA-379716 | 6.881476e-01 | 0.162 | 0 | 0 |
| Protein localization | R-HSA-9609507 | 6.924131e-01 | 0.160 | 0 | 0 |
| Neurexins and neuroligins | R-HSA-6794361 | 6.951330e-01 | 0.158 | 0 | 0 |
| G protein gated Potassium channels | R-HSA-1296059 | 6.971762e-01 | 0.157 | 0 | 0 |
| Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits | R-HSA-997272 | 6.971762e-01 | 0.157 | 0 | 0 |
| Activation of G protein gated Potassium channels | R-HSA-1296041 | 6.971762e-01 | 0.157 | 0 | 0 |
| Tight junction interactions | R-HSA-420029 | 6.971762e-01 | 0.157 | 0 | 0 |
| Laminin interactions | R-HSA-3000157 | 6.971762e-01 | 0.157 | 0 | 0 |
| Hyaluronan degradation | R-HSA-2160916 | 6.971762e-01 | 0.157 | 0 | 0 |
| PIWI-interacting RNA (piRNA) biogenesis | R-HSA-5601884 | 6.971762e-01 | 0.157 | 0 | 0 |
| Antigen Presentation: Folding, assembly and peptide loading of class I MHC | R-HSA-983170 | 6.997987e-01 | 0.155 | 0 | 0 |
| Hyaluronan metabolism | R-HSA-2142845 | 6.997987e-01 | 0.155 | 0 | 0 |
| TRAF3-dependent IRF activation pathway | R-HSA-918233 | 6.998071e-01 | 0.155 | 0 | 0 |
| mRNA decay by 5' to 3' exoribonuclease | R-HSA-430039 | 6.998071e-01 | 0.155 | 0 | 0 |
| Glycine degradation | R-HSA-6783984 | 6.998071e-01 | 0.155 | 0 | 0 |
| Fibronectin matrix formation | R-HSA-1566977 | 6.998071e-01 | 0.155 | 0 | 0 |
| Biosynthesis of maresin-like SPMs | R-HSA-9027307 | 6.998071e-01 | 0.155 | 0 | 0 |
| Synthesis, secretion, and inactivation of Glucose-dependent Insulinotropic Polypeptide (GIP) | R-HSA-400511 | 6.998071e-01 | 0.155 | 0 | 0 |
| Response to metal ions | R-HSA-5660526 | 6.998071e-01 | 0.155 | 0 | 0 |
| Regulation of RUNX1 Expression and Activity | R-HSA-8934593 | 7.172304e-01 | 0.144 | 0 | 0 |
| Adrenaline,noradrenaline inhibits insulin secretion | R-HSA-400042 | 7.172304e-01 | 0.144 | 0 | 0 |
| Signaling by FLT3 fusion proteins | R-HSA-9703465 | 7.172304e-01 | 0.144 | 0 | 0 |
| TRP channels | R-HSA-3295583 | 7.172304e-01 | 0.144 | 0 | 0 |
| Glutamate Neurotransmitter Release Cycle | R-HSA-210500 | 7.172304e-01 | 0.144 | 0 | 0 |
| Caspase activation via extrinsic apoptotic signalling pathway | R-HSA-5357769 | 7.172304e-01 | 0.144 | 0 | 0 |
| Netrin-1 signaling | R-HSA-373752 | 7.200889e-01 | 0.143 | 0 | 0 |
| EGFR interacts with phospholipase C-gamma | R-HSA-212718 | 7.211705e-01 | 0.142 | 0 | 0 |
| MET receptor recycling | R-HSA-8875656 | 7.211705e-01 | 0.142 | 0 | 0 |
| Activated NTRK2 signals through PI3K | R-HSA-9028335 | 7.211705e-01 | 0.142 | 0 | 0 |
| Regulation of NPAS4 mRNA translation | R-HSA-9768778 | 7.211705e-01 | 0.142 | 0 | 0 |
| Nef mediated downregulation of MHC class I complex cell surface expression | R-HSA-164940 | 7.211705e-01 | 0.142 | 0 | 0 |
| Toxicity of botulinum toxin type B (botB) | R-HSA-5250958 | 7.211705e-01 | 0.142 | 0 | 0 |
| Negative regulation of activity of TFAP2 (AP-2) family transcription factors | R-HSA-8866904 | 7.211705e-01 | 0.142 | 0 | 0 |
| FGFR1b ligand binding and activation | R-HSA-190370 | 7.211705e-01 | 0.142 | 0 | 0 |
| Fructose biosynthesis | R-HSA-5652227 | 7.211705e-01 | 0.142 | 0 | 0 |
| Interleukin-9 signaling | R-HSA-8985947 | 7.211705e-01 | 0.142 | 0 | 0 |
| ROBO receptors bind AKAP5 | R-HSA-9010642 | 7.211705e-01 | 0.142 | 0 | 0 |
| SLC-mediated bile acid transport | R-HSA-9958517 | 7.211705e-01 | 0.142 | 0 | 0 |
| TGFBR3 PTM regulation | R-HSA-9839383 | 7.211705e-01 | 0.142 | 0 | 0 |
| Alpha-defensins | R-HSA-1462054 | 7.211705e-01 | 0.142 | 0 | 0 |
| Sodium/Proton exchangers | R-HSA-425986 | 7.211705e-01 | 0.142 | 0 | 0 |
| Activated NTRK2 signals through FYN | R-HSA-9032500 | 7.211705e-01 | 0.142 | 0 | 0 |
| Interleukin-23 signaling | R-HSA-9020933 | 7.211705e-01 | 0.142 | 0 | 0 |
| Defective C1GALT1C1 causes TNPS | R-HSA-5083632 | 7.237047e-01 | 0.140 | 0 | 0 |
| Elevation of cytosolic Ca2+ levels | R-HSA-139853 | 7.237047e-01 | 0.140 | 0 | 0 |
| Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters | R-HSA-164938 | 7.237047e-01 | 0.140 | 0 | 0 |
| Adipogenesis | R-HSA-9843745 | 7.251769e-01 | 0.140 | 0 | 0 |
| Transport to the Golgi and subsequent modification | R-HSA-948021 | 7.279352e-01 | 0.138 | 0 | 0 |
| Disorders of transmembrane transporters | R-HSA-5619115 | 7.305321e-01 | 0.136 | 0 | 0 |
| Signaling by FGFR in disease | R-HSA-1226099 | 7.337963e-01 | 0.134 | 0 | 0 |
| Vasopressin regulates renal water homeostasis via Aquaporins | R-HSA-432040 | 7.351564e-01 | 0.134 | 0 | 0 |
| Cristae formation | R-HSA-8949613 | 7.362381e-01 | 0.133 | 0 | 0 |
| Maturation of hRSV A proteins | R-HSA-9828806 | 7.362381e-01 | 0.133 | 0 | 0 |
| Plasma lipoprotein assembly, remodeling, and clearance | R-HSA-174824 | 7.440484e-01 | 0.128 | 0 | 0 |
| Nephron development | R-HSA-9831926 | 7.459730e-01 | 0.127 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9679504 | 7.459730e-01 | 0.127 | 0 | 0 |
| Protein-protein interactions at synapses | R-HSA-6794362 | 7.499748e-01 | 0.125 | 0 | 0 |
| NRAGE signals death through JNK | R-HSA-193648 | 7.511557e-01 | 0.124 | 0 | 0 |
| MAPK1 (ERK2) activation | R-HSA-112411 | 7.517461e-01 | 0.124 | 0 | 0 |
| APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway | R-HSA-5649702 | 7.517461e-01 | 0.124 | 0 | 0 |
| Inactivation of CDC42 and RAC1 | R-HSA-428543 | 7.517461e-01 | 0.124 | 0 | 0 |
| Interleukin-21 signaling | R-HSA-9020958 | 7.517461e-01 | 0.124 | 0 | 0 |
| mRNA Editing | R-HSA-75072 | 7.517461e-01 | 0.124 | 0 | 0 |
| Regulation of signaling by NODAL | R-HSA-1433617 | 7.517461e-01 | 0.124 | 0 | 0 |
| MASTL Facilitates Mitotic Progression | R-HSA-2465910 | 7.517461e-01 | 0.124 | 0 | 0 |
| Regulation of commissural axon pathfinding by SLIT and ROBO | R-HSA-428542 | 7.517461e-01 | 0.124 | 0 | 0 |
| Interleukin-1 processing | R-HSA-448706 | 7.517461e-01 | 0.124 | 0 | 0 |
| Defects in biotin (Btn) metabolism | R-HSA-3323169 | 7.517461e-01 | 0.124 | 0 | 0 |
| Butyrophilin (BTN) family interactions | R-HSA-8851680 | 7.517461e-01 | 0.124 | 0 | 0 |
| Formation of the HIV-1 Early Elongation Complex | R-HSA-167158 | 7.542198e-01 | 0.123 | 0 | 0 |
| Formation of the Early Elongation Complex | R-HSA-113418 | 7.542198e-01 | 0.123 | 0 | 0 |
| Phase 0 - rapid depolarisation | R-HSA-5576892 | 7.542198e-01 | 0.123 | 0 | 0 |
| Inflammasomes | R-HSA-622312 | 7.542198e-01 | 0.123 | 0 | 0 |
| ATF4 activates genes in response to endoplasmic reticulum stress | R-HSA-380994 | 7.542198e-01 | 0.123 | 0 | 0 |
| Dectin-2 family | R-HSA-5621480 | 7.639217e-01 | 0.117 | 0 | 0 |
| tRNA processing | R-HSA-72306 | 7.649294e-01 | 0.116 | 0 | 0 |
| Transcriptional regulation of pluripotent stem cells | R-HSA-452723 | 7.652839e-01 | 0.116 | 0 | 0 |
| PI-3K cascade:FGFR3 | R-HSA-5654710 | 7.666818e-01 | 0.115 | 0 | 0 |
| Impaired BRCA2 binding to PALB2 | R-HSA-9709603 | 7.666818e-01 | 0.115 | 0 | 0 |
| Gastrin-CREB signalling pathway via PKC and MAPK | R-HSA-881907 | 7.666818e-01 | 0.115 | 0 | 0 |
| Signaling by FGFR2 IIIa TM | R-HSA-8851708 | 7.666818e-01 | 0.115 | 0 | 0 |
| mRNA decay by 3' to 5' exoribonuclease | R-HSA-429958 | 7.666818e-01 | 0.115 | 0 | 0 |
| E2F mediated regulation of DNA replication | R-HSA-113510 | 7.666818e-01 | 0.115 | 0 | 0 |
| Impaired BRCA2 binding to RAD51 | R-HSA-9709570 | 7.712004e-01 | 0.113 | 0 | 0 |
| DARPP-32 events | R-HSA-180024 | 7.712004e-01 | 0.113 | 0 | 0 |
| OADH complex synthesizes glutaryl-CoA from 2-OA | R-HSA-9858328 | 7.789704e-01 | 0.108 | 0 | 0 |
| Binding and entry of HIV virion | R-HSA-173107 | 7.789704e-01 | 0.108 | 0 | 0 |
| Activation of PPARGC1A (PGC-1alpha) by phosphorylation | R-HSA-2151209 | 7.789704e-01 | 0.108 | 0 | 0 |
| WNT5A-dependent internalization of FZD2, FZD5 and ROR2 | R-HSA-5140745 | 7.789704e-01 | 0.108 | 0 | 0 |
| Ion influx/efflux at host-pathogen interface | R-HSA-6803544 | 7.789704e-01 | 0.108 | 0 | 0 |
| DNA replication initiation | R-HSA-68952 | 7.789704e-01 | 0.108 | 0 | 0 |
| MECP2 regulates transcription of neuronal ligands | R-HSA-9022702 | 7.789704e-01 | 0.108 | 0 | 0 |
| MAPK3 (ERK1) activation | R-HSA-110056 | 7.789704e-01 | 0.108 | 0 | 0 |
| Defective factor IX causes hemophilia B | R-HSA-9668250 | 7.789704e-01 | 0.108 | 0 | 0 |
| Formation of apoptosome | R-HSA-111458 | 7.789704e-01 | 0.108 | 0 | 0 |
| Regulation of the apoptosome activity | R-HSA-9627069 | 7.789704e-01 | 0.108 | 0 | 0 |
| Maturation of spike protein | R-HSA-9683686 | 7.789704e-01 | 0.108 | 0 | 0 |
| Disease | R-HSA-1643685 | 7.792644e-01 | 0.108 | 0 | 0 |
| Pentose phosphate pathway | R-HSA-71336 | 7.797879e-01 | 0.108 | 0 | 0 |
| RAS processing | R-HSA-9648002 | 7.797879e-01 | 0.108 | 0 | 0 |
| PI-3K cascade:FGFR4 | R-HSA-5654720 | 7.859053e-01 | 0.105 | 0 | 0 |
| Formation of ATP by chemiosmotic coupling | R-HSA-163210 | 7.859053e-01 | 0.105 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to PALB2 loss of function | R-HSA-9701193 | 7.859053e-01 | 0.105 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function | R-HSA-9704646 | 7.859053e-01 | 0.105 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA1 loss of function | R-HSA-9701192 | 7.859053e-01 | 0.105 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function | R-HSA-9704331 | 7.859053e-01 | 0.105 | 0 | 0 |
| VxPx cargo-targeting to cilium | R-HSA-5620916 | 7.859053e-01 | 0.105 | 0 | 0 |
| BBSome-mediated cargo-targeting to cilium | R-HSA-5620922 | 7.859053e-01 | 0.105 | 0 | 0 |
| Creatine metabolism | R-HSA-71288 | 7.859053e-01 | 0.105 | 0 | 0 |
| Energy dependent regulation of mTOR by LKB1-AMPK | R-HSA-380972 | 7.872085e-01 | 0.104 | 0 | 0 |
| DAP12 signaling | R-HSA-2424491 | 7.872085e-01 | 0.104 | 0 | 0 |
| GABA synthesis, release, reuptake and degradation | R-HSA-888590 | 7.872085e-01 | 0.104 | 0 | 0 |
| RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | R-HSA-73779 | 7.935719e-01 | 0.100 | 0 | 0 |
| Interleukin-2 family signaling | R-HSA-451927 | 7.935719e-01 | 0.100 | 0 | 0 |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | R-HSA-381426 | 7.984830e-01 | 0.098 | 0 | 0 |
| Metabolism of polyamines | R-HSA-351202 | 7.992946e-01 | 0.097 | 0 | 0 |
| Neddylation | R-HSA-8951664 | 8.006723e-01 | 0.097 | 0 | 0 |
| Azathioprine ADME | R-HSA-9748787 | 8.016081e-01 | 0.096 | 0 | 0 |
| Molecules associated with elastic fibres | R-HSA-2129379 | 8.022759e-01 | 0.096 | 0 | 0 |
| Regulation of CDH11 mRNA translation by microRNAs | R-HSA-9759811 | 8.032106e-01 | 0.095 | 0 | 0 |
| Signaling by APC mutants | R-HSA-4839744 | 8.032106e-01 | 0.095 | 0 | 0 |
| AXIN missense mutants destabilize the destruction complex | R-HSA-5467340 | 8.032106e-01 | 0.095 | 0 | 0 |
| Truncations of AMER1 destabilize the destruction complex | R-HSA-5467348 | 8.032106e-01 | 0.095 | 0 | 0 |
| APC truncation mutants have impaired AXIN binding | R-HSA-5467337 | 8.032106e-01 | 0.095 | 0 | 0 |
| LGI-ADAM interactions | R-HSA-5682910 | 8.032106e-01 | 0.095 | 0 | 0 |
| vRNA Synthesis | R-HSA-192814 | 8.032106e-01 | 0.095 | 0 | 0 |
| vRNP Assembly | R-HSA-192905 | 8.032106e-01 | 0.095 | 0 | 0 |
| Conjugation of benzoate with glycine | R-HSA-177135 | 8.032106e-01 | 0.095 | 0 | 0 |
| Chylomicron assembly | R-HSA-8963888 | 8.032106e-01 | 0.095 | 0 | 0 |
| Synthesis of PI | R-HSA-1483226 | 8.032106e-01 | 0.095 | 0 | 0 |
| SARS-CoV-2 modulates autophagy | R-HSA-9754560 | 8.032106e-01 | 0.095 | 0 | 0 |
| Dissolution of Fibrin Clot | R-HSA-75205 | 8.032106e-01 | 0.095 | 0 | 0 |
| MyD88 deficiency (TLR2/4) | R-HSA-5602498 | 8.037202e-01 | 0.095 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in apoptosis | R-HSA-9824594 | 8.037202e-01 | 0.095 | 0 | 0 |
| Synthesis, secretion, and deacylation of Ghrelin | R-HSA-422085 | 8.037202e-01 | 0.095 | 0 | 0 |
| Zygotic genome activation (ZGA) | R-HSA-9819196 | 8.037202e-01 | 0.095 | 0 | 0 |
| Regulation of insulin secretion | R-HSA-422356 | 8.107966e-01 | 0.091 | 0 | 0 |
| Inwardly rectifying K+ channels | R-HSA-1296065 | 8.164363e-01 | 0.088 | 0 | 0 |
| Developmental Lineage of Multipotent Pancreatic Progenitor Cells | R-HSA-9937080 | 8.164363e-01 | 0.088 | 0 | 0 |
| RNA Polymerase II HIV Promoter Escape | R-HSA-167162 | 8.190514e-01 | 0.087 | 0 | 0 |
| HIV Transcription Initiation | R-HSA-167161 | 8.190514e-01 | 0.087 | 0 | 0 |
| RNA Polymerase II Transcription Initiation | R-HSA-75953 | 8.190514e-01 | 0.087 | 0 | 0 |
| FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | R-HSA-9615017 | 8.190514e-01 | 0.087 | 0 | 0 |
| IRAK4 deficiency (TLR2/4) | R-HSA-5603041 | 8.202042e-01 | 0.086 | 0 | 0 |
| Mitochondrial protein import | R-HSA-1268020 | 8.205050e-01 | 0.086 | 0 | 0 |
| NCAM signaling for neurite out-growth | R-HSA-375165 | 8.205050e-01 | 0.086 | 0 | 0 |
| Synthesis of PIPs at the plasma membrane | R-HSA-1660499 | 8.205050e-01 | 0.086 | 0 | 0 |
| Heme signaling | R-HSA-9707616 | 8.205050e-01 | 0.086 | 0 | 0 |
| Synthesis of diphthamide-EEF2 | R-HSA-5358493 | 8.247937e-01 | 0.084 | 0 | 0 |
| Phosphorylation of CLOCK, acetylation of BMAL1 (ARNTL) at target gene promoters | R-HSA-9931512 | 8.247937e-01 | 0.084 | 0 | 0 |
| Sensing of DNA Double Strand Breaks | R-HSA-5693548 | 8.247937e-01 | 0.084 | 0 | 0 |
| Plasmalogen biosynthesis | R-HSA-75896 | 8.247937e-01 | 0.084 | 0 | 0 |
| Signaling by AXIN mutants | R-HSA-4839735 | 8.247937e-01 | 0.084 | 0 | 0 |
| Signaling by AMER1 mutants | R-HSA-4839748 | 8.247937e-01 | 0.084 | 0 | 0 |
| Viral RNP Complexes in the Host Cell Nucleus | R-HSA-168330 | 8.247937e-01 | 0.084 | 0 | 0 |
| Cytoprotection by HMOX1 | R-HSA-9707564 | 8.269621e-01 | 0.083 | 0 | 0 |
| Diseases of carbohydrate metabolism | R-HSA-5663084 | 8.280484e-01 | 0.082 | 0 | 0 |
| HDR through Single Strand Annealing (SSA) | R-HSA-5685938 | 8.297254e-01 | 0.081 | 0 | 0 |
| Amino acids regulate mTORC1 | R-HSA-9639288 | 8.346957e-01 | 0.078 | 0 | 0 |
| Late SARS-CoV-2 Infection Events | R-HSA-9772573 | 8.349562e-01 | 0.078 | 0 | 0 |
| PI-3K cascade:FGFR1 | R-HSA-5654689 | 8.354347e-01 | 0.078 | 0 | 0 |
| Fructose metabolism | R-HSA-5652084 | 8.354347e-01 | 0.078 | 0 | 0 |
| LDL clearance | R-HSA-8964038 | 8.354347e-01 | 0.078 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9694676 | 8.354347e-01 | 0.078 | 0 | 0 |
| FCERI mediated NF-kB activation | R-HSA-2871837 | 8.411586e-01 | 0.075 | 0 | 0 |
| RNA Polymerase II Promoter Escape | R-HSA-73776 | 8.418810e-01 | 0.075 | 0 | 0 |
| TBC/RABGAPs | R-HSA-8854214 | 8.418810e-01 | 0.075 | 0 | 0 |
| NFE2L2 regulating anti-oxidant/detoxification enzymes | R-HSA-9818027 | 8.421798e-01 | 0.075 | 0 | 0 |
| NOTCH2 intracellular domain regulates transcription | R-HSA-2197563 | 8.440108e-01 | 0.074 | 0 | 0 |
| Maple Syrup Urine Disease | R-HSA-9865114 | 8.440108e-01 | 0.074 | 0 | 0 |
| Activated NTRK2 signals through FRS2 and FRS3 | R-HSA-9028731 | 8.440108e-01 | 0.074 | 0 | 0 |
| GRB2 events in EGFR signaling | R-HSA-179812 | 8.440108e-01 | 0.074 | 0 | 0 |
| Advanced glycosylation endproduct receptor signaling | R-HSA-879415 | 8.440108e-01 | 0.074 | 0 | 0 |
| Serotonin clearance from the synaptic cleft | R-HSA-380615 | 8.440108e-01 | 0.074 | 0 | 0 |
| Conjugation of salicylate with glycine | R-HSA-177128 | 8.440108e-01 | 0.074 | 0 | 0 |
| Signaling by LTK | R-HSA-9842663 | 8.440108e-01 | 0.074 | 0 | 0 |
| Trafficking and processing of endosomal TLR | R-HSA-1679131 | 8.440108e-01 | 0.074 | 0 | 0 |
| Erythrocytes take up oxygen and release carbon dioxide | R-HSA-1247673 | 8.440108e-01 | 0.074 | 0 | 0 |
| OAS antiviral response | R-HSA-8983711 | 8.440108e-01 | 0.074 | 0 | 0 |
| Integration of energy metabolism | R-HSA-163685 | 8.458930e-01 | 0.073 | 0 | 0 |
| Regulation of PTEN mRNA translation | R-HSA-8943723 | 8.494885e-01 | 0.071 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE | R-HSA-77075 | 8.494885e-01 | 0.071 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | R-HSA-167160 | 8.494885e-01 | 0.071 | 0 | 0 |
| Termination of O-glycan biosynthesis | R-HSA-977068 | 8.494885e-01 | 0.071 | 0 | 0 |
| Biosynthesis of maresins | R-HSA-9018682 | 8.494885e-01 | 0.071 | 0 | 0 |
| Interleukin-20 family signaling | R-HSA-8854691 | 8.494885e-01 | 0.071 | 0 | 0 |
| NPAS4 regulates expression of target genes | R-HSA-9768919 | 8.538370e-01 | 0.069 | 0 | 0 |
| Diseases of DNA Double-Strand Break Repair | R-HSA-9675136 | 8.538370e-01 | 0.069 | 0 | 0 |
| eNOS activation | R-HSA-203615 | 8.538370e-01 | 0.069 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA2 loss of function | R-HSA-9701190 | 8.538370e-01 | 0.069 | 0 | 0 |
| BMAL1:CLOCK,NPAS2 activates circadian expression | R-HSA-1368108 | 8.538370e-01 | 0.069 | 0 | 0 |
| Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation | R-HSA-163841 | 8.592539e-01 | 0.066 | 0 | 0 |
| PDH complex synthesizes acetyl-CoA from PYR | R-HSA-9861559 | 8.611211e-01 | 0.065 | 0 | 0 |
| OGDH complex synthesizes succinyl-CoA from 2-OG | R-HSA-9853506 | 8.611211e-01 | 0.065 | 0 | 0 |
| Processing of SMDT1 | R-HSA-8949664 | 8.611211e-01 | 0.065 | 0 | 0 |
| CREB1 phosphorylation through the activation of Adenylate Cyclase | R-HSA-442720 | 8.611211e-01 | 0.065 | 0 | 0 |
| FGFR1c ligand binding and activation | R-HSA-190373 | 8.611211e-01 | 0.065 | 0 | 0 |
| NFE2L2 regulating tumorigenic genes | R-HSA-9818030 | 8.611211e-01 | 0.065 | 0 | 0 |
| RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs) | R-HSA-8877330 | 8.611211e-01 | 0.065 | 0 | 0 |
| SLC transporter disorders | R-HSA-5619102 | 8.616571e-01 | 0.065 | 0 | 0 |
| NR1H2 and NR1H3-mediated signaling | R-HSA-9024446 | 8.618301e-01 | 0.065 | 0 | 0 |
| RNA Polymerase II Transcription Initiation And Promoter Clearance | R-HSA-76042 | 8.622378e-01 | 0.064 | 0 | 0 |
| ADORA2B mediated anti-inflammatory cytokines production | R-HSA-9660821 | 8.622378e-01 | 0.064 | 0 | 0 |
| Translocation of ZAP-70 to Immunological synapse | R-HSA-202430 | 8.624404e-01 | 0.064 | 0 | 0 |
| Complex III assembly | R-HSA-9865881 | 8.624404e-01 | 0.064 | 0 | 0 |
| Presynaptic phase of homologous DNA pairing and strand exchange | R-HSA-5693616 | 8.647346e-01 | 0.063 | 0 | 0 |
| Cardiac conduction | R-HSA-5576891 | 8.691956e-01 | 0.061 | 0 | 0 |
| Parasite infection | R-HSA-9664407 | 8.695972e-01 | 0.061 | 0 | 0 |
| Leishmania phagocytosis | R-HSA-9664417 | 8.695972e-01 | 0.061 | 0 | 0 |
| FCGR3A-mediated phagocytosis | R-HSA-9664422 | 8.695972e-01 | 0.061 | 0 | 0 |
| Diseases of DNA repair | R-HSA-9675135 | 8.715470e-01 | 0.060 | 0 | 0 |
| Inactivation, recovery and regulation of the phototransduction cascade | R-HSA-2514859 | 8.715470e-01 | 0.060 | 0 | 0 |
| PI-3K cascade:FGFR2 | R-HSA-5654695 | 8.743629e-01 | 0.058 | 0 | 0 |
| Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) | R-HSA-5693554 | 8.743629e-01 | 0.058 | 0 | 0 |
| Acyl chain remodelling of PS | R-HSA-1482801 | 8.743629e-01 | 0.058 | 0 | 0 |
| Synthesis of PIPs at the early endosome membrane | R-HSA-1660516 | 8.743629e-01 | 0.058 | 0 | 0 |
| MicroRNA (miRNA) biogenesis | R-HSA-203927 | 8.743629e-01 | 0.058 | 0 | 0 |
| Regulation of actin dynamics for phagocytic cup formation | R-HSA-2029482 | 8.750506e-01 | 0.058 | 0 | 0 |
| BCKDH synthesizes BCAA-CoA from KIC, KMVA, KIV | R-HSA-9859138 | 8.763555e-01 | 0.057 | 0 | 0 |
| Beta oxidation of hexanoyl-CoA to butanoyl-CoA | R-HSA-77350 | 8.763555e-01 | 0.057 | 0 | 0 |
| Beta oxidation of octanoyl-CoA to hexanoyl-CoA | R-HSA-77348 | 8.763555e-01 | 0.057 | 0 | 0 |
| Beta oxidation of lauroyl-CoA to decanoyl-CoA-CoA | R-HSA-77310 | 8.763555e-01 | 0.057 | 0 | 0 |
| Physiological factors | R-HSA-5578768 | 8.763555e-01 | 0.057 | 0 | 0 |
| Respiratory syncytial virus genome transcription | R-HSA-9828642 | 8.763555e-01 | 0.057 | 0 | 0 |
| Non-canonical inflammasome activation | R-HSA-9686114 | 8.763555e-01 | 0.057 | 0 | 0 |
| NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | R-HSA-9029569 | 8.797052e-01 | 0.056 | 0 | 0 |
| Transmission across Chemical Synapses | R-HSA-112315 | 8.815327e-01 | 0.055 | 0 | 0 |
| Voltage gated Potassium channels | R-HSA-1296072 | 8.844009e-01 | 0.053 | 0 | 0 |
| Diseases of branched-chain amino acid catabolism | R-HSA-9865118 | 8.853260e-01 | 0.053 | 0 | 0 |
| Synthesis of PIPs at the Golgi membrane | R-HSA-1660514 | 8.853260e-01 | 0.053 | 0 | 0 |
| Urea cycle | R-HSA-70635 | 8.853260e-01 | 0.053 | 0 | 0 |
| SHC1 events in EGFR signaling | R-HSA-180336 | 8.899195e-01 | 0.051 | 0 | 0 |
| RNA Polymerase III Chain Elongation | R-HSA-73780 | 8.899195e-01 | 0.051 | 0 | 0 |
| Telomere C-strand synthesis initiation | R-HSA-174430 | 8.899195e-01 | 0.051 | 0 | 0 |
| Protein lipoylation | R-HSA-9857492 | 8.899195e-01 | 0.051 | 0 | 0 |
| Beta oxidation of butanoyl-CoA to acetyl-CoA | R-HSA-77352 | 8.899195e-01 | 0.051 | 0 | 0 |
| Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | R-HSA-9673767 | 8.899195e-01 | 0.051 | 0 | 0 |
| Signaling by PDGFRA extracellular domain mutants | R-HSA-9673770 | 8.899195e-01 | 0.051 | 0 | 0 |
| Other semaphorin interactions | R-HSA-416700 | 8.899195e-01 | 0.051 | 0 | 0 |
| Homologous DNA Pairing and Strand Exchange | R-HSA-5693579 | 8.932436e-01 | 0.049 | 0 | 0 |
| Elastic fibre formation | R-HSA-1566948 | 8.932436e-01 | 0.049 | 0 | 0 |
| Sphingolipid de novo biosynthesis | R-HSA-1660661 | 8.945386e-01 | 0.048 | 0 | 0 |
| Signaling by FGFR3 in disease | R-HSA-5655332 | 8.953967e-01 | 0.048 | 0 | 0 |
| Insulin processing | R-HSA-264876 | 8.953967e-01 | 0.048 | 0 | 0 |
| Metabolism of proteins | R-HSA-392499 | 8.974788e-01 | 0.047 | 0 | 0 |
| IRS-related events triggered by IGF1R | R-HSA-2428928 | 9.013436e-01 | 0.045 | 0 | 0 |
| Aquaporin-mediated transport | R-HSA-445717 | 9.013436e-01 | 0.045 | 0 | 0 |
| Entry of Influenza Virion into Host Cell via Endocytosis | R-HSA-168275 | 9.019962e-01 | 0.045 | 0 | 0 |
| Atorvastatin ADME | R-HSA-9754706 | 9.019962e-01 | 0.045 | 0 | 0 |
| Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion | R-HSA-434316 | 9.019962e-01 | 0.045 | 0 | 0 |
| Fructose catabolism | R-HSA-70350 | 9.019962e-01 | 0.045 | 0 | 0 |
| Differentiation of T cells | R-HSA-9945266 | 9.019962e-01 | 0.045 | 0 | 0 |
| Differentiation of naive CD+ T cells to T helper 1 cells (Th1 cells) | R-HSA-9942503 | 9.019962e-01 | 0.045 | 0 | 0 |
| Carnitine synthesis | R-HSA-71262 | 9.019962e-01 | 0.045 | 0 | 0 |
| Caspase activation via Death Receptors in the presence of ligand | R-HSA-140534 | 9.019962e-01 | 0.045 | 0 | 0 |
| Attachment and Entry | R-HSA-9678110 | 9.019962e-01 | 0.045 | 0 | 0 |
| Signaling by FGFR2 in disease | R-HSA-5655253 | 9.035440e-01 | 0.044 | 0 | 0 |
| PI3K Cascade | R-HSA-109704 | 9.035440e-01 | 0.044 | 0 | 0 |
| Signaling by Insulin receptor | R-HSA-74752 | 9.039237e-01 | 0.044 | 0 | 0 |
| Signaling by PDGF | R-HSA-186797 | 9.077634e-01 | 0.042 | 0 | 0 |
| Mitochondrial tRNA aminoacylation | R-HSA-379726 | 9.091272e-01 | 0.041 | 0 | 0 |
| The phototransduction cascade | R-HSA-2514856 | 9.103512e-01 | 0.041 | 0 | 0 |
| POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation | R-HSA-2892247 | 9.127487e-01 | 0.040 | 0 | 0 |
| Transcriptional regulation of testis differentiation | R-HSA-9690406 | 9.127487e-01 | 0.040 | 0 | 0 |
| Passive transport by Aquaporins | R-HSA-432047 | 9.127487e-01 | 0.040 | 0 | 0 |
| Beta oxidation of decanoyl-CoA to octanoyl-CoA-CoA | R-HSA-77346 | 9.127487e-01 | 0.040 | 0 | 0 |
| Synthesis of PG | R-HSA-1483148 | 9.127487e-01 | 0.040 | 0 | 0 |
| Galactose catabolism | R-HSA-70370 | 9.127487e-01 | 0.040 | 0 | 0 |
| Coenzyme A biosynthesis | R-HSA-196783 | 9.127487e-01 | 0.040 | 0 | 0 |
| Defects of contact activation system (CAS) and kallikrein/kinin system (KKS) | R-HSA-9651496 | 9.127487e-01 | 0.040 | 0 | 0 |
| mRNA Capping | R-HSA-72086 | 9.131127e-01 | 0.039 | 0 | 0 |
| Downstream signaling of activated FGFR3 | R-HSA-5654708 | 9.131127e-01 | 0.039 | 0 | 0 |
| Purine ribonucleoside monophosphate biosynthesis | R-HSA-73817 | 9.162369e-01 | 0.038 | 0 | 0 |
| Transcriptional Regulation by NPAS4 | R-HSA-9634815 | 9.167274e-01 | 0.038 | 0 | 0 |
| Insulin receptor signalling cascade | R-HSA-74751 | 9.195140e-01 | 0.036 | 0 | 0 |
| IGF1R signaling cascade | R-HSA-2428924 | 9.195140e-01 | 0.036 | 0 | 0 |
| Downstream signaling of activated FGFR4 | R-HSA-5654716 | 9.208758e-01 | 0.036 | 0 | 0 |
| Synthesis of PIPs at the late endosome membrane | R-HSA-1660517 | 9.223220e-01 | 0.035 | 0 | 0 |
| Regulation of NPAS4 gene expression | R-HSA-9768759 | 9.223220e-01 | 0.035 | 0 | 0 |
| Metabolism of ingested H2SeO4 and H2SeO3 into H2Se | R-HSA-2408550 | 9.223220e-01 | 0.035 | 0 | 0 |
| Choline catabolism | R-HSA-6798163 | 9.223220e-01 | 0.035 | 0 | 0 |
| Uptake and function of anthrax toxins | R-HSA-5210891 | 9.223220e-01 | 0.035 | 0 | 0 |
| Nucleotide biosynthesis | R-HSA-8956320 | 9.226949e-01 | 0.035 | 0 | 0 |
| Scavenging by Class A Receptors | R-HSA-3000480 | 9.228358e-01 | 0.035 | 0 | 0 |
| Formation of the cornified envelope | R-HSA-6809371 | 9.240569e-01 | 0.034 | 0 | 0 |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | R-HSA-2404192 | 9.248776e-01 | 0.034 | 0 | 0 |
| Transcriptional regulation of white adipocyte differentiation | R-HSA-381340 | 9.279251e-01 | 0.032 | 0 | 0 |
| Respiratory syncytial virus (RSV) attachment and entry | R-HSA-9820960 | 9.279820e-01 | 0.032 | 0 | 0 |
| Activation of GABAB receptors | R-HSA-991365 | 9.289554e-01 | 0.032 | 0 | 0 |
| GABA B receptor activation | R-HSA-977444 | 9.289554e-01 | 0.032 | 0 | 0 |
| Incretin synthesis, secretion, and inactivation | R-HSA-400508 | 9.289554e-01 | 0.032 | 0 | 0 |
| Leishmania infection | R-HSA-9658195 | 9.299531e-01 | 0.032 | 0 | 0 |
| Parasitic Infection Pathways | R-HSA-9824443 | 9.299531e-01 | 0.032 | 0 | 0 |
| Cytosolic iron-sulfur cluster assembly | R-HSA-2564830 | 9.308454e-01 | 0.031 | 0 | 0 |
| Synaptic adhesion-like molecules | R-HSA-8849932 | 9.308454e-01 | 0.031 | 0 | 0 |
| PKA activation | R-HSA-163615 | 9.308454e-01 | 0.031 | 0 | 0 |
| PKA activation in glucagon signalling | R-HSA-164378 | 9.308454e-01 | 0.031 | 0 | 0 |
| FGFR1 ligand binding and activation | R-HSA-190242 | 9.308454e-01 | 0.031 | 0 | 0 |
| Organic anion transport by SLC5/17/25 transporters | R-HSA-428643 | 9.308454e-01 | 0.031 | 0 | 0 |
| Vitamin D (calciferol) metabolism | R-HSA-196791 | 9.308454e-01 | 0.031 | 0 | 0 |
| Metabolism of carbohydrates and carbohydrate derivatives | R-HSA-71387 | 9.326511e-01 | 0.030 | 0 | 0 |
| Paracetamol ADME | R-HSA-9753281 | 9.334896e-01 | 0.030 | 0 | 0 |
| Signaling by WNT in cancer | R-HSA-4791275 | 9.344820e-01 | 0.029 | 0 | 0 |
| Mitochondrial biogenesis | R-HSA-1592230 | 9.372632e-01 | 0.028 | 0 | 0 |
| Pyrimidine biosynthesis | R-HSA-500753 | 9.384340e-01 | 0.028 | 0 | 0 |
| Specification of the neural plate border | R-HSA-9834899 | 9.384340e-01 | 0.028 | 0 | 0 |
| Conjugation of carboxylic acids | R-HSA-159424 | 9.384340e-01 | 0.028 | 0 | 0 |
| Amino Acid conjugation | R-HSA-156587 | 9.384340e-01 | 0.028 | 0 | 0 |
| O2/CO2 exchange in erythrocytes | R-HSA-1480926 | 9.384340e-01 | 0.028 | 0 | 0 |
| Methionine salvage pathway | R-HSA-1237112 | 9.384340e-01 | 0.028 | 0 | 0 |
| Diseases of hemostasis | R-HSA-9671793 | 9.384340e-01 | 0.028 | 0 | 0 |
| Erythrocytes take up carbon dioxide and release oxygen | R-HSA-1237044 | 9.384340e-01 | 0.028 | 0 | 0 |
| DAP12 interactions | R-HSA-2172127 | 9.398759e-01 | 0.027 | 0 | 0 |
| Amine ligand-binding receptors | R-HSA-375280 | 9.398759e-01 | 0.027 | 0 | 0 |
| Resolution of D-loop Structures through Holliday Junction Intermediates | R-HSA-5693568 | 9.404232e-01 | 0.027 | 0 | 0 |
| Synthesis of IP3 and IP4 in the cytosol | R-HSA-1855204 | 9.404232e-01 | 0.027 | 0 | 0 |
| Class I MHC mediated antigen processing & presentation | R-HSA-983169 | 9.421896e-01 | 0.026 | 0 | 0 |
| IRS-mediated signalling | R-HSA-112399 | 9.428999e-01 | 0.026 | 0 | 0 |
| Transcriptional activation of mitochondrial biogenesis | R-HSA-2151201 | 9.448789e-01 | 0.025 | 0 | 0 |
| Wax and plasmalogen biosynthesis | R-HSA-8848584 | 9.451903e-01 | 0.024 | 0 | 0 |
| Signaling by NODAL | R-HSA-1181150 | 9.451903e-01 | 0.024 | 0 | 0 |
| Common Pathway of Fibrin Clot Formation | R-HSA-140875 | 9.451903e-01 | 0.024 | 0 | 0 |
| Pregnenolone biosynthesis | R-HSA-196108 | 9.451903e-01 | 0.024 | 0 | 0 |
| Resolution of D-Loop Structures | R-HSA-5693537 | 9.458499e-01 | 0.024 | 0 | 0 |
| Miscellaneous transport and binding events | R-HSA-5223345 | 9.458499e-01 | 0.024 | 0 | 0 |
| Effects of PIP2 hydrolysis | R-HSA-114508 | 9.458499e-01 | 0.024 | 0 | 0 |
| Purinergic signaling in leishmaniasis infection | R-HSA-9660826 | 9.492235e-01 | 0.023 | 0 | 0 |
| Cell recruitment (pro-inflammatory response) | R-HSA-9664424 | 9.492235e-01 | 0.023 | 0 | 0 |
| FCERI mediated MAPK activation | R-HSA-2871796 | 9.495501e-01 | 0.022 | 0 | 0 |
| Infection with Mycobacterium tuberculosis | R-HSA-9635486 | 9.497993e-01 | 0.022 | 0 | 0 |
| Post-translational protein modification | R-HSA-597592 | 9.498722e-01 | 0.022 | 0 | 0 |
| Regulation of TLR by endogenous ligand | R-HSA-5686938 | 9.508034e-01 | 0.022 | 0 | 0 |
| TNFR1-induced proapoptotic signaling | R-HSA-5357786 | 9.512055e-01 | 0.022 | 0 | 0 |
| PKA-mediated phosphorylation of CREB | R-HSA-111931 | 9.512055e-01 | 0.022 | 0 | 0 |
| Intrinsic Pathway of Fibrin Clot Formation | R-HSA-140837 | 9.512055e-01 | 0.022 | 0 | 0 |
| Phenylalanine metabolism | R-HSA-8964208 | 9.512055e-01 | 0.022 | 0 | 0 |
| Abacavir metabolism | R-HSA-2161541 | 9.512055e-01 | 0.022 | 0 | 0 |
| Extracellular matrix organization | R-HSA-1474244 | 9.525321e-01 | 0.021 | 0 | 0 |
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | R-HSA-983695 | 9.535072e-01 | 0.021 | 0 | 0 |
| Antigen processing: Ubiquitination & Proteasome degradation | R-HSA-983168 | 9.537225e-01 | 0.021 | 0 | 0 |
| Downstream signaling of activated FGFR2 | R-HSA-5654696 | 9.553224e-01 | 0.020 | 0 | 0 |
| Downstream signaling of activated FGFR1 | R-HSA-5654687 | 9.553224e-01 | 0.020 | 0 | 0 |
| Mitochondrial protein degradation | R-HSA-9837999 | 9.564319e-01 | 0.019 | 0 | 0 |
| FRS-mediated FGFR3 signaling | R-HSA-5654706 | 9.565608e-01 | 0.019 | 0 | 0 |
| Molybdenum cofactor biosynthesis | R-HSA-947581 | 9.565608e-01 | 0.019 | 0 | 0 |
| Glutathione synthesis and recycling | R-HSA-174403 | 9.565608e-01 | 0.019 | 0 | 0 |
| Attachment and Entry | R-HSA-9694614 | 9.565608e-01 | 0.019 | 0 | 0 |
| Developmental Cell Lineages of the Exocrine Pancreas | R-HSA-9820448 | 9.567859e-01 | 0.019 | 0 | 0 |
| Metal ion SLC transporters | R-HSA-425410 | 9.572017e-01 | 0.019 | 0 | 0 |
| Formation of Fibrin Clot (Clotting Cascade) | R-HSA-140877 | 9.594423e-01 | 0.018 | 0 | 0 |
| Triglyceride catabolism | R-HSA-163560 | 9.594423e-01 | 0.018 | 0 | 0 |
| FGFR2 mutant receptor activation | R-HSA-1839126 | 9.594423e-01 | 0.018 | 0 | 0 |
| FRS-mediated FGFR4 signaling | R-HSA-5654712 | 9.613287e-01 | 0.017 | 0 | 0 |
| WNT ligand biogenesis and trafficking | R-HSA-3238698 | 9.613287e-01 | 0.017 | 0 | 0 |
| Ethanol oxidation | R-HSA-71384 | 9.613287e-01 | 0.017 | 0 | 0 |
| Cholesterol biosynthesis via lathosterol | R-HSA-6807062 | 9.613287e-01 | 0.017 | 0 | 0 |
| TRAF6 mediated IRF7 activation | R-HSA-933541 | 9.631964e-01 | 0.016 | 0 | 0 |
| Metabolism of folate and pterines | R-HSA-196757 | 9.631964e-01 | 0.016 | 0 | 0 |
| Cell surface interactions at the vascular wall | R-HSA-202733 | 9.634642e-01 | 0.016 | 0 | 0 |
| Free fatty acids regulate insulin secretion | R-HSA-400451 | 9.655735e-01 | 0.015 | 0 | 0 |
| Interleukin receptor SHC signaling | R-HSA-912526 | 9.655735e-01 | 0.015 | 0 | 0 |
| Formation of the ureteric bud | R-HSA-9830674 | 9.655735e-01 | 0.015 | 0 | 0 |
| Synthesis of UDP-N-acetyl-glucosamine | R-HSA-446210 | 9.655735e-01 | 0.015 | 0 | 0 |
| Carnitine shuttle | R-HSA-200425 | 9.655735e-01 | 0.015 | 0 | 0 |
| ABC transporters in lipid homeostasis | R-HSA-1369062 | 9.655735e-01 | 0.015 | 0 | 0 |
| CYP2E1 reactions | R-HSA-211999 | 9.693526e-01 | 0.014 | 0 | 0 |
| Assembly of active LPL and LIPC lipase complexes | R-HSA-8963889 | 9.693526e-01 | 0.014 | 0 | 0 |
| Plasma lipoprotein assembly | R-HSA-8963898 | 9.693526e-01 | 0.014 | 0 | 0 |
| Mitochondrial RNA degradation | R-HSA-9836573 | 9.693526e-01 | 0.014 | 0 | 0 |
| Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) | R-HSA-381771 | 9.697274e-01 | 0.013 | 0 | 0 |
| Metabolism of amino acids and derivatives | R-HSA-71291 | 9.716916e-01 | 0.012 | 0 | 0 |
| FRS-mediated FGFR1 signaling | R-HSA-5654693 | 9.727170e-01 | 0.012 | 0 | 0 |
| Formation of the nephric duct | R-HSA-9830364 | 9.727170e-01 | 0.012 | 0 | 0 |
| Kidney development | R-HSA-9830369 | 9.741281e-01 | 0.011 | 0 | 0 |
| Maturation of spike protein | R-HSA-9694548 | 9.751336e-01 | 0.011 | 0 | 0 |
| Phosphorylated BMAL1:CLOCK (ARNTL:CLOCK) activates expression of core clock genes | R-HSA-9931510 | 9.757123e-01 | 0.011 | 0 | 0 |
| Sphingolipid catabolism | R-HSA-9845614 | 9.757123e-01 | 0.011 | 0 | 0 |
| Abacavir ADME | R-HSA-2161522 | 9.757123e-01 | 0.011 | 0 | 0 |
| PI Metabolism | R-HSA-1483255 | 9.761629e-01 | 0.010 | 0 | 0 |
| Leishmania parasite growth and survival | R-HSA-9664433 | 9.762384e-01 | 0.010 | 0 | 0 |
| Anti-inflammatory response favouring Leishmania parasite infection | R-HSA-9662851 | 9.762384e-01 | 0.010 | 0 | 0 |
| Neuronal System | R-HSA-112316 | 9.765382e-01 | 0.010 | 0 | 0 |
| Intra-Golgi traffic | R-HSA-6811438 | 9.774740e-01 | 0.010 | 0 | 0 |
| Signaling by BMP | R-HSA-201451 | 9.783789e-01 | 0.009 | 0 | 0 |
| FCGR activation | R-HSA-2029481 | 9.793649e-01 | 0.009 | 0 | 0 |
| COPII-mediated vesicle transport | R-HSA-204005 | 9.797675e-01 | 0.009 | 0 | 0 |
| Fatty acyl-CoA biosynthesis | R-HSA-75105 | 9.797675e-01 | 0.009 | 0 | 0 |
| FRS-mediated FGFR2 signaling | R-HSA-5654700 | 9.807529e-01 | 0.008 | 0 | 0 |
| Pyrimidine salvage | R-HSA-73614 | 9.807529e-01 | 0.008 | 0 | 0 |
| Prednisone ADME | R-HSA-9757110 | 9.807529e-01 | 0.008 | 0 | 0 |
| Regulation of lipid metabolism by PPARalpha | R-HSA-400206 | 9.821476e-01 | 0.008 | 0 | 0 |
| Early SARS-CoV-2 Infection Events | R-HSA-9772572 | 9.822558e-01 | 0.008 | 0 | 0 |
| Thyroxine biosynthesis | R-HSA-209968 | 9.828663e-01 | 0.008 | 0 | 0 |
| Regulation of pyruvate dehydrogenase (PDH) complex | R-HSA-204174 | 9.828663e-01 | 0.008 | 0 | 0 |
| Methylation | R-HSA-156581 | 9.832847e-01 | 0.007 | 0 | 0 |
| Assembly of collagen fibrils and other multimeric structures | R-HSA-2022090 | 9.837853e-01 | 0.007 | 0 | 0 |
| RAB GEFs exchange GTP for GDP on RABs | R-HSA-8876198 | 9.841702e-01 | 0.007 | 0 | 0 |
| Aspirin ADME | R-HSA-9749641 | 9.842320e-01 | 0.007 | 0 | 0 |
| Rab regulation of trafficking | R-HSA-9007101 | 9.843162e-01 | 0.007 | 0 | 0 |
| Potassium Channels | R-HSA-1296071 | 9.846350e-01 | 0.007 | 0 | 0 |
| Neurotransmitter clearance | R-HSA-112311 | 9.847478e-01 | 0.007 | 0 | 0 |
| Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | R-HSA-1474151 | 9.847478e-01 | 0.007 | 0 | 0 |
| GABA receptor activation | R-HSA-977443 | 9.851881e-01 | 0.006 | 0 | 0 |
| Cargo concentration in the ER | R-HSA-5694530 | 9.864227e-01 | 0.006 | 0 | 0 |
| Synthesis of PC | R-HSA-1483191 | 9.876278e-01 | 0.005 | 0 | 0 |
| Plasma lipoprotein remodeling | R-HSA-8963899 | 9.888142e-01 | 0.005 | 0 | 0 |
| Diseases associated with glycosylation precursor biosynthesis | R-HSA-5609975 | 9.892413e-01 | 0.005 | 0 | 0 |
| Recycling of bile acids and salts | R-HSA-159418 | 9.892413e-01 | 0.005 | 0 | 0 |
| Class B/2 (Secretin family receptors) | R-HSA-373080 | 9.893533e-01 | 0.005 | 0 | 0 |
| Xenobiotics | R-HSA-211981 | 9.897200e-01 | 0.004 | 0 | 0 |
| Chemokine receptors bind chemokines | R-HSA-380108 | 9.898893e-01 | 0.004 | 0 | 0 |
| Glyoxylate metabolism and glycine degradation | R-HSA-389661 | 9.898893e-01 | 0.004 | 0 | 0 |
| PPARA activates gene expression | R-HSA-1989781 | 9.899413e-01 | 0.004 | 0 | 0 |
| Acyl chain remodelling of PC | R-HSA-1482788 | 9.904230e-01 | 0.004 | 0 | 0 |
| Vitamin B5 (pantothenate) metabolism | R-HSA-199220 | 9.904230e-01 | 0.004 | 0 | 0 |
| Heme degradation | R-HSA-189483 | 9.904230e-01 | 0.004 | 0 | 0 |
| tRNA modification in the nucleus and cytosol | R-HSA-6782315 | 9.914517e-01 | 0.004 | 0 | 0 |
| Glycosaminoglycan-protein linkage region biosynthesis | R-HSA-1971475 | 9.914750e-01 | 0.004 | 0 | 0 |
| RA biosynthesis pathway | R-HSA-5365859 | 9.914750e-01 | 0.004 | 0 | 0 |
| Branched-chain amino acid catabolism | R-HSA-70895 | 9.917454e-01 | 0.004 | 0 | 0 |
| Complex IV assembly | R-HSA-9864848 | 9.917454e-01 | 0.004 | 0 | 0 |
| FCGR3A-mediated IL10 synthesis | R-HSA-9664323 | 9.921765e-01 | 0.003 | 0 | 0 |
| Acyl chain remodelling of PE | R-HSA-1482839 | 9.924114e-01 | 0.003 | 0 | 0 |
| Metabolism of ingested SeMet, Sec, MeSec into H2Se | R-HSA-2408508 | 9.924114e-01 | 0.003 | 0 | 0 |
| Defects in vitamin and cofactor metabolism | R-HSA-3296482 | 9.924114e-01 | 0.003 | 0 | 0 |
| G alpha (s) signalling events | R-HSA-418555 | 9.928386e-01 | 0.003 | 0 | 0 |
| Collagen formation | R-HSA-1474290 | 9.928981e-01 | 0.003 | 0 | 0 |
| Collagen biosynthesis and modifying enzymes | R-HSA-1650814 | 9.929000e-01 | 0.003 | 0 | 0 |
| Glycosphingolipid transport | R-HSA-9845576 | 9.932451e-01 | 0.003 | 0 | 0 |
| Lysine catabolism | R-HSA-71064 | 9.939872e-01 | 0.003 | 0 | 0 |
| NCAM1 interactions | R-HSA-419037 | 9.939872e-01 | 0.003 | 0 | 0 |
| Phenylalanine and tyrosine metabolism | R-HSA-8963691 | 9.939872e-01 | 0.003 | 0 | 0 |
| Collagen chain trimerization | R-HSA-8948216 | 9.939872e-01 | 0.003 | 0 | 0 |
| tRNA processing in the mitochondrion | R-HSA-6785470 | 9.946478e-01 | 0.002 | 0 | 0 |
| Purine salvage | R-HSA-74217 | 9.946478e-01 | 0.002 | 0 | 0 |
| rRNA processing in the mitochondrion | R-HSA-8868766 | 9.957594e-01 | 0.002 | 0 | 0 |
| Metabolism of nucleotides | R-HSA-15869 | 9.957720e-01 | 0.002 | 0 | 0 |
| ROS and RNS production in phagocytes | R-HSA-1222556 | 9.959581e-01 | 0.002 | 0 | 0 |
| Aflatoxin activation and detoxification | R-HSA-5423646 | 9.962254e-01 | 0.002 | 0 | 0 |
| Triglyceride metabolism | R-HSA-8979227 | 9.963639e-01 | 0.002 | 0 | 0 |
| SLC-mediated transport of neurotransmitters | R-HSA-442660 | 9.966402e-01 | 0.001 | 0 | 0 |
| Neurotransmitter release cycle | R-HSA-112310 | 9.966783e-01 | 0.001 | 0 | 0 |
| RAB geranylgeranylation | R-HSA-8873719 | 9.967209e-01 | 0.001 | 0 | 0 |
| Signaling by Retinoic Acid | R-HSA-5362517 | 9.967209e-01 | 0.001 | 0 | 0 |
| FCERI mediated Ca+2 mobilization | R-HSA-2871809 | 9.972318e-01 | 0.001 | 0 | 0 |
| Cholesterol biosynthesis | R-HSA-191273 | 9.972374e-01 | 0.001 | 0 | 0 |
| Defensins | R-HSA-1461973 | 9.973381e-01 | 0.001 | 0 | 0 |
| Pyrimidine catabolism | R-HSA-73621 | 9.973381e-01 | 0.001 | 0 | 0 |
| Synthesis of Leukotrienes (LT) and Eoxins (EX) | R-HSA-2142691 | 9.976307e-01 | 0.001 | 0 | 0 |
| Peptide hormone metabolism | R-HSA-2980736 | 9.976472e-01 | 0.001 | 0 | 0 |
| CD22 mediated BCR regulation | R-HSA-5690714 | 9.978350e-01 | 0.001 | 0 | 0 |
| mitochondrial fatty acid beta-oxidation of saturated fatty acids | R-HSA-77286 | 9.978911e-01 | 0.001 | 0 | 0 |
| Degradation of the extracellular matrix | R-HSA-1474228 | 9.982334e-01 | 0.001 | 0 | 0 |
| O-linked glycosylation of mucins | R-HSA-913709 | 9.985743e-01 | 0.001 | 0 | 0 |
| Synthesis of Prostaglandins (PG) and Thromboxanes (TX) | R-HSA-2162123 | 9.988220e-01 | 0.001 | 0 | 0 |
| Diseases associated with O-glycosylation of proteins | R-HSA-3906995 | 9.989594e-01 | 0.000 | 0 | 0 |
| ECM proteoglycans | R-HSA-3000178 | 9.989594e-01 | 0.000 | 0 | 0 |
| Purine catabolism | R-HSA-74259 | 9.990633e-01 | 0.000 | 0 | 0 |
| Role of phospholipids in phagocytosis | R-HSA-2029485 | 9.991540e-01 | 0.000 | 0 | 0 |
| Asparagine N-linked glycosylation | R-HSA-446203 | 9.992432e-01 | 0.000 | 0 | 0 |
| Citric acid cycle (TCA cycle) | R-HSA-71403 | 9.993174e-01 | 0.000 | 0 | 0 |
| Metabolism of amine-derived hormones | R-HSA-209776 | 9.994145e-01 | 0.000 | 0 | 0 |
| SLC-mediated transport of organic anions | R-HSA-9955298 | 9.995032e-01 | 0.000 | 0 | 0 |
| Interleukin-10 signaling | R-HSA-6783783 | 9.995032e-01 | 0.000 | 0 | 0 |
| Glutathione conjugation | R-HSA-156590 | 9.996326e-01 | 0.000 | 0 | 0 |
| Biosynthesis of DHA-derived SPMs | R-HSA-9018677 | 9.996388e-01 | 0.000 | 0 | 0 |
| Role of LAT2/NTAL/LAB on calcium mobilization | R-HSA-2730905 | 9.996448e-01 | 0.000 | 0 | 0 |
| Nucleotide salvage | R-HSA-8956321 | 9.996731e-01 | 0.000 | 0 | 0 |
| Endogenous sterols | R-HSA-211976 | 9.996731e-01 | 0.000 | 0 | 0 |
| Collagen degradation | R-HSA-1442490 | 9.996731e-01 | 0.000 | 0 | 0 |
| Complex I biogenesis | R-HSA-6799198 | 9.997410e-01 | 0.000 | 0 | 0 |
| Keratinization | R-HSA-6805567 | 9.997493e-01 | 0.000 | 0 | 0 |
| Sulfur amino acid metabolism | R-HSA-1614635 | 9.998096e-01 | 0.000 | 0 | 0 |
| Metabolism of steroid hormones | R-HSA-196071 | 9.998376e-01 | 0.000 | 0 | 0 |
| Glycosphingolipid catabolism | R-HSA-9840310 | 9.998855e-01 | 0.000 | 0 | 0 |
| Metabolism of cofactors | R-HSA-8978934 | 9.998981e-01 | 0.000 | 0 | 0 |
| Metabolism of porphyrins | R-HSA-189445 | 9.998981e-01 | 0.000 | 0 | 0 |
| Drug ADME | R-HSA-9748784 | 9.998995e-01 | 0.000 | 0 | 0 |
| Binding and Uptake of Ligands by Scavenger Receptors | R-HSA-2173782 | 9.999006e-01 | 0.000 | 0 | 0 |
| Bile acid and bile salt metabolism | R-HSA-194068 | 9.999214e-01 | 0.000 | 0 | 0 |
| Metabolism of steroids | R-HSA-8957322 | 9.999269e-01 | 0.000 | 0 | 0 |
| Antimicrobial peptides | R-HSA-6803157 | 9.999290e-01 | 0.000 | 0 | 0 |
| Aerobic respiration and respiratory electron transport | R-HSA-1428517 | 9.999469e-01 | 0.000 | 0 | 0 |
| Developmental Lineage of Pancreatic Acinar Cells | R-HSA-9925561 | 9.999599e-01 | 0.000 | 0 | 0 |
| Metabolic disorders of biological oxidation enzymes | R-HSA-5579029 | 9.999599e-01 | 0.000 | 0 | 0 |
| Synthesis of bile acids and bile salts | R-HSA-192105 | 9.999622e-01 | 0.000 | 0 | 0 |
| Respiratory electron transport | R-HSA-611105 | 9.999713e-01 | 0.000 | 0 | 0 |
| G alpha (q) signalling events | R-HSA-416476 | 9.999774e-01 | 0.000 | 0 | 0 |
| Peroxisomal lipid metabolism | R-HSA-390918 | 9.999776e-01 | 0.000 | 0 | 0 |
| Bacterial Infection Pathways | R-HSA-9824439 | 9.999905e-01 | 0.000 | 0 | 0 |
| Nucleotide catabolism | R-HSA-8956319 | 9.999918e-01 | 0.000 | 0 | 0 |
| Transport of small molecules | R-HSA-382551 | 9.999936e-01 | 0.000 | 1 | 0 |
| Visual phototransduction | R-HSA-2187338 | 9.999938e-01 | 0.000 | 0 | 0 |
| Mitochondrial Fatty Acid Beta-Oxidation | R-HSA-77289 | 9.999951e-01 | 0.000 | 0 | 0 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | R-HSA-198933 | 9.999959e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation elongation | R-HSA-5389840 | 9.999961e-01 | 0.000 | 0 | 0 |
| Sphingolipid metabolism | R-HSA-428157 | 9.999964e-01 | 0.000 | 0 | 0 |
| Peptide ligand-binding receptors | R-HSA-375276 | 9.999967e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation initiation | R-HSA-5368286 | 9.999969e-01 | 0.000 | 0 | 0 |
| Phospholipid metabolism | R-HSA-1483257 | 9.999980e-01 | 0.000 | 0 | 0 |
| Mitochondrial ribosome-associated quality control | R-HSA-9937383 | 9.999983e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation termination | R-HSA-5419276 | 9.999992e-01 | 0.000 | 0 | 0 |
| Glycerophospholipid biosynthesis | R-HSA-1483206 | 9.999993e-01 | 0.000 | 0 | 0 |
| G alpha (i) signalling events | R-HSA-418594 | 9.999995e-01 | 0.000 | 0 | 0 |
| Glycosaminoglycan metabolism | R-HSA-1630316 | 9.999997e-01 | 0.000 | 0 | 0 |
| O-linked glycosylation | R-HSA-5173105 | 9.999997e-01 | 0.000 | 0 | 0 |
| Biosynthesis of specialized proresolving mediators (SPMs) | R-HSA-9018678 | 9.999999e-01 | 0.000 | 0 | 0 |
| Glycosphingolipid metabolism | R-HSA-1660662 | 9.999999e-01 | 0.000 | 0 | 0 |
| Cytochrome P450 - arranged by substrate type | R-HSA-211897 | 9.999999e-01 | 0.000 | 0 | 0 |
| Arachidonate metabolism | R-HSA-2142753 | 9.999999e-01 | 0.000 | 0 | 0 |
| Metabolism of water-soluble vitamins and cofactors | R-HSA-196849 | 1.000000e+00 | 0.000 | 0 | 0 |
| Synthesis of substrates in N-glycan biosythesis | R-HSA-446219 | 1.000000e+00 | 0.000 | 0 | 0 |
| Diseases of glycosylation | R-HSA-3781865 | 1.000000e+00 | 0.000 | 0 | 0 |
| Mitochondrial translation | R-HSA-5368287 | 1.000000e+00 | 0.000 | 0 | 0 |
| Phase I - Functionalization of compounds | R-HSA-211945 | 1.000000e+00 | 0.000 | 0 | 0 |
| Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein | R-HSA-446193 | 1.000000e+00 | 0.000 | 0 | 0 |
| SLC-mediated transmembrane transport | R-HSA-425407 | 1.000000e+00 | 0.000 | 0 | 0 |
| Phase II - Conjugation of compounds | R-HSA-156580 | 1.000000e+00 | 0.000 | 0 | 0 |
| Class A/1 (Rhodopsin-like receptors) | R-HSA-373076 | 1.000000e+00 | 0.000 | 0 | 0 |
| Diseases of metabolism | R-HSA-5668914 | 1.000000e+00 | 0.000 | 0 | 0 |
| GPCR downstream signalling | R-HSA-388396 | 1.000000e+00 | 0.000 | 0 | 0 |
| Signaling by GPCR | R-HSA-372790 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of vitamins and cofactors | R-HSA-196854 | 1.000000e+00 | 0.000 | 0 | 0 |
| Fatty acid metabolism | R-HSA-8978868 | 1.000000e+00 | 0.000 | 0 | 0 |
| GPCR ligand binding | R-HSA-500792 | 1.000000e+00 | 0.000 | 0 | 0 |
| Biological oxidations | R-HSA-211859 | 1.000000e+00 | 0.000 | 0 | 0 |
| Expression and translocation of olfactory receptors | R-HSA-9752946 | 1.000000e+00 | -0.000 | 0 | 0 |
| Metabolism | R-HSA-1430728 | 1.000000e+00 | -0.000 | 0 | 0 |
| Olfactory Signaling Pathway | R-HSA-381753 | 1.000000e+00 | -0.000 | 0 | 0 |
| Metabolism of lipids | R-HSA-556833 | 1.000000e+00 | -0.000 | 0 | 0 |
| Sensory Perception | R-HSA-9709957 | 1.000000e+00 | -0.000 | 0 | 0 |